

11-17-00

A

Please type a plus sign (+) inside this box ☒

Approved for use through 10/31/2002 OMB 0651-0032
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

11/16/00

3866 U.S. PAT.

UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No. RPMS 101 CON(3)
First Inventor David William Holden
Title IDENTIFICATION OF GENES
Express Mail Label No. EL 381 202 131 US

3866 U.S. PAT.

09/714602
11/16/00

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

- ☒ Fee Transmittal Form (e.g., PTO/SB/17)
(Submit an original and a duplicate for fee processing)
- ☐ Applicant claims small entity status.
See 37 CFR 1.27.
- ☒ Specification [Total Pages 262]
(preferred arrangement set forth below)
 - Descriptive title of the invention
 - Cross Reference to Related Applications
 - Statement Regarding Fed sponsored R & D
 - Reference to sequence listing, a table, or a computer program listing appendix
 - Background of the Invention
 - Brief Summary of the Invention
 - Brief Description of the Drawings (if filed)
 - Detailed Description
 - Claim(s)
 - Abstract of the Disclosure
- ☒ Drawing(s) (35 U.S.C. 113) [Total Sheets 112]
- Oath or Declaration [Total Pages 2]
 - ☐ Newly executed (original or copy)
 - ☒ Copy from a prior application (37 CFR 1.63 (d))
(for continuation/divisional with Box 17 completed)
 - ☐ **DELETION OF INVENTOR(S)**
Signed statement attached deleting inventor(s)
named in the prior application see 37 CFR 1.63(d)(2) and 1.33(b)
- ☐ Application Data Sheet. See 37 CFR 1.76

ADDRESS TO: Assistant Commissioner for Patents
Box Patent Application
Washington, DC 20231

- ☐ CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)
- Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)
 - ☒ Computer Readable Form (CRF)
 - Specification Sequence Listing on:
 - ☐ CD-ROM or CD-R (2 copies); or
 - ☒ paper
- ☒ Statements verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

- ☒ Assignment Papers (cover sheet & document(s))
- ☒ 37 CFR 3.73(b) Statement (when there is an assignee) ☐ Power of Attorney
- ☐ English Translation Document (if applicable)
- ☐ Information Disclosure Statement (IDS)/PTO-1449 ☐ Copies of IDS Citations
- ☒ Preliminary Amendment
- ☒ Return Receipt Postcard (MPEP 503) (Should be specifically itemized)
- ☐ Certified Copy of Priority Document(s) (if foreign priority is claimed)
- ☒ Other Check for \$988.00

17 If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:

☒ Continuation ☐ Divisional ☐ Continuation-in-part (CIP)

of prior application No 09 / 201,945

Prior application information

Examiner Robert Schwartzman

Group / Art Unit 1636

For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been specifically omitted from the submitted application parts.

18. CORRESPONDENCE ADDRESS

☒ Customer Number or Bar Code Label

23579

or ☐ Correspondence address below

Name Patrea L. Pabst
Arnall Golden & Gregory, LLP
Address 2800 One Atlantic Center
1201 West Peachtree Street
City Atlanta State GA Zip Code 30309-3450
Country United States Telephone (404) 873-8794 Fax (404) 873-8795

Name (Print/Type) Robert A. Hodges Registration No. (Attorney/Agent) 41,074

Signature [Signature] Date November 16, 2000

Burden Hour Statement This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

FEE TRANSMITTAL for FY 2001

Patent fees are subject to annual revision

Express Mail Label No.: EL 381 202 131 US

TOTAL AMOUNT OF PAYMENT (\$988.00)

Complete if Known

Application Number	Not Yet Assigned
Filing Date	November 16, 2000
First Named Inventor	David William Holden
Examiner Name	Not Yet Assigned
Group Art Unit	Not Yet Assigned
Attorney Docket No.	RPMS 101 CON(3)

JC945 U.S. PTO

09/11/00



METHOD OF PAYMENT (check one)

1. ☐ The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to:

Deposit Account Number: 01-2507
 Deposit Account Name: Arnall Golden & Gregory

☒ Charge Any Additional Fee Required Under 37 CFR 1.16 and 1.17

☐ Applicant claims small entity status See 37 CFR 1.27

2. ☒ Payment Enclosed:

☒ Check ☐ Credit card ☐ Money Order ☐ Other

FEE CALCULATION

1. BASIC FILING FEE

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid
101 710	201 355	Utility filing fee	710.00
106 320	206 160	Design filing fee	
107 490	207 245	Plant filing fee	
108 710	208 355	Reissue filing fee	
114 150	214 75	Provisional filing fee	

SUBTOTAL (1) (\$710.00)

2. EXTRA CLAIM FEES

Total Claims: 31 - Extra Claims: 11 x Fee from below: 18.00 = 198.00
 Independent Claims: 4 - x Fee from below: 80.00 = 80.00
 Multiple Dependent: x Fee from below: 0.00 = 0.00

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description
103 18	203 9	Claims in excess of 20
102 80	202 40	Independent claims in excess of 3
104 270	204 135	Multiple dependent claim, if not paid
109 80	209 40	** Reissue independent claims over original patent
110 18	210 9	** Reissue claims in excess of 20 and over original patent

SUBTOTAL (2) (\$278.00)

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid
105 130	205 65	Surcharge - late filing fee or oath	
127 50	227 25	Surcharge - late provisional filing fee or cover sheet	
139 130	139 130	Non-English specification	
147 2,520	147 2,520	For filing a request for ex parte reexamination	
112 920*	112 920*	Requesting publication of SIR prior to Examiner action	
113 1,840*	113 1,840*	Requesting publication of SIR after Examiner action	
115 110	215 55	Extension for reply within first month	
116 390	216 195	Extension for reply within second month	
117 890	217 445	Extension for reply within third month	
118 1,390	218 695	Extension for reply within fourth month	
128 1,890	228 945	Extension for reply within fifth month	
119 310	219 155	Notice of Appeal	
120 310	220 155	Filing a brief in support of an appeal	
121 270	221 135	Request for oral hearing	
138 1,510	138 1,510	Petition to institute a public use proceeding	
140 110	240 55	Petition to revive - unavoidable	
141 1,240	241 620	Petition to revive - unintentional	
142 1,240	242 620	Utility issue fee (or reissue)	
143 440	243 220	Design issue fee	
144 600	244 300	Plant issue fee	
122 130	122 130	Petitions to the Commissioner	
123 50	123 50	Petitions related to provisional applications	
126 240	126 240	Submission of Information Disclosure Stmt	
581 40	581 40	Recording each patent assignment per property (times number of properties)	
146 710	246 355	Filing a submission after final rejection (37 CFR § 1.129(a))	
149 710	249 355	For each additional invention to be examined (37 CFR § 1.129(b))	
179 710	279 355	Request for Continued Examination (RCE)	
169 900	169 900	Request for expedited examination of a design application	

Other fee (specify) _____

* Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$0.00)

SUBMITTED BY

Name (Print/Type)

Robert A. Hodges

Registration No. (Attorney/Agent)

41,074

Complete (if applicable)

Telephone

(404) 873-8796

Signature

Date

November 16, 2000

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: David William Holden

Serial No: Continuation of 09/201,945

Express Mail Label No.
EL 381 202 131 US

Filed: November 16, 2000

Date of Deposit:
November 16, 2000

For: *IDENTIFICATION OF GENES*

BOX PATENT APPLICATION
Assistant Commissioner for Patents
Washington, D.C. 20231

**REQUEST FOR FILING A
CONTINUATION APPLICATION UNDER 37 C.F.R. § 1.53(b)**

Sir:

Pursuant to 35 U.S.C. § 21(a) as amended by Public Law 97-247 and 37 C.F.R. § 1.10, David William Holden encloses for filing the attached patent application entitled "Identification of Genes." The application includes 1 page of Abstract, 83 pages of Specification, 8 pages of claims, 112 sheets of Formal Drawings, 170 pages of Sequence Listing, and a copy of an executed Declaration for Patent Application. This application is a continuation of pending prior application Serial No. 09/201,945 filed December 1, 1998, entitled "Identification of Genes", by David William Holden, which is a continuation of prior Application No. 08/871,355, filed June 9, 1997, which is a continuation of 08/637,759, filed December 11, 1995, which is a 371 of PCT/GB95/02875, filed December 11, 1995.

RPMS 101 CON(3)
20001/10



09/714602 11/16/00

Continuation of U.S.S.N. 09/201,945
Applicant: David William Holden
Date of Deposit: November 16, 2000
REQUEST FOR FILING A CONTINUATION
APPLICATION UNDER 37 C.F.R. § 1.53(b)
Express Mail Label No.: EL 381 202 131 US

Submitted with the above-identified application are (1) a check in the amount of \$988.00 to cover the filing fee, (2) a Preliminary Amendment, (3) a copy of the assignment from David William Holden to RPMS Technology Limited as filed in prior application Serial No. 08/637,759, and recorded at Reel 9113, Frame 0723 on July 19, 1997, (4) a copy of the assignment from RPMS Technology Limited to Imperial College Innovations Limited as filed in prior Application Serial Nos. 08/637,759, 08/871,355, and 09/201,945, and recorded at Reel 010113, Frame 0746 on July 26, 1999; (5) executed Combined Declaration for Patent Application, filed in Application Serial Nos. 08/737,759 and 09/201,945; (6) Statement Under 37 C.F.R. 3.73(b), (7) Associate Power of Attorney Under 37 C.F.R. § 1.34; and (8) Fee Transmittal.

Please preliminarily amend the application in accordance with the Preliminary Amendment.

It is believed that \$988.00 is the proper filing fee since the application will include 4 independent claims and a total of 31 claims after entry of the Preliminary Amendment. The Commissioner is hereby authorized to charge any additional fees, which may be required, or credit any overpayment to Account No. 01-2507. To facilitate this process, applicant has enclosed a duplicate of this letter.

Pursuant to 37 C.F.R. § 1.63(d), the copy of the executed Declaration included in the above-identified application is a copy of the executed Declaration filed in parent Application

RPMS 101 CON(3)
20001/10

Continuation of U.S.S.N. 09/201,945
Applicant: David William Holden
Date of Deposit: November 16, 2000
REQUEST FOR FILING A CONTINUATION
APPLICATION UNDER 37 C.F.R. § 1.53(b)
Express Mail Label No.: EL 381 202 131 US

Serial No. 09/201,945, to which the present application claims benefit. The power of attorney in the prior application is to Patrea L. Pabst, Madeline I. Johnston, and Dolly A. Vance. An Associate Power of Attorney is enclosed. The inventorship for the claims in the present application differs from the inventorship in the parent application, Serial No. 09/201,945, in that David William Holden is the sole inventor of the claims in the present Application, following entry of the Preliminary Amendment.

The subject matter of this application is also related to the subject matter of Application Serial No. 08/637,759, filed December 11, 1995, Application Serial No. 08/871,355, filed on June 9, 1997, and Application Serial No. 09/201,945, filed December 1, 1998, by David William Holden.

This application contains nucleic acid and/or protein sequences as defined in 37 C.F.R. § 1.821-1.825. The sequence listing for the new application is identical to the sequence listing for application Serial No. 08/637,759, filed December 11, 1995, by David William Holden.

Sequence Listings in computer readable form were submitted in Application Serial No. 08/871,355, filed June 9, 1997, entitled "Identification of Genes", by David William Holden on October 31, 1997 and January 26, 1999. Accordingly, pursuant to 37 C.F.R. § 1.821(e), applicant hereby requests that the computer readable form of the sequence listing submitted on January 26, 1999, in application Serial No. 08/871,355 be used as the computer readable form of the

Continuation of U.S.S.N. 09/201,945
Applicant: David William Holden
Date of Deposit: November 16, 2000
REQUEST FOR FILING A CONTINUATION
APPLICATION UNDER 37 C.F.R. § 1.53(b)
Express Mail Label No.: EL 381 202 131 US

sequence listing for the above-identified application. The application has a paper copy of the Sequence Listing incorporated therein.

I declare that the paper copy of the Sequence Listing in the present application is identical to the material in the prior sequence listing, and that the Sequence Listing does not add new matter to the application, and that all statements made on information and belief are believed to be true and further that these statements were made with the knowledge that willful false statements may jeopardize the validity of the application or any patent issuing thereon.


This application is being filed on November 16, 2000, by mailing the application to Box Patent Application, Commissioner for Patents and Trademarks, Washington, D.C. 20231 via the United States Postal Service "Express Mail Post Office to Addressee" Service under 37 C.F.R. § 1.10. The Express Mail Label No. EL 381 202 131 US appears in the heading of this paper, which is attached to the application, pursuant to 37 C.F.R. § 1.10(b).

Continuation of U.S.S.N. 09/201,945
Applicant: David William Holden
Date of Deposit: November 16, 2000
REQUEST FOR FILING A CONTINUATION
APPLICATION UNDER 37 C.F.R. § 1.53(b)
Express Mail Label No.: EL 381 202 131 US

All correspondence concerning this application should be mailed to:

Patrea L. Pabst, Esq.
ARNALL GOLDEN & GREGORY, LLP
2800 One Atlantic Center
1201 West Peachtree Street
Atlanta, GA 30309-3450

Respectfully submitted,



Robert A. Hodges
Reg. No. 41,074

Date: November 16, 2000

ARNALL, GOLDEN & GREGORY, LLP
2800 One Atlantic Center
1201 West Peachtree Street
Atlanta, Georgia 30309-3450
(404) 873-8796
(404) 873-8797 (fax)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: David William Holden

Serial No.: Continuation of
09/201,945

Express Mail Label No.
EL 381 202 131 US

Filed: November 16, 2000

Date of Deposit: November 16, 2000

For: *IDENTIFICATION OF GENES*

Box Patent Application
Assistant Commissioner for Patents
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Sir:

Prior to examination, please amend the application as follows. This Preliminary Amendment is being filed along with a Continuation Application filed under 37 C.F.R. § 1.53(b). It is believed that no fee is required with this Amendment. However, should a fee be required, the Commissioner is hereby authorized to charge any required fees to Deposit Account No. 01-2507.

Amendment

In the Specification

On page 1, after the title "IDENTIFICATION OF GENES" and before line 3, which begins "The present invention" please insert as a new paragraph

-- This application is a continuation of copending Application Serial No. 09/201,945, filed December 1, 1998, entitled "IDENTIFICATION OF GENES," by David William Holden, which

is a continuation of 08/637,759, filed July 19, 1997, which is a 371 of PCT/GB95/02875, filed December 11, 1995. Application Serial No. 09/201,945, filed December 1, 1998, and Application Serial No. 08/637,759, filed July 19, 1997, are hereby incorporated herein by reference.--

On page 22, line 13, following "5 and 6" please add --(SEQ ID Nos 39-44 and 8-36)--.

On page 22, line 20, following "11 and 12" please add --(SEQ ID Nos 37 and 38)--.

On page 39, lines 19-20, please replace "12301 Parklawn Drive, Rockville, Maryland 20852" with --10801 University Boulevard, Manassas, Virginia 20110-2209--.

On page 43, line 7, please replace "Figure 1 illustrates" with --Figures 1A and 1B illustrate--.

On page 43, line 29, please replace "Figure 5 shows" with --Figures 5A through 5D show--.

On page 44, line 1, following "genome" please add --(SEQ ID Nos 39 and 40)--.

On page 44, line 3, please replace "Figure 6 shows" with --Figures 6A through 6H show--.

On page 44, line 6, please replace "Figure 7 shows" with --Figure 7A and 7B show--.

On page 44, line 20, please replace "Figure 8 shows" with --Figures 8A, 8B, and 8C show--.

On page 45, line 19, please replace "Figure 10 shows" with --Figures 10A and 10B show--.

On page 45, line 27, please replace "Figure 11 shows" with --Figures 11A through 11BW show--.

On page 45, line 29, please replace "2" with --8--.

On page 45, line 29, please replace "all six" with --three forward--.

On page 45, line 29, following "reading frames" please add --(the amino acid sequences in the "a" reading frame are SEQ ID Nos. 45-187, the amino acid sequences in the "b" reading frame are SEQ ID Nos. 188-356, and the amino acid sequences in the "c" reading frame are SEQ ID Nos. 357-501)--.

On page 46, line 6, please replace "Figure 12 shows" with --Figures 12A through 12P show--.

On page 46, line 7, please replace "Figure 2" with --Figure 8--.

On page 46, lines 7 and 8, please delete "DNA is translated in all six reading frames and the".

On page 56, line 28, following "Figure 5" please add --; SEQ ID Nos 39 and 40--.

On page 57, line 2, following "B1 to B5" please add --; SEQ ID Nos 8-36--.

In the Claims

Please amend the claims as follows.

3. (Amended) [A] The method according to [Claims 1 or 2] Claim 57 further comprising [the steps:

(1A)] after step (a), removing auxotrophs from the plurality of [mutants produced in step (1)]; or

(6A) determining whether the mutant selected in step (6) is an auxotroph; or
both (1A) and (6A)] mutant microorganisms.

Please add the following new claims.

57. (New) A method for identifying a mutant microorganism having a reduced adaptation to a particular environment comprising the steps of

(a) providing a plurality of mutant microorganisms wherein each microorganism contains a different marker sequence;

(b) introducing the plurality of microorganisms of step (a) into the said particular environment and allowing those microorganisms which are able to do so to grow in the said environment;

(c) retrieving microorganisms from the said environment or a selected part thereof; and

(d) selecting an individual microorganism having a reduced capacity to proliferate in the particular environment by comparing any marker sequences in the nucleic acid present in the retrieved microorganisms in step (c) to the different marker sequences referred to in step (a).

58. (New) The method of Claim 57 for identifying a gene which allows a microorganism to adapt to a particular environment further comprising the step:

(e) identifying the gene which is mutated in the individual microorganism having a reduced capacity to proliferate in the particular environment.

59. (New) The method of Claim 58 for isolating a gene which allows a microorganism to adapt to a particular environment further comprising the step:

(f) isolating from a wild-type microorganism the corresponding wild-type gene.

60. (New) The method of Claim 59 wherein the particular environment is a differentiated multicellular organism.

61. (New) The method of Claim 60 wherein the multicellular organism is a plant.

62. (New) The method of Claim 61 wherein the microorganism is a bacterium pathogenic to plants.

63. (New) The method of Claim 61 wherein the microorganism is a fungus pathogenic to plants.

64. (New) The method of Claim 60 wherein the multicellular organism is a non-human animal.

65. (New) The method of Claim 64 wherein the animal is selected from the group consisting of a mouse, rat, rabbit, dog and monkey.

66. (New) The method of Claim 65 wherein the animal is a mouse.

67. (New) The method of Claim 64 wherein the microorganism is a fungus pathogenic to animals.

68. (New) The method of Claim 67 wherein the fungus is selected from the group consisting of *Aspergillus* spp., *Cryptococcus neoformans* and *Histoplasma capsulatum*.

69. (New) The method of Claim 64 wherein in step (b) the microorganisms are introduced orally, intravenously, intranasally, or intraperitoneally.

70. (New) The method of Claim 69 wherein in step (c) the microorganisms are retrieved from the spleen.

71. (New) The method of Claim 64 wherein the microorganism is a bacterium pathogenic to animals.

72. (New) The method of Claim 71 wherein the bacterium is selected from the group consisting of *Bordetella pertussis*, *Campylobacter jejuni*, *Clostridium botulinum*, *Escherichia coli*, *Haemophilus decreyi*, *Haemophilus influenzae*, *Helicobacter pylori*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Listeria* spp., *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Pseudomonas* spp., *Salmonella* spp., *Shigella* spp., *Staphylococcus aureus*, *Streptococcus pyogenes*, *Streptococcus pneumoniae*, *Vibrio* spp., and *Yersinia pestis*.

73. (New) The method of Claim 60 wherein in step (c) the microorganisms are retrieved from the said environment at a site remote from the site of introduction in step (b).

74. (New) A gene obtained by the method of Claim 59.

75. (New) A mutant microorganism comprising a mutation in a gene identified using the method of Claim 58.

76. (New) The method of Claim 57 wherein the microorganism is a bacterium.

77. (New) The method of Claim 57 wherein the microorganism is a fungus.

78. (New) The method of Claim 57 wherein in step (d) the comparison of any marker sequences in the nucleic acid of the mutants retrieved in step (c) to the marker sequences referred to in step (a) uses DNA amplification techniques and oligonucleotide primers.

79. (New) A mutant microorganism obtained by the method of Claim 57.

80. (New) A non-human animal or plant, or an animal or plant cell culture, containing a plurality of mutant microorganisms wherein each mutant contains a different marker sequence.

81. (New) The non-human animal or plant, or an animal or plant cell culture, of Claim 80 wherein the microorganism is a pathogenic microorganism.

82. (New) A non-human animal or an animal cell culture containing a plurality of mutant microorganisms wherein each mutant contains a different marker sequence and wherein the microorganism is pathogenic to animals.

83. (New) The non-human animal or an animal cell culture of Claim 82 wherein the microorganism is selected from the group consisting of *Bordetella pertussis*, *Campylobacter jejuni*, *Clostridium botulinum*, *Escherichia coli*, *Haemophilus ducreyi*, *Haemophilus influenzae*, *Helicobacter pylori*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Listeria* spp., *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Pseudomonas* spp., *Salmonella* spp., *Shigella* spp., *Staphylococcus aureus*, *Streptococcus pyogenes*, *Streptococcus pneumoniae*, *Vibrio* spp., and *Yersinia pestis*.

84. (New) The non-human animal of Claim 83 which is a mouse or rat or rabbit or dog or monkey.

85. (New) The non-human animal of Claim 82 which is a mouse or rat or rabbit or dog or monkey.

86. (New) A method for identifying a microorganism having a reduced adaptation to a particular environment comprising the steps of

(a) providing a plurality of microorganisms wherein each microorganism contains a different marker sequence;

(b) introducing the plurality of microorganisms of step (a) into the said particular environment and allowing those microorganisms which are able to do so to grow in the said environment;

(c) retrieving microorganisms from the said environment or a selected part thereof; and

(d) selecting an individual microorganism having a reduced capacity to proliferate in the particular environment by comparing any marker sequences in the nucleic acid present in the retrieved microorganisms in step (c) to the different marker sequences referred to in step (a).

Please cancel claims 1, 2, and 4-56.

Remarks

Claims 3 and 57-86 are pending. Claim 3 has been amended. Claims 1, 2, and 4-56 have been canceled. Claims 57-86 are newly added. Claim 3 was amended to conform claim 3 to the language of new claim 57, from which it depends. New claims 57 and 86 recite forms of the disclosed method embodied in Example 1 (pages 46-56) and find support there. Example 1 provides microorganisms containing different marker sequences. The microorganisms were

produced by introducing marker sequences into microorganisms. Claims 57 and 75 also find support in original claim 1. New claim 58 finds support at least on page 17, lines 1-2, and in original claim 4. Claims 59-79 find support at least in original claims 5-7, 16, 17, 8-10, 19, 12, 13, 18, 20, 21, 11, 30, 27, 14, 15, 25, and 26, respectively. New claim 69 also finds support on page 15, lines 18-24. New claims 80 and 82 find support at least in original claims 1, 7, and 8, and on page 15, lines 26-30. New claim 81 finds support at least in original claims 7, 8, 16, and 17 and on page 15, lines 26-30, and page 4, lines 25-27. New claim 83 finds support at least in original claims 1, 7, 8, and 20, and on page 15, lines 26-30. New claims 84 and 85 find support at least in original claims 1, 7, 8, 9, and 20, and on page 15, lines 26-30. A copy of all of the pending claims as they are believed to have been amended is attached to this Amendment as an appendix.


The specification has been amended to include reference to the parent applications and to annotate sequences in the specification. These amendments to the specification generally

009111 20911 250

U.S.S.N. Continuation of 09/201,945
Express Mail Label No.: EL 381 202 131 US
Date of Deposit: November 16, 2000
PRELIMINARY AMENDMENT

correspond to amendments made during the course of prosecution of parent application Serial
No. 09/201,945.

Respectfully submitted,




Robert A. Hodges
Reg. No. 41,074

Date: November 16, 2000

ARNALL, GOLDEN & GREGORY, LLP
2800 One Atlantic Center
1201 West Peachtree Street
Atlanta, Georgia 30309-3450
(404) 873-8796
(404) 873-8797 (fax)

Certificate of Mailing Under 37 C.F.R. § 1.10

I hereby certify that this paper and any documents referred to as attached or enclosed are being deposited with the United States Postal Service on this date, November 16, 2000, in an envelope as "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10, Mailing Label Number EL 381 202 131 US addressed to Box Patent Application, Assistant Commissioner for Patents, Washington, D.C. 20231.


Teresa R. Spratt

Date: November 16, 2000

Appendix: Claims As Pending After Amendment

3. (Amended) [A] The method according to [Claims 1 or 2] Claim 57 further comprising [the steps:

(1A)] after step (a), removing auxotrophs from the plurality of [mutants produced in step (1)]; or

(6A) determining whether the mutant selected in step (6) is an auxotroph; or

both (1A) and (6A)] mutant microorganisms.

57. (New) A method for identifying a mutant microorganism having a reduced adaptation to a particular environment comprising the steps of

(a) providing a plurality of mutant microorganisms wherein each mutant contains a different marker sequence;

(b) introducing the plurality of mutants of step (a) into the said particular environment and allowing those microorganisms which are able to do so to grow in the said environment;

(c) retrieving microorganisms from the said environment or a selected part thereof; and

(d) selecting an individual mutant having a reduced capacity to proliferate in the particular environment by comparing any marker sequences in the nucleic acid present in the retrieved microorganisms in step (c) to the different marker sequences referred to in step (a).

58. (New) The method of Claim 57 for identifying a gene which allows a microorganism to adapt to a particular environment further comprising the step:

(e) identifying the gene which is mutated in the individual mutant having a reduced capacity to proliferate in the particular environment.

59. (New) The method of Claim 58 for isolating a gene which allows a microorganism to adapt to a particular environment further comprising the step:

(f) isolating from a wild-type microorganism the corresponding wild-type gene.

60. (New) The method of Claim 59 wherein the particular environment is a differentiated multicellular organism.

61. (New) The method of Claim 60 wherein the multicellular organism is a plant.

62. (New) The method of Claim 61 wherein the microorganism is a bacterium pathogenic to plants.

63. (New) The method of Claim 61 wherein the microorganism is a fungus pathogenic to plants.

64. (New) The method of Claim 60 wherein the multicellular organism is a non-human animal.

65. (New) The method of Claim 64 wherein the animal is selected from the group consisting of a mouse, rat, rabbit, dog and monkey.

66. (New) The method of Claim 65 wherein the animal is a mouse.

67. (New) The method of Claim 64 wherein the microorganisms is a fungus pathogenic to animals.

68. (New) The method of Claim 67 wherein the fungus is selected from the group consisting of *Aspergillus* spp., *Cryptococcus neoformans* and *Histoplasma capsulatum*.

69. (New) The method of Claim 64 wherein in step (b) the microorganisms are introduced orally, intravenously, intranasally, or intraperitoneally.

70. (New) The method of Claim 69 wherein in step (c) the microorganisms are retrieved from the spleen.

71. (New) The method of Claim 64 wherein the microorganism is a bacterium pathogenic to animals.

72. (New) The method of Claim 71 wherein the bacterium is selected from the group consisting of *Bordetella pertussis*, *Campylobacter jejuni*, *Clostridium botulinum*, *Escherichia coli*, *Haemophilus decreyi*, *Haemophilus influenzae*, *Helicobacter pylori*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Listeria* spp., *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Pseudomonas* spp., *Salmonella* spp., *Shigella* spp., *Staphylococcus aureus*, *Streptococcus pyogenes*, *Streptococcus pneumoniae*, *Vibrio* spp., and *Yersinia pestis*.

73. (New) The method of Claim 60 wherein in step (c) the microorganisms are retrieved from the said environment at a site remote from the site of introduction in step (b).

74. (New) A gene obtained by the method of Claim 59.
75. (New) A mutant microorganism comprising a mutation in a gene identified using the method of Claim 58.
76. (New) The method of Claim 57 wherein the microorganism is a bacterium.
77. (New) The method of Claim 57 wherein the microorganism is a fungus.
78. (New) The method of Claim 57 wherein in step (d) the comparison of any marker sequences in the nucleic acid of the mutants retrieved in step (c) to the marker sequences referred to in step (a) uses DNA amplification techniques and oligonucleotide primers.
79. (New) A mutant microorganism obtained by the method of Claim 57.
80. (New) A non-human animal or plant, or an animal or plant cell culture, containing a plurality of mutant microorganisms wherein each mutant contains a different marker sequence.
81. (New) The non-human animal or plant, or an animal or plant cell culture, of Claim 80 wherein the microorganism is a pathogenic microorganism.
82. (New) A non-human animal or an animal cell culture containing a plurality of mutant microorganisms wherein each mutant contains a different marker sequence and wherein the microorganism is pathogenic to animals.
83. (New) The non-human animal or an animal cell culture of Claim 82 wherein the microorganism is selected from the group consisting of *Bordetella pertussis*, *Campylobacter jejuni*, *Clostridium botulinum*, *Escherichia coli*, *Haemophilus ducreyi*, *Haemophilus influenzae*, *Helicobacter pylori*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Listeria* spp., *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Pseudomonas* spp., *Salmonella* spp., *Shigella* spp., *Staphylococcus aureus*, *Streptococcus pyogenes*, *Streptococcus pneumoniae*, *Vibrio* spp., and *Yersinia pestis*.
84. (New) The non-human animal of Claim 83 which is a mouse or rat or rabbit or dog or monkey.
85. (New) The non-human animal of Claim 82 which is a mouse or rat or rabbit or dog or monkey.

86. (New) A method for identifying a microorganism having a reduced adaptation to a particular environment comprising the steps of

(a) providing a plurality of microorganisms wherein each microorganism contains a different marker sequence;

(b) introducing the plurality of microorganisms of step (a) into the said particular environment and allowing those microorganisms which are able to do so to grow in the said environment;

(c) retrieving microorganisms from the said environment or a selected part thereof; and

(d) selecting an individual microorganism having a reduced capacity to proliferate in the particular environment by comparing any marker sequences in the nucleic acid present in the retrieved microorganisms in step (c) to the different marker sequences referred to in step (a).

00714603-114600

IDENTIFICATION OF GENES

The present invention relates to methods for the identification of genes involved in the adaptation of a microorganism to its environment, particularly the identification of genes responsible for the virulence of a pathogenic microorganism.

Background to the invention

Antibiotic resistance in bacterial and other pathogens is becoming increasingly important. It is therefore important to find new therapeutic approaches to attack pathogenic microorganisms.

Pathogenic microorganisms have to evade the host's defence mechanisms and be able to grow in a poor nutritional environment to establish an infection. To do so a number of "virulence" genes of the microorganism are required.

Virulence genes have been detected using classical genetics and a variety of approaches have been used to exploit transposon mutagenesis for the identification of bacterial virulence genes. For example, mutants have been screened for defined physiological defects, such as the loss of iron regulated proteins (Holland *et al*, 1992), or in assays to study the penetration of epithelial cells (Finlay *et al*, 1988) and survival within macrophages (Fields *et al*, 1989; Miller *et al*, 1989a; Groisman *et al*, 1989). Transposon mutants have also been tested for altered virulence in live animal models of infection (Miller *et al*, 1989b). This approach has the advantage that genes can be identified which are important during different stages of infection, but is severely limited by the need to test a wide range of mutants individually for alterations to virulence. Miller *et*

al (1989b) used groups of 8 to 10 mice and infected orally 95 separate groups with a different mutant thereby using between 760 and 950 mice. Because of the extremely large numbers of animals required, comprehensive screening of a bacterial genome for virulence genes has not
5 been feasible.

Recently a genetic system (*in vivo* expression technology [IVET]) was described which positively selects for *Salmonella* genes that are specifically induced during infection (Mahan *et al*, 1993). The technique
10 will identify genes that are expressed at a particular stage in the infection process. However, it will not identify virulence genes that are regulated posttranscriptionally, and more importantly, will not provide information on whether the gene(s) which have been identified are actually required for, or contribute to, the infection process.

15 Lee & Falkow (1994) *Methods Enzymol.* 236, 531-545 describe a method of identifying factors influencing the invasion of *Salmonella* into mammalian cells *in vitro* by isolating hyperinvasive mutants.

20 Walsh and Cepko (1992) *Science* 255, 434-440 describe a method of tracking the spatial location of cerebral cortical progenitor cells during the development of the cerebral cortex in the rat. The Walsh and Cepko method uses a tag that contains a unique nucleic acid sequence and the lacZ gene but there is no indication that useful mutants or genes could be
25 detected by their method.

WO 94/26933 and Smith *et al* (1995) *Proc. Natl. Acad. Sci. USA* 92, 6479-6483 describe methods aimed at the identification of the functional regions of a known gene, or at least of a DNA molecule for which some
30 sequence information is available.

Groisman *et al* (1993) *Proc. Natl. Acad. Sci. USA* **90**, 1033-1037 describes the molecular, functional and evolutionary analysis of sequences specific to *Salmonella*.

- 5 Some virulence genes are already known for pathogenic microorganisms such as *Escherichia coli*, *Salmonella typhimurium*, *Salmonella typhi*, *Vibrio cholerae*, *Clostridium botulinum*, *Yersinia pestis*, *Shigella flexneri* and *Listeria monocytogenes* but in all cases only a relatively small number of the total have been identified.

10

The disease which *Salmonella typhimurium* causes in mice provides a good experimental model of typhoid fever (Carter & Collins, 1974). Approximately forty two genes affecting *Salmonella* virulence have been identified to date (Groisman & Ochman, 1994). These represent
15 approximately one third of the total number of predicted virulence genes (Groisman and Saier, 1990).

The object of the present invention is to identify genes involved in the adaptation of a microorganism to its environment, particularly to identify
20 further virulence genes in pathogenic microorganisms, with increased efficiency. A further object is to reduce the number of experimental animals used in identifying virulence genes. Still further objects of the invention provide vaccines, and methods for screening for drugs which reduce virulence.

25

Summary of the invention

A first aspect of the invention provides a method for identifying a microorganism having a reduced adaptation to a particular environment
30 comprising the steps of:

- (1) providing a plurality of microorganisms each of which is independently mutated by the insertional inactivation of a gene with a nucleic acid comprising a unique marker sequence so that each mutant contains a different marker sequence, or clones of the said microorganism;
- 5 (2) providing individually a stored sample of each mutant produced by step (1) and providing individually stored nucleic acid comprising the unique marker sequence from each individual mutant;
- (3) introducing a plurality of mutants produced by step (1) into the said particular environment and allowing those microorganisms which
- 10 are able to do so to grow in the said environment;
- (4) retrieving microorganisms from the said environment or a selected part thereof and isolating the nucleic acid from the retrieved microorganisms;
- (5) comparing any marker sequences in the nucleic acid isolated
- 15 in step (4) to the unique marker sequence of each individual mutant stored as in step (2); and
- (6) selecting an individual mutant which does not contain any of the marker sequences as isolated in step (4).
- 20 Thus, the method uses negative selection to identify microorganisms with reduced capacity to proliferate in the environment.

A microorganism can live in a number of different environments and it is known that particular genes and their products allow the microorganism

25 to adapt to a particular environment. For example, in order for a pathogenic microorganism, such as a pathogenic bacterium or pathogenic fungus, to survive in its host the product of one or more virulence genes is required. Thus, in a preferred embodiment of the invention a gene of a microorganism which allows the microorganism to adapt to a particular

30 environment is a virulence gene.

Conveniently, the particular environment is a differentiated multicellular organism such as a plant or animal. Many bacteria and fungi are known to infect plants and they are able to survive within the plant and cause disease because of the presence of and expression from virulence genes.

- 5 Suitable microorganisms when the particular environment is a plant include the bacteria *Agrobacterium tumefaciens* which forms tumours (galls) particularly in grape; *Erwinia amylovora*; *Pseudomonas solanacearum* which causes wilt in a wide range of plants; *Rhizobium leguminosarum* which causes disease in beans; *Xanthomonas campestris* p.v. *citri* which causes canker in citrus fruits; and include the fungi
- 10 *Magnaporthe grisea* which causes rice blast disease; *Fusarium* spp. which cause a variety of plant diseases; *Erysiphe* spp.; *Colletotrichum gloeosporioides*; *Gaeumannomyces graminis* which causes root and crown diseases in cereals and grasses; *Glomus* spp., *Laccaria* spp.; *Leptosphaeria*
- 15 *maculans*; *Phoma tracheiphila*; *Phytophthora* spp., *Pyrenophora teres*; *Verticillium albo-atrum* and *V. dahliae*; and *Mycosphaerella musicola* and *M. fijiensis*. As described in more detail below, when the microorganism is a fungus a haploid phase to its life cycle is required.
- 20 Similarly, many microorganisms including bacteria, fungi, protozoa and trypanosomes are known to infect animals, particularly mammals including humans. Survival of the microorganism within the animal and the ability of the microorganism to cause disease is due in large part to the presence of and expression from virulence genes. Suitable bacteria include
- 25 *Bordetella* spp. particularly *B. pertussis*, *Campylobacter* spp. particularly *C. jejuni*, *Clostridium* spp. particularly *C. botulinum*, *Enterococcus* spp. particularly *E. faecalis*, *Escherichia* spp. particularly *E. coli*, *Haemophilus* spp. particularly *H. ducreyi* and *H. influenzae*, *Helicobacter* spp. particularly *H. pylori*, *Klebsiella* spp. particularly *K. pneumoniae*,
- 30 *Legionella* spp. particularly *L. pneumophila*, *Listeria* spp. particularly *L.*

monocytogenes, *Mycobacterium* spp. particularly *M. smegmatis* and *M. tuberculosis*, *Neisseria* spp. particularly *N. gonorrhoeae* and *N. meningitidis*, *Pseudomonas* spp., particularly *Ps. aeruginosa*, *Salmonella* spp., *Shigella* spp., *Staphylococcus* spp. particularly *S. aureus*,
 5 *Streptococcus* spp. particularly *S. pyogenes* and *pneumoniae*, *Vibrio* spp. and *Yersinia* spp. particularly *Y. pestis*. All of these bacteria cause disease in man and also there are animal models of the disease. Thus, when these bacteria are used in the method of the invention, the particular environment is an animal which they can infect and in which they cause
 10 disease. For example, when *Salmonella typhimurium* is used to infect a mouse the mouse develops a disease which serves as a model for typhoid fever in man. *Staphylococcus aureus* causes bacteraemia and renal abscess formation in mice (Albus *et al* (1991) *Infect. Immun.* **59**, 1008-1014) and endocarditis in rabbits (Perlman & Freedman (1971) *Yale J. Biol. Med.*
 15 **44**, 206-213).

It is required that a fungus or higher eukaryotic parasite is haploid for the relevant parts of its life (such as growth in the environment). Preferably, a DNA-mediated integrative transformation system is available and, when
 20 the microorganism is a human pathogen, conveniently an animal model of the human disease is available. Suitable fungi pathogenic to humans include certain *Aspergillus* spp. (for example *A. fumigatus*), *Cryptococcus neoformans* and *Histoplasma capsulatum*. Clearly the above-mentioned fungi have a haploid phase and a DNA-mediated integrative transformation
 25 systems are available for them. *Toxoplasma* may also be used, being a parasite with a haploid phase during infection. Bacteria have a haploid genome.

Animal models of human disease are often available in which the animal
 30 is a mouse, rat, rabbit, dog or monkey. It is preferred if the animal is a

mouse. Virulence genes detected by the method of the invention using an animal model of a human disease are clearly very likely to be genes which determine the virulence of the microorganism in man.

- 5 Particularly preferred microorganisms for use in the methods of the invention are *Salmonella typhimurium*, *Staphylococcus aureus*, *Streptococcus pneumoniae*, *Enterococcus faecalis*, *Pseudomonas aeruginosa* and *Aspergillus fumigatus*.
- 10 A preferred embodiment of the invention is now described.

A nucleic acid comprising a unique marker sequence is made as follows. A complex pool of double stranded DNA sequence "tags" is generated using oligonucleotide synthesis and a polymerase chain reaction (PCR).

- 15 Each DNA "tag" has a unique sequence of between about 20 and 80 bp, preferably about 40 bp which is flanked by "arms" of about 15 to 30 bp, preferably about 20 bp, which are common to all "tags". The number of bp in the unique sequence is sufficient to allow large numbers (for example $> 10^{10}$) of unique sequences to be generated by random
- 20 oligonucleotide synthesis but not too large to allow the formation of secondary structures which may interfere with a PCR. Similarly, the length of the arms should be sufficient to allow efficient priming of oligonucleotides in a PCR.
- 25 It is well known that the sequence at the 5' end of the oligonucleotide need not match the target sequence to be amplified.

- It is usual that the PCR primers do not contain any complementary structures with each other longer than 2 bases, especially at their 3' ends,
- 30 as this feature may promote the formation of an artifactual product called

“primer dimer”. When the 3' ends of the two primers hybridize, they form a “primed template” complex, and primer extension results in a short duplex product called “primer dimer”.

- 5 Internal secondary structure should be avoided in primers. For symmetric PCR, a 40-60% G+C content is often recommended for both primers, with no long stretches of any one base. The classical melting temperature calculations used in conjunction with DNA probe hybridization studies often predict that a given primer should anneal at a specific temperature
10 or that the 72°C extension temperature will dissociate the primer/template hybrid prematurely. In practice, the hybrids are more effective in the PCR process than generally predicted by simple T_m calculations.

- Optimum annealing temperatures may be determined empirically and may
15 be higher than predicted. *Taq* DNA polymerase does have activity in the 37-55°C region, so primer extension will occur during the annealing step and the hybrid will be stabilized. The concentrations of the primers are equal in conventional (symmetric) PCR and, typically, within 0.1- to 1- μ M range.

20

- The “tags” are ligated into a transposon or transposon-like element to form the nucleic acid comprising a unique marker sequence. Conveniently, the transposon is carried on a suicide vector which is maintained as a plasmid in a “helper” organism, but which is lost after
25 transfer to the microorganism of the method of the invention. For example, the “helper” organism may be a strain of *Escherichia coli*, the microorganism of the method may be *Salmonella* and the transfer is a conjugal transfer. Although the transposon can be lost after transfer, in a proportion of cells it undergoes a transposition event through which it
30 integrates at random, along with its unique tag, into the genome of the

microorganism used in the method. It is most preferred if the transposon or transposon-like element can be selected. For example, in the case of *Salmonella*, a kanamycin resistance gene may be present in the transposon and exconjugants are selected on medium containing kanamycin. It is also possible to complement an auxotrophic marker in the recipient cell with a functional gene in the nucleic acid comprising the unique marker. This method is particularly convenient when fungi are used in the method.

Preferably the complementing functional gene is not derived from the same species as the recipient microorganism, otherwise non-random integration events may occur.

It is also particularly convenient if the transposon or transposon-like element is carried on a vector which is maintained episomally (ie not as part of the chromosome) in the microorganism used in the method of the first aspect of the invention when in a first given condition whereas, upon changing that condition to a second given condition, the episome cannot be maintained permitting the selection of a cell in which the transposon or transposon-like element has undergone a transposition event through which it integrates at random, along with its unique tag, into the genome of the microorganism used in the method. This particularly convenient embodiment is advantageous because, once a microorganism carrying the episomal vector is made, then each time the transposition event is selected for or induced by changing the condition of the microorganism (or a clone thereof) from a first given condition to a second given condition, the transposon can integrate at a different site in the genome of the microorganism. Thus, once a master collection of microorganisms are made, each member of which contains a unique tag sequence in the transposon or transposon-like element carried on the episomal vector (when in the first given condition), it can be used repeatedly to generate

pools of random insertional mutants, each of which contains a different tag
 sequence (ie unique within the pool). This embodiment is particularly
 useful because (a) it reduces the number and complexity of manipulations
 required to generate the plurality ("pool") of independently mutated
 5 microorganisms in step (1) of the method; and (b) the number of different
 tags need only be the same as the number of microorganisms in the
 plurality of microorganisms in step (1) of the method. Point (a) makes the
 method easier to use in organisms for which transposon mutagenesis is
 more difficult to perform (for example, *Staphylococcus aureus*) and point
 10 (b) means that tag sequences with particularly good hybridisation
 characteristics can be selected therefore making quality control easier. As
 is described in more detail below, the "pool" size is conveniently about
 100 or 200 independently-mutated microorganisms and, therefore the
 master collection of microorganisms is conveniently stored in one or two
 15 96-well microtitre plates.

In a particularly preferred embodiment the first given condition is a first
 particular temperature or temperature range such as 25°C to 32°C, most
 preferably about 30°C and the second given condition is a second
 20 particular temperature or temperature range such as 35°C to 45°C, most
 preferably 42°C. In further preferred embodiments the first given
 condition is the presence of an antibiotic, such as streptomycin, and the
 second given condition is the absence of the said antibiotic; or the first
 given condition is the absence of an antibiotic and the second given
 25 condition is the presence of the said antibiotic.

Transposons suitable for integration into the genome of Gram negative
 bacteria include Tn5, Tn10 and derivatives thereof. Transposons suitable
 for integration into the genome of Gram positive bacteria include Tn916
 30 and derivatives or analogues thereof. Transposons particularly suited for

use with *Staphylococcus aureus* include Tn917 (Cheung *et al* (1992) *Proc. Natl. Acad. Sci. USA* 89, 6462-6466) and Tn918 (Albus *et al* (1991) *Infect. Immun.* 59, 1008-1014).

- 5 It is particularly preferred if the transposons have the properties of the Tn917 derivatives described by Camilli *et al* (1990) *J. Bacteriol.* 172, 3738-3744, and are carried by a temperature-sensitive vector such as pE194Ts (Villafane *et al* (1987) *J. Bacteriol.* 169, 4822-4829).
- 10 It will be appreciated that although transposons are convenient for insertionally inactivating a gene, any other known method, or method developed in the future may be used. A further convenient method of insertionally inactivating a gene, particularly in certain bacteria such as *Streptococcus*, is using insertion-duplication mutagenesis such as that
- 15 described in Morrison *et al* (1984) *J. Bacteriol.* 159, 870 with respect to *S. pneumoniae*. The general method may also be applied to other microorganisms, especially bacteria.

- For fungi, insertional mutations are created by transformation using DNA
- 20 fragments or plasmids carrying the "tags" and, preferably, selectable markers encoding, for example, resistance to hygromycin B or phleomycin (see Smith *et al* (1994) *Infect. Immunol.* 62, 5247-5254). Random, single integration of DNA fragments encoding hygromycin B resistance into the genome of filamentous fungi, using restriction enzyme mediated
 - 25 integration (REMI; Schiestl & Petes (1991); Lu *et al* (1994) *Proc. Natl. Acad. Sci. USA* 91, 12649-12653) are known.

- A simple insertional mutagenesis technique for a fungus is described in Schiestl & Petes (1994) incorporated herein by reference, and include, for
- 30 example, the use of Ty elements and ribosomal DNA in yeast.

Random integration of the transposon or other DNA sequence allows isolation of a plurality of independently mutated microorganisms wherein a different gene is insertionally inactivated in each mutant and each mutant contains a different marker sequence.

5

A library of such insertion mutants is arrayed in well microtitre dishes so that each well contains a different mutant microorganism. DNA comprising the unique marker sequence from each individual mutant microorganism (conveniently, the total DNA from the clone is used) is stored. Conveniently, this is done by removing a sample of the microorganism from the microtitre dish, spotting it onto a nucleic acid hybridisation membrane (such as nitrocellulose or nylon membranes), lysing the microorganism in alkali and fixing the nucleic acid to the membrane. Thus, a replica of the contents of the well microtitre dishes is made.

15

Pools of the microorganisms from the well microtitre dish are made and DNA is extracted. This DNA is used as a target for a PCR using primers that anneal to the common "arms" flanking the "tags" and the amplified DNA is labelled, for example with ^{32}P . The product of the PCR is used to probe the DNA stored from each individual mutant to provide a reference hybridisation pattern for the replicas of the well microtitre dishes. This is a check that each of the individual microorganisms does, in fact, contain a marker sequence and that the marker sequence can be amplified and labelled efficiently.

25

Pools of transposon mutants are made to introduce into the particular environment. Conveniently, 96-well microtitre dishes are used and the pool contains 96 transposon mutants. However, the lower limit for the pool is two mutants; there is no theoretical upper limit to the size of the

30

pool but, as discussed below, the upper limit may be determined in relation to the environment into which the mutants are introduced.

- Once the microorganisms are introduced into the said particular environment those microorganisms which are able to do so are allowed to grow in the environment. The length of time the microorganisms are left in the environment is determined by the nature of the microorganism and the environment. After a suitable length of time, the microorganisms are recovered from the environment, DNA is extracted and the DNA is used as a template for a PCR using primers that anneal to the "arms" flanking the "tags". The PCR product is labelled, for example with ^{32}P , and is used to probe the DNA stored from each individual mutant replicated from the welled microtitre dish. Stored DNA are identified which hybridise weakly or not at all with the probe generated from the DNA isolated from the microorganisms recovered from environment. These non-hybridising DNAs correspond to mutants whose adaptation to the particular environment has been attenuated by insertion of the transposon or other DNA sequence.
- In a particularly preferred embodiment the "arms" have no, or very little, label compared to the "tags". For example, the PCR primers are suitably designed to contain no, or a single, G residue, the ^{32}P -labelled nucleotide is dCTP and, in this case, no or one radiolabelled C residue is incorporated in each "arm" but a greater number of radiolabelled C residues are incorporated in the "tag". It is preferred if the "tag" has at least ten-fold more label incorporated than the "arms"; preferably twenty-fold or more; more preferably fifty-fold or more. Conveniently the "arms" can be removed from the "tag" using a suitable restriction enzyme, a site for which may be incorporated in the primer design.

As discussed above, a particularly preferred embodiment of the invention is when the microorganism is a pathogenic microorganism and the particular environment is an animal. In this embodiment, the size of the pool of mutants introduced into the animal is determined by (a) the number of cells of each mutant that are likely to survive in the animal (assuming a virulence gene has not been inactivated) and (b) the total inoculum of the microorganism. If the number in (a) is too low then false positive results may arise and if the number in (b) is too high then the animal may die before enough mutants have had a chance to grow in the desired way. The number of cells in (a) can be determined for each microorganism used but it is preferably more than 50, more preferably more than 100.

The number of different mutants that can be introduced into a single animal is preferably between 50 and 500, conveniently about 100. It is preferred if the total inoculum does not exceed 10^6 cells (and it is preferably 10^5 cells) although the size of the inoculum may be varied above or below this amount depending on the microorganism and the animal.

In a particularly convenient method an inoculum of 10^5 is used containing 1000 cells each of 100 different mutants for a single animal. It will be appreciated that in this method one animal can be used to screen 100 mutants compared to prior art methods which require at least 100 animals to screen 100 mutants.

However, it is convenient to inoculate three animals with the same pool of mutants so that at least two can be investigated (one as a replica to check the reliability of the method), whilst the third is kept as a back-up. Nevertheless, the method still provides a greater than 30-fold saving in the

number of animals used.

The time between the pool of mutants being introduced into the animal and the microorganisms being recovered may vary with the microorganism and animal used. For example, when the animal is a mouse and the microorganism is *Salmonella typhimurium*, the time between inoculation and recovery is about three days.

In one embodiment of the invention microorganisms are retrieved from the environment in step (5) at a site remote from the site of introduction in step (4), so that the virulence genes being investigated include those involved in the spread of the microorganism between the two sites.

For example, in a plant the microorganism may be introduced in a lesion in the stem or at one site on a leaf and the microorganism retrieved from another site on the leaf where a disease state is indicated.

In the case of an animal, the microorganism may be introduced orally, intraperitoneally, intravenously or intranasally and is retrieved at a later time from an internal organ such as the spleen. It may be useful to compare the virulence genes identified by oral administration and those identified by intraperitoneal administration as some genes may be required to establish infection by one route but not by the other. It is preferred if *Salmonella* is introduced intraperitoneally.

Other preferred environments which may be used to identify virulence genes are animal cells in culture (particularly macrophages and epithelial cells) and plant cells in culture. Although using cells in culture will be useful in its own right, it will also complement the use of the whole animal or plant, as the case may be, as the environment.

It is also preferred if the environment is a part of the animal body. Within a given host-parasite interaction, a number of different environments are possible, including different organs and tissues, and parts thereof such as the Peyer's patch.

5

The number of individual microorganisms (ie cells) recovered from the environment should be at least twice, preferably at least ten times, more preferably 100-times the number of different mutants introduced into the environment. For example, when an animal is inoculated with 100
10 different mutants around 10,000 individual microorganisms should be retrieved and their marker DNA isolated.

A further preferred embodiment comprises the steps:

15 (1A) removing auxotrophs from the plurality of mutants produced in step (1); or

(6A) determining whether the mutant selected in step (6) is an auxotroph;
or

20

both (1A) and (6A).

It is desirable to distinguish an auxotroph (that is a mutant microorganism which requires growth factors not needed by the wild type or by
25 prototrophs) and a mutant microorganism wherein a gene allowing the microorganism to adapt to a particular environment is inactivated. Conveniently, this is done between steps (1) and (2) or after step (6).

Preferably auxotrophs are not removed when virulence genes are being
30 identified.

A second aspect of the invention provides a method of identifying a gene which allows a microorganism to adapt to a particular environment, the method comprising the method of the first aspect of the invention, followed by the additional step:

5

(7) isolating the insertionally-inactivated gene or part thereof from the individual mutant selected in step (6).

Methods for isolating a gene containing a unique marker are well known
10 in the art of molecular biology.

A further preferred embodiment comprises the further additional step:

(8) isolating from a wild-type microorganism the corresponding wild-
15 type gene using the insertionally-inactivated gene isolated in step (7) or part thereof as a probe.

Methods for gene probing are well known in the art of molecular biology.

20 Molecular biological methods suitable for use in the practice of the present invention are disclosed in Sambrook *et al* (1989) incorporated herein by reference.

When the microorganism is a microorganism pathogenic to an animal and
25 the gene is a virulence gene and a transposon has been used to insertionally inactivate the gene, it is convenient for the virulence genes to be cloned by digesting genomic DNA from the individual mutant selected in step (6) with a restriction enzyme which cuts outside the transposon, ligating size-fractionated DNA containing the transposon into
30 a plasmid, and selecting plasmid recombinants on the basis of antibiotic

resistance conferred by the transposon and not by the plasmid. The microorganism genomic DNA adjacent to the transposon is sequenced using two primers which anneal to the terminal regions of the transposon, and two primers which anneal close to the polylinker sequences of the plasmid. The sequences may be subjected to DNA database searches to determine if the transposon has interrupted a known virulence gene. Thus, conveniently, sequence obtained by this method is compared against the sequences present in the publicly available databases such as EMBL and GenBank. Finally, if the interrupted sequence appears to be in a new virulence gene, the mutation is transferred to a new genetic background (for example by phage P22-mediated transduction in the case of *Salmonella*) and the LD₅₀ of the mutant strain is determined to confirm that the avirulent phenotype is due to the transposition event and not a secondary mutation.

The number of individual mutants screened in order to detect all of the virulence genes in a microorganism depends on the number of genes in the genome of the microorganism. For example, it is likely that 3000-5000 mutants of *Salmonella typhimurium* need to be screened in order to detect the majority of virulence genes whereas for *Aspergillus* spp., which has a larger genome than *Salmonella*, around 20 000 mutants are screened. Approximately 4% of non-essential *S. typhimurium* genes are thought to be required for virulence (Grossman & Saier, 1990) and, if so, the *S. typhimurium* genome contains approximately 150 virulence genes. However, the methods of the invention provide a faster, more convenient and much more practicable route to identifying virulence genes.

A third aspect of the invention provides a microorganism obtained using the method of the first aspect of the invention.

Such microorganisms are useful because they have the property of not being adapted to survive in a particular environment.

In a preferred embodiment, a pathogenic microorganism is not adapted to survive in a host organism (environment) and, in the case of microorganisms that are pathogenic to animals, particularly mammals, more particularly humans, the mutant obtained by the method of the invention may be used in a vaccine. The mutant is avirulent, and therefore expected to be suitable for administration to a patient, but it is expected to be antigenic and give rise to a protective immune response.

In a further preferred embodiment the pathogenic microorganism not adapted to survive in a host organism, obtained by the methods of the invention, is modified, preferably by the introduction of a suitable DNA sequence, to express an antigenic epitope from another pathogen. This modified microorganism can act as a vaccine for that other pathogen.

A fourth aspect of the invention provides a microorganism comprising a mutation in a gene identified using the method of the second aspect of the invention.

Thus, although the microorganism of the third aspect of the invention is useful, it is preferred if a mutation is specifically introduced into the identified gene. In a preferred embodiment, particularly when the microorganism is to be used in a vaccine, the mutation in the gene is a deletion or a frameshift mutation or any other mutation which is substantially incapable of reverting. Such gene-specific mutations can be made using standard procedures such as introducing into the microorganism a copy of the mutant gene on an autonomous replicon (such as a plasmid or viral genome) and relying on homologous

recombination to introduce the mutation into the copy of the gene in the genome of the microorganism.

- Fifth and sixth aspects of the invention provide a suitable microorganism
 5 for use in a vaccine and a vaccine comprising a suitable microorganism and a pharmaceutically-acceptable carrier.

The suitable microorganism is the aforementioned avirulent mutant.

- 10 Active immunisation of the patient is preferred. In this approach, one or more mutant microorganisms are prepared in an immunogenic formulation containing suitable adjuvants and carriers and administered to the patient in known ways. Suitable adjuvants include Freund's complete or incomplete adjuvant, muramyl dipeptide, the "Iscoms" of EP 109 942, EP
 15 180 564 and EP 231 039, aluminium hydroxide, saponin, DEAE-dextran, neutral oils (such as miglyol), vegetable oils (such as arachis oil), liposomes, Pluronic polyols or the Ribi adjuvant system (see, for example GB-A-2 189 141). "Pluronic" is a Registered Trade Mark. The patient to be immunised is a patient requiring to be protected from the disease
 20 caused by the virulent form of the microorganism.

The aforementioned avirulent microorganisms of the invention or a formulation thereof may be administered by any conventional method including oral and parenteral (eg subcutaneous or intramuscular) injection.

- 25 The treatment may consist of a single dose or a plurality of doses over a period of time.

- Whilst it is possible for an avirulent microorganism of the invention to be administered alone, it is preferable to present it as a pharmaceutical
 30 formulation, together with one or more acceptable carriers. The carrier(s)

must be "acceptable" in the sense of being compatible with the avirulent microorganism of the invention and not deleterious to the recipients thereof. Typically, the carriers will be water or saline which will be sterile and pyrogen free.

5

It will be appreciated that the vaccine of the invention, depending on its microorganism component, may be useful in the fields of human medicine and veterinary medicine.

- 10 Diseases caused by microorganisms are known in many animals, such as domestic animals. The vaccines of the invention, when containing an appropriate avirulent microorganism, particularly avirulent bacterium, are useful in man but also in, for example, cows, sheep, pigs, horses, dogs and cats, and in poultry such as chickens, turkeys, ducks and geese.

15

Seventh and eighth aspects of the invention provide a gene obtained by the method of the second aspect of the invention, and a polypeptide encoded thereby.

- 20 By "gene" we include not only the regions of DNA that code for a polypeptide but also regulatory regions of DNA such as regions of DNA that regulate transcription, translation and, for some microorganisms, splicing of RNA. Thus, the gene includes promoters, transcription terminators, ribosome-binding sequences and for some organisms introns and splice recognition sites.
- 25

Typically, sequence information of the inactivated gene obtained in step 7 is derived. Conveniently, sequences close to the ends of the transposon are used as the hybridisation site of a sequencing primer. The derived

30 sequence or a DNA restriction fragment adjacent to the inactivated gene

itself is used to make a hybridisation probe with which to identify, and isolate from a wild-type organism, the corresponding wild type gene.

It is preferred if the hybridisation probing is done under stringent conditions to ensure that the gene, and not a relative, is obtained. By "stringent" we mean that the gene hybridises to the probe when the gene is immobilised on a membrane and the probe (which, in this case is >200 nucleotides in length) is in solution and the immobilised gene/hybridised probe is washed in 0.1 x SSC at 65°C for 10 min. SSC is 0.15 M NaCl/0.015 M Na citrate.

Preferred probe sequences for cloning *Salmonella* virulence genes are shown in Figures 5 and 6 and described in Example 2.

In a particularly preferred embodiment the *Salmonella* virulence genes comprise the sequence shown in Figures 5 and 6 and described in Example 2.

In further preference the genes are those contained within, or at least part of which is contained within, the sequences shown in Figures 11 and 12 and which have been identified by the method of the second aspect of the invention. The sequences shown in Figures 11 and 12 are part of a gene cluster from *Salmonella typhimurium* which I have called virulence gene cluster 2 (VGC2). The position of transposon insertions are indicated within the sequence, and these transposon insertions inactivate a virulence determinant of the organism. As is discussed more fully below, and in particular in Example 4, when the method of the second aspect of the invention is used to identify virulence genes in *Salmonella typhimurium*, many of the nucleic acid insertions (and therefore genes identified) are clustered in a relatively small part of the genome. This region, VGC2,

contains other virulence genes which, as described below, form part of the invention.

5 The gene isolated by the method of the invention can be expressed in a suitable host cell. Thus, the gene (DNA) may be used in accordance with known techniques, appropriately modified in view of the teachings contained herein, to construct an expression vector, which is then used to transform an appropriate host cell for the expression and production of the polypeptide of the invention. Such techniques include those disclosed in
10 US Patent Nos. 4,440,859 issued 3 April 1984 to Rutter *et al*, 4,530,901 issued 23 July 1985 to Weissman, 4,582,800 issued 15 April 1986 to Crawl, 4,677,063 issued 30 June 1987 to Mark *et al*, 4,678,751 issued 7 July 1987 to Goeddel, 4,704,362 issued 3 November 1987 to Itakura *et al*, 4,710,463 issued 1 December 1987 to Murray, 4,757,006 issued 12 July
15 1988 to Toole, Jr. *et al*, 4,766,075 issued 23 August 1988 to Goeddel *et al* and 4,810,648 issued 7 March 1989 to Stalker, all of which are incorporated herein by reference.

20 The DNA encoding the polypeptide constituting the compound of the invention may be joined to a wide variety of other DNA sequences for introduction into an appropriate host. The companion DNA will depend upon the nature of the host, the manner of the introduction of the DNA into the host, and whether episomal maintenance or integration is desired.

25 Generally, the DNA is inserted into an expression vector, such as a plasmid, in proper orientation and correct reading frame for expression. If necessary, the DNA may be linked to the appropriate transcriptional and translational regulatory control nucleotide sequences recognised by the desired host, although such controls are generally available in the
30 expression vector. The vector is then introduced into the host through

standard techniques. Generally, not all of the hosts will be transformed by the vector. Therefore, it will be necessary to select for transformed host cells. One selection technique involves incorporating into the expression vector a DNA sequence, with any necessary control elements, that codes for a selectable trait in the transformed cell, such as antibiotic resistance. Alternatively, the gene for such selectable trait can be on another vector, which is used to co-transform the desired host cell.

Host cells that have been transformed by the recombinant DNA of the invention are then cultured for a sufficient time and under appropriate conditions known to those skilled in the art in view of the teachings disclosed herein to permit the expression of the polypeptide, which can then be recovered.

Many expression systems are known, including bacteria (for example *E. coli* and *Bacillus subtilis*), yeasts (for example *Saccharomyces cerevisiae*), filamentous fungi (for example *Aspergillus*), plant cells, animal cells and insect cells.

The vectors include a prokaryotic replicon, such as the ColE1 *ori*, for propagation in a prokaryote, even if the vector is to be used for expression in other, non-prokaryotic, cell types. The vectors can also include an appropriate promoter such as a prokaryotic promoter capable of directing the expression (transcription and translation) of the genes in a bacterial host cell, such as *E. coli*, transformed therewith.

A promoter is an expression control element formed by a DNA sequence that permits binding of RNA polymerase and transcription to occur. Promoter sequences compatible with exemplary bacterial hosts are typically provided in plasmid vectors containing convenient restriction sites

for insertion of a DNA segment of the present invention.

Typical prokaryotic vector plasmids are pUC18, pUC19, pBR322 and pBR329 available from Biorad Laboratories, (Richmond, CA, USA) and
5 pTrc99A and pKK223-3 available from Pharmacia, Piscataway, NJ, USA.

A typical mammalian cell vector plasmid is pSVL available from Pharmacia, Piscataway, NJ, USA. This vector uses the SV40 late promoter to drive expression of cloned genes, the highest level of
10 expression being found in T antigen-producing cells, such as COS-1 cells.

An example of an inducible mammalian expression vector is pMSG, also available from Pharmacia. This vector uses the glucocorticoid-inducible promoter of the mouse mammary tumour virus long terminal repeat to
15 drive expression of the cloned gene.

Useful yeast plasmid vectors are pRS403-406 and pRS413-416 and are generally available from Stratagene Cloning Systems, La Jolla, CA 92037, USA. Plasmids pRS403, pRS404, pRS405 and pRS406 are Yeast
20 Integrating plasmids (YIps) and incorporate the yeast selectable markers *HIS3*, *TRP1*, *LEU2* and *URA3*. Plasmids pRS413-416 are Yeast Centromere plasmids (YCps)

A variety of methods have been developed to operably link DNA to
25 vectors via complementary cohesive termini. For instance, complementary homopolymer tracts can be added to the DNA segment to be inserted to the vector DNA. The vector and DNA segment are then joined by hydrogen bonding between the complementary homopolymeric tails to form recombinant DNA molecules.

Synthetic linkers containing one or more restriction sites provide an alternative method of joining the DNA segment to vectors. The DNA segment, generated by endonuclease restriction digestion as described earlier, is treated with bacteriophage T4 DNA polymerase or *E. coli* DNA
5 polymerase I, enzymes that remove protruding, 3'-single-stranded termini with their 3'-5'-exonucleolytic activities, and fill in recessed 3'-ends with their polymerizing activities.

The combination of these activities therefore generates blunt-ended DNA
10 segments. The blunt-ended segments are then incubated with a large molar excess of linker molecules in the presence of an enzyme that is able to catalyze the ligation of blunt-ended DNA molecules, such as bacteriophage T4 DNA ligase. Thus, the products of the reaction are
15 DNA segments carrying polymeric linker sequences at their ends. These DNA segments are then cleaved with the appropriate restriction enzyme and ligated to an expression vector that has been cleaved with an enzyme that produces termini compatible with those of the DNA segment.

Synthetic linkers containing a variety of restriction endonuclease sites are
20 commercially available from a number of sources including International Biotechnologies Inc, New Haven, CN, USA.

A desirable way to modify the DNA encoding the polypeptide of the invention is to use the polymerase chain reaction as disclosed by Saiki *et*
25 *al* (1988) *Science* **239**, 487-491.

In this method the DNA to be enzymatically amplified is flanked by two specific oligonucleotide primers which themselves become incorporated into the amplified DNA. The said specific primers may contain restriction
30 endonuclease recognition sites which can be used for cloning into

expression vectors using methods known in the art.

Variants of the genes also form part of the invention. It is preferred if the variant has at least 70% sequence identity, more preferably at least 85 %
5 sequence identity, most preferably at least 95 % sequence identity with the genes isolated by the method of the invention. Of course, replacements, deletions and insertions may be tolerated. The degree of similarity between one nucleic acid sequence and another can be determined using the GAP program of the University of Wisconsin Computer Group.

10

Similarly, variants of proteins encoded by the genes are included.

By "variants" we include insertions, deletions and substitutions, either conservative or non-conservative, where such changes do not substantially
15 alter the normal function of the protein.

By "conservative substitutions" is intended combinations such as Gly, Ala; Val, Ile, Leu; Asp, Glu; Asn, Gln; Ser, Thr; Lys, Arg; and Phe, Tyr.

20 Such variants may be made using the well known methods of protein engineering and site-directed mutagenesis.

A ninth aspect of the invention provides a method of identifying a compound which reduces the ability of a microorganism to adapt to a
25 particular environment comprising the steps of selecting a compound which interferes with the function of (1) a gene obtained by the method of the second aspect of the invention or of (2) a polypeptide encoded by such a gene.

30 Pairwise screens for compounds which affect the wild type cell but not a

09714602.11600

cell overproducing a gene isolated by the methods of the invention form part of this aspect of the invention.

For example, in one embodiment one cell is a wild type cell and a second
5 cell is the *Salmonella* which is made to overexpress the gene isolated by the method of the invention. The viability and/or growth of each cell in the particular environment is determined in the presence of a compound to be tested to identify which compound reduces the viability or growth of the wild type cell but not the cell overexpressing the said gene.

10

It is preferred if the gene is a virulence gene.

For example, in one embodiment the microorganism (such as *S. typhimurium*) is made to over-express the virulence gene identified by the
15 method of the first aspect of the invention. Each of (a) the "over-expressing" microorganism and (b) an equivalent microorganism (which does not over-express the virulence gene) are used to infect cells in culture. Whether a particular test compound will selectively inhibit the virulence gene function is determined by assessing the amount of the test
20 compound which is required to prevent infection of the host cells by (a) the over-expressing microorganism and (b) the equivalent microorganism (at least for some virulence gene products it is envisaged that the test compound will inactivate them, and itself be inactivated, by binding to the virulence gene product). If more of the compound is required to prevent
25 infection by the (a) than (b) then this suggests that the compound is selective. It is preferred if the microorganisms (such as *Salmonella*) are destroyed extracellularly by a mild antibiotic such as gentamicin (which does not penetrate host cells) and that the effect of the test compound in preventing infection of the cell by the microorganism is by lysing the said
30 cell and determining how many microorganisms are present (for example

by plating on agar).

Pairwise screens and other screens for compounds are generally disclosed in Kirsch & Di Domenico (1993) in "The Discovery of Natural Products with a Therapeutic Potential" (Ed, V.P. Gallo), Chapter 6, pages 177-221, Butterworths, V.K. (incorporated herein by reference).

Pairwise screens can be designed in a number of related formats in which the relative sensitivity to a compound is compared using two genetically related strains. If the strains differ at a single locus, then a compound specific for that target can be identified by comparing each strain's sensitivity to the inhibitor. For example, inhibitors specific to the target will be more active against a super-sensitive test strain when compared to an otherwise isogenic sister strain. In an agar diffusion format, this is determined by measuring the size of the zone of inhibition surrounding the disc or well carrying the compound. Because of diffusion, a continuous concentration gradient of compound is set up, and the strain's sensitivity to inhibitors is proportional to the distance from the disc or well to the edge of the zone. General antimicrobials, or antimicrobials with modes of action other than the desired one are generally observed as having similar activities against the two strains.

Another type of molecular genetic screen, involving pairs of strains where a cloned gene product is overexpressed in one strain compared to a control strain. The rationale behind this type of assay is that the strain containing an elevated quantity of the target protein should be more resistant to inhibitors specific to the cloned gene product than an isogenic strain, containing normal amounts of the target protein. In an agar diffusion assay, the zone size surrounding a specific compound is expected to be smaller in the strain overexpressing the target protein compared to an

otherwise isogenic strain.

Additionally or alternatively selection of a compound is achieved in the following steps:

5

1. A mutant microorganism obtained using the method of the first aspect of the invention is used as a control (it has a given phenotype, for example, avirulence).

10

2. A compound to be tested is mixed with the wild-type microorganism.

3. The wild-type microorganism is introduced into the environment (with or without the test compound).

15

4. If the wild-type microorganism is unable to adapt to the environment (following treatment by, or in the presence of, the compound), the compound is one which reduces the ability of the microorganism to adapt to, or survive in, the particular environment.

20

When the environment is an animal body and the microorganism is a pathogenic microorganism, the compound identified by this method can be used in a medicament to prevent or ameliorate infection with the microorganism.

25

A tenth aspect of the invention therefore provides a compound identifiable by the method of the ninth aspect.

30

It will be appreciated that uses of the compound of the tenth aspect are related to the method by which it can be identified, and in particular in

relation to the host of a pathogenic microorganism. For example, if the compound is identifiable by a method which uses a virulence gene, or polypeptide encoded thereby, from a bacterium which infects a mammal, the compound may be useful in treating infection of a mammal by that bacterium.

Similarly, if the compound is identifiable by a method which uses a virulence gene, or polypeptide encoded thereby, from a fungus which infects a plant, the compound may be useful in treating infection of a plant by that fungus.

An eleventh aspect of the invention provides a molecule which selectively interacts with, and substantially inhibits the function of, a gene of the seventh aspect of the invention or a nucleic acid product thereof.

By "nucleic acid product thereof" we include any RNA, especially mRNA, transcribed from the gene.

Preferably a molecule which selectively interacts with, and substantially inhibits the function of, said gene or said nucleic acid product is an antisense nucleic acid or nucleic acid derivative.

More preferably, said molecule is an antisense oligonucleotide.

Antisense oligonucleotides are single-stranded nucleic acid, which can specifically bind to a complementary nucleic acid sequence. By binding to the appropriate target sequence, an RNA-RNA, a DNA-DNA, or RNA-DNA duplex is formed. These nucleic acids are often termed "antisense" because they are complementary to the sense or coding strand of the gene. Recently, formation of a triple helix has proven possible where the

oligonucleotide is bound to a DNA duplex. It was found that oligonucleotides could recognise sequences in the major groove of the DNA double helix. A triple helix was formed thereby. This suggests that it is possible to synthesise sequence-specific molecules which specifically bind double-stranded DNA via recognition of major groove hydrogen binding sites.

Clearly, the sequence of the antisense nucleic acid or oligonucleotide can readily be determined by reference to the nucleotide sequence of the gene in question. For example, antisense nucleic acid or oligonucleotides can be designed which are complementary to a part of the sequence shown in Figures 11 or 12, especially to sequences which form a part of a virulence gene.

Oligonucleotides are subject to being degraded or inactivated by cellular endogenous nucleases. To counter this problem, it is possible to use modified oligonucleotides, eg having altered internucleotide linkages, in which the naturally occurring phosphodiester linkages have been replaced with another linkage. For example, Agrawal *et al* (1988) *Proc. Natl. Acad. Sci. USA* 85, 7079-7083 showed increased inhibition in tissue culture of HIV-1 using oligonucleotide phosphoramidates and phosphorothioates. Sarin *et al* (1988) *Proc. Natl. Acad. Sci. USA* 85, 7448-7451 demonstrated increased inhibition of HIV-1 using oligonucleotide methylphosphonates. Agrawal *et al* (1989) *Proc. Natl. Acad. Sci. USA* 86, 7790-7794 showed inhibition of HIV-1 replication in both early-infected and chronically infected cell cultures, using nucleotide sequence-specific oligonucleotide phosphorothioates. Leither *et al* (1990) *Proc. Natl. Acad. Sci. USA* 87, 3430-3434 report inhibition in tissue culture of influenza virus replication by oligonucleotide phosphorothioates.

Oligonucleotides having artificial linkages have been shown to be resistant to degradation *in vivo*. For example, Shaw *et al* (1991) in *Nucleic Acids Res.* **19**, 747-750, report that otherwise unmodified oligonucleotides become more resistant to nucleases *in vivo* when they are blocked at the
 5 3' end by certain capping structures and that uncapped oligonucleotide phosphorothioates are not degraded *in vivo*.

A detailed description of the H-phosphonate approach to synthesizing oligonucleoside phosphorothioates is provided in Agrawal and Tang (1990)
 10 *Tetrahedron Letters* **31**, 7541-7544, the teachings of which are hereby incorporated herein by reference. Syntheses of oligonucleoside methylphosphonates, phosphorodithioates, phosphoramidates, phosphate esters, bridged phosphoramidates and bridge phosphorothioates are known in the art. See, for example, Agrawal and Goodchild (1987) *Tetrahedron*
 15 *Letters* **28**, 3539; Nielsen *et al* (1988) *Tetrahedron Letters* **29**, 2911; Jager *et al* (1988) *Biochemistry* **27**, 7237; Uznanski *et al* (1987) *Tetrahedron Letters* **28**, 3401; Bannwarth (1988) *Helv. Chim. Acta.* **71**, 1517; Crosstick and Vyle (1989) *Tetrahedron Letters* **30**, 4693; Agrawal *et al* (1990) *Proc. Natl. Acad. Sci. USA* **87**, 1401-1405, the teachings of which
 20 are incorporated herein by reference. Other methods for synthesis or production also are possible. In a preferred embodiment the oligonucleotide is a deoxyribonucleic acid (DNA), although ribonucleic acid (RNA) sequences may also be synthesized and applied.

25 The oligonucleotides useful in the invention preferably are designed to resist degradation by endogenous nucleolytic enzymes. *In - vivo* degradation of oligonucleotides produces oligonucleotide breakdown products of reduced length. Such breakdown products are more likely to engage in non-specific hybridization and are less likely to be effective,
 30 relative to their full-length counterparts. Thus, it is desirable to use

oligonucleotides that are resistant to degradation in the body and which are able to reach the targeted cells. The present oligonucleotides can be rendered more resistant to degradation *in vivo* by substituting one or more internal artificial internucleotide linkages for the native phosphodiester linkages, for example, by replacing phosphate with sulphur in the linkage. Examples of linkages that may be used include phosphorothioates, methylphosphonates, sulphone, sulphate, ketyl, phosphorodithioates, various phosphoramidates, phosphate esters, bridged phosphorothioates and bridged phosphoramidates. Such examples are illustrative, rather than limiting, since other internucleotide linkages are known in the art. See, for example, Cohen, (1990) *Trends in Biotechnology*. The synthesis of oligonucleotides having one or more of these linkages substituted for the phosphodiester internucleotide linkages is well known in the art, including synthetic pathways for producing oligonucleotides having mixed internucleotide linkages.

Oligonucleotides can be made resistant to extension by endogenous enzymes by "capping" or incorporating similar groups on the 5' or 3' terminal nucleotides. A reagent for capping is commercially available as Amino-Link II™ from Applied BioSystems Inc, Foster City, CA. Methods for capping are described, for example, by Shaw *et al* (1991) *Nucleic Acids Res.* 19, 747-750 and Agrawal *et al* (1991) *Proc. Natl. Acad. Sci. USA* 88(17), 7595-7599, the teachings of which are hereby incorporated herein by reference.

A further method of making oligonucleotides resistant to nuclease attack is for them to be "self-stabilized" as described by Tang *et al* (1993) *Nucl. Acids Res.* 21, 2729-2735 incorporated herein by reference. Self-stabilized oligonucleotides have hairpin loop structures at their 3' ends, and show increased resistance to degradation by snake venom

phosphodiesterase, DNA polymerase I and fetal bovine serum. The self-stabilized region of the oligonucleotide does not interfere in hybridization with complementary nucleic acids, and pharmacokinetic and stability studies in mice have shown increased *in vivo* persistence of self-stabilized oligonucleotides with respect to their linear counterparts.

In accordance with the invention, the inherent binding specificity of antisense oligonucleotides characteristic of base pairing is enhanced by limiting the availability of the antisense compound to its intend locus *in vivo*, permitting lower dosages to be used and minimizing systemic effects. Thus, oligonucleotides are applied locally to achieve the desired effect. The concentration of the oligonucleotides at the desired locus is much higher than if the oligonucleotides were administered systemically, and the therapeutic effect can be achieved using a significantly lower total amount. The local high concentration of oligonucleotides enhances penetration of the targeted cells and effectively blocks translation of the target nucleic acid sequences.

The oligonucleotides can be delivered to the locus by any means appropriate for localized administration of a drug. For example, a solution of the oligonucleotides can be injected directly to the site or can be delivered by infusion using an infusion pump. The oligonucleotides also can be incorporated into an implantable device which when placed at the desired site, permits the oligonucleotides to be released into the surrounding locus.

The oligonucleotides are most preferably administered via a hydrogel material. The hydrogel is noninflammatory and biodegradable. Many such materials now are known, including those made from natural and synthetic polymers. In a preferred embodiment, the method exploits a

hydrogel which is liquid below body temperature but gels to form a shape-retaining semisolid hydrogel at or near body temperature. Preferred hydrogel are polymers of ethylene oxide-propylene oxide repeating units. The properties of the polymer are dependent on the molecular weight of the polymer and the relative percentage of polyethylene oxide and polypropylene oxide in the polymer. Preferred hydrogels contain from about 10 to about 80% by weight ethylene oxide and from about 20 to about 90% by weight propylene oxide. A particularly preferred hydrogel contains about 70% polyethylene oxide and 30% polypropylene oxide. Hydrogels which can be used are available, for example, from BASF Corp., Parsippany, NJ, under the tradename Pluronic^R.

In this embodiment, the hydrogel is cooled to a liquid state and the oligonucleotides are admixed into the liquid to a concentration of about 1 mg oligonucleotide per gram of hydrogel. The resulting mixture then is applied onto the surface to be treated, for example by spraying or painting during surgery or using a catheter or endoscopic procedures. As the polymer warms, it solidifies to form a gel, and the oligonucleotides diffuse out of the gel into the surrounding cells over a period of time defined by the exact composition of the gel.

The oligonucleotides can be administered by means of other implants that are commercially available or described in the scientific literature, including liposomes, microcapsules and implantable devices. For example, implants made of biodegradable materials such as polyanhydrides, polyorthoesters, polylactic acid and polyglycolic acid and copolymers thereof, collagen, and protein polymers, or non-biodegradable materials such as ethylenevinyl acetate (EVAc), polyvinyl acetate, ethylene vinyl alcohol, and derivatives thereof can be used to locally deliver the oligonucleotides. The oligonucleotides can be incorporated into the

material as it is polymerized or solidified, using melt or solvent evaporation techniques, or mechanically mixed with the material. In one embodiment, the oligonucleotides are mixed into or applied onto coatings for implantable devices such as dextran coated silica beads, stents, or catheters.

The dose of oligonucleotides is dependent on the size of the oligonucleotides and the purpose for which is it administered. In general, the range is calculated based on the surface area of tissue to be treated.

10 The effective dose of oligonucleotide is somewhat dependent on the length and chemical composition of the oligonucleotide but is generally in the range of about 30 to 3000 μg per square centimetre of tissue surface area.

The oligonucleotides may be administered to the patient systemically for both therapeutic and prophylactic purposes. The oligonucleotides may be administered by any effective method, for example, parenterally (eg intravenously, subcutaneously, intramuscularly) or by oral, nasal or other means which permit the oligonucleotides to access and circulate in the patient's bloodstream. Oligonucleotides administered systemically

15 preferably are given in addition to locally administered oligonucleotides, but also have utility in the absence of local administration. A dosage in the range of from about 0.1 to about 10 grams per administration to an adult human generally will be effective for this purpose.

20

25 It will be appreciated that the molecules of this aspect of the invention are useful in treating or preventing any infection caused by the microorganism from which the said gene has been isolated, or a close relative of said microorganism. Thus, the said molecule is an antibiotic.

30 Thus, a twelfth aspect of the invention provides a molecule of the eleventh

aspect of the invention for use in medicine.

A thirteenth aspect of the invention provides a method of treating a host which has, or is susceptible to, an infection with a microorganism, the
5 method comprising administering an effective amount of a molecule according to the eleventh aspect of the invention wherein said gene is present in said microorganisms, or a close relative of said microorganism.

By "effective amount" we mean an amount which substantially prevents
10 or ameliorates the infection. By "host" we include any animal or plant which may be infected by a microorganism.

It will be appreciated that pharmaceutical formulations of the molecule of the eleventh aspect of the invention form part of the invention. Such
15 pharmaceutical formulations comprise the said molecule together with one or more acceptable carriers. The carrier(s) must be "acceptable" in the sense of being compatible with the said molecule of the invention and not deleterious to the recipients thereof. Typically, the carriers will be water or saline which will be sterile and pyrogen free.

20 As mentioned above, and as described in more detail in Example 4 below, I have found that certain virulence genes are clustered in *Salmonella typhimurium* in a region of the chromosome that I have called VGC2. DNA-DNA hybridisation experiments have determined that sequences
25 homologous to at least part of VGC2 are found in many species and strains of *Salmonella* but are not present in the *E. coli* and *Shigella* strains tested (see Example 4). These sequences almost certainly correspond to conserved genes, at least in *Salmonella*, and at least some of which are virulence genes. It is believed that equivalent genes in other *Salmonella*
30 species and, if present, equivalent genes in other enteric or other bacteria

will also be virulence genes.

Whether a gene within the VGC2 region is a virulence gene is readily determined. For example, those genes within VGC2 which have been
 5 identified by the method of the second aspect of the invention (when applied to *Salmonella typhimurium* and wherein the environment is an animal such as a mouse) are virulence genes. Virulence genes are also identified by making a mutation in the gene (preferably a non-polar mutation) and determining whether the mutant strain is avirulent.
 10 Methods of making mutations in a selected gene are well known and are described below.

A fourteenth aspect of the invention provides the VGC2 DNA of *Salmonella typhimurium* or a part thereof, or a variant of said DNA or a
 15 variant of a part thereof.

The VGC2 DNA of *Salmonella typhimurium* is depicted diagrammatically in Figure 8 and is readily obtainable from *Salmonella typhimurium* ATCC 14028 (available from the American Type Culture Collection, 12301
 20 Parklawn Drive, Rockville, Maryland 20852, USA; also deposited at the NCTC, Public Health Laboratory Service, Colindale, UK under accession no. NCTC 12021) using the information provided in Example 4. For example, probes derived from the sequences shown in Figures 11 and 12 may be used to identify λ clones from a *Salmonella typhimurium* genomic
 25 library. Standard genome walking methods can be employed to obtain all of the VGC2 DNA. The restriction map shown in Figure 8 can be used to identify and locate DNA fragments from VGC2.

By "part of the VGC2 DNA of *Salmonella typhimurium*" we mean any
 30 DNA sequence which comprises at least 10 nucleotides, preferably at least

20 nucleotides, more preferably at least 50 nucleotides, still more preferably at least 100 nucleotides, and most preferably at least 500 nucleotides of VGC2. A particularly preferred part of the VGC2 DNA is the sequence shown in Figure 11, or a part thereof. Another
 5 particularly preferred part of the VGC2 DNA is the sequence shown in Figure 12, or a part thereof.

Advantageously, the part of the VGC2 DNA is a gene, or part thereof.

- 10 Genes can be identified within the-VGC2 region by statistical analysis of the open reading frames using computer programs known in the art. If an open reading frame is greater than about 100 codons it is likely to be a gene (although genes smaller than this are known). Whether an open reading frame corresponds to the polypeptide coding region of a gene can
 15 be determined experimentally. For example, a part of the DNA corresponding to the open reading frame may be used as a probe in a northern (RNA) blot to determine whether mRNA is expressed which hybridises to the said DNA; alternatively or additionally a mutation may be introduced into the open reading frame and the effect of the mutation
 20 on the phenotype of the microorganism can be determined. If the phenotype is changed then the open reading frame corresponds to a gene. Methods of identifying genes within a DNA sequence are known in the art.
- 25 By "variant of said DNA or a variant of a part thereof" we include any variant as defined by the term "variant" in the seventh aspect of the invention.

Thus, variants of VGC2 DNA of *Salmonella typhimurium* include
 30 equivalent genes, or parts thereof, from other *Salmonella* species, such as

Salmonella typhi and *Salmonella enterica*, as well as equivalent genes, or parts thereof, from other bacteria such as other enteric bacteria.

By "equivalent gene" we include genes which are functionally equivalent and those in which a mutation leads to a similar phenotype (such as avirulence). It will be appreciated that before the present invention VGC2 or the genes contained therein had not been identified and certainly not implicated in virulence determination.

Thus, further aspects of the invention provide a mutant bacterium wherein if the bacterium normally contains a gene that is the same as or equivalent to a gene in VGC2, said gene is mutated or absent in said mutant bacterium; methods of making a mutant bacterium wherein if the bacterium normally contains a gene that is the same as or equivalent to a gene in VGC2, said gene is mutated or absent in said mutant bacterium.

The following is a preferred method to inactivate a VGC2 gene. One first subclones the gene on a DNA fragment from a *Salmonella* λ DNA library or other DNA library using a fragment of VGC2 as a probe in hybridisation experiments, and map the gene with respect to restriction enzyme sites and characterise the gene by DNA sequencing in *Escherichia coli*. Using restriction enzymes, one then introduces into the coding region of the gene a segment of DNA encoding resistance to an antibiotic (for example, kanamycin), possibly after deleting a portion of the coding region of the cloned gene by restriction enzymes. Methods and DNA constructs containing an antibiotic resistance marker are available to ensure that the inactivation of the gene of interest is preferably non-polar, that is to say, does not affect the expression of genes downstream from the gene of interest. The mutant version of the gene is then transferred from *E. coli* to *Salmonella typhimurium* using phage P22 transduction and transductants checked by Southern hybridisation for homologous

recombination of the mutant gene into the chromosome.

This approach is commonly used in *Salmonella* (and can be used in *S. typhi*), and further details can be found in many papers, including Galan
5 *et al* (1992) 174, 4338-4349.

Still further aspects provide a use of said mutant mutant bacterium in a vaccine; pharmaceutical compositions comprising said bacterium and a pharmaceutically acceptable carrier; a polypeptide encoded by VGC2
10 DNA of *Salmonella typhimurium* or a part thereof, or a variant of a part thereof; a method of identifying a compound which reduces the ability of a bacterium to infect or cause disease in a host; a compound identifiable by said method; a molecule which selectively interacts with, and substantially inhibits the function of, a gene in VGC2 or a nucleic product
15 thereof; and medical uses and pharmaceutical compositions thereof.

The VGC2 DNA contains genes which have been identified by the methods of the first and second aspects of the invention as well as genes which have been identified by their location (although identifiable by the
20 methods of the first and second aspects of the invention). These further aspects of the invention relate closely to the fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth and thirteenth aspects of the invention and, accordingly, the information given in relation to those aspects, and preferences expressed in relation to those aspects, applies to
25 these further aspects.

It is preferred if the gene is from VGC2 or is an equivalent gene from another species of *Salmonella* such as *S. typhi*. It is preferred if the mutant bacterium is a *S. typhimurium* mutant or a mutant of another
30 species of *Salmonella* such as *S. typhi*.

It is believed that at least some of the genes in VGC2 confer the ability for the bacterium, such as *S. typhimurium*, to enter cells.

The invention will now be described with reference to the following
5 Examples and Figures wherein:

Figure 1 illustrates diagrammatically one particularly preferred method of the invention.

10 Figure 2 shows a Southern hybridisation analysis of DNA from 12 *S. typhimurium* exconjugants following digestion with *EcoRV*. The filter was probed with the kanamycin resistance gene of the mini-Tn5 transposon.

Figure 3 shows a colony blot hybridisation analysis of DNA from 48 *S.*
15 *typhimurium* exconjugants from a half of a microtitre dish (A1-H6). The filter was hybridised with a probe comprising labelled amplified tags from DNA isolated from a pool of the first 24 colonies (A1-D6).

Figure 4 shows a DNA colony blot hybridisation analysis of 95 *S.*
20 *typhimurium* exconjugants of a microtitre dish (A1-H11), which were injected into a mouse. Replicate filters were hybridised with labelled amplified tags from the pool (inoculum pattern), or with labelled amplified tags from DNA isolated from over 10,000 pooled colonies that were recovered from the spleen of the infected animal (spleen pattern).
25 Colonies B6, A11 and C8 gave rise to weak hybridisation signals on both sets of filters. Hybridisation signals from colonies A3, C5, G3 (*aroA*), and F10 are present on the inoculum pattern but not on the spleen pattern.

Figure 5 shows the sequence of a *Salmonella* gene isolated using the
30 method of the invention and a comparison to the *Escherichia coli* *clp*

protease genome.

Figure 6 shows partial sequences of further *Salmonella* gene isolated using the method of the invention (SEQ ID Nos. 8 to 36).

5

Figure 7 shows the mapping of VGC2 on the *S. typhimurium* chromosome. (A) DNA probes from three regions of VGC2 were used in Southern hybridisation analysis of lysates from a set of *S. typhimurium* strains harbouring locked in Mud-P22 prophages. Lysates which
 10 hybridised to a 7.5 kb *Pst*I fragment (probe A in Figure 8) are shown. The other two probes used hybridised to the same lysates. (B) The insertion points and packaging directions of the phage are shown along with the map position in minutes (edition VIII, ref 22 in Example 4). The phage designations correspond to the following strains: 18P, TT15242;
 15 18Q, 15241; 19P, TT15244; 19Q, TT15243; 20P, TT15246 and 20Q, TT15245 (Ref in Example 4). The locations of mapped genes are shown by horizontal bars and the approximate locations of other genes are indicated.

20 Figure 8 shows a physical and genetic map of VGC2. (A) The positions of 16 transposon insertions are shown above the line. The extent of VGC2 is indicated by the thicker line. The position and direction of transcription of ORFs described in the text of Example 4 are shown by arrows below the line, together with the names of similar genes, with the
 25 exception of ORFs 12 and 13 whose products are similar to the sensor and regulatory components respectively, of a variety of two component regulatory systems. (B) The location of overlapping clones and an *Eco*RI/*Xba*I restriction fragment from Mud-P22 prophage strain TT15244 are shown as filled bars. Only the portions of the λ clones which have
 30 been mapped are shown and the clones may extend beyond these limits.

(C) The positions of restriction sites are marked: B, *Bam*HI; E, *Eco*RI; V, *Eco*RV; H, *Hind*III; P, *Pst*I and X, *Xba*I. The positions of the 7.5 kb *Pst*I fragment (probe A) used as a probe in Figure 7 and that of the 2.2 kb *Pst*I/*Hind*III fragment (probe B) used as a probe in Figure 10 are shown below the restriction map. The positions of Sequence 1 (described in Figure 11) and Sequence 2 (described in Figure 12) are shown by the thin arrows (labelled Sequence 1 and Sequence 2).

Figure 9 describes mapping the boundaries of VGC2. (A) The positions of mapped genes at minutes 37 to 38 on the *E. coli* K12 chromosome are aligned with the corresponding region of the *S. typhimurium* LT2 chromosome (minutes 30 to 31). An expanded map of the VGC2 region is shown with 11 *S. typhimurium* (*S. t.*) DNA fragments used as probes (thick bars) and the restriction sites used to generate them: B, *Bam*HI; C, *Cla*I; H, *Hind*II; K, *Kpn*I; P, *Pst*I; N, *Nsi*I and S, *Sal*I. Probes that hybridised to *E. coli* K12 (*E. c.*) genomic DNA are indicated by +; those which failed to hybridise are indicated by -.

Figure 10 shows that VGC2 is conserved among and specific to the *Salmonellae*. Genomic DNA from *Salmonella* serovars and other pathogenic bacteria was restricted with *Pst*I (A), *Hind*III or *Eco*RV (B) and subjected to Southern hybridisation analysis, using a 2.2 kb *Pst*I/*Hind*III fragment from λ clone 7 as a probe (probe B Figure 2). The filters were hybridised and washed under stringent (A) or non-stringent (B) conditions.

Figure 11 shows the DNA sequence of "Sequence 1" of VGC2 from the centre to the left-hand end (see the arrow labelled Sequence 1 in Figure 2). The DNA is translated in all six reading frames and the start and stop positions of putative genes, and the transposon insertion positions for

various mutants identified by STM are indicated (SEQ ID No 37).

As is conventional a * indicates a stop codon and standard nucleotide ambiguity codes are used where necessary.

5

Figure 12 shows the DNA sequence of "Sequence 2" of VGC2 (cluster C) (see the arrow labelled Sequence 2 in Figure 2). The DNA is translated in all six reading frames and the start and stop positions of putative genes, and the transposon insertion positions for various mutants identified by STM are indicated (SEQ ID No 38).

10

As is conventional a * indicates a stop codon and standard nucleotide ambiguity codes are used where necessary.

15 Figures 7 to 12 are most relevant to Example 4.

Example 1: Identification of virulence genes in *Salmonella typhimurium*

20 **Materials and Methods**

Bacterial Strains and Plasmids

Salmonella typhimurium strain 12023 (equivalent to American Type Culture Collection (ATCC) strain 14028) was obtained from the National Collection of Type Cultures (NCTC), Public Health Laboratory Service, Colindale, London, UK. A spontaneous nalidixic acid resistant mutant of this strain (12023 Nal^r) was selected in our laboratory. Another derivative of strain 12023, CL1509 (*aroA::Tn10*) was a gift from Fred Heffron.

25 *Escherichia coli* strains CC118 λ pir (Δ [*ara-leu*], *araD*, Δ *lacX74*, *galE*,

30

galK, *phoA20*, *thi-1*, *rpsE*, *rpoB*, *argE*(Am), *recA1*, λ *pir* phage lysogen) and S17-1 λ *pir* (Tp^r , Sm^r , *recA*, *thi*, *pro*, *hsdR* $\cdot M^+$, RP4:2-Tc:Mu:KmTn7, λ *pir*) were gifts from Kenneth Timmis. *E. coli* DH5 α was used for propagating pUC18 (Gibco-BRL) and Bluescript (Stratagene) plasmids containing *S. typhimurium* DNA. Plasmid pUTmini-Tn5Km2 (de Lorenzo *et al*, 1990) was a gift from Kenneth Timmis.

Construction of semi-random sequence tags and ligations

10 The oligonucleotide pool RT1(5'-CTAGGTACCTACAACCTCAAGCTT-[NK]₂₀-AAGCTTGGTTAGAATGGGTACCATG-3') (SEQ ID No 1), and primers P2 (5'-TACCTACAACCTCAAGCT-3') (SEQ ID No 2), P3 (5'-CATGGTACCCATTCTAAC-3') (SEQ ID No 3), P4 (5'-TACCCATTCTAACCAAGC-3') (SEQ ID No 4) and P5 (5'-CTAGGTACCTACAACCTC-3') (SEQ ID No 5) were synthesized on a
15 oligonucleotide synthesizer (Applied Biosystems, model 380B). Double stranded DNA tags were prepared from RT1 in a 100 μ l volume PCR containing 1.5 mM MgCl₂, 50 mM KCl, and 10 mM Tris-Cl (pH 8.0) with 200 pg of RT1 as target; 250 μ M each dATP, dCTP, dGTP, dTTP; 100 pM of
20 primers P3 and P5; and 2.5 U of Amplitaq (Perkin-Elmer Cetus). Thermal cycling conditions were 30 cycles of 95°C for 30 s, 50°C for 45 s, and 72°C for 10 s. The PCR product was gel purified (Sambrook *et al*, 1989), passed through an elutipD column (available from Schleicher and Schull) and digested with *Kpn*I prior to ligation into pUC18 or pUTmini-Tn5Km2. For ligations,
25 plasmids were digested with *Kpn*I and dephosphorylated with calf intestinal alkaline phosphatase (Gibco-BRL). Linearized plasmid molecules were gel-purified (Sambrook *et al*, 1989) prior to ligation to remove any residual uncut plasmid DNA from the digestion. Ligation reactions contained approximately 50 ng each of plasmid and double stranded tag DNA in a 25 μ l volume with 1
30 unit T4 DNA ligase (Gibco-BRL) in a buffer supplied with the enzyme.

Ligations were carried out for 2 h at 24°C. To determine the proportion of bacterial colonies arising from either self ligation of the plasmid DNA or uncut plasmid DNA, a control reaction was carried out in which the double stranded tag DNA was omitted from the ligation reaction. This yielded no ampicillin resistant bacterial colonies following transformation of *E. coli* CC118 (Sambrook *et al*, 1989), compared with 185 colonies arising from a ligation reaction containing the double stranded tag DNA.

Bacterial Transformation and Matings

The products of several ligations between pUT mini-Tn5Km2 and the double stranded tag DNA were used to transform *E. coli* CC118 (Sambrook *et al*, 1989). A total of approximately 10,300 transformants were pooled and plasmid DNA extracted from the pool was used to transform *E. coli* S-17 λ pir (de Lorenzo & Timmis, 1994). For mating experiments, a pool of approximately 40,000 ampicillin resistant *E. coli* S-17 λ pir transformants, and *S. typhimurium* 12023 Nal^r were cultured separately to an optical density (OD)₅₈₀ of 1.0. Aliquots of each culture (0.4 ml) were mixed in 5 ml 10 mM MgSO₄, and filtered through a Millipore membrane (0.45 μ m diameter). The filters were placed on the surface of agar containing M9 salts (de Lorenzo & Timmis, 1994) and incubated at 37°C for 16 h. The bacteria were recovered by shaking the filters in liquid LB medium for 40 min at 37°C and exconjugants were selected by plating the suspension onto LB medium containing 100 μ g ml⁻¹ nalidixic acid (to select against the donor strain) and 50 μ g ml⁻¹ kanamycin (to select for the recipient strain). Each exconjugant was checked by transferring nalidixic acid resistant (nal^r), kanamycin resistant (kan^r) colonies to MacConkey Lactose indicator medium (to distinguish between *E. coli* and *S. typhimurium*), and to LB medium containing ampicillin. Approximately 90% of the nal^r, kan^r colonies were sensitive to ampicillin, indicating that these resulted from authentic

transposition events (de Lorenzo & Timmis, 1994). Individual ampicillin-sensitive exconjugants were stored in 96 well microtitre dishes containing LB medium. For long term storage at -80°C , either 7% DMSO or 15% glycerol was included in the medium.

5

Phenotypic characterisation of mutants

Mutants were replica plated from microtitre dishes onto solid medium containing M9 salts and 0.4% glucose (Sambrook *et al*, 1989) to identify
10 auxotrophs. Mutants with rough colony morphology were detected by low magnification microscopy of colonies on agar plates.

Colony Blots, DNA extractions, PCRs, DNA labelings and hybridisations

15 For colony blot hybridizations, a 48-well metal replicator (Sigma) was used to transfer exconjugants from microtitre dishes to Hybond N nylon filters (Amersham, UK) that had been placed on the surface of LB agar containing $50\text{ }\mu\text{g ml}^{-1}$ kanamycin. After overnight incubation at 37°C , the filters supporting the bacterial colonies were removed and dried at room
20 temperature for 10 min. The bacteria were lysed with 0.4 N NaOH and the filters washed with 0.5 N Tris-Cl pH 7.0 according to the filter manufacturer's instructions. The bacterial DNA was fixed to the filters by exposure to UV light from a Stratalinker (Stratagene). Hybridisations to ^{32}P -labelled probes were carried out under stringent conditions as previously
25 described (Holden *et al*, 1989). For DNA extractions, *S. typhimurium* transposon mutant strains were grown in liquid LB medium in microtitre dishes or resuspended in LB medium following growth on solid media. Total DNA was prepared by the hexadecyltrimethylammoniumbromide (CTAB) method according to Ausubel *et al* (1987). Briefly, cells from 150
30 to 1000 μl volumes were precipitated by centrifugation and resuspended in

- 576 μl TE. To this was added 15 μl of 20% SDS and 3 μl of 20 mg ml^{-1} proteinase K. After incubating at 37°C for 1 hour, 166 μl of 3 M NaCl was added and mixed thoroughly, followed by 80 μl of 10% (w/v) CTAB and 0.7 M NaCl. After thorough mixing, the solution was incubated at
- 5 65°C for 10 min. Following extraction with phenol and phenol-chloroform, the DNA was precipitated by addition of isopropanol, washed with 70% ethanol and resuspended in TE at a concentration of approximately 1 μg μl^{-1} .
- 10 The DNA samples were subjected to two rounds of PCR to generate labelled probes. The first PCR was performed in 100 μl reactions containing 20 mM Tris-Cl pH 8.3; 50 mM KCl; 2 mM MgCl_2 ; 0.01% Tween 80; 200 μM each dATP, dCTP, dGTP, dTTP; 2.5 units of Amplitaq polymerase (Perkin-Elmer Cetus); 770 ng each primer P2 and P4; and 5 μg
- 15 target DNA. After an initial denaturation of 4 min at 95°C, thermal cycling consisted of 20 cycles of 45 s at 50°C, 10 s at 72°C, and 30 s at 95°C. PCR products were extracted with chloroform/isoamyl alcohol (24/1) and precipitated with ethanol. DNA was resuspended in 10 μl TE and the PCR products were purified by electrophoresis through a 1.6% Seaplaque (FMC
- 20 Bioproducts) gel in TAE buffer. Gel slices containing fragments of about 80 bp were excised and used for the second PCR. This reaction was carried out in a 20 μl total volume, and contained 20 mM Tris-Cl pH 8.3; 50 mM KCl; 2 mM MgCl_2 ; 0.01% Tween 80; 50 μM each dATP, dTTP, dGTP; 10 μl ^{32}P -dCTP (3000 Ci/mmol, Amersham); 150 ng each primer P2
- 25 and P4; approximately 10 ng of target DNA (1-2 μl of 1.6% Seaplaque agarose containing the first round PCR product); 0.5 units of Amplitaq polymerase. The reaction was overlaid with 20 μl mineral oil and thermal cycling was performed as described above. Incorporation of the radioactive label was quantitated by absorbance to Whatman DE81 paper (Sambrook *et*
- 30 *al.*, 1989).

Infection Studies

- Individual *Salmonella* exconjugants containing tagged transposons were grown in 2% tryptone, 1% yeast extract, 0.92% v/v glycerol, 0.5% Na₂PO₄, 1% KNO₃ (TYGPN medium) (Ausubel *et al*, 1987) in microtitre plates overnight at 37°C. A metal replicator was used to transfer a small volume of the overnight cultures to a fresh microtitre plate and the cultures were incubated at 37°C until the OD₅₈₀ (measured using a Titertek Multiscan microtitre plate reader) was approximately 0.2 in each well.
- Cultures from individual wells were then pooled and the OD₅₅₀ determined using a spectrophotometer. The culture was diluted in sterile saline to approximately 5x10⁵ cfu ml⁻¹. Further dilutions were plated out onto TYGPN containing nalidixic acid (100 mg ml⁻¹) and kanamycin (50 mg ml⁻¹) to confirm the cfu present in the inoculum.
- Groups of three female BALB/c mice (20-25g) were injected intraperitoneally with 0.2 ml of bacterial suspension containing approximately 1x10⁵ cfu ml⁻¹. Mice were sacrificed three days post-inoculation and their spleens were removed to recover bacteria. Half of each spleen was homogenized in 1 ml of sterile saline in a microfuge tube. Cellular debris was allowed to settle and 1 ml of saline containing cells still in suspension was removed to a fresh tube and centrifuged for two minutes in a microfuge. The supernatant was aspirated and the pellet resuspended in 1 ml of sterile distilled water. A dilution series was made in sterile distilled water and 100 µl of each dilution was plated onto TYGPN agar containing nalidixic acid (100 µg ml⁻¹) and kanamycin (50 µg ml⁻¹). Bacteria were recovered from plates containing between 1000 and 4000 colonies, and a total of over 10,000 colonies recovered from each spleen were pooled and used to prepare DNA for PCR generation of probes to screen colony blots.

Virulence gene cloning and DNA sequencing

Total DNA was isolated from *S. typhimurium* exconjugants and digested separately with *Sst*I, *Sal*I, *Pst*I and *Sph*I. Digests were fractionated through agarose gels, transferred to Hybond N⁺ membranes (Amersham) and subjected to Southern hybridisation analysis using the kanamycin resistance gene of pUT mini-Tn5Km2 as a probe. The probe was labelled with digoxigenin (Boehringer-Mannheim) and chemiluminescence detection was carried out according to the manufacturer's instructions. The hybridisation and washing conditions were as described above. Restriction enzymes which gave rise to hybridising fragments in the 3-5 kb range were used to digest DNA for a preparative agarose gel, and DNA fragments corresponding to the sizes of the hybridisation signals were excised from this, purified and ligated into pUC18. Ligation reactions were used to transform *E. coli* DH5a to kanamycin resistance. Plasmids from kanamycin-resistant transformants were purified by passage through an elutipD column and checked by restriction enzyme digestion. Plasmid inserts were partially sequenced by the di-deoxy method (Sanger *et al*, 1977) using the -40 primer and reverse sequencing primer (United States Biochemical Corporation) and the primers P6 (5'-CCTAGGCGGCCAGATCTGAT-3') (SEQ ID No 6) and P7 (5'GCACTTGTGTATAAGAGTCAG-3') (SEQ ID No 7) which anneal to the I and O termini of Tn5, respectively. Nucleotide sequences and deduced amino acid sequences were assembled using the Macvector 3.5 software package run on a Macintosh SE/30 computer. Sequences were compared with the EMBL and Genbank DNA databases using the UNIX/SUN computer system at the Human Genome Mapping Project Resource Centre, Harrow, UK.

Results

Tag Design

- 5 The structure of the DNA tags is shown in Figure 1a. Each tag consists of a variable central region flanked by “arms”, of invariant sequence. The central region sequence $([NK]_{20})$ was designed to prevent the occurrence of sites for the commonly used 6 bp-recognition restriction enzymes, but is sufficiently variable to ensure that statistically, the same sequence should
- 10 only occur once in 2×10^{11} molecules (DNA sequencing of 12 randomly selected tags showed that none shared more than 50% identity over the variable region). (N means any base (A, G, C or T) and K means G or T.) The arms contain *KpnI* sites close to the ends to facilitate the initial cloning step, and the *HindIII* sites bordering the variable region were used to release
- 15 radiolabelled variable regions from the arms prior to hybridisation analysis. The arms were also designed such that primers P2 and P4 each contain only one guanine residue. Therefore during a PCR using these primers, only one cytosine will be incorporated into each newly synthesised arm, compared to an average of ten in the unique sequence. When radiolabelled dCTP is
- 20 included in the PCR, an average of ten-fold more label will be present in the unique sequence compared with each arm. This is intended to minimise background hybridisation signals from the arms, after they have been released from the unique sequences by digestion with *HindIII*. Double stranded tags were ligated into the *KpnI* site of the mini-Tn5 transposon
- 25 Km2, carried on plasmid pUT (de Lorenzo & Timmis, 1994). Replication of this plasmid is dependent on the R6K-specified π product of the *pir* gene. It carries the *oriT* sequence of the RP4 plasmid, permitting transfer to a variety of bacterial species (Miller & Mekalanos, 1988), and the *tnp** gene needed for transposition of the mini-Tn5 element. The tagged mini-Tn5
- 30 transposons were transferred to *S. typhimurium* by conjugation, and 288

exconjugants resulting from transposition events were stored in the wells of microtitre dishes. Total DNA isolated from 12 of these was digested with *EcoRV*, and subjected to Southern hybridisation analysis using the kanamycin resistance gene of the mini-Tn5 transposon as a probe. In each case, the exconjugant had arisen as a result a single integration of the transposon into a different site of the bacterial genome (Figure 2).

Specificity and sensitivity studies

We next determined the efficiency and uniformity of amplification of the DNA tags in PCRs involving pools of exconjugant DNAs as targets for the reactions. In an attempt to minimise unequal amplification of tags in the PCR, we determined the maximum quantity of DNA target that could be used in a 100 μ l reaction, and the minimum number of PCR cycles, that resulted in products which could be visualised by ethidium bromide staining of an agarose gel (5 μ g DNA and 20 cycles, respectively).

S. typhimurium exconjugants which had reached stationary growth phase in microtitre dishes were combined, and used to extract DNA. This was subjected to a PCR using primers P2 and P4. PCR products of 80 bp were gel-purified and used as targets for a second PCR, using the same primers but with 32 P-labelled CTP. This resulted in over 60% of the radiolabelled dCTP being incorporated into the PCR products. The radiolabelled products were digested with *HindIII* and used to probe colony blotted DNA from their corresponding microtitre dishes. Of the 1510 mutants tested in this way, 358 failed to yield a clear signal on an autoradiogram following an overnight exposure of the colony blot. There are three potential explanations for this. Firstly, it is possible that a proportion of the transposons did not carry tags. However, by comparing the transformation frequencies resulting from ligation reactions involving the transposon in the

presence or absence of tags, it seems unlikely that untagged transposons could account for more than approximately 0.5% of the total (see Materials and Methods). More probable causes are that the variable sequence was truncated in some of the tags, and/or that some of the sequences formed

5 secondary structures, both of which might have prevented amplification. Mutants which failed to give clear signals were not included in further studies. The specificity of the efficiently amplifiable tags was demonstrated by generating a probe from 24 colonies of a microtitre dish, and using it to probe a colony blot of 48 colonies, which included the 24 used to generate

10 the probe. The lack of any hybridisation signal from the 24 colonies not used to generate the probe (Figure 3) shows that the hybridisation conditions employed were sufficiently stringent to prevent cross-hybridisation among labelled tags, and suggests that each exconjugant is not reiterated within a microtitre dish.

15 There are further considerations in determining the maximum pool size that can be used as an inoculum in animal experiments. As the quantity of labelled tag for each transposon is inversely proportional to the complexity of the tag pool, there is a limit to the pool size above which hybridisation

20 signals become too weak to be detected after overnight exposure of an autoradiogram. More importantly, as the complexity of the pool increases, so must the likelihood of failure of a virulent representative of the pool to be present in sufficient numbers, in the spleen of an infected animal, to produce enough labelled probe. We have not determined the upper limit for

25 pool size in the murine model of salmonellosis that we have employed, but it must be in excess of 96.

Virulence tests of the transposon mutants

30 A total of 1152 uniquely tagged insertion mutants (from two microtitre

dishes) were tested for virulence in BALB/c mice in twelve pools, each representing a 96-well microtitre dish. Animals received an intraperitoneal injection of approximately 10^3 cells of each of 96 transposon mutants of a microtitre dish (10^5 organisms in total). Three days after injection mice were sacrificed, and bacteria were recovered by plating spleen homogenates onto laboratory medium. Approximately 10,000 colonies recovered from each mouse were pooled and DNA was extracted. The tags present in this DNA sample were amplified and labelled by the PCR, and colony blots probed and compared with the hybridisation pattern obtained using tags amplified from the inoculum (Figure 3). As a control, an *aroA* mutant of *S. typhimurium* was tagged and employed as one of the 96 mutants in the inoculum. This strain would not be expected to be recovered in the spleen because its virulence is severely attenuated (Buchmeier *et al*, 1993). Forty-one mutants were identified whose DNA hybridized to labelled tags from the inoculum but not from labelled tags from bacteria recovered from the spleen. The experiment was repeated and the same forty-one mutants were again identified. Two of these were the *aroA* mutant (one per pool), as expected. Another was an auxotrophic mutant (it failed to grow on minimal medium). All of the mutants had normal colony morphology.

20

Example 2: Cloning and partial characterisation of sequences flanking the transposon

DNA was extracted from one of the mutants described in Example 1 (Pool 1, F10), digested with *Sst*I, and subcloned on the basis of kanamycin resistance. The sequence of 450 bp flanking one end of the transposon was determined using primer P7. This sequence shows 80% identity to the *E. coli* *clp* (*lon*) gene, which encodes a heat-regulated protease (Figure 5). To our knowledge, this gene has not previously been implicated as a virulence determinant.

30

Partial sequences of thirteen further *Salmonella typhimurium* virulence genes are shown in Figure 6 (sequences A2 to A9 and B1 to B5). Deduced amino acid sequences of P2D6, S4C3, P3F4, P7G2 and P9B7 bear similarities to a family of secretion-associated proteins that have been conserved throughout bacterial pathogens of animals and plants, and which are known in *Salmonella* as the *inv* family. In *S. typhimurium* the *inv* genes are required for bacterial invasion into intestinal tissue. The virulence of *inv* mutants is attenuated when they are inoculated by the oral route, but not when they are administered intraperitoneally. The discovery of *inv*-related genes that are required for virulence following intraperitoneal inoculation suggests a new secretion apparatus which might be required for invasion of non-phagocytic cells of the spleen and other organs. The products of these new genes might represent better drug targets than the *inv* proteins in the treatment of established infections.

Further characterisation of the genes identified in this example is described in Example 4.

Example 3: LD₅₀ determinations and mouse vaccination study

Mutations identified by the method of the invention attenuate virulence.

Five of the mutations in genes not previously implicated in virulence were transferred by P22-mediated transduction to the nalidixic acid-sensitive parent strain of *S. typhimurium* 12028. Transductants were checked by restriction mapping then injected by the intraperitoneal route into groups of BALB/c mice to determine their 50% lethal dose (LD₅₀). The LD₅₀ values for mutants S4C3, P7G2, P3F4 and P9B7 were all several orders of magnitude higher than that of the wild-type strain. No difference in the LD₅₀ was detected for mutant P1F10; however, there was a statistically

significant decrease in the proportion of P1F10 cells recovered from the spleens of mice injected with an inoculum consisting of an equal proportion of this strain and the wild-type strain. This implies that this mutation does attenuate virulence, but to a degree that is not detectable by LD₅₀.

5

Mutants P3F4 and P9B7 were also administered by the oral route at an inoculum level of 10⁷ cells/mouse. None of the mice became ill, indicating that the oral LD₅₀ levels of these mutants are at least an order of magnitude higher than that of the wild-type strain.

10

In the mouse vaccination study groups of five female BALB/c mice of 20-25 g in mass were initially inoculated orally (p.o.) or intraperitoneally (i.p.) with serial ten fold dilutions of *Salmonella typhimurium* mutant strains P3F4 and P9B7. After four weeks the mice were then inoculated with 500 c.f.u.

15 of the parental wild type strain. Deaths were then recorded over four weeks.

A group of two mice of the same age and batch as the mice inoculated with the mutant strains were also inoculated i.p. with 500 c.f.u. of the wild type strain as a positive control. Both non-immunised mice died as expected within four weeks.

20

Results are tabulated below:

25 1) p.o. initial inoculation with mutant strain P3F4

initial inoculum in c.f.u.	no. mice surviving first challenge	no. mice surviving wild type challenge
5 x 10 ⁹	5	2 (40%)
5 x 10 ⁸	5	2 (40%)

5×10^7	5	0 (0%)
-----------------	---	--------

2) i.p. initial inoculum with mutant strain P3F4

5	initial inoculum in c.f.u.	no. mice surviving first challenge	no. mice surviving wild type challenge
	5×10^6	3	3 (100%)
	5×10^5	5	4 (80%)
	5×10^4	6	5 (83%)
10	5×10^3	5	4 (80%)

3) p.o. initial inoculum with mutant strain P9B7

15	initial inoculum in c.f.u.	no. mice surviving first challenge	no. mice surviving wild type challenge
	5×10^9	5	0 (0%)

4) i.p. initial inoculum with mutant P9B7

20	initial inoculum in c.f.u.	no. mice surviving first challenge	no. mice surviving wild type challenge
	5×10^6	4	2 (50%)

From these experiments I conclude that mutant P3P4 appears to give some protection against subsequent wild type challenge. This protection appears greater in mice that were immunised i.p.

Example 4: Identification of a virulence locus encoding a second type III secretion system in *Salmonella typhimurium*

30

Abbreviations used in this Example are VGC1, virulence gene cluster 1; VGC2, virulence gene cluster 2.

Background to the experiments described

Salmonella typhimurium is a principal agent of gastroenteritis in humans and produces a systemic illness in mice which serves as a model for human typhoid fever (1). Following oral inoculation of mice with *S. typhimurium*, the bacteria pass from the lumen of the small intestine through the intestinal mucosa, via enterocytes or M cells of the Peyer's patch follicles (2). The bacteria then invade macrophages and neutrophils, enter the reticuloendothelial system and disseminate to other organs, including the spleen and liver, where further reproduction results in an overwhelming and fatal bacteremia (3). To invade host cells, to survive and replicate in a variety of physiologically stressful intracellular and extracellular environments and to circumvent the specific antibacterial activities of the immune system, *S. typhimurium* employs a sophisticated repertoire of virulence factors (4).

To gain a more comprehensive understanding of virulence mechanisms of *S. typhimurium* and other pathogens the transposon mutagenesis system described in Example 1, which is conveniently called 'signature-tagged mutagenesis' (STM), which combines the strength of mutational analysis with the ability to follow simultaneously the fate of a large number of different mutants within a single animal (5 and Example 1; Reference 5 was published after the priority date for this invention). Using this approach we identified 43 mutants with attenuated virulence from a total of 1152 mutants that were screened. The nucleotide sequences of DNA flanking the insertion points of transposons in 5 of these mutants showed that they were related to genes encoding type III secretion systems of a variety of bacterial pathogens (6, 7). The products of the *inv/spa* gene cluster of *S. typhimurium* (8, 9) are proteins that form a type III secretion system required for the assembly of surface appendages mediating entry into

epithelial cells (10). Hence the virulence of strains carrying mutations in the *inv/spa* cluster is attenuated only if the inoculum is administered orally and not when given intraperitoneally (8). In contrast the 5 mutants identified by STM are avirulent following intraperitoneal inoculation (5).

5

In this example we show that the transposon insertion points of these 5 mutants and an additional 11 mutants identified by STM all map to the same region of the *S. typhimurium* chromosome. Further analysis of this region reveals additional genes whose deduced products have sequence similarity to other components of type III secretion systems. This chromosomal region which we refer to as virulence gene cluster 2 (VGC2) is not present in a number of other enteric bacteria, and represents an important locus for *S. typhimurium* virulence.

15 Materials and Methods

Bacterial Strains, Transduction and Growth Media. *Salmonella enterica* serotypes 5791 (*abderdeen*), 423180 (*gallinarum*), 7101 (*cubana*) and 12416 (*typhimurium* LT2) were obtained from the National Collections of Type Cultures, Public Health Laboratory Service, UK. *Salmonella typhi* BRD123 genomic DNA was a gift from G. Dougan, enteropathogenic *Escherichia coli* (EPEC), enterohemorrhagic *E. coli* (EHEC), *Vibrio cholera* biotype *El Tor*, *Shigella flexneri* serotype 2 and *Staphylococcus aureus* were clinical isolates obtained from the Department of Infectious Diseases and Bacteriology, Royal Postgraduate Medical School, UK. Genomic DNA from *Yersinia pestis* was a gift from J. Heesemann. However, genomic DNA can be isolated using standard methods. The bacterial strains and the methods used to generate signature-tagged mini-Tn5 transposon mutants of *S. typhimurium* NCTC strain 12023 have been described previously (5, 11).

30 Routine propagation of plasmids was in *E. coli* DH5 α . Bacteria were

grown in LB broth (12) supplemented with the appropriate antibiotics. Before virulence levels of individual mutant strains were assessed, the mutations were first transferred by phage P22 mediated transduction (12) to the nalidixic acid sensitive parental strain of *S. typhimurium* 12023.

- 5 Transductants were analysed by restriction digestion and Southern hybridisation before use as inoculum.

Lambda Library Screening. Lambda (λ) clones with overlapping insert DNAs covering VGC2 were obtained by standard methods (13) from a
 10 λ 1059 library (14) containing inserts from a partial *Sau*3A digest of *S. typhimurium* LT2 genomic DNA. The library was obtained via K. Sanderson, from the Salmonella Genetic Stock Centre (SGSC), Calgary, Canada.

- 15 **Mud-P22 Lysogens.** Radiolabelled DNA probes were hybridised to Hybond N (Amersham) filters bearing DNA prepared from lysates of a set of *S. typhimurium* strains harbouring Mud-P22 prophages at known positions in the *S. typhimurium* genome. Preparation of mitomycin-induced Mud-P22 lysates was as described (12, 15). The set of Mud-P22 prophages
 20 was originally assembled by Benson and Goldman (16) and was obtained from the SGSC.

Gel Electrophoresis and Southern Hybridisation. Gel electrophoresis was performed in 1% or 0.6% agarose gels run in 0.5 x TBE. Gel fractionated
 25 DNA was transferred to Hybond N or N+ membranes (Amersham) and stringent hybridisation and washing procedures (permitting hybridisation between nucleotide sequences with 10% or less mismatches) were as described by Holden *et al*, (17). For non-stringent conditions (permitting hybridisation between sequences with 50% mismatches) filters were
 30 hybridised overnight at 42°C in 10% formamide/0.25 M Na₂HPO₄/7% SDS

and the most stringent step was with 20 mM Na₂HPO₄/1% SDS at 42°C. DNA fragments used as probes were labelled with [³²P]dCTP using the 'Radprime' system (Gibco-BRL) or with [digoxigenin-11]dUTP and detected using the Digoxigenin system (Boehringer Mannheim) according to the manufacturers' instructions, except that hybridisation was performed in the same solution as that used for radioactively labelled probes. Genomic DNA was prepared for Southern hybridisation as described previously (13).

Molecular Cloning and Nucleotide Sequencing. Restriction endonucleases and T4 DNA ligase were obtained from Gibco-BRL. General molecular biology techniques were as described in Sambrook *et al*, (18). Nucleotide sequencing was performed by the dideoxy chain termination method (19) using a T7 sequencing kit (Pharmacia). Sequences were assembled with the MacVector 3.5 software or AssemblyLIGN packages. Nucleotide and derived amino acid sequences were compared with those in the European Molecular Biology Laboratory (EMBL) and SwissProt databases using the BLAST and FASTA programs of the GCG package from the University of Wisconsin (version 8) (20) on the network service at the Human Genome Mapping Project Resource Centre, Hinxton, UK.

Virulence Tests. Groups of five female BALB/c mice (20-25g) were inoculated orally (p.o.) or intraperitoneally (i.p.) with 10-fold dilutions of bacteria suspended in physiological saline. For preparation of the inoculum, bacteria were grown overnight at 37°C in LB broth with shaking (50 rpm) and then used to inoculate fresh medium for various lengths of time until an optical density (OD) at 560 nm of 0.4 to 0.6 had been reached. For cell densities of 5 x 10⁸ colony forming units (cfu) per ml and above, cultures were concentrated by centrifugation and resuspended in saline. The concentration of cfu/ml was checked by plating a dilution series of the inoculum onto LB agar plates. Mice were inoculated i.p. with 0.2 ml

volumes and p.o. by gavage with the same volume of inoculum. The LD₅₀ values were calculated after 28 days by the method of Reed and Meunch (21).

5 Results

Localisation of Transposon Insertions. The generation of a bank of *Salmonella typhimurium* mini Tn5 transposon mutants and the screen used to identify 43 mutants with attenuated virulence have been described previously (5). Transposons and flanking DNA regions were cloned from exconjugants by selection for kanamycin resistance or by inverse PCR. Nucleotide sequences of 300-600 bp of DNA flanking the transposons were obtained for 33 mutants. Comparison of these sequences with those in the DNA and protein databases indicated that 14 mutants resulted from transposon insertions into previously known virulence genes, 7 arose from insertions into new genes with similarity to known genes of the enterobacteria and 12 resulted from insertions into sequences without similarity to entries in the DNA and protein databases (ref. 5, Example 1 and this Example).

20

Three lines of evidence suggested that 16 of 19 transposon insertions into new sequences were clustered in three regions of the genome, initially designated A, B and C. First, comparing nucleotide sequences from regions flanking transposon insertion points with each other and with those in the databases showed that some sequences overlapped with one another or had strong similarity to different regions of the same gene. Second, Southern analysis of genomic DNA digested with several restriction enzymes and probed with restriction fragments flanking transposon insertion points indicated that some transposon insertions were located on the same restriction fragments. Third, when the same DNA probes were hybridised

30

to plaques from a *S. typhimurium* λ DNA library, the probes from mutants which the previous two steps had suggested might be linked were found to hybridise to the same λ DNA clones. Thus two mutants (P9B7 and P12F5) were assigned to cluster A, five mutants (P2D6, P9B6, P11C3, P11D10 and
 5 P11H10) to cluster B and nine mutants (P3F4, P4F8, P7A3, P7B8, P7G2, P8G12, P9G4, P10E11 and P11B9) to cluster C (Figure 8).

Hybridisation of DNA probes from these three clusters to lysates from a set of *S. typhimurium* strains harbouring locked-in Mud-P22 prophages (15, 16)
 10 showed that the three loci were all located in the minute 30 to 31 region (edition VIII, ref. 22) (Figure 7), indicating that the three loci were closely linked or constituted one large virulence locus. To determine if any of the λ clones covering clusters A, B and C contained overlapping DNA inserts, DNA fragments from the terminal regions of each clone were used as
 15 probes in Southern hybridisation analysis of the other λ clones. Hybridising DNA fragments showed that several λ clones overlap and that clusters A, B and C comprise one contiguous region (Figure 8). DNA fragments from the ends of this region were then used to probe the λ library to identify further clones containing inserts representing the adjacent regions. No λ
 20 clones were identified that covered the extreme right hand terminus of the locus so this region was obtained by cloning a 6.5 kb *EcoRI/XbaI* fragment from a lysate of the Mud-P22 prophage strain TT15244 (16).

Restriction mapping and Southern hybridisation analysis were then used to
 25 construct a physical map of this locus (Figure 8). To distinguish this locus from the well characterised *inv/spa* gene cluster at minute 63 (edition VIII, ref. 22) (8, 9, 23, 24, 25, 26), we refer to the latter as virulence gene cluster 1 (VGC1) and have termed the new virulence locus VGC2. Figure 2 shows the position of two portions of DNA whose nucleotide sequence
 30 has been determined ("Sequence 1" and "Sequence 2"). The nucleotide

sequence is shown in Figures 11 and 12.

Mapping the boundaries of VGC2 on the *S. typhimurium* chromosome.

Nucleotide sequencing of λ clone 7 at the left hand side of VGC2 revealed
 5 the presence of an open reading frame (ORF) whose deduced amino acid
 sequence is over 90% identical to the derived product of a segment of the
ydhE⁺ gene of *E. coli* and sequencing of the 6.5 kb *EcoRI/XbaI* cloned
 fragment on the right hand side of VGC2 revealed the presence of an ORF
 whose predicted amino acid sequence is over 90% identical to pyruvate
 10 kinase I of *E. coli* encoded by the *pykF* gene (27). On the *E. coli*
 chromosome *ydhE* and *pykF* are located close to one another, at minute 37
 to 38 (28). Eleven non-overlapping DNA fragments distributed along the
 length of VGC2 were used as probes in non-stringent Southern hybridisation
 analysis of *E. coli* and *S. typhimurium* genomic DNA. Hybridising DNA
 15 fragments showed that a region of approximately 40 kb comprising VGC2
 was absent from the *E. coli* genome and localised the boundaries of VGC2
 to within 1 kb (Figure 9). Comparison of the location of the *XbaI* site close
 to the right hand end of VGC2 (Figure 8) with a map of known *XbaI* sites
 (29) at the minute 30 region of the chromosome (22) enables a map position
 20 of 30.7 minutes to be deduced for VGC2.

Structure of VGC2. Nucleotide sequencing of portions of VGC2 has
 revealed the presence of 19 ORFs (Figure 8). The G+C content of
 approximately 26 kb of nucleotide sequence within VGC2 is 44.6%,
 25 compared to 47% for VGC1 (9) and 51-53% estimated for the entire
Salmonella genome (30).

The complete deduced amino acid sequences of ORFs 1-11 are similar to
 those of proteins of type III secretion systems (6, 7), which are known to
 30 be required for the export of virulence determinants in a variety of bacterial

pathogens of plants and animals (7). The predicted proteins of ORFs 1 - 8 (Figure 8) are similar in organisation and sequence to the products of the *yscN-U* genes of *Yersinia pseudotuberculosis* (31), to *invC/spaS* of the *inv/spa* cluster in VGC1 of *Salmonella typhimurium* (8, 9) and to *spa47/spa40* of the *spa/mxi* cluster of *Shigella flexneri* (32, 33, 34, 35,). For example the predicted amino acid sequence of ORF 3 (Figure 8) is 50% identical to YscS of *Y. pseudotuberculosis* (31), 34% identical to Spa9 from *S. flexneri* (35) and 37% identical to SpaQ of VGC1 of *S. typhimurium* (9). The predicted protein product of ORF9 is closely related to the LcrD family of proteins with 43% identity to LcrD of *Y. enterocolitica* (36), 39% identity to MxiA of *S. flexneri* (32) and 40% identity to InvA of VGC1 (23). Partial nucleotide sequences for the remaining ORFs shown in Figure 8 indicate that the predicted protein from ORF10 is most similar to *Y. enterocolitica* YscJ (37) a lipoprotein located in the bacterial outer membrane, with ORF11 similar to *S. typhimurium* InvG, a member of the PulD family of translocases (38). ORF12 and ORF13 show significant similarity to the sensor and regulatory subunits respectively, from a variety of proteins comprising two component regulatory systems (39). There is ample coding capacity for further genes between ORFs 9 and 10, ORFs 10 and 11, and between ORF 19 and the right hand end of VGC2.

VGC2 is conserved among and is specific to the *Salmonellae*. A 2.2 kb *PstI/HindIII* fragment located at the centre of VGC2 (probe B, Figure 8) lacking sequence similarity to entries in the DNA and protein databases was used as a probe in Southern hybridisation analysis of genomic DNA from *Salmonella* serovars and other pathogenic bacteria (Figure 10A). - DNA fragments hybridising under non-stringent conditions showed that VGC2 is present in *S. aberdeen*, *S. gallinarum*, *S. cubana*, *S. typhi* and is absent from EPEC, EHEC, *Y. pestis*, *S. flexneri*, *V. cholera* and *S. aureus*. Thus VGC2 is conserved among and is likely to be specific to the *Salmonellae*.

To determine if the organisation of the locus is conserved among the *Salmonella* serovars tested, stringent Southern hybridisations with genomic DNA digested with two further restriction enzymes were carried out. Hybridising DNA fragments showed that there is some heterogeneity in the arrangement of restriction sites between *S. typhimurium* LT2 and *S. gallinarum*, *S. cubana* and *S. typhi* (Figure 10B). Furthermore, *S. gallinarum* and *S. typhi* contain additional hybridising fragments to those present in the other *Salmonellae* examined, suggesting that regions of VGC2 have been duplicated in these species.

VGC2 is required for virulence in mice. Previous experiments showed that the LD₅₀ values for i.p. inoculation of transposon mutants P3F4, P7G2, P9B7 and P11C3 were at least 100-fold greater than the wild type strain (5). In order to clarify the importance of VGC2 in the process of infection, the p.o. and i.p. LD₅₀ values for mutants P3F4 and P9B7 were determined (Table 1). Both mutants showed a reduction in virulence of at least five orders of magnitude by either route of inoculation in comparison with the parental strain. This profound attenuation of virulence by both routes of inoculation demonstrates that VGC2 is required for events in the infective process after epithelial cell penetration in BALB/c mice.

Table 1. LD₅₀ values of *S. typhimurium* strains.

Strain	LD ₅₀ (cfu)	
	i.p.	p.o.
12023 wild type	4.2	6.2 x 10 ⁴
P3F4	1.5 x 10 ⁶	> 5 x 10 ⁹
P9B7	> 1.5 x 10 ⁶	> 5 x 10 ⁹

cfu, colony forming units

Discussion

A hitherto unknown virulence locus in *S. typhimurium* of approximately 40 kb located at minute 30.7 on the chromosome by mapping the insertion points of a group of signature-tagged transposon mutants with attenuated virulence has been identified (5). This locus is referred to as virulence gene cluster 2 (VGC2) to distinguish it from the *inv/spa* virulence genes at 63 minutes (edition VIII, ref. 22) which we suggest be renamed VGC1. VGC1 and VGC2 both encode components of type III secretion systems. However, these secretion systems are functionally distinct.

Of 19 mutants that arose from insertions into new genes (ref. 5 and this example) 16 mapped to the same region of the chromosome. It is possible that mini-Tn5 insertion occurs preferentially in VGC2. Alternatively, as the negative selection used to identify mutants with attenuated virulence (5) was very stringent (reflected by the high LD₅₀ values for VGC2 mutants) it is possible that, among the previously unknown genes, only mutations in those of VGC2 result in a degree of attenuation sufficient to be recovered in the screen. The failure of previous searches for *S. typhimurium* virulence determinants to identify VGC2 might stem from reliance on cell culture assays rather than a live animal model of infection. A previous study which identified regions of the *S. typhimurium* LT2 chromosome unique to *Salmonellae* (40) located one such region (RF333) to minutes 30.5 - 32. Therefore, RF333 may correspond to VGC2, although it was not known that RF333 was involved in virulence determination.

Comparisons with the type III secretion systems encoded by the virulence plasmids of *Yersinia* and *Shigella* as well as with VGC1 of *Salmonella* indicates that VGC2 encodes the basic structural components of the secretory apparatus. Furthermore, the order of ORFs 1-8 in VGC2 is the

- same as the gene order in homologues in *Yersinia*, *Shigella* and VGC1 of *S. typhimurium*. The fact that the organisation and structure of the VGC2 secretion system is no more closely related to VGC1 than to the corresponding genes of *Yersinia*, together with the low G+C content of
- 5 VGC2 suggests that VGC2, like VGC1 (40, 41, 42) was acquired independently by *S. typhimurium* via horizontal transmission. The proteins encoded by ORFs 12 and 13 show strong similarity to bacterial two component regulators (39) and could regulate either ORFs 1-11 and/or the secreted proteins of this system.
- 10 Many genes in VGC1 have been shown to be important for entry of *S. typhimurium* into epithelial cells. This process requires bacterial contact (2) and results in cytoskeletal rearrangements leading to localised membrane ruffling (43, 44). The role of VGC1 and its restriction to this stage of the infection is reflected in the approximately 50-fold attenuation of virulence
- 15 in BALB/c mice inoculated p.o. with VGC1 mutants and by the fact that VGC1 mutants show no loss of virulence when administered i.p. (8). The second observation also explains why no VGC1 mutants were obtained in our screen (5). In contrast, mutants in VGC2 are profoundly attenuated following both p.o. and i.p. inoculation. This shows that, unlike VGC1,
- 20 VGC2 is required for virulence in mice after epithelial cell penetration, but these findings do not exclude a role for VGC1 in this early stage of infection.

- Thus in summary mapping the insertion points of 16 signature-tagged
- 25 transposon mutants on the *Salmonella typhimurium* chromosome led to the identification of a 40 kb virulence gene cluster at minute 30.7. This locus is conserved among all other *Salmonella* species examined, but not present in a variety of other pathogenic bacteria or in *Escherichia coli* K12. Nucleotide sequencing of a portion of this locus revealed 11 open reading
- 30 frames whose predicted proteins encode components of a type III secretion

system. To distinguish between this and the type III secretion system encoded by the *inv/spa* invasion locus we refer to the *inv/spa* locus as virulence gene cluster 1 (VGC1) and the new locus as VGC2. VGC2 has a lower G+C content than that of the *Salmonella* genome and is flanked by genes whose products share greater than 90% identity with those of the *E. coli ydhE* and *pykF* genes. Thus VGC2 was probably acquired horizontally by insertion into a region corresponding to that between the *ydhE* and *pykF* genes of *E. coli*. Virulence studies of VGC2 mutants have shown them to be attenuated by at least five orders of magnitude compared with the wild type strain following oral or intraperitoneal inoculation.

References for this Example

1. Carter, P.B. & Collins, F.M. (1974) *J. Exp. Med.* **139**, 1189-1203.
- 15 2. Takeuchi, A. (1967) *Am. J. Pathol.* **50**, 109-136.
3. Finlay, B.B. (1994) *Curr. Top. Microbiol. Immunol.* **192**, 163-185.
4. Groisman, E.A. & Ochman, H. (1994) *Trends Microbiol.* **2**, 289-293.
5. Hensel, M., Shea, J.E., Gleeson, C., Jones, M.D., Dalton, E. & Holden, D.W. (1995) *Science* **269**, 400-403.
- 20 6. Salmond, G.P.C. & Reeves, P.J. (1993) *Trends Biochem. Sci.* **18**, 7-12.
7. Van Gijsegem, F., Genin, S. & Boucher, C. (1993) *Trends Microbiol.* **1**, 175-180.
- 25 8. Galan, J.E. & Curtiss, R. (1989) *Proc. Natl. Acad. Sci. U.S.A.* **86**, 6383-6387.
9. Groisman, E.A. & Ochman, H. (1993) *EMBO J.* **12**, 3779-3787.
10. Ginocchio, C.C., Olmsted, S.B., Wells, C.L. & Galan, J.E. (1994) *Cell* **76**, 717-724.
- 30 11. de Lorenzo, V. & Timmis, K.N. (1994) *Methods Enzymol.* **264**,

12. Davis, R.H., Botstein, D. & Roth, J.R. (1980) *Advanced Bacterial Genetics*, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
- 5 13. Ausubel, F.M., Brent, R., Kingston, R.E., Moore, D.D., Seidman, J.G., Smith, J.A. and Struhl, K. (1987) *Current Protocols in Molecular Biology* Vol 4 John Wiley and Sons, Inc, New York.
14. Maurer, R., Osmond, B.C., Shekhtman, E., Wong, A. & Botstein, D. (1984) *Genetics* 108, 1-23.
- 10 15. Youderain, P., Sugiono, P., Brewer, K.L., Higgins, N.P. & Elliott, T. (1988) *Genetics* 118, 581-592.
16. Benson, N.R. & Goldman, B.S. (1992) *J. Bacteriol.* 174, 1673-1681.
17. Holden, D.W., Kronstad, J.W. & Leong, S. (1989) *EMBO J.* 8, 1927-1934.
- 15 18. Sambrook, J., Fritsch, E.F. & Maniatis, T. (1989) *Molecular cloning: a laboratory manual* (Cold Spring Harbor Laboratory, Cold Spring Harbor, New York).
19. Sanger, F., Nicklen, S. & Coulson, A.R. (1977) *Proc. Natl. Acad. Sci. U.S.A.* 74, 5463-5467.
- 20 20. Devereux, J., Hearberli, P. & Smithies, O. (1984) *Nucl. Acids Res.* 12, 387-399.
21. Reed, L.J. & Muench, H. (1938) *Am. J. Hyg.* 27, 493-497.
22. Sanderson, K.E., Hessel, A. & Rudd, K.E. (1995) *Microbiol. Rev.* 59, 241-303.
- 25 23. Galan, J.E., Ginocchio, C. & Costeas, P. (1992) *J. Bacteriol.* 174, 4338-4349.
24. Ginocchio, C., Pace, J. & Galan, J.E. (1992) *Proc. Natl. Acad. Sci. U.S.A.* 89, 5976-5980.

25. Eichelberg, K., Ginocchio, C.C. & Galan, J.E. (1994) *J. Bacteriol.* **176**, 4501-4510.
26. Collazo, C.M., Zierler, M.K. & Galan, J.E. (1995) *Mol. Microbiol.* **15**, 25-38.
- 5 27. Ohara, O., Dorit, R.L. & Gilbert, W. (1989) *Proc. Natl. Acad. Sci. USA* **86**, 6883-6887.
28. Bachman, B. (1990) *Micro. Rev.* **54**, 130-197.
29. Liu, S.L., Hessel, A. & Sanderson, K.E. (1993) *J. Bacteriol.* **175**, 4104-4120.
- 10 30. Fasman, G.D. (1976) *CRC Handbook of Biochemistry and Molecular Biology*, CRC Press, Cleveland.
31. Bergman, T., Erickson, K., Galyov, E., Persson, C. & Wolf Watz, H. (1994) *J. Bacteriol.* **176**, 2619-2626.
32. Andrews, G.P. & Maurelli, A.T. (1992) *Infect. Immun.* **60**, 3287-3295.
- 15 33. Allaoui, A., Sansonetti, P.J. & Parsot, C. (1993) *Mol. Microbiol.* **7**, 59-68.
34. Venkatesan, M., Buysse, J.M. & Oaks, E.V. (1992) *J. Bacteriol.* **174**, 1990-2001.
- 20 35. Sasakawa, C., Komatsu, K., Tobe, T., Suzuki, T. & Yoshikawa, M. (1993) *J. Bacteriol.* **175**, 2334-2346.
36. Plano, G.V., Barve, S.S. & Straley, S.C. (1991) *J. Bacteriol.* **173**, 7293-7303.
37. Michiels, T., Vanooteghem, J.C., Lambert de Rouvroit, C., China, B., Gustin, A., Boudry, P. & Cornelis, G.R. (1991) *J. Bacteriol.* **173**, 4994-5009.
- 25 38. Kaniga, K., Bossio, J.C. & Galan, J.E. (1994) *Mol. Microbiol.* **13**, 555-568.
39. Ronson, C.W., Nixon, B.T. & Ausubel, F.M. (1987) *Cell* **49**, 579-581.
- 30

40. Groisman, E.A., Sturmoski, M.A., Solomon, F.R., Lin, R. & Ochman, H. (1993) *Proc. Natl. Acad. Sci. U.S.A.* **90**, 1033-1037.
41. Altmeyer, R.M., McNern, J.K., Bossio, J.C., Rosenshine, I., Finlay, B.B. & Galan, J.E. (1993) *Mol. Microbiol.* **7**, 89-98.
- 5 42. Li, J., Ochman, H., Groisman, E.A., Boyd, E.F., Soloman, F., Nelson, K. & Selander, R.K. (1995) *Proc. Natl. Acad. Sci. USA* **92**, 7252-7256.
43. Finlay, B.B. & Rauschkowski, S. (1991) *J. Cell Sci.* **99**, 283-296.
44. Francis, C.L., Starnbach, M.N. & Falkow, S. (1992) *Mol.*
- 10 *Microbiol.* **6**, 3077-3087. -

Example 5: Identification of virulence genes in *Streptococcus pneumoniae*

(a) Mutagenesis

- 15 In the absence of a convenient transposon system, the most efficient way of creating tagged mutants of *Streptococcus pneumoniae* is to use insertion-duplication mutagenesis (Morrison *et al* (1984) *J. Bacteriol.* **159**, 870). Random *S. pneumoniae* DNA fragments of 200-400 bp will be generated by genomic DNA digestion with a restriction enzyme or by
- 20 physical shearing by sonication followed by gel fractionation and DNA end-repair using T4 DNA polymerase. The fragments are ligated into plasmid pJDC9 (Pearce *et al* (1993) *Mol. Microbiol.* **9**, 1037 which carries the *erm* gene for erythromycin selection in *E. coli* and *S. pneumoniae*), previously modified by incorporation of DNA sequence tags into one of the
- 25 polylinker cloning sites. The size of cloned *S. pneumoniae* DNA is sufficient to ensure homologous recombination, and reduces the possibility of generating an unrepresentative library in *E. coli* (expression of *S. pneumoniae* proteins can be toxic to *E. coli*). Alternative vectors carrying different selectable markers are available and can be used in place of
- 30 pJDC9. Tagged plasmids carrying DNA fragments are introduced to an

appropriate *S. pneumoniae* strain selected on the basis of serotype and virulence in a murine model of pneumococcal pneumonia. Regulation of competence for genetic transformation in *S. pneumoniae* is governed by competence factor, a peptide of 17 amino acids which has been characterized recently by Don Morrison's group at the University of Illinois at Chicago and which is described Havarstein, Coomaraswamy and Morrison (1995) *Proc. Natl. Acad. Sci. USA* 92, 11140-11144. Incorporation of minute quantities of this peptide in transformation experiments leads to very efficient transformation frequencies in some encapsulated clinical isolates of *S. pneumoniae*. This overcomes a major hurdle in pneumococcal molecular genetics and the availability of the peptide greatly facilitates the construction of *S.*

pneumoniae mutant banks and allows flexibility in choosing the strain(s) to be mutated. A proportion of transformants are analysed to verify homologous integration of the plasmid sequences, and checked for stability. The very low level of reversion associated with mutants generated by insertion-duplication is minimized by the fact that the duplicated regions will be short (200-400 bp); however if the level of reversion is unacceptably high, antibiotic selection is maintained during growth of the transformants in culture and during growth in the animal.

(b) Animal model

The *S. pneumoniae* mutant bank is organized into pools for inoculation into Swiss and/or C57B1/6 mice. Preliminary experiments are conducted to determine the optimum complexity of the pools and the optimum inoculum level. One attractive model utilises inocula of 10^5 cfu, delivered by mouth to the trachea (Veber *et al* (1993) *J. Antimicrobial Chemotherapy* 32, 473). Swiss mice develop acute pneumonia within 3-4 days, and C57B1/6 mice develop subacute pneumonia within 8-10 days. These pulmonary models of infection yield 10^8 cfu/lung (Veber *et al* (1993) *J. Antimicrobial*

Chemotherapy 32, 473) at the time of death. If required, mice are also injected intraperitoneally for the identification of genes required for bloodstream infection (Sullivan *et al* (1993) *Antimicrobial Agents and Chemotherapy* 37, 234).

5

(c) Virulence gene identification

Once the parameters of the infection model are optimized, a mutant bank consisting of several thousand strains is subjected to virulence tests. Mutants with attenuated virulence are identified by hybridisation analysis, using labelled tags from the 'input' and 'recovered' pools as probes. If *S. pneumoniae* DNA cannot be colony blotted easily, chromosomal DNA is liberated chemically or enzymatically in the wells of microtitre dishes prior to transfer onto nylon membranes using a dot-blot apparatus. DNA flanking the integrated plasmid is cloned by plasmid rescue in *E. coli* (Morrison *et al* (1984) *J. Bacteriol.* 159, 870), and sequenced. Genomic DNA libraries are constructed in appropriate vectors maintained in either *E. coli* or a Gram-positive host strain, and are probed with restriction fragments flanking the integrated plasmid to isolate cloned virulence genes which is then fully sequenced and subjected to detailed functional analysis.

20

Example 6: Identification of virulence genes in *Enterococcus faecalis*

(a) Mutagenesis

Mutagenesis of *E. faecalis* is accomplished using plasmid pAT112 or a derivative, developed for this purpose. pAT112 carries genes for selection in both Gram-negative and Gram-positive bacteria, and the *att*-site of Tn/545. It therefore requires the presence in the host strain of the integrase for transposition, and stable, single copy insertions are obtained if the host does not contain an excisionase gene (Trieu-Cuot *et al* (1991) *Gene* 106, 21). Recovery of DNA flanking the integrated plasmid is accomplished by

30

restriction digestion of genomic DNA, intramolecular ligation and transformation of *E. coli*. The presence of single sites for restriction enzymes in pAT112 and its derivatives will (Trieu-Cuot *et al* (1991) *Gene* 106, 21) allows the incorporation of DNA sequence tags prior to transfer
 5 to a virulent strain of *E. faecalis* carrying plasmid pAT145 (to provide the integrase function) by either conjugation, electroporation or transformation (Trieu-Cuot *et al* (1991) *Gene* 106, 21; Wirth *et al* (1986) *J. Bacteriol.* 165, 831).

10 (b) Animal model

A large number of insertion mutants are analysed for random integration of the plasmid by isolating DNA from transciipients, restriction enzyme digestion and Southern hybridisation. Individual mutants are stored in the wells of microtitre dishes, and complexity and size of pooled inocula are
 15 optimised prior to screening of the mutant bank. Two different models of infection caused by *E. faecalis* are employed. The first is a well established rat model of endocarditis, involving tail vein injection of up to 10^8 cfu of *E. faecalis* into animals that have a catheter inserted across the aortic valve (Whitman *et al* (1993) *Antimicrobial Agents and Chemotherapy* 37, 1069).
 20 Animals are sacrificed at various times after inoculation, and bacterial vegetations on the aortic valve are excised, homogenized and plated to culture medium to recover bacterial colonies. Virulent bacteria are also recovered from the blood at various times after inoculation. The second model is of peritonitis in mice, following intraperitoneal injection of up to
 25 10^9 cfu of *E. faecalis* (Chenoweth *et al* (1990) *Antimicrobial Agents and Chemotherapy* 34, 1800). As with the *S. pneumoniae* model, preliminary experiments are done to establish the optimum complexity of the pools and the optimum inoculum level, prior to screening the mutant
 bank.

(c) Virulence gene identification

Isolation of DNA flanking the site of integration of pAT112 using its *E. coli* origin of replication is simplified by the lack of sites for most of the commonly used 6 bp recognition restriction enzymes in the vector.

- 5 Therefore DNA from the strains of interest are digested with one of these enzymes, self-ligated, transformed into *E. coli* and sequenced using primers based on the sequences adjacent to the *att* sites on the plasmid. A genomic DNA library of *E. faecalis* are probed with sequences of interest to identify intact copies of virulence genes which are then sequenced.

10

Example 7: Identification of virulence genes in *Pseudomonas aeruginosa*

(a) Mutagenesis

- 15 Since transposon Tn5 has been used by others to mutagenise *Pseudomonas aeruginosa*, and the mini-Tn5 derivative that was used for the identification of *Salmonella typhimurium* virulence genes (Example 1) is reported to have broad utilisation among Gram-negative bacteria, including several pseudomonads (DeLorenzo and Timaris (1994) *Methods Enzymol.* 264,
- 20 386), a *P. aeruginosa* mutant bank is constructed using our existing pool of signature tagged mini-Tn5 transposons by conjugal transfer of the suicide vector to one or more virulent (and possibly mucoid) recipient strains. This approach represents a significant time saving. Other derivatives of Tn5 designed specifically for *P. aeruginosa* mutagenesis (Rella *et al* (1985) *Gene*
- 25 33, 293), may alternatively be employed with the mini Tn5 transposon.

(b) Animal model and virulence gene identification

The bank of *P. aeruginosa* insertion mutants is screened for attenuated virulence in a chronic pulmonary infection model in rats. Suspensions of

- 30 *P. aeruginosa* cells are introduced into a bronchus following tracheotomy,

and disease develops over a 30 day period (Woods *et al* (1982) *Infect. Immun.* 36, 1223). Bacteria are recovered by plating lung homogenates to laboratory medium and sequence tags from these are used to probe DNA colony blots of bacteria used as the inoculum. It is also possible to subject

5 the mutant bank to virulence tests in a model of endogenous bacteremia (Hirakata *et al* (1992) *Antimicrobial Agents and Chemotherapy* 36, 1198), and cystic fibrosis (Davidson *et al* (1995) *Nature Genetics* 9, 351) in mice. Cloning and sequencing of DNA flanking the transposons is done as described in Example 1. Genomic DNA libraries for the isolation and

10 sequencing of intact copies of the genes are constructed in the laboratory by standard methods.

Example 8: Identification of virulence genes in *Aspergillus fumigatus*

15 (a) Mutagenesis

The functional equivalent of transposon mutagenesis in fungi is restriction enzyme mediated integration (REMI) of transforming DNA (Schiestl and Petes (1991) *Proc. Natl. Acad. Sci.* 88, 7585). In this process, fungal cells are transformed with DNA fragments carrying a selectable marker in the

20 presence of a restriction enzyme, and single copy integrations occur at different genomic sites, defined by the target sequence of the restriction enzyme. REMI has already been used successfully to isolate virulence genes of *Cochliobolus* (Lu *et al* (1994) *Proc. Natl. Acad. Sci. USA* 91, 12649) and *Ustilago* (Bolker *et al* (1995) *Mol. Gen. Genet.* 248, 547), and

25 have shown that incorporation of active restriction enzyme with a plasmid encoding hygromycin resistance leads to single and apparently random integration of the linear plasmid into the *A. fumigatus* genome. Sequence tags are introduced into a convenient site in one of two vectors for hygromycin resistance, and used to transform a clinical isolate of *A.*

30 *fumigatus*.

(b) Animal model and virulence gene identification

The low-dose model of aspergillosis in neutropenic mice in particular closely matches the course of pulmonary disease in humans (Smith *et al* (1994) *Infect. Immun.* **62**, 5247). Mice are inoculated intranasally with up
5 to 1,000,000 conidiospores/mouse, and virulent fungal mutants are recovered 7-10 days later by using lung homogenates to inoculate liquid medium. Hyphae are collected after a few hours, from which DNA is extracted for amplification and labelling of tags to probe colony blots of DNA from the pool of transformants comprising the inoculum. DNA from
10 the regions flanking the REMI insertion points are cloned by digesting the transformant DNA with a restriction enzyme that cuts outside the REMI vector, self ligation and transformation of *E. coli*. Primers based on the known sequence of the plasmid are used to determine the adjacent *A. fumigatus* DNA sequences. To prove that the insertion of the vector was
15 the cause of the avirulent phenotype, the recovered plasmid is recut with the same restriction enzyme used for cloning, and transformed back into the wild-type *A. fumigatus* parent strain. Transformants that have arisen by homologous recombination are then subjected to virulence tests.

REFERENCES (other than for Example 4)

- Ausubel, F.M., Brent, R., Kingston, R.E., Moore, D.D., Seidman, J.G., Smith, J.A. and Struhl, K. (1987) *Current Protocols in Molecular Biology*, New York: John Wiley and Sons.
- Buchmeier, N.A., Lipps, C.J., So, M.Y. and Heffron, F. (1993) Recombination-deficient mutants of *Salmonella typhimurium* are avirulent and sensitive to the oxidative burst of macrophages. *Mol. Microbiol.* 7, 933-936.
- 10 Carter, P.B. and Collins, F.M. (1974) The route of enteric infection in normal mice. *J. Exp. Med.* 139, 1189-1203.
- de Lorenzo, V. and Timmis, K.N. (1994) Analysis and construction of stable phenotypes in Gram-negative bacteria with Tn5- and Tn10-derived minitransposons. *Methods Enzymol.* 264, 386-405.
- 15 de Lorenzo, V., Herrero, M., Jakubzik, U. and Timmis, K.N. (1990) Mini-Tn5 transposon derivatives for insertion mutagenesis, promoter probing, and chromosomal insertion of cloned DNA in gram-negative eubacteria. *J. Bacteriol.* 172, 6568-6572.
- 20 Fields, P.I., Groisman, E.A. and Heffron, F. (1989) A *Salmonella* locus that controls resistance to microbicidal proteins from phagocytic cells. *Science* 243, 1059-1062.
- Finlay, B.B., Starnbach, M.N., Francis, C.L., Stocker, B.A., Chatfield, S., Dougan, G. and Falkow, S. (1988) Identification and characterization of TnphoA mutants of *Salmonella* that are unable to pass through a

polarized MDCK epithelial cell monolayer. *Mol. Microbiol.* 2, 757-766.

Groisman, E.A., Chiao, E., Lipps, C.J., Heffron, F. (1989) *Salmonella typhimurium phoP* virulence gene is a transcriptional regulator. *Proc. Natl. Acad. Sci. USA.* 86, 7077-7081.

- 5 Groisman, E.A. and Ochman, H. (1994) How to become a pathogen. *Trends Microbiol.* 2, 289-293.

Groisman, E.A. and Saier, M.H., Jr. (1990) *Salmonella* virulence: new clues to intramacrophage survival. *Trends Biochem. Sci.* 15, 30-33.

- 10 Herrero, M., de Lorenzo, V. and Timmis, K.N. (1990) Transposon vectors containing non-antibiotic resistance selection markers for cloning and stable chromosomal insertion of foreign genes in Gram-negative bacteria. *J. Bacteriol.* 172, 6557-6567.

Holden D.W., Kronstad J.W., Leong S.A. (1989) Mutation in a heat-regulated *hsp70* gene of *Ustilago maydis*. *EMBO J.* 8, 1927-1934.

- 15 Holland J., Towner K.J., Williams P. (1992) Tn916 insertion mutagenesis in *Escherichia coli* and *Haemophilus influenzae* type b following conjugative transfer. *J. Gen. Microbiol.* 138, 509-515.

- 20 Mahan, M.J., Slauch, J.M., Mekalanos, J.J. (1993) Selection of bacterial virulence genes that are specifically induced in host tissues. *Science* 259, 686-688.

Miller, S.I., Kukral, A.M. and Mekalanos, J.J. (1989a) A two-component regulatory system (*phoP phoQ*) controls *Salmonella typhimurium* virulence. *Proc. Natl. Acad. Sci. USA.* 86, 5054-5058.

- Miller, I., Maskell, D., Hormaeche, C., Johnson, K., Pickard, D. and Dougan, G. (1989b) Isolation of orally attenuated *Salmonella typhimurium* following *TnphoA* mutagenesis. *Infect. Immun.* **57**, 2758-2763.
- 5 Miller, V.L. and Mekalanos, J.J. (1988) A novel suicide vector and its use in construction of inversion mutations: osmoregulation of outer membrane proteins and virulence determinants in *Vibrio cholerae* requires *toxR*. *J. Bacteriol.* **170**, 2575-2583.
- Sambrook, J., Fritsch, E.F. and Maniatis, T. (1989) *Molecular cloning: a laboratory manual*, Cold Spring Harbor, New York: Cold Spring Harbor Laboratory.
- 10 Sanger, F., Nicklen, S. and Coulson, A.R. (1977) DNA sequencing with chain terminating inhibitors. *Proc. Natl. Acad. Sci. USA.* **74**, 5463-5467.
- 15 Schiestl R.H., and Petes T.D. (1991) Integration of DNA fragments by illegitimate recombination in *Saccharomyces cerevisiae*. *Proc. Natl. Acad. Sci USA.* **88**, 7585-7589.

CLAIMS

1. A method for identifying a microorganism having a reduced adaptation to a particular environment comprising the steps of:

- 5 (1) providing a plurality of microorganisms each of which is independently mutated by the insertional inactivation of a gene with a nucleic acid comprising a unique marker sequence so that each mutant contains a different marker sequence, or clones of the said microorganism;
- (2) providing individually a stored sample of each mutant
10 produced by step (1) and providing individually stored nucleic acid comprising the unique marker sequence from each individual mutant;
- (3) introducing a plurality of mutants produced by step (1) into the said particular environment and allowing those microorganisms which are able to do so to grow in the said environment;
- 15 (4) retrieving microorganisms from the said environment or a selected part thereof and isolating the nucleic acid from the retrieved microorganisms;
- (5) comparing any marker sequences in the nucleic acid isolated in step (4) to the unique marker sequence of each individual mutant stored
20 as in step (2); and
- (6) selecting an individual mutant which does not contain any of the marker sequences as isolated in step (4).

2. A method according to Claim 1 wherein the plurality of
25 microorganisms as defined in step (1) is produced from a plurality of microorganisms, each of which comprises a nucleic acid comprising a unique marker sequence, by changing their condition from a first given condition to a second given condition wherein (a) in the first given condition the said nucleic acid comprising a unique marker is maintained episomally
30 and (b) in the second given condition the said nucleic acid comprising a

unique marker sequence insertionally inactivates a gene.

3. A method according to Claims 1 or 2 further comprising the steps:
 - (1A) removing auxotrophs from the plurality of mutants produced
- 5 in step (1); or
 - (6A) determining whether the mutant selected in step (6) is an auxotroph; or
 - both (1A) and (6A).
- 10 4. A method of identifying a gene which allows a microorganism to adapt to a particular environment, the method comprising the method of any one of Claims 1 to 3 followed by the step:
 - (7) isolating the insertionally-inactivated gene from the individual
- 15 mutant selected in step (6).
5. A method according to Claim 4 further comprising the step:
 - (8) isolating from a wild-type microorganism the corresponding
- 20 wild-type gene using the insertionally-inactivated gene isolated in step (7) as a probe.
6. A method according to any one of Claims 1 to 5 wherein the particular environment is a differentiated multicellular organism.
7. A method according to Claim 6 wherein the multicellular organism
- 25 is a plant.
8. A method according to Claim 6 wherein the multicellular organism is a non-human animal.
- 30 9. A method according to Claim 8 wherein the animal is a mouse, rat,

rabbit, dog or monkey.

10. A method according to Claim 9 wherein the animal is a mouse.
- 5 11. A method according to any one of Claims 6 to 10 wherein in step (4) the microorganisms are retrieved from the said environment at a site remote from the site of introduction in step (3).
12. A method according to any one of Claims 8 to 10 wherein in step (3)
10 the microorganism is introduced orally or intraperitoneally.
13. A method according to Claim 12 when dependent on Claims 8 or 9 wherein in step (4) the microorganisms are retrieved from the spleen.
- 15 14. A method according to any one of the preceding claims wherein the microorganism is a bacterium.
15. A method according to any one of Claims 1 to 13 wherein the microorganism is a fungus.
20
16. A method according to Claim 7 wherein the microorganism is a bacterium pathogenic to plants.
17. A method according to Claim 7 wherein the microorganism is a
25 fungus pathogenic to plants.
18. A method according to any one of Claims 8 to 10 wherein the microorganism is a bacterium pathogenic to animals.
- 30 19. A method according to any one of Claims 8 to 10 wherein the

microorganism is a fungus pathogenic to animals.

20. A method according to Claim 18 wherein the bacterium is any one of *Bordetella pertussis*, *Campylobacter jejuni*, *Clostridium botulinum*,
5 *Escherichia coli*, *Haemophilus ducreyi*, *Haemophilus influenzae*,
Helicobacter pylori, *Klebsiella pneumoniae*, *Legionella pneumophila*,
Listeria spp., *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Pseudomonas*
spp., *Salmonella* spp., *Shigella* spp., *Staphylococcus aureus*, *Streptococcus*
pyogenes, *Streptococcus pneumoniae*, *Vibrio* spp., and *Yersinia pestis*.
10
21. A method according to Claim 19 wherein the fungus is any one of
Aspergillus spp., *Cryptococcus neoformans* and *Histoplasma capsulatum*.
22. A method according to any one of the preceding claims wherein in
15 step (1) the gene is insertionally inactivated using a transposon or
transposon like element or other DNA sequence carrying a unique marker
sequence.
23. A method according to any one of the preceding claims wherein in
20 step (1) each different marker sequence is flanked on either side by
sequences common to each said nucleic acid.
24. A method according to Claim 23 wherein in step (2) the nucleic acid
comprising the unique marker is isolated using DNA amplification
25 techniques and oligonucleotide primers which hybridise to the said common
sequences.
25. A method according to Claim 23 or 24 wherein in step (4) the
nucleic acid comprising a plurality of said marker sequences is isolated
30 using DNA amplification techniques and oligonucleotide primers which

5

10

15

20

25

30

34. A method of identifying a compound which reduces the ability of a microorganism to adapt to a particular environment comprising the step of

selecting a compound which interferes with the function of a gene according to any one of Claims 30 to 32 or a polypeptide according to Claim 33.

35. A compound identifiable by the method of Claim 34.

5

36. A compound according to Claim 35 wherein the particular environment is a host organism.

10 37. A compound according to Claim 36 wherein the host organism is a plant.

38. A compound according to Claim 36 wherein the host organism is an animal.

15 39. Use of a compound according to any one of Claim 36 to Claim 38 for treating infection of said host organism with said microorganism.

20 40. A molecule which selectively interacts with, and substantially inhibits the function of, a gene according to any one of Claims 30 to 32 or a nucleic acid product thereof.

41. A molecule according to Claim 40 which is an antisense nucleic acid or nucleic acid derivative.

25 42. A molecule according to Claim 40 or 41 which is an antisense oligonucleotide.

43. A molecule according to any one of Claims 40 to 42 for use in medicine.

30

44. A method of treating a host which has, or is susceptible to, an infection with a microorganism, the method comprising administering an effective amount of a molecule or compound according to Claim 36 or 40 wherein said gene is present in said microorganism, or a close relative of said microorganism.

45. A pharmaceutical composition comprising a molecule or compound according to Claim 38 or 40 and a pharmaceutically acceptable carrier.

46. The VGC2 DNA of *Salmonella typhimurium* or a part thereof, or a variant of said DNA or a variant of a part thereof.

47. A mutant bacterium wherein if the bacterium normally contains a gene that is the same as or equivalent to a gene in VGC2, said gene is mutated or absent in said mutant bacterium.

48. A method of making a bacterium according to Claim 47.

49. Use of a mutant bacterium according to Claim 47 in a vaccine.

50. A pharmaceutical composition comprising a bacterium according to Claim 47 and a pharmaceutically acceptable carrier.

51. A polypeptide encoded by VGC2 DNA of *Salmonella typhimurium* or a part thereof, or a variant of said polypeptide or a variant of a part thereof.

52. A method of identifying a compound which reduces the ability of a bacterium to infect or cause disease in a host comprising the step of selecting a compound which interferes with the function of a gene in VGC2

according to Claim 46 or a polypeptide according to Claim 51.

53. A compound identifiable by the method of Claim 52.

5 54. A molecule which selectively interacts with, and substantially inhibits
the function of, a gene in VGC2 of *Salmonella typhimurium* or a nucleic
product thereof.

10 55. A molecule or compound according to Claim 53 or 54 for use in
medicine.

56. Any novel feature or combination of features disclosed herein.

0974503.1.doc

ABSTRACTIDENTIFICATION OF GENES

5 A method for identifying a microorganism having a reduced adaptation to a particular environment comprising the steps of:

(1) providing a plurality of microorganisms each of which is independently mutated by the insertional inactivation of a gene with a nucleic acid comprising a unique marker sequence so that each mutant
10 contains a different marker sequence, or clones of the said microorganism;

(2) providing individually a stored sample of each mutant produced by step (1) and providing individually stored nucleic acid comprising the unique marker sequence from each individual mutant;

(3) introducing a plurality of mutants produced by step (1) into the
15 said particular environment and allowing those microorganisms which are able to do so to grow in the said environment;

(4) retrieving microorganisms from the said environment or a selected part thereof and isolating the nucleic acid from the retrieved microorganisms;

20 (5) comparing any marker sequences in the nucleic acid isolated in step (4) to the unique marker sequence of each individual mutant stored as in step (2); and

(6) selecting an individual mutant which does not contain any of the marker sequences as isolated in step (4).

25

(Figure No 1)

Chen et al. 1998

DNA sequence tag




FIG. 1A

FIG. 2

1 2 3 4 5 6 7 8 9 10 11 12




FIG.4A

Inoculum pattern




FIG.4B




FIG.4C

Spleen pattern





FIG.4D



Name: mpcc2 1

J05534 Escherichia coli ATP-dependent clp
protease proteolytic component (clpP) gene
complete cds. Length = 1236

Minus Strand HSPs:

Score = 453 (125.2 bits), Expect = 4.3e-28, P = 4.3e-28
Identities = 113/141 (80%), Positives = 113/141 (80%),
Strand = Minus

Query is our Salmonella sequence

Query:359 CCACGAGCCGCTGGGTACCAGGCCAGCGCATATTGA 318
|||| | | | ||||| ||||| ||||| ||||| |
Sbjct:785 CCAACCGTTGGCGGCTACCAGGCCAGCGCATATCGA 826
c/pP gene

Query:317 AATTCACGCCCGGAAATTTGAAAGTAAAGGCGCATGAA 276
||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Sbjct:827 AATTCATGCCCGTGAAATCTGAAAGTTAAAGGCGCATGAA 867

Query:275 TGAACCTATGRMKYKMMATACGGTCACTCTTGA 240
||||| ||||| ||||| ||||| ||||| ||||| |||||
Sbjct:868 TGAACCTATGGCGCTTCATACGGGTCAATCATTAGA 904

Query:239 GCAGATTGAASGTGATACTGA 219
||||| ||||| ||||| ||||| ||||| ||||| |||||
Sbjct:905 ACAGATTGAACGTGATACCGA 925

FIG. 5A

FIG. 5B

Score = 231 (63.8 bits), Expect = 4.0e-24,
Poisson P(2) = 4.03-24
I tities = 55/66 (83%), Positives = 55/66 (83%),
Strand = Minus
Query:194 TGAAGCGGTAGAGTACGGTTTGGTTGACTCAATTGACCCA 154
||||| || ||||| ||||| || ||||| |||||
Sbjct:950 TGAAGCGGTGGAATACGGTCTGGTCGATTCGATTCGACCCA 990

Query:153 TCGTAATTGATGCCCTGG 135
||||| ||||| ||||| |
Sbjct:991 TCGTAATTGATGCCAGAG 1009

Query:134 ACGCAA 129
|||||
Sbjct:1010 GCGCAA 1015

Co. to make by 01/10/10
2/11/10 10:10

FIG. 5D

Score = 231 (63.8 bits), Expect = 6.8e-24,
Poisson P(2) = 6.8e-24
Identities = 55/66 (83%), Positives = 55/66 (83%),
Strand = Minus

Query:194	TGAAGCGGTAGAGTACGGTTGGTTGACTCAATTTGACCCA	154
Sbjct:132	TGAAGCGGTGGAATACGGTCTGGTCGATTCTGACCCA	172

Query:153	TCGTAATTGATGCCCTGG	135
Sbjct:173	TCGTAATTGATGCCCAGAG	191

Query:134	ACGCAA	129	Fetch → Gb_ba:Ecoclppa
			- OK then type J Biol Chem 265, 12536
Sbjct:192	GCGCAA	197	(1990)

Continuation of Figure 6A
2000-10-17

A) new virulence factors with similarity to sequenced genes:

1. p1F10

similarity to *clpP* (*E. coli*)

(Figure 5)

2. p2D6

similarity to *lcrD* (*Yersinia* spp.)

sequence p2D6_1_I

GGTCTTAATGTACGGGCATGGTCTGCATCGATAACTCCGGCAGCGCAAATCG
CCATCGATACTCATTTGTTTGGCTGGCATCCCATCAAGCGAGAAACGTGCG
CTAACTTCCGCCACCCTCTCGATACCTTTTGTAATGACAATAAATTGCACG
ATAGTAATGATGGTAAATACGACCAACCCAACGGTGAGATTTCTCCTACG
ACAACTTACCGAAAGCATCCACAAATATTACCGGCATTATGTTGTAACAG
TACCCAGCCGTGATGTGCTGATTGGGGAGTTAACAACCGATTTAT

3. s4C3

probably same gene as p2D6, but different region

similarity to *S. typhimurium invA* and *Yersinia*

spp.lcrD

sequence s4C3_1_U

CGCGGACGCTAGTGTGGTGGGTGACAGCCAGACGTTACCGAACGGGATGG
GGCAGATCTGTTGGCTTACAAAAGACATGGCCCATAAGGCGCAAGGTTTTG
GGACTGGACGTTTTTCGCGGGCAGACAACGTATCTCTGTCTTATTAAATGT
GTCCTGCTTCGGCATATGTATCGAACCCTCGGAGCAAAGTCGTTTGGGCGC
AGAATTAGTACGTTTGGGTGCGTTGCTGTTATTCCTTGGGCTCGGAAAAG
AGTGCCAGCGTGAAGGAGTGGGATTTGGCAGACTGGCCGCCTAAT

sequence s4C3_1_R

CACTATAGGGAAAGCTTGCATGCCTGCAGGTCGACTCTAGAGGATCTACTA
GTCATATGGATTGCACTTGTGTATAAGAGTCAGGATTAGAGGACATGCGCC
GGGAACCATACTATCTTTTTCCGGTGCTTCGACGCCATTTGCGGAAACCAC
AGACTTTTTGCGGCGAATGAGGATAATTGGCAATGCTAACAACGCTGAAAA
GAAAGCGAGAGTGATAAAAGGAAAGCCAGGAATTAAAGCGAGGAGCATTAA
AACCACAGCGGCTAATATGAGCGACTGAGGTTGTCTGGCAATTTG

Figure 6A

4. p3F4
similarity to *invG* (*S. typhimurium*)
sequence p3F4_1_U

TGCAGGCCGACTCTAGAGGATCCCCGGGTACCGGTAATTTCTTTAACCTCG
CATCCCCGGTGGATGAAAGGATATTCTGGCTGCGTAAGTAATGAATGAACCG
CCCAGTAGATAAAATATTGAAAGTGATAACCTGATGTTTTAATAACGATGC
AGGATATACATATAACATGCTGGCATCAAACCAGGTAAGCAAATCATATTG
TGCTGCCAGGTTATTCAAACATATCGACCGGTGGTCCAGGCGGGAATTTTTC
CACTAAATGTAGGTGGGATCAATGGGCTAATTGGTATAGGCGGAT

5. p7G2
similarity to *yscC* (*Yersinia spp.*)
sequence p7G2_1_U

CCTGTGATTCCGGATGAAATAGCTTTTACGAAAGCTGTCAGACNTGCTGAA
GAATACGCTGCAAATGGTAAGCTTGTAACCTTTTGGGTATTGTTCCAACGCA
TGCTGAAACGGGTATATGGATATATTCGTCGCGGTGAGTTGATAGGAAATGA
CGCTTATGCAGTGGCTGAATTTGTGGAGAAACCGGATATCGATACCGCCCG
TGAATTTTCAAATCAGGGGAAATATTACTGGCCTAGCGGCGATGTTTTTA
TTTCGCGCAAAGCCCTTATTTAAACGAATTAAACGTATCTATCACCCCCAA
ATTCATACAGCTTGTGAA

sequence p7G2_3_0

TTACTAAACAGGGCCCCGGACCATGTAAACACCACGCTTGCCAACACTAAA
AAACGATGCTTGCCGTAAAAAAATTGAACGTTATTTACTTAATACGCCTAT
TTTATTTTACATTATGCACGGACAGAGGGTGAGGATTAAATGGATAATATTG
ATAATAAGTATACTCCACAGCTATGTAAAATTTTGGGGGCTATATCGGATT
TGGTTGTTTTTAAATTTAGCCTTATGGCTTTCCTAGGATGTGTCTATTTTT
TTTGTGGTCAAGCACAGAGATTTATTTCCCAACCACC

sequence p7G2_1_I

TTTCCTTGCCGTGACAGTCCGGGATGCGAGGTTAACGAAATTACCGGCACC
AAAGCTGTGGAGGTGAGCGGTGTCCCCAGCTGCCTGACTCGTATTAGTCAA
TTAGCTTCAGTGCTGGATAATGCGTTAATCAAACGAAAAGACAGTGCGGTG
AGTGTAAGTATATACACGCTTAAGTATGCCACTGCGATGGATACCCAGTAC
CATTATCGCGATCAGTCCGTGCTGGTTCCAGGGGTGCCTAGTGTATTGCG
TGAGATGAGTAACACCAGCGTCCCGACGTCATCGACGAACAATGG

Figure 6B

6. p9B7
similarity to *fliQ*, *invX* (*E. coli*)
sequence p9B7_1_I

CATGAGTAACCTACCCAACCTGTAATCTTTACCAATATGCATCATAATCTTC
TGCTGGTAAATGATTGGTAATATCGGAAAGGTAAGTGACATAAGCACGCCA
TTACGTAAAAGTGCGGCCCCCTAAACTGCCACTTTTTTAATAAGGGAAGTAAT
AAAGAAAGGCTCAATGGTTCGAATAAAAGCCACAGCCAATGCAATAAGCCAC
TCATTTACCTGTTGTGCCATTCAACCATGCTCTCCAATTCGTAACATTATC
TGCCGGGTATAATTCAACAGGATACCGCTAAGCCATGGGTAG

sequence p9B7_3_0

ATTCCAGCCCCCGGGCCATCTAACCCTATGAACAATCATCTTCTGGGTGG
ACAATCATTTGGTACCATCGGCCAGGCTTGTGCAATATGTATGTCATCACGT
AAAAGCGCGGCCCTTAATCTCCCCATTCTTCCTTAAGGGCAGTTATCACG
GCTGGCTCAATGGCCGGCTTAACAGCCACAG

7. s6F5
similarity to *yscU* (*Y. enterocolitica*)
sequence s6F5_1_0

GAGGCGCGTCTTCGGTTGAGGGTCGCCCTCCAGATCTTTATGCTCCTGTTT
TACGTCATCTTTACTCATTTTTAAGATCTTTTCTAATCTTATAATATTGAAA
AGAATAGTCCAGTATGCCAACGACGAAATAAAGAAACATCACCCCAACCCA
TAACCATTTTTTTCAATGATGAAAGCACAGCACGCCACAGGCTACACCACA
GCCCCGAGGGGGCCGGAAAGTGCTGGGATCTTGATTAATGAAAAAGGCAAA
GGGAAGAGATAGGATGATGCATGCTGGTTGGAGGCAGATTATTCATCTTCG

Figure 6C

Confidential - 6025 - 3
(13)

B) new sequences without similarity to entries in DNA or protein database:

1. s4D10

sequence s4D10_1_U

AGTTGCCGTATTTATTAAATATTCACCTCAGGTCAATATGGAGGTCTTCCC
GGCTAAAAATCATTGCTTTTACTAGAGATATCACTCCCTGGGTGCAATACA
GTACGATTAGTTATCTTGATGCAGCCTGCTGATTTTCAGAATGGCAGCTGAC
GTACCCGCGAGACAAACATTCTGGATTATGGACGTTATCAACGCCAATATA
GGGAAGGTGGTGAAGTGGTTGATGAAATACCCCTATCCCTTGCATGTTATC
GCTGACAGGACTGTTATCAGGAGCGGGCATCCTCGATCGGCT

sequence s4D10_1_R

CAAGAGACAGATCCAACCTCGGGCCGATCGCCATAACGCCAGCAGTTTGAAA
GATGAAAGCCCAGCTTATCCAGCCATTCCGGTACAGCGTAACGAGCAGGTT
GCCAGAAATAACGATAAAGTTGCAACACCTCGGGATCAGGTCGGCTCAAAA
ACGGGGTCTCAGGCAGAAAATAGCCGATCAGGATGCCCACTCCTAATAACAG
TCCTGTCAACGATAACATCAACGGATAAGGGTATTTTCATCAACCACTTCAC
CACCTTCCCTTTATTGGCGTTGGATAACGTCCATAATCCAGA

2. s4H10

sequence s4H10_1_U

AGGGCTTTATTGATTCCATTTTTTACACTGATGAATGTTCCGTTGCGCTGCC
CGGATTACAGCCGGATCCTCTAGAGTCGACCTGCAGAACCGAGCCAGGAGC
AAATTAATTTTTTTTGGGCAATTGCTGAAAGATGAAGCATCCACCAGTAACG
CCAGTGCTTTATTACCGCAGGTTATGTTGACCAGACAAATAGATTATATGC
AGTTAACGGTAGGCGTCGATTATCTTGTGAGAATATCAGGCGCAGCATCGC
AAGCGCTTAATAAGCTGGGTAAACATGGCATGAAGGGGCAACCC

sequence s4H10_1_R

CACTATAGGGAAAGCTTGCATGCCTGCAGGTGACTCTAGAGGATCTACTA
GTCATATGGATTCCCTAGGCGGCCAGATCTGATCAAGAGACAGATCCAACCTC
GGGCCGATCGCCATAACGCCAGCAGTTTGAAAGATGAAAGCCCAGCTTATC
CAGCCATTCCGGTACAGCGTAACGAGCAGGTTGCCAGAAATAACGATAAAG
TTGCAACACCTCGGGATCAGGTGCGGCTCAAAAACGGGGTCTCAGGCAGAAA
TAGCCGATCAGGATGCCCACTCCTAATAACAGTCCTGTCAACG

Figure 6D

CONFIDENTIAL - 6025 - 3

3. p4G5
sequence p4G5_1_0

CCCCCCCCCTTCTCCTGGCTTACACAGCCCCAGACCGGCGCTGGAAAAGGC
CATTCCCGCCATACAGGAGGCCAGCAACATATTTTCACGCGCCGCCAGATC
GTGGCCGTAACCCACGGCTTTCGGCAGCGATTTGCCAATCATCGCTATCGC
GCCAATCGCCAGGCTGTCTGGTAAACGGCGTGGCGTTGAGCGCGCTGTAGGC
CTCAATCGCATGCGTCAACGCATCGATAACGGTCATCGCCGTCACGTTTGG
CGGAACGCCTTCGGTCACGGAAGCATCAAGAATCGCCACGTCCGGC

sequence p4G5_1_U

CGCGAACGTGCGCCGCAACTGCTTGTGGACGGTGAATTGCAGTTTGACGCC
GCTTTTCGTGCCGGAGGTGCGCCGCGCAAAAAGCGCCTGACAGCCCGCTGCAA
GGCCGCGCCAACGTGATGATTTTCCCGTCGCTGGAGGCGGGCAATATTGGC
TACAAAATCACTCAGCGTCTGGGAGGCTATCGCGCTGTTGGGCCGCTAATT
CAGGGGCTTGGCGCGCCGCTTCACGACCTCTCCCGAGGCTGTAGCGTGCAG
GAAATTATCGAACTGCGGTTGGTGAGAAAACCAA

4. p7A3
sequence p7A3_1_U

CGCCCTAGCATGCCTGGCGTTGTCCGGTTATTGCTCGTCAAGCGAACAGAT
GCAAAAGGTGAGAGCGACTCTCGAATCATGGGGGGTTCATGTATCGGGATGG
TGTAATCTGTGATGACTTATTGGTACGAGAAGTGCAGGATGTTTTTGGATAA
AAATGGGTACCCTGCATGCTGAAGTATCCAGCGAAGGGCCGGGGAGCGTGT
TAATTCATGATGATATACAAATGGATCAGCAATGGCGCAAGGTTCAACCAT
TACTTGCAGATATTCCCGGGTTATTGCACTGGCAGATTAGTCACTCTC

sequence p7A3_1_I

CCCTTCCCAGGCTCGACAGGTACACAGCCAGCCACTGGTGCAGGCAGTTAC
TTGCTTTTCATCATGGGAAGGAGCAATATCCTGATATATTAAAGAAAGAGCG
GGATCCCCCTTTCTTTACTGCTGCTAACGTTTCTTGCAAAATGCGTTGATGA
GATTCATCCAGCACACCACTGATAACAAAAGAGCGCCGCATTGGCGTAACA
TTGACAAGCCCCACTAAACCGCTCTCTATTATCGCAGAAATAATATCATCC
CCCTGAGACTGATGAGAGTGACTATTCTGCCAGCGCAAATAAACC

5. p10E11
sequence p10E11_1

ATACCGAGTATTAAGCGGCTGTGTAACATCGTCATCCAACAACATACGCAG
CGAGCCGCCACGCCGGA AAAACCGCATCGTGTGCATGTGCCTGTTGTAGGGT
CGGGTCTTTTTTTCATGAGTACGTTTTCTGCGCTATCATACTGGAAATTTCC
CCCCACTTACTGATAAGCCCTGTCAGTTGGGTAAAGACAGAGTTAAGCTCC
TGAGACATTTTTTGGAAATGGTTATCTTTCCCCGACTCATAAAATCGGTATT
CCCGCTGGGGGCAATATCCAAGACGCTTTGGTCGCCCCGTAGGGCACC

Figure 6E

Cont. 26 of 27
RPM 1010.7

sequence p10E11_U

GCCGTATGCCTGCAGTTGCCCGGTTATTGCTCGTCAAGCGAACCGATGCCA
AAGGTGAGAGCGACTCTCGAATCATGGGGGGTCATGTATCGGGATGGTGTA
ATCTGTGATGACTTATTGGTACGAGAAGTGCAGGATGTTTTGGTAAAAATG
GGTTACCCCATGCTGAAGTATCCAGCGAAGGGGCGGGGAGCGTGTTAATT
CACGATGATATTCAAATGGGTCAGCAATGGGGCAAGGTTCAACCCCCACTT
GCAGATATTCCCCCCCCCTATTGGACTGGCAGATTAGTCACTCTCA

6. s4B9

sequence s4B9_1_O

GGGCGACCTGCCCGCGGCGCAACTTTCCCCGAAGCGTTTTCCATTTCTTG
TTCTTAAATGACCTGGAAAGCTTACCTAAGCCTTGCTCTTGCCTATGTGACA
ATACTGCTTGGAGAACACCCGGACGTCCATGATTATGCTATACAGATCACA
GCGGATGGGGGATGGTGAATCGGTTATTATACCACAAGTCGCAGCTCTGAG
CTTATTGCTATTGAGATAGAAAAACACCCCGCTTCAACTTGGATTTTGAAT
AATGTAATACGCAATCACCATACTATATTTCGGGTGGCGTATAA

sequence s4B9_1_R

TTCGAGCTGGGGCACCGCTAATATCTTTAACCTCGCATCCCGGTGATGAAA
GGATATTCTGGCTGCGTAAGTAATGAATGAACCGCCAGCAGATAAAATAT
TGACAGTGATAACCCGATGTTTTTTTAACGATGCAGGCTATACATATAACA
TAGCTGGCCACCAACACAGCTGAAGTAAATCATATTGTTGCTGCCAGGCTA
CTTCACACTATTGTCCGGCGGGCCAGCGGGGATTTTCCCCCTAAATCTCGC
TGGTTCTCAAA

7. p4F8

sequence p4F8_1_I

AGTCTACGATTTTCGCTATATCTTCTCTTAATCATGGCCGCCATTTGTGGAT
GCGATTTTAAATATCCGGGCGATCTTTTCATTAAAAAATAAAGATTCCCCA
TGACTTCACAGATAAAGGTATCGGTATTTTGAGTGATACGTAACAATTCTGT
TCTCTTCGTGTGGGTCCATGATGCGAAGAATAATGGTGGCATCATTTTCAT
GAGGATTATGAACCCGAAATCTTTCTCTTTGCGATGCGCAGGCTAACTCTT
TCAACTCAAAAAAATCTCTGTAAGCCGCTCTCGTGTGGGGGCGC

8. p7B8

sequence p7B8_1_O

GCGCCCCTTTAATTGGTTGAGGCGGCTGGTATTCTTGTAAGGGTAATACTA
GCGAGACCCAGGTTCCACCCCCGGGGACACTTTTGTAGTGTCAGATTACCGC
CCATCATTTTGTAGCCAGGCTTGACGCAATAGTCAGTCCAATTCTGTACCTT
GCGAATTTGTGTCTGCTTGATAAAAAGCAGAAAAGATTTGAGACTGCTGCT
GTTTTTCAATCCCCCACCAGCTATCGCTAACCAGAAATATTAATTGTTCTT
CACCAAGATTGAGCGCCAGACGTATCCCTCCCCCCTCGGGAAAT

Figure 6F

0944500.4.4.00

9. p8G12
sequence p8G12_1_I

GGATAAGATCCCGGATAAGTATGTCAGGCTCGTATGCACAACAGGCATTAT
AAACCTCTAGACCATTTTTTAACATGCTCTACTATTTTAAAATGAGGCCAGG
GTAATAAGGCATTCATAATGCCGTTAATGATGATTTTCATGATCGTCTACTA
ATAAGATCTTATATTCTTTTCATTTGGCTGCCCTCGCGAAAATTAAGATAAT
ATTAAGTAATGGTGTAGGTTGTGGAGATCATACTGATTTTTCTGGCGTAAGT
CGGTTAGTTCCTCCAGCGCGATGATTTTCCCCATTTTTTACGCGAT

10. p9G4
sequence p9G4_1_O

TTCCATATTGCTCGTCCGGGGAGCGTGTTAATTCTTGATGATATACCAATG
GATCTGCAATGGCGCAAGGTTCAACCATTACTTGGAGATATTCCTGGGTTA
TTGTACTGGGAGATTAGTCACTCTCATCAGTCTCAGGGGGGTGATGTTATT
TCTGGGATAATAGAGCAACGGCGTTAGCAGGGGTTCGGTCAGTAGTCACGGC
CAACTTCGGTGCACTTTTGCGTATCACTGGGGTATCATAACTGAATCTCAT
CCCCCCCCACTTTGGTAATCACAC

sequence p9G4_1_U

AATTCTTTTACCTCCATAAGCTGCGTGGCATAGCGATACAGAGTATTAAGC
GGGTGTGTTACATCGTCATCCAACAACATACGCAGCGAGCCGCCACGCCGG
AAAAACCGCATCGTGTTCATGTGCCTGTTGTAGGGTTCGGGTCTTTTTTTTCAT
GAGTACGTGTTCTGCGCTATCATACTGGAAATTTCCCCCCTTACTGATA
AGCCCTGTCAGTTGGGTAAAGGACAGCGTTAAGCTCCTGAGACATTTTTTTGA
GTTGTTATCTGCCCCCGACTCATAAGATCGGGTATTCCGCGGTGG

11. p9B6
sequence p9B6_1

ATATCCCTAATGCTTTTCTTAAATAAATACCACGGAAGGATACTGGCCA
CCTAGCCAAATTTAGAAAGCAATGAACATCCGGTTTATTCCTGAAAACGAT
TACTCCGGCGCACGTTGTTCTGGCGTTACCTGAGCCAGCAAACGATATAAT
GGGGTGGTGACCCGCATACCGGTCATTGGCATCCCATCCACACCGGAGGGA
GTAAAACTCATTAGGCCATAGGTAATATCATTAAGACGCTCTAATAAATGA
GGGTGGGGGGCCCAAACCTACCACTCCAGTATGTATTGAGTCA

Figure 6G

Chen et al. 1996
BMC Biol. 4(1):1-10

12. p6G5
sequence p6G5_2_1

CCCATGGGCGCAATTTGTTGCGCAGCGTTTACCCGACCATCGCGTTTATGA
GCTGTAATTCATGGGGGGTAAAAACGGGCGTGACGACCCCAACGGAAGATA
AGGCCGGGCTTAAACAGGAGATTATTGCTAATGCGCAGCGCAAAGTGTTGC
TGGCGGACAGCAGTAAGTATGGCGCGCATTCGCTCTTTAATGTGGTGCCGC
TTGAGCGCTTTAATGACGTGATTACCGACGTCAATCTGCCGCCGTCAGCGC
AGGTTGAACTGAAAGGGCGCGCTTTTTGCGCTAACG

Figure 6H

009117 2034760

00911" 20911" 250





FIG. 7A

FIG. 7B








FIG. 8C




[illegible]

Colony morphology of *S. typhimurium* and *S. typhi*

FIG. 10A

Pst I




- S. typhimurium*
- S. aberdeen*
- S. gallinarum*
- S. cubana*
- S. typhi*
- EPEC
- EHEC
- Y. pestis*
- S. flexneri*
- V. cholera*
- S. aureus*

FIG. 10B

Hind III

Eco RV



- S. typhimurium*
- S. aberdeen*
- S. gallinarum*
- S. cubana*
- S. typhi*
- S. typhimurium*
- S. aberdeen*
- S. gallinarum*
- S. cubana*
- S. typhi*

09714602, 111600

CTTAATAAGCTGGATAACATGGCATGAAGTTCATCGTATAGTATTTCTTACTGTCCCTTA
-----+-----+-----+-----+-----+-----+-----+
GAATTATTCGACCTATTGTACCGTACTTCCAAGTAGCATATCATAAAGAATGACAGGAAT

a
b
c

CGTTCTTTCTTACGGCATGTGATGTGGATCTTTATCGCTCATTTGCCAGAAAGATGAAGCGA
-----+-----+-----+-----+-----+-----+-----+
GCAAGAAAGAATGCCGTACACTACCTAGAAATAGCGAGTAACGGTCTTCTACTTCGCT

```

a      R S F L R H V M W I F I A H C Q K M K R
b      V L S Y G M - C G S L S L I A R R - S E
c      F F L T A C D V D L Y R S L P E D E A N
      start yscJ*?
      ATCAAATGCTGGCATTACTTATGCAGCATCATATTGATCGGAAAAAACAAGAGGA
      -----+-----+-----+-----+-----+-----+
      TAGTTACGACCGTAATGAATACGTCGTAGTATACTACGCTTTTITGTCTTCTCCT
301
360

```

a I K C W H Y L C S I I L M R K K T G R G
b S N A G I T Y A A S Y - C E K K Q E E D
c Q M L A L M Q H H I D A K K N R K R M

Figure 11B

Continuation of exhibit
R1470-12 (b)(3)

541 TTGAAGGAATGCTGAGTCAGATGGAGGGCGTGATTAATGGCAAAAGTGACCATTCGGCT 600
 -----+-----+-----+-----+-----+-----+-----+
 AACTTCCTTACGACTCAGTCACCTCCCGCAGTAAATACCGTTTTCACCTGGTAACGCCGA
 a L K E C - V R W R G V I N G K S D H C A
 b - R N A E S D G G A - L M A K V T I A L
 c E G M L S Q M E G R D - W Q K - P L R Y
 601 ACCGACTTATGATGAGGGAAGTAACGCTTCTCCGAGCTCAGTTGCCGTATTATAAAATA 660
 -----+-----+-----+-----+-----+-----+-----+
 TGGCTGAATACTACTCCCTTCATTGCGAAGAGGCTCGAGTCAACGGCATAAATATTTAT
 a T D L - - G K - R F S E L S C R I Y K I
 b P T Y D E G S N A S P S S V A V F I K Y
 c R L M M R E V T L L R A Q L P Y L - N I
 661 TTCACCTCAGGTCAATATGGAGGCCCTTTCGGTAAATAAAGATTAAATAGAGATGTC 720
 -----+-----+-----+-----+-----+-----+-----+
 AAGTGGAGTCCAGTTATACCTCCGGAAAGCCCATTTTAAATTCTCTAAATTATCTCTACAG
 a F T S G Q Y G G L S G K N - R F N R D V
 b S P Q V N M E A F R V K I K D L I E M S
 c H L R S I W R P F G - K L K I - - R C Q

Figure 11D

Continued by 009111"20941460
 (Page 10 of 13)

009111" 20941460
1000 1000

Tn insertion P11H11

ACTGTTATTAGGAGTGGGCATCCTGATCGGCTATTTTTCCTGAGACGCCGTTTGTGAGC 960
-----+-----+-----+-----+-----+-----+-----+
TGACAAATAATCCTCACCCGTAGGACTAGCCGATATAAAACGGACTCTGCGGCAAAACTCG

901

a T V I R S G H P D R L F L P E T P F L S
b L L L G V G I L I G Y F C L R R R F - A
c C Y - E W A S - S A I F A - D A V F E P

CGACCTGATCCCGAGGTGTGCAACTTTATCGTTATTTCTGGCAACCTGCTCGTTACGCT
-----+-----+-----+-----+-----+-----+
GCTGGACTAGGCTCCACAACTTGAAATAGCAATAAAGACCGTTGGACGAGCAATGCGA 1020

961

a R P D P E V L Q L Y R Y F W Q P A R Y A
b D L I P R C C N F I V I S G N L L V T L
c T - S R G V A T L S L F L A T C S L R C
Tn insertion P11D10

GTACCGGAATGGCTGGATAAGCTGGGCTTTTCATCTTCAAACCTGCTGGCGTTATGGCGATC
-----+-----+-----+-----+-----+-----+
CATGGCCTTACCGACCTATTTCGACCCGAAAGTAGAAGTTTGACGACCGCAATACCGCTAG 1080

1021

a V P E W L D K L G F H L Q T A G V M A I
b Y R N G W I S W A F I F K L L A L W R S
c T G M A G - A G L S S S N C W R Y G D R

Figure 11F


```

1081  GGCCCCGAGTTGGATCGTCTTCTTGACAGAGCGTTAAATAGACTAAGAGGAGCTCTGTTA 1140
-----+-----+-----+-----+-----+-----+-----+
CCGGGCTCAACCTAGCAGAAGAACTGTCTCGCAATTTATCTGATTCTCCTTCGAGACAAT

      G P S W I V F L T E R - I D - E A L L
      A R V G S S - Q S V K - T K R K L C
      P E L D R L L D R A L N R L R G S S V I

1141  TTCCAGCCCTGTTAAATGACAGGCAAAAACGGCAGGTTCTGCTTGGCCGCGTATATCGG 1200
-----+-----+-----+-----+-----+-----+-----+
AAGTCGGACAAATTTACTGTCCGTTTTCGCGTCCAAGCAGAACGGCGGCATATAGCC

      F Q P V - M T G K N G R F V L R R V Y R
      S S L F K - Q A K T A G S S C A A Y I G
      P A C L N D R Q K R Q V R L A P R I S A

1201  CATTTGCCCTTTGGGCTGGGATTATTCAAACTCAGGTGTAGTGACTATTTTATGCTACCAG 1260
-----+-----+-----+-----+-----+-----+-----+
GTAAACGGAAACCCGACCCCTAATAAGTTTGAGTCCACATCACTGATAAAATACGATGGTC

                                     start lcrE*?
      H L P L G W D Y S N S G V V T I L C Y Q
      I C L W A G I I Q T Q V - - L F Y A T R
      F A F G L G L F K L R C S D Y F M L P E

```

Figure 11G

Continuation of 009T1"2094T250
(11/11/19)

1261 AGTATCGGCAATTGCTTCTACAGTGGTTTAGCGAGGATGAGATCTGGCAGCTATATGGTT 1320
-----+-----+-----+-----+-----+-----+-----+-----+
TCATAGCCGTTAACGAAGATGTCACCAAAATCGCTCCTACTCTAGACCGTCGATATACCAA

a S I G N C F Y S G L A R M R S G S Y M V
b V S A I A S T V V - R G - D L A A I W L
c Y R Q L L L Q W F S E D E I W Q L Y G W

1321 GGTTGGGGCAAAGAGATGGCAAATTACTTCTCCGCAAGTGATGCAACAACTGCATTGC 1380
-----+-----+-----+-----+-----+-----+-----+-----+
CCAAACCCCGTTTCTCTACCGTTTAATGAAGAGGCGTTCACTACGTTGTTTGACGTAACG

a G W G K E M A N Y F L R K - C N K L H C
b V G A K R W Q I T S S A S D A T N C I A
c L G Q R D G K L L P P Q V M Q Q T A L Q

1381 AGATCGGTACCGCCATTCTTAATCGGGAAGCGCATGACGATGCGGGTTTACATGCGCTA 1440
-----+-----+-----+-----+-----+-----+-----+-----+
TCTAGCCATGGCGTAAGAAATTAGCCCTTCGCGTACTGCTACGCCCCAAATGTACGCGAT

a R S V P P F L I G K R M T M R V L H A L
b D R Y R H S - S G S A - R C G F Y M R Y
c I G T A I L N R E A H D D A G F T C A I

Figure 11H

1441 TTAGTATTATACCCCTCCGAGCGGTATACTTTGGCCGAAGACTTCTCTTACCGAGATT 1500
 -----+-----+-----+-----+-----+-----+-----+
 AATCATAATAATGGGAGCGTCGCATATGAAACCGGCTTCTGAAGAGAATGGCTCTAA
 L V L L P P P Q R I L W P K T S L T E I
 - Y Y Y P L R S V Y F G R R L L L P R L
 S I I T P S A A Y T L A E D F S Y R D Y

1501 ATCTTCATGGAGCATTTGCTATGAGTTTACTTCACTTCCTCTGACGGAATTAACCATA 1560
 -----+-----+-----+-----+-----+-----+-----+
 TAGAAGTACCTCGTAAACGATACTCAAAATGAAGTGAAGGAGACTGCCCTTTAATTGGTAT
 I F M E H L L - V L L H F L - R K L T I
 S S W S I C Y E F Y F T S S D G N - P -
 L H G A F A M S F T S L P L T E I N H K

1561 AGCTACCCGCTCGAAATATTATTGAGTCACAGTGGATAACATTACAATTACTTTATTG 1620
 -----+-----+-----+-----+-----+-----+-----+
 TCGATGGCGAGCTTTATAATAACTCAGTGTACCTATTGTAATGTTAATTGAAATAAAC
 S Y P L E I L L S H S G - H Y N - L Y L
 A T R S K Y Y - V T V D N I T I N F I C
 L P A R N I I E S Q W I T L Q L T L F A

Figure 11I

1621 CGCAAGAGCAACAAGCTAAGAGAGTTTACATGCTATTGTGAGCTCCGCTTACCGTAAGG 1680
 -----+-----+-----+-----+-----+-----+-----+
 GCGTTCTCGTTGTTTCGATTCTCTCAAAGTGACGATAACACTCGAGGCGAATGGCATTCC
 a R K S N K L R E F H M L L - A P L T V R
 b A R A T S - E S F T C Y C E L R L P - G
 c Q E Q Q A K R V S H A I V S S A Y R K A

1681 CTGAAAAAATCATCCGAGACGCCCTATCGTTATCAGCGTGAACAGAAAGTTGAGCAGCAAC 1740
 -----+-----+-----+-----+-----+-----+-----+
 GACTTTTGTAGGCTCTGCGGATAGCAATAGTCGCACTTGTCCTTCAACTCGTCGTTG
 a L K K S S E T P I V I S V N R K L S S N
 b - K N H P R R L S L S A - T E S - A A T
 c E K I I R D A Y R Y Q R E Q K V E Q Q Q

1740 AAGAACTAGCGTGCTTGCGTAAATAACGCTGGAATAATGGAAGTGGAATGGCTGGAAC 1800
 -----+-----+-----+-----+-----+-----+-----+
 TTCTTGATCGCACGAACGCATTTTATGCGACCTTTTACCTTACCTTACCGACCTTG
 a K N - R A C V K I R W K K W K W N G W N
 b R T S V L A - K Y A G K N G S G M A G T
 c E L A C L R K N T L E K M E V E W L E Q

Figure 11J

RPm13 10/1002 (2)

1981 CGCTTTATTGCGTATTCATCCTGAAAAAGAGGCATTGATGCGAGAAACTTTTGGCAAGC 2040
 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+
 GCGAAATAACGCATAAGTAGGACTTTTCTCCGTAACTACGCTCTTTGAAAAACCGTTTCG
 a R F I C V F I L K K R H - C E K L L A S
 b A L F A Y S S - K R G I D A R N F W Q A
 c L Y L R I H P E K E A L M R E T F G K R
 2040 GGTTACGTTGATTATCGAGCCTGGTTTCTCTCCGATCAGGCTGAACCTTCTCAACAC 2100
 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+
 CCAAATGCAACTAATAGCTCGGACCAAGAGAGGGCTAGTCCGACTTGAAAGGAGTTGTG
 a G L R - L S S L V S L P I R L N F P Q H
 b V Y V D Y R A W F L S R S G - T F L N T
 c F T L I I E P G F S P D Q A E L S S T R
 2101 GATATGCCGTTGAATTTTCACTTTCTCGTCATTTCAACGCGTTACTGAAATGTTACGTA 2160
 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+
 CTATACGGCAACTTAAAGTGAAAGAGCAGTAAGTTGCGCAATGACTTTACCAATGCAT
 a D M P L N F H F L V I S T R Y - N G Y V
 b I C R - I F T F S S F Q R V T E M V T -
 c Y A V E F S L S R H F N A L L K W L R N

Figure 11L

009111" 20941260
R218 0111 (3)

2161 ATGGTGAAGATAAAAGAGGTAGCGATGAATATTAATAATGAGATAAAATGACGCC 2220
-----+-----+-----+-----+-----+-----+
TACCACTTCTATTTCTCCATCGCTACTTATAATTTTAAATTACTCTATTTTACTGCGGG
M V K I K E V A M N I K I N E I K M T P
W - R - K R - R - I L K L M R - K - R P
G E D K R G S D E Y - N - - D K N D A P
2221 CCTACAGCATTTACCCCTGGCCAGGTTATAGAGGAACAAGAGGTTATTTCGCTTCAATG 2280
-----+-----+-----+-----+-----+-----+
GGATGTCGTAAATGGGACCGGTCCAATATCTCCTTGTTCTCCAATAAAGCGGAAGTTAC
P T A F T P G Q V I E E Q E V I S P S M
L Q H L P L A R L - R N K R L F R L Q C
Y S I Y P W P G Y R G T R G Y F A F N V
2281 TTAGCTCTCCAGGATTACAGGAACGACGGGGCAGCGCTCTATGAGACGATGGAAGAA 2340
-----+-----+-----+-----+-----+-----+
AATCGAGAGTCCCTCAATGTCCTTTGCTGCCCGCCGTCGCGAGATACTCTGCTACCTTCTT
L A L Q E L Q E T T G A A L Y E T M E E
- L S R S Y R K R R G Q R S M R R W K K
S S P G V T G N D G G S A L - D D G R N

Figure 11M

ATTATCGCTCTTGCAATGGCGCTTACTGCCGGGTTGTCAAAAAGAAAAACGCGAT
 -----+-----+-----+-----+-----+-----+-----+ 2580
 TAATACGAGAACGTTACCGCGAATGACGGCCGCCAACAGTTTTCCTTTTTCGCGCTA

a	I	I	A	L	A	M	A	L	T	A	G	G	L	S	K	K	K	K	R	D
b	L	S	L	L	Q	W	R	L	L	P	A	G	C	Q	K	R	K	N	A	I
c	Y	R	S	C	N	G	A	Y	C	R	R	V	V	K	K	E	K	T	R	F

TTGCAATCGCAACTGGATACGTTACAGCGGAGGATGGAACTTGCCGTTTTAGTT
 -----+-----+-----+-----+-----+-----+-----+
 AACGTTAGCGTTGACCTATGCAATGTCGCCCTCCTCCCTACCCCTTGAAACGGCAAAATCAA
 2640

a L Q S Q L D T L Q R R R D G N L P F L V
b C N R N W I R Y S G G M G T C R F - F
c A I A T G Y V T A E E G W E L A V F S L

TACTGGAAC TTGGCGAAG TGGATACCGTACGCTGTCTCTGAAGCGTTTATGCAACA
 -----+-----+-----+-----+-----+-----+-----+
 ATGACCTTGAACCGCTTCACCTATGGCATGCGACAGAGAGACTTCGCAAAATACGTTGT

a Y W N L A K W I P Y A V L S E A F Y A T
b T G T W R S G Y R T L S S L K R F M Q Q
c L E L G E V D T V R C P L - S V L C N R

Figure 110

2701 GCGATAGACAAAGATGAAATGCCCTTATCGCAGTGGTTGAGACGCGTGGCAGACTGGCC 2760
 -----+-----+-----+-----+-----+-----+-----+-----+
 CCGCTATCTGTTGCTACTTTACGGGAATAGCGTCACCAAGTCTGCGCACCGTCTGACCGG
 a G D R Q R - N A L I A V V Q T R G R L A
 b A I D N D E M P L S Q W F R R V A D W P
 c R - T T M K C P Y R S G S D A W Q T G R
 2761 GGATCGCTGTGAACGGTCCGTATTTTGCTAAGACGAGTAGCCTTTGAACCTTAGCATATG 2820
 -----+-----+-----+-----+-----+-----+-----+-----+
 CCTAGCGACACTTGCCCGGCATAAACGATTCTCGTCATCGGAAACTTGAATCGTATAC
 a G S L - T G P Y F A K S S L - T - H M
 b D R C E R V R I L L R A V A F E L S I C
 c I A V N G S V F C - E Q - P L N L A Y A
 2821 CATCGAACCTCGGAGCAAAGTCGTTTGGCCGAGCATTAGTACGTTTGCCTGTTGCT 2880
 -----+-----+-----+-----+-----+-----+-----+-----+
 GTAGCTTGGAGCCTCGTTTCAGCAAACCGGCGTCGTAATCATGCAAAACGCAGCAAAACGA
 a H R T L G A K S F G R S I S T F A S F A
 b I E P S E Q S R L A A A L V R L R R L L
 c S N P R S K V V W P Q H - Y V C V C C

Figure 11P

Continuation of 09/20/95
RPMs 10125(3)

2881 GTTATTCCTTGGCCTTGAAAAAGAGTGCCAGCGTGAGGAGTGGAATTGCCAGTTGCCGCC
-----+-----+-----+-----+-----+-----+-----+ 2940
CAATAAGGAACCGAACTTTTCTCACGGTCGCACCTCCTCACCTAAACGGTCAACGGCGG

a V I P W P - K R V P A - G V D L P V A A
b L F L G L E K E C Q R E E W I C Q L P P
c Y S L A L K K S A S V R S G F A S C R L

2941 TAATACATTACTGCCGCTACTACTCGATATTATTGTGAGCGCTGGCTTTTCAGTGATTG
-----+-----+-----+-----+-----+-----+ 3000
ATTATGTAATGACGGCGATGATGAGCTATAATAAACACTCGCGACCGAAAAGTCACTAAC

a - Y I T A A T T R Y Y L - A L A F Q - L
b N T L L P L L L D I I C E R W L F S D W
c I H Y C R Y Y S I L F V S A G F S V I G

3001 GTTGCTTGATAGACTTACCGCTATAGTTTCTTCATCGAAGATGTTCAATCGGTTACTCCA
-----+-----+-----+-----+-----+-----+ 3060
CAACGAACTATCTGAATGGCGATATCAAGAAGTAGCTTCTACAAGTTAGCCAATGAGGT

a V A - - T Y R Y S F F I E D V Q S V T P
b L L D R L T A I V S S S K M F N R L L Q
c C L I D L P L - F L H R R C S I G Y S N

Figure 11Q

Continued by 0-1301-743
R112 (0-112)

3241 GGATCTCATTAAGTAATATTCAGCTTTTATTCAATTAGCAGGATTAGCTGAACG 3300
-----+-----+-----+-----+-----+-----+
CCTAGAGTAATGACTTGCAATTATAAGTCGAAAAATAAGTTAATCGTCCTAATCGACTTGC

a G S H Y - T - Y S A F Y S I S R I S - T
b D L I T E R N I Q L F I Q L A G L A E R
c I S L L N V I F S F L F N - Q D - L N G

3301 GCCTTAGCAACCAATATGTTCTGGCGGCAAGACAATAATGAAACTATCATAACGGTCGT 3360
-----+-----+-----+-----+-----+-----+
CGGAAATCGTTGTTATACAAGACCGCGTTCCTGTTATACTTTGATAGTATTGCCAGCA

a A F S N Q Y V L A A R T I - N Y H N G R
b P L A T N M F W R Q G Q Y E T I I T V V
c L - Q P I C S G G K D N M K L S - R S Y

3361 ATTCTTTATGTCAGATACTCAAGCAAACCTTCTTAGACGAGAACTGCTTTTAAAGCG 3420
-----+-----+-----+-----+-----+-----+
TAAGAGAATACAGTCTATGAGTTCGTTTGGAAGAATCTGCTTCTTGACGAAAAATTTTCGC

a I L L C Q I L K Q T F L D E E L L F K A
b F S Y V R Y S S K P S - T K N C F L K R
c S L M S D T Q A N L L R R R T A F - S V

Figure 11S

003111" 20941460
R1111111(3)

3421 TTGGCTAACTGGAACCCGACGCTTCCAGGTATTCCTCAACGATTATTTTGTTCGC 3480
-----+-----+-----+-----+-----+-----+
AACCGATTGACCTTTGGCGTCGCAAGGTCCCATAGGAGTTGCTAATAAAACAACGCG
L A N W K P A A F Q G I P Q R L F L L R
W L T G N P Q R S R V F L N D Y F C C A
G - L E T R S V P G Y S S T I I F V A R

3481 GATGGCTTGCAATGAGTTGTTCTCCACCTCTTCCAGCTCCGCCGAGCTCTGGTTACGA 3540
-----+-----+-----+-----+-----+-----+
CTACCCGAACGTTACTCAACAAGAGGTGGAGAAAGTTCGAGCGGCTCGAGACCAATGCT
D G L A M S C S P P L S S S A E L W L R
M G L Q - V V L H L F P A P S S G Y D
W A C N E L F S T S F Q L R R A L V T I

3541 TTACATCATCGACAAATAAAATTCNTGGAGTCGCAATGCGTTTCATGTTAGTGAGGGA 3600
-----+-----+-----+-----+-----+-----+
AATGTAGTAGCTGTTTATTTTAAAGNACCTCAGCGTTACGCAAGTACCAATCCACTCCCT
L H H R Q I K F X G V A M R S W L G E G
Y I I D K - N F X E S Q C V H G - V R E
T S S T N K I X W S R N A F M V R - G S

Figure 11T

3601 GTCAGGGCGCAACAGTGGCTCAGTGATGCGGGTCCGGCAGGATATGGTTCTGGCGACG 3660
 -----+-----+-----+-----+-----+-----+-----+
 CAGTCCCGGTTGTCACCGAGTCACATACGCGCCAGCGTCCTATACCAAGACCGCTGC

start lcrD*
 a V R A Q Q W L S V C A G R Q D M V L A T
 b S G R N S G S V Y A R V G R I W F W R R
 c Q G A T V A Q C M R G S A G Y G S G D G

3661 GTGTTATTAATCGCTATTGTGATGCTGTTACCCCTTGCCGACCTGGATGGTTGATATC 3720
 -----+-----+-----+-----+-----+-----+-----+
 CACAATAATTAGCGATAACACTACTACGACAATGGGAACGGCTGGACCTACCAACTATAG

a V L L I A I V M M L L P L P T W M V D I
 b C Y - S L L - - C C Y P C R P G W L I S
 c V I N R Y C D D A V T L A D L D G - Y P

3721 CTGATTACTATCAACCTTATGTTTTCAGTGATCCCTGCTCTTAATTGCTATTATCTTAGT 3780
 -----+-----+-----+-----+-----+-----+-----+
 GACTAATGATAGTTGGAATACAAAAGTCACCTAGGACGAGAAATTACGATAAATAGAAATCA

a L I T I N L M F S V I L L L I A I Y L S
 b - L L S T L C F Q - S C S - L L F I L V
 c D Y Y Q P Y V F S D P A L N C Y L S - -

Figure 11U

3961 ATCATTACTATCGTGCAATTATTGTCATTACAAAAGGTATCGAGAGGGTGGCGGAAGTT 4020
 -----+-----+-----+-----+-----+-----+-----+
 TAGTAATGATAGCACGTTAAATAACAGTAATGTTTCCATAGCTCTCCACCGCCTTCAA
 a I I T I V Q F I V I T K G I E R V A E V
 b S L L S C N L L S L Q K V S R G W R K L
 c H Y Y R A I Y C H Y K R Y R E G G S -

4021 AGCGCACGTTTCTCGCTTGATGGGATGCCAGGCAAAACAATGAGTATCGATGGCGATTG 4080
 -----+-----+-----+-----+-----+-----+-----+
 TCGCGTGCAAGAGCGAACTACCCCTACGGTCCGTTGTTTACTCATAGCTACCGCTAAAC
 a S A R F S L D G M P G K Q M S I D G D L
 b A H V S R L M G C Q A N K - V S M A I C
 c R T F L A - W D A R Q T N E Y R W R F A

Tn insertion P2D6
 ↓

4081 CGTGCCGAGTTATCGATGCAGACCATGCCCGTACATTAAAGACAGCATGTCCAGCAGGAA 4140
 -----+-----+-----+-----+-----+-----+-----+
 GCACGGCCTCAATAGCTACGTCTGTTACGGGCATGTAATTCTGTCTACAGGTCGTCCCTT
 a R A G V I D A D H A R T L R Q H V Q Q E
 b V P E L S M Q T M P V H - D S M S S R K
 c C R S Y R C R P C P Y I K T A C P A G K

Figure 11W

Colony hybridization
of P2D6

TGTGGCAAATTCCATCGCTGCTGATTTCCTTAGCGGGGAATTATTGTACCCGTGTC 4380
 -----+-----+-----+-----+-----+-----+-----+
 ACACCCGTTTAAGGTAGCAGCACTAAAGGAATCGCGCCCTTAATAACAGTGGGCACAG

4321

a C G Q I P S L L I S L S A G I I V T R V
 b V G K F H R C - F P L A R E L L S P V S
 c W A N S I A A D F P - R G N Y C H P C P

CCGGTGAGAAACGCCAGAACCTGGCGACAGAGTTGAGTTCTCAAATTGCCAGACAACCT 4440
 -----+-----+-----+-----+-----+-----+-----+
 GGCCCACTCTTGGGCTTGGACCGCTGTCTCAACTCAAGAGTTTAAACGGTCTGTTGGA

4481

a P G E K R Q N L A T E L S S Q I A R Q P
 b R V R N A R T W R Q S - V L K L P D N L
 c G - E T P E P G D R V E F S N C Q T T S

CAGTCGCTCATATAACCGCTGTGGTTTAAATGCTCCTCGCTTTAATTCCTGGCTTTCCT 4500
 -----+-----+-----+-----+-----+-----+-----+
 GTCAGCGAGTATAATTGGCGACACCAAAATTACGAGGAGCGGAAATTAAGGACCGAAAGGA

4441

a Q S L I L T A V V L M L L A L I P G F P
 b S R S Y - P L W F - C S S L - F L A F L
 c V A H I N R C G F F N A P R F N S W L S F

Figure 11Y

TTTATCACTCTCGCTTCTTTTCAGCGTTGTTAGCATTGCCAATTATCCTCATTCGCCGC
 -----+-----+-----+-----+-----+-----+-----+ 4560
 AATAGTGAGAGCGAAGAAAAGTCGCAACAATCGTAACGGTTAATAGGAGTAAGCGGCG

a b c

Tn insertion P11C3

4561
 AAAAAGTCTGTGTTTCCGCAAAATGGCGTCGAAGCACCGGAAAAAGATAGTATGGTTCCC
 4620
 TTTTTCAGACACCAAGGCGTTTACCGCAGCTTCGTGGCCTTTTCTATCATACCAAGG

a
b
c

4621
GGCGCATGTCCTCTAATCTTACGCTTAGCCCGACGTTACATTCTGCCGACCTGATTCGT
-----+-----+-----+-----+-----+-----+ 4680
CCGCGTACAGGAGATTAGAAATGCAGAAATCGGGCTGCAATGTAAAGACGGCTGGACTAAGCA

a G A C P L I L R L S P T L H S A D L I R V
b A H V L - S Y V L A R R Y I L P T - F
c R M S S N L T S - P D V T F C R P D S -

Figure 11Z

Continuation of page 10
R.R. 10/10/10

00347 2034760
2034760(3)

5221 GATGTCTGATGTTGACAGAATAATGTCGGTATCGCGCTTCGTCGTCAATTTCTGCGTCGT 5280
-----+-----+-----+-----+-----+-----+-----+-----+
CTACAGGACTACAACTGTCTTATACAGGCATAGCGGAAGCAGCAGTATAAGACGCAGCA

a D V L M L T E Y V R I A L R R H I L R R
b M S - C - Q N M S V S R F V V I F C V V
c C P D V D R I C P Y R A S S S Y S A S S

5281 CTTAATCCGGAAGGAAACCGCTGCCGATTTTGGGATCGCGAAGGTATTGAAAACCTC 5340
-----+-----+-----+-----+-----+-----+-----+-----+
GAATTAGGCCCTTCCCTTTGGCGACGGCTAAACGCCCTAGCCGCTTCATAACTTTTGGAG

a L N P E G K P L P I L R I G E G I E N L
b L I R K E N R C R F C G S A K V L K T S
c - S G R K T A A D F A D R R R Y - K P R

5341 GTGCGTGAATCCATTCGCCAGACGGCAATGGGACCTATACTGCGCTGTCTCGTCAT 5400
-----+-----+-----+-----+-----+-----+-----+-----+
CAGCCTTAGGTAAGCGGTCTGCCGTTACCCCTGGATATGACGCGACAGCAGCAGCAGTA

a V R E S I R Q T A M G T Y T A L S S R H
b C V N P F A R R Q W G P I L R C R L V I
c A - I H S P D G N G D L Y C A V V S S -

Figure 11AD

GenBank: 2034450
RPM 1000000

AAGACGAGATCCTGCAACTTATCGAGCAGCGCTGAAGCAGTCAGCCAAATTATTCATT 5460
-----+-----+-----+-----+-----+-----+-----+
TTCGCGCTAGGACGTTGAATAGCTCGTCGCGACTTCGTCAGTCGGTTTAATAAGTAA

5401

a K T Q I L Q L I E Q A L K Q S A K L F I
b R R R S C N L S S R R - S S Q P N Y S L
c D A D P A T Y R A G A E A V S Q I I H C

GTCACCTTCTGACACCCGACGTTTCTTGCAGAAAATTACAGAAGCCACCTTGTTCGAC 5520
-----+-----+-----+-----+-----+-----+-----+
CAGTGAAGACAGCTGTGGGCTGCAAGAAGCGCTTTTAAATGTCTTCGGTGGAAACAAGCTG

5461

a V T S V D T R R F L R K I T E A T L F D
b S L L S T P D V S C E K L Q K P P C S T
c H F C R H P T F L A K N Y R S H L V R R

GTACCGATTTGTGTCAGGAAATTAGGAGAGGAGAGCCCTTATACAAGTGGTAGAAAGT 5580
-----+-----+-----+-----+-----+-----+-----+
CATGGCTAAAACAGTACCGTCCTTAATCCTCTCCTCCTCGGAATATGTTACCATCTTTCA

5521

a V P I L S W Q E L G E E S L I Q V V E S
b Y R F C H G R N - E R R A L Y K W - K V
c T D F V M A G I R R G E P Y T S G R K Y

Figure 11AE

5581 ATTGACCTTAGCGAAGAGGAGTTGGCGGACAAATGAAGAAATGATGCAACGCTGAG 5640
-----+-----+-----+-----+-----+-----+-----+
TAACTGGAATCGCTTCTCCTCAACCGCCTGTACTTCTTACTTAACTACGTTGCAGACTC
a I D L S E E E L A D N E E - I D A T S E start yscN*?
b L T L A K R S W R T M K N E L M O R L R end lcrD*
c - P - R R G V G G Q - R M N - C N V - G
5641 GCTGAAATATCCGCCCCCGATGTTATTGTCGATGGGGCCGAATTCAGGATGTCAGCGC 5700
-----+-----+-----+-----+-----+-----+-----+
CGACTTTATAGCGGGGGCTACCAATAACAGCTACCCGGCTTAAGTCTACAGTCGCGG
a A E I S A P R W L L S M G P N S G C Q R
b L K Y P P D G Y C R W G R I Q D V S A
c - N I R P P M V I V D G A E F R M S A Q
5701 AACGTTGTTAAATGCGTGGTTGCTGGGTATTATGGCGAGTTGTGCTGTATAAAGCC 5760
-----+-----+-----+-----+-----+-----+-----+
TTGCAACAATTACGCACCAACGGACCCCATAAATACCCGCTCAACACGACATATTTCGG
a N V V K C V V A W G I Y G R V V L Y K A
b T L L N A W L P G V F M G E L C C I K P
c R C - M R G C L G Y L W A S C A V - S L

Figure 11AF

Copy sent to G. R. S. 1/10/70

5941 G G C C G G A A C T G C C C G A C G T C T G T G G A A G A C T A T G A T G C A A T G C C T C C T C C C G C A A T G + 6000
 - - - - - + - - - - - + - - - - - + - - - - - + - - - - - + - - - - - + - - - - - + - - - - - +
 C C G G C G C T T G A C G G C T G C A G A C G A C C T T T C T G A T A C T A C G T T A C G G A G G A G G C G T T A C
 a G R E L P D V C W K D Y D A M P P P A M
 b A A N C P T S A G K T M M Q C L L P Q W
 c P R T A R R L L E R L - C N A S S R N G
 6001 G T T C G A C G C C T A T C A C T C A A C C A T T A A T G A C G G G A T T C G C G C T A T T G A T A G C G T T G C G + 6060
 - - - - - + - - - - - + - - - - - + - - - - - + - - - - - + - - - - - + - - - - - +
 C A A G C T G T C G G A T A G T G G T A A T T A C T G C C C C T A A G C G G A T A A C T A T C G C A A C G C
 a V R Q P I T Q P L M T G I R A I D S V A
 b F D S L S L N H - - R G F A L L I A L R
 c S T A Y H S T I N D G D S R Y - - R C D
 6061 A C C T G T G G C G A A G G C A A C G A G T G G G T A T T T T T C T G C T C C T G G C G T G G G A A A G C A C G + 6120
 - - - - - + - - - - - + - - - - - + - - - - - + - - - - - + - - - - - + - - - - - +
 T G G A C A C C G C T T C C C G T T G C T C A C C C A T A A A A G A C G A G G A C C G C A C C C T T T C G T G C
 a T C G E G Q R V G I F S A P G V G K S T
 b P V A K G N E W V F F L L L A W G K A R
 c L W R R A T S G Y F F C S W R G E K H A

Figure 11AH

CTTCTGGCGATGCTGTGTAATGCGCCAGACGACAGCAATGTTCTGGTGAATTGGT 6180
 -----+-----+-----+-----+-----+-----+-----+
 GAAGACCGCTACGACACATTACGCGGTCTGCGTCTGCTGCTTACAAGACCAATTAACCA

6121

a L L A M L C N A P D A D S N V L V L I G
 b F W R C C V M R Q T Q T A M F W C - L V
 c S G D A V - C A R R R Q Q C S G V N W -

GAACGTGACGAGAAGTCCGCGAATTCAATCGATTTTACACTGTCTGAAGAGACCCGAAAA 6240
 -----+-----+-----+-----+-----+-----+-----+
 CTTGCACCTGCTCTTCAGGCGCTTAAGTAGCTAAATGTGACAGACTTCTCTGGGCTTT

6181

a E R G R E V R E F I D F T L S E E T R K
 b N V D E K S A N S S I L H C L K R P E N
 c T W T R S P R I H R F Y T V - R D P K T

CGTTGTGTCATTGTTGTCGAACCTCTGACAGACCCGCTTAGAGCGGTGAGGCGCTG 6300
 -----+-----+-----+-----+-----+-----+-----+
 GCAACACAGTAACAACAGCGTTGGAGACTGTCTGGGCGGAATCTCGCGCACTCCCGGAC

6241

a R C V I V V A T S D R P A L E R V R A L
 b V V S L L S Q P L T D P P - S A - G R C
 c L C H C C R N L - Q T R L R A R E G A V

Figure 11AI

TTTGTGGCCACGATAGCAGAAATTTTTCGCGATAATGAAAGCGAGTCGTCTTGCTT 6360
 -----+-----+-----+-----+-----+-----+-----+
 AAACACGGTGGTCTATCGTCTTAAAAAAGCGCTATTACCTTTCGCTCAGCAGAACGAA

6301

a F V A T T I A E F F R D N G K R V V L L
 b L W P P R - Q N F F A I M E S S C L
 c C G H H D S R I F S R - W K A S R L A C

GCCGACTCACTGACGCGTTATGCCAGGCCGACGGAATCGCTCTGGCGCCGGAGAGAC 6420
 -----+-----+-----+-----+-----+-----+-----+
 CGGCTGAGTGACTGCGCAATACGGTCCC GGCTGCTTATAGCGAGACCGCGGCTCTCTG

6361

a A D S L T R Y A R A A R K S L W R R R D
 b P T H - R V M P G P H G N R S G A G E T
 c R L T D A L C Q G R T E I A L A P E R P

CGCGGTTTCTGGAGAAATATGCCAGCGGTATTAGTGCAATGCCACGACTTTTAGAACGT 6480
 -----+-----+-----+-----+-----+-----+-----+
 GCGCCAAAGACCTCTTATAGCGGTCCGCATAAATCACGTAACGGTGCTGAAATCTTGCA

6421

a R G F W R I S P G V F S A L P R L L E R
 b A V S G E Y R Q A Y L V H C H D F - N V
 c R F L E N I A R R I - C I A T T F R T Y

Figure 11AJ

ACGGGAATGGGAGAAAAAGGCAGTATTACCGCATTTTATACGGTACTGGTGAAGGCGAT 6540
 -----+-----+-----+-----+-----+-----+-----+
 TGCCCTTACCCCTCTTTTCCGTCATAATGGCGTAAATAATGCCATGACCACTTCCGCTA

a T G M G E K G S I T A F Y T V L V E G D
 b R E W E K K A V L P H F I R Y W W K A M
 c G N G R K R Q Y Y R I L Y G T G G R R -

GATATGAATGAAGCCGTTGGCGGATGAAGTCCGTTCACTGCTTGATGGACATATTGTACT 6600
 -----+-----+-----+-----+-----+-----+-----+
 CTATACTTACTTCGGCAACCGCCTACTTCAGGCAAGTGACGAACTACCTGTATAACATGA

yscN*
 a D M N E A V G G - S P F T A - W T Y C T
 b I - M K P L A D E V R S L L D G H I V L
 c Y E - S R W R M K S V H C L M D I L Y Y

ATCCCGACGGCTTGACAGAGAGGGGCATTATCCTGCCATTGACGTGTGGCAACGCTCAG 6660
 -----+-----+-----+-----+-----+-----+-----+
 TAGGGCTGCCGAACGTCTCTCCCCCGTAATAGGACGGTAAGTGCACAAACCGTTGCGAGTC

a I P T A C R E G A L S C H - R V G N A Q
 b S R R L A E R G H Y P A I D V L A T L S
 c P D G L Q R G G I I L P L T C W Q R S A

Figure 11AK

6720

ந டு உ

6780

ന മ ഉ

6840

നമു

Figure 11AL

Continued from page 10
 2094160

ACAAAGTAAGGATGAAGTATGCGGACCGAGCTACTATAGAAAAATTACACCAAATACT
 -----+-----+-----+-----+-----+-----+ 6900
 TGTTTCATTCCTACTTCATACGCCCTGGGCTCGATGAATATCTTTTAATGTGTTTATGA

6841

end yscN*
 T K - G - S M R T R A T Y R K I T P N T
 Q S K D E V C G P E L L I E K L H Q I L
 K V R M K Y A D P S Y L - K N Y T K Y S

CACCGAGTGATCATGAAACTTTGCTGGAGATAATCGCGCGCTGAAAAGCAATTACGCG
 -----+-----+-----+-----+-----+-----+ 6960
 GTGGCTCACTAGTACCTTTGAAACGACCTCTATTAGCGCGCGACTTTTCGTTAATGCGC

6901

yscO*
 H R V I M E T L L E I I A R L K S N Y A
 T E - S W K L C W R - S R G - K A I T R
 P S D H G N F A G D N R A A E K Q L R G
 GCAAGCTTACCGTACTTGATCAGCAGCAACAGGCGATTATTACGGAACAGCAGATTGCC
 -----+-----+-----+-----+-----+-----+ 7020
 CGTTCGAATGGCATGAACACTAGTCGTGTTGTCGCTAATAATGCCTTGTCTGCTAAACGG

6961

A S L P Y L I S S N R R L L R N S R F A
 Q A Y R T - S A A T G D Y Y G T A D L P
 K L T V L D Q Q Q Q A I I T E Q Q I C Q

Figure 11AM

AGACGGCGCTTTAGCAGTGTCTACGACTGAAAGAATTAATGGCTGGCAAGGTACGT 7080
 -----+-----+-----+-----+-----+-----+-----+
 TCTGCGCGCGAAATCGTCACAGATGGTCTGACTTTCTTAATTACCCGACCGTTCCATGCA

7021

a R R A L - Q C L P D - K N - W A G K V R
 b D A R F S S V Y Q T E R I N G L A R Y V
 c T R A L A V S T R L K E L M G W Q G T L

TATCTTGTCATTATTTGGATAAGAAACAACAATGGCCGGTTATTCACTCAGGCGC 7140
 -----+-----+-----+-----+-----+-----+-----+
 ATAGAACAGTAAATAACAACCTATTCTTTGTTTACCGGCCCAATAAGTGAGTCCGCG

7081

a Y L V I Y C W I R N N K W P G Y S L R R
 b I L S F I V G - E T T N G R V I H S G A
 c S C H L L L D K K Q Q M A G L F T Q A Q

AGAGCTTTTACGCAACGGCAAGCAGTTAGAGAATCAGTATCAGCAGCTTGTCTCCCGG 7200
 -----+-----+-----+-----+-----+-----+-----+
 TCTCGAAAACCTGCGTTGCCGTTCGTCAATCTCTTAGTCATAGTCGTCGAACAGAGGCGC

7141

a R A F - R N G K Q L E N Q Y Q Q L V S R
 b E L F D A T A S S - R I S I S S L S P G
 c S F L T Q R Q A V R E S V S A A C L P A

Figure 11AN

Continuation of 6572 45
 (2094T/50)

Continued by 03/20/95
RPM 10 (15)

CGAAGCGAATTACAGAAGAATTTTAATGCGCTTATGAAAAAGAAAAAATTACTATG 7260
-----+-----+-----+-----+-----+-----+
GCTTCGCTTAATGTCTTCTTAAATACGCGAATACTTTTCTTCTTCTTTTAAATGATAC

7201

end yscO*
R S E L Q K N F N A L M K K K E K I T M
E A N Y R R I L M R L - K R K K L L W
K R I T E E F - C A Y E K E R K N Y Y G

GTATTAAGCGATGCGTATTACCAAAGTTGAGGGAAGTCTTGGTTGCCATGCCAGTCTTA 7320
-----+-----+-----+-----+-----+-----+
CATAATTGCTACGCATAATGGTTTCAACTCCCTTCAGAAACCCAAACGGTACGGTCAGAAT

7261

start yscP*
V L S D A Y Y Q S - G K S W V A M P V L
Y - A M R I T K V E G S L G L P C Q S Y
I K R C V L P K L R E V L G C H A S L I

a
b
c

TCAGGATGATAACGAGCGGAGCGGAACGTATGACTTTGAACAACATCATGCACCAGGC 7380
-----+-----+-----+-----+-----+-----+
AGTCCTACTATTGCTCCGCCCTCCGCCCTTGCACTACCTGAACCTTGTGAGTACGTGGTCCG

7321

S G - - R G G G T Y G L - T H A P G
Q D D N E A E A E R M D F E Q L M H Q A
R M I T R R R R N V W T L N N S C T R H

a
b
c

Figure 11AO

7381 ATTACCCATTGGTGAGAAATAATCCTCCTGCAGCATTGAATAAGAACGTGGTTTTCACGCA 7440
 -----+-----+-----+-----+-----+-----+-----+
 TAATGGGTAACCACTCTTATTAGGAGGACGTCGTAACCTTATTCTTGCACCAAAAGTGCGGT
 a I T H W - E - S S C S I E - E R G F H A
 b L P I G E N N P P A A L N K N V V F T Q
 c Y P L V R I I L L Q H - I R T W F S R N
 7441 ACGTTATCGTGTAGTGCGGGTTATCTTGACGGGTGAGAGTGTGAAGTATGTGAATCAGG 7500
 -----+-----+-----+-----+-----+-----+-----+
 TGCAATAGCACAAATCACCGCCAATAGAACTGCCACATCTCACACTTCATACACTTAGTCC
 a T L S C - W R L S - R C R V - S M - I R
 b R Y R V S G G Y L D G V E C E V C E S G
 c V I V L V A V I L T V - S V K Y V N Q G
 7501 GGGGCTAATCCAGTTAAGAATCAATGTCCCTCATCATGAAATTTACCGTTCGATGAAAGC 7560
 -----+-----+-----+-----+-----+-----+-----+
 CCCCATTAGGTCAATTCTTAGTTACAGGGAGTAGTACTTTAAATGGCAAGCTACTTTCG
 a G A N P V K N Q C P S S - N L P F D E S
 b G L I Q L R I N V P P H H E I Y R S M K A
 c G - S S - E S M S L I M K F T V R - K R

Figure 11AP

003117 2094160
 12. 10. 1960

7561 GCTAAAGCAGTGGCTGGAGTCTCAGTTGCTGCATATGGGGTATATAATTTCCTGGAGAT 7620
-----+-----+-----+-----+-----+-----+-----+-----+
CGATTTCGTCACCGACCTCAGAGTCAACGACGTATACCCCATATATTAAGGGACCTCTA

a A K A V A G V S V A A Y G V Y N F P G D
b L K Q W L E S Q L L H M G Y I I S L E I
c - S S G W S L S C C I W G I - F P W R Y

7621 ATTCTATGTTAAGAATAGCGAATGAAGAGCGTCCGTGGTGGAGATACTTCCAACGCAAG 7680
-----+-----+-----+-----+-----+-----+-----+-----+
TAAGATACAAATTCTTATCGCTTACTTCTCGCAGGCACCCACCTCTATGAAGGTTCGCTTC

end yscP* start yscQ*?

a I L C - E - R M K S V R G W R Y F Q R K
b F Y V K N S E - R A S V G G D T S N A R
c S M L R I A N E E R P W V E I L P T Q G

7681 GCGTACCATTGGTGAGCTGACATTGAGTATGCAACAATATCCAGTACAGCAAGGACAT 7740
-----+-----+-----+-----+-----+-----+-----+-----+
CGCGATGGTAACCACTCGACTGTAACTCATACGTTGTTATAGGTCATGTCGTTCCCTGTA

start yscQ*?

a A L P L V S - H - V C N N I Q Y S K G H
b R Y H W - A D I E Y A T I S S T A R D I
c A T I G E L T L S M O O Y P V Q Q G T L

Figure 11AQ

7741 TATTACCATAAATTATCATAATGAGCTGGGTAGGGTGTGATTGCAGAAACAATGCTGGC 7800
 -----+-----+-----+-----+-----+-----+-----+
 ATAAATGGTATTTAATAGTATTACTCGACCCATCCACACCTAACGTCTTGTACGACCG
 Y L P - I I I M S W V G C G L Q N N A G
 I Y H K L S - - A G - G V D C R T M L A
 F T I N Y H N E L G R V W I A E Q C W Q
 7801 AGCGTGTGTGAAGGCTAATTGGCACCGCTAATCGATCGGCTATCGATCCTGAATTGC 7860
 -----+-----+-----+-----+-----+-----+-----+
 TCGGACCACACTTCCCGATTAAACCGTGGCGATTAGCTAGCCGATAGCTAGGACTTAACG
 S A G V K G - L A P L I D R L S I L N C
 A L V - R A N W H R - S I G Y R S - I A
 R W C E G L I G T A N R S A I D P E L L
 7861 TATATGGAATAGCTGAATGGGGGCTGGCGCGTTATTGCAAGCCAGTGATGCAACCCCTCT 7920
 -----+-----+-----+-----+-----+-----+-----+
 ATATACCTTATCGACTTACCCCGACCGCGCAATAACGTTCCGTCACCTACGTTGGGAGA
 Y M E - L N G G W R R Y C K P V M Q P S
 I W N S - M G A G A V I A S Q - C N P L
 Y G I A E W G L A P L L Q A S D A T L C

Figure 11AR

Continued on page 11B
 0034460

*Continued on page 11B
Rms 10/10/88*

GTCAGAACGAGCGCCAAACATCCTGCAGTAATCTACCAATCAGCTAGCGTTGCATATTA 7980
-----+-----+-----+-----+-----+-----+-----+
CAGTCTTGCTCGGCGTTGTAGGACGTCAATTAGATGGTGTAGTCGATCGCAACGTATAAT

7921

a V R T S R Q H P A V I Y H I S - R C I L
b S E R A A N I L Q - S T T S A S V A Y -
c Q N E P P T S C S N L P H Q L A L H I K

AATGGACAGTTGAAGACATGAGTTCATAGCATTAATTTTACATGGCCAAACGGGTTTT 8040
-----+-----+-----+-----+-----+-----+-----+
TTACCTGTCAACTTCTCGTACTCAAGGTATCGTAATAAATAATGTACCGGTTGCCCAAAAA

7981

a N G Q L K S M S I A L F L H G Q R V F
b M D S - R A - V P - H Y F Y M A N G F F
c W T V E E H E F H S I I F T W P T G F L

TGCGCAATATAGTCGGAGAGCTTTCTGCTGAGCGACAACAGATTTATCCTGCCCTCCTG 8100
-----+-----+-----+-----+-----+-----+-----+
ACGCGTTATATCAGCCTCTCGAAAGACGACTCGCTGTTGTCTAAATAGGACGGGGAGGAC

8041

a C A I - S E S F L L S D N R F I L P L L
b A Q Y S R R A F C - A T T D L S C P S C
c R N I V G E L S A E R Q Q I Y P A P P V

Figure 11AS

8101 TGGTAGTCCCTGTATATT CAGGCTGGTGCCAGCTTACATTAATCGAACTTGAGTCTATCG 8160
 -----+-----+-----+-----+-----+-----+-----+
 ACCATCAGGACATATAAGTCCGACCACGGTCGAATGTAATTAGCTTGAACCTCAGATAGC
 a W - S L Y I Q A G A S L H - S N L S L S
 b G S P C I F R L V P A Y I N R T - V Y R
 c V V P V Y S G W C Q L T L I E L E S I E

8161 AAATCGCATGGCGTTCCGATTCA TTGCTTCGGCCGACATCAGACTCGGTTTTTTTGCTA 8220
 -----+-----+-----+-----+-----+-----+-----+
 TTTAGCCGTACCCGCAAGCCTAAGTAACGAAGCCGCTGTAGTCTGAGCCAAAACGAT
 a K S A W A F G F I A S A T S D S V F L L
 b N R H G R S D S L L R R H Q T R F F C Y
 c I G M G V R I H C F G D I R L G F F A I

8221 TTCAACTACCTGGGGAATCTACGCAAGGTTGTTGCTGACAGAGGATAACAGATGAAAT 8280
 -----+-----+-----+-----+-----+-----+-----+
 AAGTTGATGGACCCCTTAGATGCGTTCCCAACGACTGTCTCCTATTGTGCTACTTTA
 a F N Y L G E S T Q G C C - Q R I T R - N
 b S T T W G N L R K G V A D R G - H D E I
 c Q L P G G I Y A R V L L T E D N T M K F

Figure 11AT

8281 TTGACGAATTAGTCCAGGATATCGAAACGCTACTTGCGTCAGGGAGCCCAATGTCAAAGA 8340
 -----+-----+-----+-----+-----+-----+-----+
 AACTGCTTAATCAGGTCCTATAGCTTTGCGATGAACGCAGTCCCTCGGTTACAGTTTCT
 L T N - S R I S K R Y L R Q G A Q C Q R
 - R I S P G Y R N A T C V R E P N V K E
 D E L V Q D I E T L L A S G S P M S K S

8341 GTGACGGAACGCTTTCAGTCTGAACTTGAGCAGATACCACAACAGGTGCTCTTTGAGGTCTG 8400
 -----+-----+-----+-----+-----+-----+-----+
 CACTGCCCTTGCAGAAGTCAGCTTGAACCTCGTCTATGTTGTGTCCACGAGAACTCCAGC
 V T E R L Q S N L S R Y H N R C S L R S
 - R N V F S R T - A D T T T G A L - G R
 D G T S S V E L E Q I P Q Q V L F E V G

8401 GACGTGCGAGTCTGGAAATTGGACAATTACGACAACCTTAAACGGGGGACGTTTTCCTG 8460
 -----+-----+-----+-----+-----+-----+-----+
 CTGCACGCTCAGACCTTTAACCTGTTAATGCTGTGTAATTTGCCCCCTGCAAAACGGAC
 D V R V W K L D N Y D N L K R G T F C L
 T C E S G N W T I T T T - N G G R F A C
 R A S L E I G Q L R Q L K T G D V L P V

Figure 11AU

Continued on next page

TCGTGTCATGAGAGATACAGTATGCTTTACCCGATTTCGCCCTTTGCAACTGATTGGTATA 8700

AGCACAGTACTCTCTATGTCATACAGAAATGGGCTAAGCGGAAACGTTGACTAACCATAT

8641

start yscr*?

a S C H E R Y S M S L P D S P L Q L I G I
b R V M R D T V C L Y P I R L C N - L V Y
c V S - E I Q Y V F T R F A F A T D W Y I

TTGTTTCTGCTTTCAATACGCTCTCATTTATCGTCATGGGAACCTTTTCCTTAAACTG 8760
AACAAAGACGAAAGTTATGACGGAGAGTAATAGCAGTACCCCTTGAAGAAAGGAATTTGAC

8701

a L F L L S I L P L I I V M G T S F L K L
b C F C F Q Y C L S L S S W E L L S L N W
c V S A F N T A S H Y R H G N F F P - T G

GCGGTGTTATTTTCGATTTTACGAAATGCTCTGGGTATTCAACAAGTCCCCCAAATATC 8820
CGCCACCATAAAAGCTAAAATGCTTTACGAGACCCATAAGTTGTTCAGGGGGTTTATAG

8761

a A V V F S I L R N A L G I Q Q V P P N I
b R W Y F R F Y E M L W V F N K S P Q I S
c G G I F D F T K C S G Y S T S P P K Y R

Figure 11AW

Contig: 20547460

8821 GCACGTATGGCCTTGGCCTTGACTTTCCTTATTCATTATGGGGCCGACGCTATTAGCT 8880
 -----+-----+-----+-----+-----+-----+-----+
 CGTGACATACCGAACGCGAACATGAAGGAATAAGTAATACCCCGGCTGCGATAATCGA
 a A L Y G L A L V L S L F I M G P T L L A
 b H C M A L R L Y F P Y S L W G R R Y - L
 c T V W P C A C T F L I H Y G A D A I S C
 8881 GTAAAAGCGCTGGCATCCGGTTCAGGTCGCTGGCGCTCCTTTCTGGACGCTGAGTGG 8940
 -----+-----+-----+-----+-----+-----+-----+
 CATTTCTCGGACCGTAGGCCAAGTCCAGCGACCGCGAGGAAGACCTGCAGACTCACC
 a V K E R W H P V Q V A G A P F W T S E W
 b - K S A G I R F R S L A L L S G R L S G
 c K R A L A S G S G R W R S F L D V - V G
 8941 GACAGTAAAGCATTAGCGCCTTATCGACAGTTTTTGCAAAAAAACTCTGAAGAGAGGAA 9000
 -----+-----+-----+-----+-----+-----+-----+
 CTGTCATTCGTAATCGCGGAATAGCTGTCAAAAACGTTTTTTTGAGACTTCTCTTCCTT
 a D S K A L A P Y R Q F L Q K N S E E K E
 b T V K H - R L I D S F C K K T L K R R K
 c Q - S I S A L S T V F A K K L - R E G S

Figure 11AX

ATAGTGGCTATGGGATGATGATGTCGCCGATGACCATTTTATTACCGTTTAAG 9240
-----+-----+-----+-----+-----+-----+
TATGACGACCGATACCCCTACTACTACACAGCGGCTACTGGTAAAGTAATGGCAAATTC

9181

a I L L A M G M M M V S P M T I S L P F K
b Y C W L W G - - W C R R - P F H Y R L S
c T A G Y G D D D G V A D D H F I T V - A

CTGCTAATATTTTACTGGCAGCGGTTGGATCTGACACTGGCGCAATTGGTACAGAGC 9300
-----+-----+-----+-----+-----+-----+
GACGATTATAAAATGACCGTCCGCCAACCTAGACTGTGACCGCGTTAACCATGTCTCG

9241

end yscr*
L L I F L L A G G W D L T L A Q L V Q S
C - Y F Y W Q A V G I - H W R N W Y R A
A N I F T G R R L G S D T G A I G T E L

TTTTCATGAATGATTCGAATTGACGCAATTGTACGCAACTTTTATGGATCGTCCTTT 9360
-----+-----+-----+-----+-----+-----+
AAAAGTACTTAAGACTTAAGTAAACATTCGTTGAAATACCTAGCAGGAAA

9301

start yscs*
F S - M I L N - R N L - R N F Y G S S F
F H E - F - I D A I C N A T F M D R P F
F M N D S E L T Q F V T Q L L W I V L F

Figure 11AZ

Cont. 24/1/201 745
RPNB (13)

TTACGTCATGCCGCTAGTGTGGTGGCATCGGTAGTTGGTGTCAATCGTAAGCCTTGTTC
-----+-----+-----+-----+-----+-----+ 9420
AATGCAGATACGGCCATCACAACCCGCTAGCCATCAACACAGTAGCATTCGGAACAAG

9361

a L R L C R - C W W H R - L V S S - A L F
b Y V Y A G S V G G I G S W C H R K P C S
c T S M P V V L V A S V V G V I V S L V Q

AGGCCTTGACTCAAATACAGGACCAACGCTACAGTTCAATGATTAATTAATGGCAATTG
-----+-----+-----+-----+-----+-----+ 9480
TCCGGAACCTGAGTTTATGTCTGTTGCGATGTCAGTACTAATTTAATAACCGTTAAC

9421

a R P - L K Y R T K R Y S S - L N Y W Q L
b G L D S N T G P N A T V H D - I I G N C
c A L T Q I Q D Q T L Q F M I K L L A I A

CAATAACCTTAATGGTCAGCTACCCATGGCTTAGCGGTATCCTGTGAATTATACCCGGC
-----+-----+-----+-----+-----+-----+ 9540
GTTATTGGAATTACCAGTCGATGGGTACCGAATCGCCATAGGACAACCTTAATATGGGCCG

9481

a Q - P - W S A T H G L A V S C - I I P G
b N N L N G Q L P M A - R Y P V E L Y P A
c I T L M V S Y P W L S G I L L N Y T R Q

Figure 11BA

Contig: 08/20 11:15
K110111111

AGATAATGTTACGAATTGGAGAGCATGTTGAATGGCACAACAGGTAATGAGTGGCTTA 9600

9541

TCTATTACAATGCTTAACCTCTCGTACCCTTACCGTGTGTCATTACTCACC GAAT

end yscS* start yscT*
a R - C Y E L E S M V E W H N R - M S G L
b D N V T N W R A W L N G T T G K - V A Y
c I M L R I G E H G - M A O Q V N E W L I

TTGCATTGGCTGGCTTTTATTCGACCATGAGCCCTTCTTTATTACTTCCCTTATTAA 9660

9601

AACGTAACCGACACCGAAATAAGCTGTAACTCGGAAAGAAATAATGAAGGGAATAATT

a L H W L W L L F D H - A F L Y Y F P Y -
b C I G C G F Y S T I E P F F I T S L I K
c A L A V A F I R P L S L S L L L P L L K

AAAGTGGCAGTTAGGGCCGCACCTTTACGTAATGGCGTCTTATGTCACCTTACCTTC 9720

9661

TTTCACCGTCAAAATCCCGCGGTGAAAATGCATTACCGCACGAATACAGTGAATGGAAAG

a K V A V - G P H F Y V M A C L C H L P F
b K W Q F R G R T F T - W R A Y V T Y L S
c S G S L G A A L L R N G V L M S L T F P

Figure 11BB

Cont. vol. 26 04/20/94
R17.510100 15)

9901 TGGGTACGATATTCAATTCTACAATAGAAGCTGAAACCTCATTCTTTTGGCTTGCTTTTCA 9960
-----+-----+-----+-----+-----+-----+-----+
ACCCATGCTATAAGTTAAGATGTTATCTTCGACTTTGGAGTGAAAAACCGAACGAAAAGT
W V R Y S I L Q - K L K P H F L A C F S
G Y D I Q F Y N R S - N L T F W L A F Q
G T I F N S T I E A E T S L F G L L F S
9961 GCCAGTCTTGTTGTTATTTCTTTATAAGCGGGCATGGAGTTTATATTAACATTC 10020
-----+-----+-----+-----+-----+-----+-----+
CGGTCAAGAACACACAATAAAAGAAATATTCGCCGCTACCTCAAATATAATTGTAAG
A S S C V L F S L - A A A W S L Y - T F
P V L V C Y F L Y K R R H G V Y I K H S
Q F L C V I F F I S G G M E F I L N I L
10021 TGTATGAGTCATATCAATATTTACCACGCGGTACTTTTATTATTGACCAGCAATTTT 10080
-----+-----+-----+-----+-----+-----+-----+
ACATACTCAGTATAGTTATAAATGGTGGTCCCGCATGAAATAATAAACTGTCGTTAAAA
C M S H I N I Y H Q G V L Y Y L T S N F
V - V I S I F T T R A Y F I I - P A I F
Y E S Y Q Y L P P G R T L L F D Q Q F L

Figure 11BD

Figure 11BE

10261 CCTGATCTCATCCCTTATGCTCTTCATCACTATTGTTGAAAGCGATAAAATTTATAT 10320
 -----+-----+-----+-----+-----+-----+-----+
 GGAAGTAAGGAATACGAGAAGTAGTGATAAACCACTTTCGCTATTATAAAATATA

a P D L I P L C S S S L F G - K R - I L Y
 b L I S F P Y A L H H Y L V E S D K F Y I
 c - S H S L M L F I T I W L K A I N F I F

10321 TTATCTAAAGACTGGTTTCCATCTGTATGAGCGAGAAACAGAACGCCCTACAGAAAAG
 -----+-----+-----+-----+-----+-----+-----+
 AATAGATTTCTGACCAAGGTAGACATACTCGCTCTTTTGTCTTGTCTGGATGCTTTTC

end yscT* start yscU*
 a L S K R L V S I C M S E K T E Q P T E K
 b Y L K D W F P S V - A R K Q N S L Q K R
 c I - K T G F H L Y E R E N R T A Y R K E

10381 AAATTACGTGATGCCGTAAGGAAGGCGAGGTGTCAAAGTATTGAAATAACATCATTA 10440
 -----+-----+-----+-----+-----+-----+-----+
 TTTAATGCACCTACCGCATTCCTTCCCGTCCAACAGTTTTCATAACTTTATTGTAGTAAT

a K L R D G R K E G Q V V K S I E I T S L
 b N Y V M A V R K G R L S K V L K - H H Y
 c I T - W P - G R A G C Q K Y - N N I I I

Figure 11BF

009111 2054460
 RPN15 101 (0013)

10441 TTTGAGCTGATTGCGCTTTATTTGTATTTTTCATTTCTTTACTGAAAAGATGATTTTGATA 10500
 -----+-----+-----+-----+-----+-----+-----+
 AAAGTCGACTAACGCGAAATAAACATAAAAGTAAGAAATGACTTTTCTACTAAACTAT
 a F Q L I A L Y L Y F H F F T E K M I L I
 b F S - L R F I C I F I S L L K R - F - Y
 c S A D C A L F V F S F L Y - K D D F D T

10501 CTGATTGAGTCAATAACTTTCACATTACAATTAGTAAATAAACCATTTTCTTATGCATTA 10560
 -----+-----+-----+-----+-----+-----+-----+
 GACTAACTCAGTTATTGAAAGTGTAATGTTAATCATTTTATTTGGTAAAGAATACGTAAT
 a L I E S I T F T L Q L V N K P F S Y A L
 b - L S Q - L S H Y N - - I N H F L M H -
 c D - V N N F H I T I S K - T I F L C I N

10561 ACGCAATTGAGTCATGCTTTAATAGAGTCAGTCTGACTTCTGCACTGCTGTTTCTGGCGCT 10620
 -----+-----+-----+-----+-----+-----+-----+
 TGCCTTAACCTCAGTACGAAATTATCTCAGTGACTGAAGACGTGACGACAAAGACCCGCGA
 a T Q L S H A L I E S L T S A L L F L G A
 b R N - V M L - - S H - L L H C C F W A L
 c A I E S C F N R V T D F C T A V S G R W

Figure 11BG

10621 GGGTAATAGTTGCTACTGTGGGTAGCGTGTCTTCAGGTGGGGTGGTTATTGCCAGC 10680
 -----+-----+-----+-----+-----+-----+-----+
 CCCCATTAACGATGACACCCCATCGCACAAAGAAGTCCACCCCAACCAATAACGGTGC

a G V I V A T V G S V F L Q V G V V I A S
 b G - - L L L W V A C F F R W G W L L P A
 c G N S C Y C G - R V S S G G G Y C Q Q

10681 AAGCCATTGGTTTTAAAGCGAGCATATAAATCCGGTAAGTAATTTAAGCAGATATTC 10740
 -----+-----+-----+-----+-----+-----+-----+
 TTCCGGTAACCAAAATTTTCGCTCGTATATTAGGCCATTCAATTAATAATTCGTCTATAAG

a K A I G F K S E H I N P V S N F K Q I F
 b R P L V L K A S I - I R - V I L S R Y S
 c G H W F - K R A Y K S G K - F - A D I L

10741 TCTTTACATAGCGTAGAATTATGTAATCCAGCCCTAAAGTTATCATGCTATCTCTT 10800
 -----+-----+-----+-----+-----+-----+-----+
 AGAAATGTATCGCATCATCTTAATACATTTAGGTCGGATTTTCAATAGTACGATAGAGAA

a S L H S V V E L C K S S L K V I M L S L
 b L Y I A - - N Y V N P A - K L S C Y L L
 c F T - R S R I M - I Q P K S Y H A I S Y

Figure 11BH

Continuation of page 7.5
 11/10/1961

10801
ATCTTTGCCCTTTTCTTTTATTATGCCAGTACTTTTCGGCGCTACCGTACTGTGGG
-----+-----+-----+-----+-----+-----+ 10860
TAGAAACGGAAAAAGAAAAATAATAACGGTCATGAAAAGCCCGCATGGCATGACACCC

a I F A F F Y Y Y A S T F R A L P Y C G
b S L P F S F I I M P V L F G R Y R T V G
c L C L F L L L L C Q Y F S G A T V L W V

10861
TTAGCCCTGTGGCGTCTTGTGGTTCTTCTTTAATAAAATGTTATGGGTAGGGTGATG
-----+-----+-----+-----+-----+-----+ 10920
AATCGGACACCGCACGAAACACCAAGAAATTTTACCAATACCCATCCCCACTAC

a L A C G V L V V S S L I K W L W V G V M
b - P V A C L W F L L - - N G Y G - G - W
c S L W R A C G F F F N K M V M G R G D G

10921
GTTTTTATATCGTCGTTGGCATACTGGACTATTCTTTCAATATATATAAGATTAGAAA
-----+-----+-----+-----+-----+-----+-----+
CAAAAAATATAGCAGCAACCGTATGACCTGATAAGAAAAGTTATAATATCTAATCTTTT
10980

a $V_F Y I V V G I L D Y S F Q Y Y K I R K$

b $F F I S S L A Y W T I L F F N I I R L E K S$

c $F L Y R R W H T G L F F S I L - D - K S$

Figure 11BI

Continuation of 009111-5
P12F5 (20341250)

10981 GCTATCTAAAAATGAGTAAAGATGACGTAAACAGGAGCATAAAGATCTGGAGGGCGACC 11040
-----+-----+-----+-----+-----+-----+-----+
CGATAGATTTTACTCATTTCTACTGCAATTTTGTCCTCGTATTTCTAGACCTCCCGCTGG

a A I - K - V K M T - N R S I K I W R A T
b L S K N E - R - R K T G A - R S G G R P
c Y L K M S K D D V K Q E H K D L E G D P

Tn insertion P12F5
⇓

11041 CTCAAATGAAGACGGCGGTCGGAATGCAGAGTGAAATACAAAGTGGAGTTTAGCTCA 11100
-----+-----+-----+-----+-----+-----+-----+
GAGTTTACTTCTGCGCCGAGCCCTTTACGTCTCACTTTATGTTTCAACCCTCAAATCGAGT

a L K - R R G V G N A E - N T K W E F S S
b S N E D A A S E M Q S E I Q S G S L A Q
c Q M K T R R R K C R V K Y K V G V - L N

11101 ATCTGTTAAACAATCTGTTGCGGTAGTGCCTAATCCAACGCATATTGCGGTTTGTCTTGG 11160
-----+-----+-----+-----+-----+-----+-----+
TAGACAATTTGTTAGACAACGCCATCACGCATTAGGTTGCGTATAACGCCAACAGAAACC

a I C - T I C C G S A - S N A Y C G L S W
b S V K Q S V A V R N P T H I A V C L G
c L L N N L L R - C V I Q R I L R F V L A

Figure 11BJ

Continued on page 11
20941.60

CTATCATCCACGATATGCCAATACACGCTCCTGGAAAAAGGCAGTGATGCTCAAGC 11161
-----+-----+-----+-----+-----+-----+-----+
GATAGTAGGGTGGCTATACGGTTATGGTGGCAGGACCTTTTCCGTCACCTACGAGTTCCG

a L S S H R Y A N T T R P G K R Q - C S S
b Y H P T D M P I P R V L E K G S D A Q A
c I I P P I C Q Y H A S W K K A V M L K L

TAACTATATTGTTAACATCGCTGAACGCAACTGCATCCCCGTTGTTGAAAAATGTTGAGCT 11221
-----+-----+-----+-----+-----+-----+-----+
ATTGATATAACAATTGTAGCGACTTGCGTTGACGTAGGGCAACAACCTTTTACAACCTCGA

a - L Y C - H R - T Q L H P R C - K C - A
b N Y I V N I A E R N C I P V V E N V E L
c T I L L T S L N A T A S P L L K M L S W

GGCCCGCTCATTATTTTGAAGTGGAACGGGAGATAAAATTCCTGAAACGTTATTGA 11281
-----+-----+-----+-----+-----+-----+-----+
CCGGGCGAGTAATAAAAACCTTCACCTTGGCCTCTATTTTAAGGACTTTGCAATAAACT

a G P L I I F - S G T R R - N S - N V I -
b A R S L F F E V E R G D K I P E T L F E
c P A H Y F L K W N A E I K F L K R Y L N

Figure 11BK

Cellulose 11BL 113
R11 11 113

11341 ACCCGTTGCAGCCTTGTACGTATGGTGATGAAGATAGATTATGCGCATTTCTACCGAAAC 11400
-----+-----+-----+-----+-----+-----+-----+
TGGGCAACGTCGGAACAATGCATACCACTACTTCTATCTAATACGCGTAAGATGGCTTTG

a T R C S L V T Y G D E D R L C A F Y R N
b P V A A L L R M V M K I D Y A H S T E T
c P L Q P C Y V W - - R - I M R I L P K H
end yscU*

11401 ACCATAAATGCTTTTGGTATGCTTCTTCAGGCCACTGCGAAGGTTAAGAGGGTAATAGCG 11460
-----+-----+-----+-----+-----+-----+-----+
TGGTATTACGAAACCATACGAAGAAGTCCGGTGACGCTTCCAAATTCCTCCCATATATCGC

a T I N A F G M L L Q A T A K V K R V I A
b P - M L L V C F R P L R R L R G - - R
c H K C F W Y A S S G H C E G - E G N S V

11461 TATAGACAGTGCTTGACGATAAAGGTGAGAGACTGAAAAATAATCGCTTTTAGCCTGGCA 11520
-----+-----+-----+-----+-----+-----+-----+
ATATCTCGTCACGAACTGCTATTTCCTACTCTCTGACTTTTATTATAGCGAAAAATCGGACCGT

a Y R A V L D D K G E R L K I I A F S L A
b I E Q C L T I K V R D - K - S L L A W H
c - S S A - R - R - E T E N N R R F - P G T

Figure 11BL

CAAGCACCAGATAGCGTATTATAAAATTAAACAAGATAATGGATTGGTGCGTCTGAATGG 11580
 -----+-----+-----+-----+-----+-----+-----+
 GTTCGTGGTCTATCGCATAAATTTTAATTGTCTTATTACCTAACCGCAGACTTACC

11521

a Q A P D S V L - N - T R - W I G A S E W
 b K H Q I A Y Y K I K Q D N G L V R L N G
 c S T R - R I I K L N K I M D W C V - M D

ACTCGAACCACCTCGACCCCAACATGTCAAGGTGGTGCTCTAACCAACTGAGCTATGAAC 11640
 -----+-----+-----+-----+-----+-----+
 TGAGCTTGGTGAGCTGGGGGTGACAGTTCACCCACGAGATTGGTTGACTCGATACTTG

11581

a T R T T R P P P C Q G G A L T N - A M N
 b L E P L D P H H V K V V L - P T E L - T
 c S N H S T P T M S R W C S N Q L S Y E R

GGCAACGTTGTAGTGACAACGGGGACGAATATTAGCGTCACAACCGCAATGAGGCAAGA 11700
 -----+-----+-----+-----+-----+-----+
 CCGTTGCAACATCCACTGTTGCCCTGCTTATAATCGCAGTGTGGCGTTACTCCGTTCT

11641

a G N V V G D N G D E Y - R H N R N E A R
 b A T L - V T T G T N I S V T T A M R Q E
 c Q R C R - Q R G R I L A S Q P Q - G K R

Figure 11BM

Unpublished
 11. 01. 00

11701 GGGAAATCGCAATTTTCTTCTGAAATCACCTGATTGCGGTGGAATAATGCAACATGTCCG 11760
 -----+-----+-----+-----+-----+-----+-----+
 CCGTTAGCGTTAAAGAAGGACTTTAGTGGACTAACGCCACCTTTATACGTTGTACAGC
 a G K S Q F S S - N H L I A V E I C N M S
 b G N R N F L P E I T - L R W K Y A T C R
 c E I A I F F L K S P D C G G N M Q H V E

11761 AGAAATAGCCGCATGCGACGGCTATCGTATTATCGGAGCGCGCTGCAAAATGATG 11820
 -----+-----+-----+-----+-----+-----+-----+
 TCTTTATCGGCGTACGCTGCCGATAGCAGCATAATAGCCTCGCGGACGTTTACTAC
 a R K - P P C D G Y R R I I G A R C K M M
 b E N S R H A T A I V V L S E R A A K - W
 c K I A A M R R L S S Y Y R S A L Q N D G

11821 GCGGACGGCTGACGTTGTAGATAGCGCATCCGTAGCATCATTAACACCGCCGAGGTC 11880
 -----+-----+-----+-----+-----+-----+-----+
 CGCCTGCCGACTGCAACATCTATCGCGTAGGCATCGTAGTAATTGTGGCGGCGCTCCAG
 a A D G - R C R - R I R S I I N T A A E V
 b R T A D V V D S A S V A S L T P P P R S
 c G R L T L - I A H P - H H - H R R R G Q

Figure 11BN

SERIAL NO.: Continuation of 09/201,945

FILED: November 16, 2000

ART UNIT: Not Yet Assigned

EXAMINER: Not Yet Assigned

FOR: *IDENTIFICATION OF GENES*

09/201,945

12241 GTTAGCCCTGGCCAGACCGATAACCCACTCGAATCGTTACCGCGCAGCCAGCGACAT 12300
 -----+-----+-----+-----+-----+-----+-----+
 CAACTCGGACCGGTCTGGCTATTGGGTAGCTTAGCAATGGCGGCGTGGTCTGCTGTA

a V E P W P R P I T H S N R Y R R S Q R H
 b L S P G P D R - P T R I V T A A A S D I
 c - A L A Q T D N P L E S L P P Q P A T S

12301 CGGCAGTACGAACATCAGCGAGCTAAAGTTAAGCGCAATCTGATGACCGGCGACATCCAC 12360
 -----+-----+-----+-----+-----+-----+-----+
 GCCGTCAATGCTGTAGTCGCTCGATTCAATTGCGTTAGACTACTGGCCGCTGTAGGTG

a R Q Y E H Q R A K V K R N L M T G D I H
 b G S T N I S E L K L S A I - - P A T S T
 c A V R T S A S - S - A Q S D D R R H P Q

12361 AATACCTAATGGCGAAACCAGCAGCGCAACGACCGCAAATAACGTCACCTTCAAAGAACAG 12420
 -----+-----+-----+-----+-----+-----+-----+
 TTATGGATTACCGCTTTGGTCGTCGCGTTGCTGGCGTTTATTGCAGTGAAGTTTCTTGTG

a N T - W R N Q Q R N D R K - R H F K E Q
 b I P N G E T S S A T T A N N V T S K N S
 c Y L M A K P A A Q R P Q I T S L Q R T A

Figure 11BQ

Continued to 11BQ.1
11BQ.1

12421
 CCAGCGCAATCGGCAACCCAGTTGAATCAGGCGCTTCATGACGAGCTATCGGGTTGC
 -----+-----+-----+-----+-----+-----+
 12480
 GGTCGCGTTAGCCGTTGGGGTCAACTTAGTCCGGAAGTACTGCTGCGATAGCCCAAACG

a P A Q S A T P V E S G A S - R R Y R V C
b Q R N R Q P Q L N Q A L H D D A I G F A P
c S A I G N P S - I R R F M T T L S G L P

CAAAGCCTTTTCAATTACGAATATCACGCATTGAACGCCGCGTGTTTAATGTAAAGAACGA
-----+-----+-----+-----+-----+-----+
12481
GTTTCGGAAAAAGTAATGCTTATAGTGCGTAACCTGCGGCACAAAATTACATTCCTTCGT
-----+-----+-----+-----+-----+-----+ 12540

a Q S L F H Y E Y H A L N A R V - C K K A
b K A F F I T N I T H - T R V F N V R K H
c K P F S L R I S R I E R A C L M - E S M

TGGCGATAAACATCACCCCAATAGACCGCCGCGCAGTCGCAACGCCGCAGCCGATACCGCCGA
-----+-----+-----+-----+-----+-----+
12541

ACCGCTATTGTAGTGGGTTATCTGGCGCGCTCAGCGTTGCGGCGTGCGGCTATGGCGGCT
-----+-----+-----+-----+-----+-----+
12600

a W R - T S P N R P P Q S Q R R S R Y R R E S
b G D K H P I D R R S R N A A A D T A E S
c A I N I T Q - T A A V A T P Q P I P P S

Figure 11BR

Continuation of Spec. 23
 27.13.64 (3)

12601 GTTCCGGCATACCAAAATGGCCATAGATAAAATATAGTTCACCGGAATATTCACCAGCA 12660
 -----+-----+-----+-----+-----+-----+-----+-----+
 CAAGGCCGTATGGTTTACCGGTATCTATTTTATATATCAAGTGGCCTTATAAGTGGTCGT

a V P A Y Q N G H R - K Y S S P E Y S P A
 b F R H T K M A I D K N I V H R N I H Q Q
 c S G I P K W P - I K I - F T G I F T S R

12661 GGCCCCAAAATCCCATCACCATACCCGGTTTGGTTTGGCCAGACCTTCGCACGTGGTTTC 12720
 -----+-----+-----+-----+-----+-----+-----+-----+
 CCGGGTTTATAGGTAGTGGTATGGCCAAACCAAAACCGGTCTGGAAGCGTGACCAAAG

a G P K I P S P Y P V W F W P D L R T G F
 b A Q K S H H T R F G F G Q T F A L V S
 c P K N P I T I P G L V L A R P S H W F R

12721 GCGTACCTGAAAGAAAGTATCCTGCGCCCCACAGCAGCGCGGAAGATAACCCACGG 12780
 -----+-----+-----+-----+-----+-----+-----+-----+
 CGCGATGGACTTCTTTCCATAGGACGCGGGGTGTCGTCGCGCGCTTCTATTGGGTGCC

a A L P E R K G I L R P T A A R E D N P R
 b R Y L K E K V S C A P Q Q R A K I T H G
 c A T - K K R Y P A P H S S A R R - P T A

Figure 11BS

Conte et al. 1990

Continued on p. 12
Rm 1004

12781 CTTATCGGCCAGCGCCGGATCAATATATGATAGAGCGGATAATGTATCCGGCATTCC 12840
-----+-----+-----+-----+-----+-----+-----+
GAAATAGCCGGTCGGCCTAGTTATAATACGTATCTCGCCTATTACATAGGCCGTAAGG

a L Y R P A P D Q Y Y A - S G - C I R H S
b F I G Q R R I N I M H R A D N V S G I P
c L S A S A G S I L C I E R I M Y P A F H

12841 ACAGGACGATCATCACCAGCACGGAGACAAAGCCCGCAGCCAGAACCCCTTGTGGAACCT 12900
-----+-----+-----+-----+-----+-----+-----+
TGTCCTGCTAGTAGTGGTCGTGCCTCTGTTTCGGGCGGTCGGTCTTGGGAACAGCCTTGGA

a T G R S S P A R R Q S P P A R T L V E P
b Q D D H H Q H G D K A R Q P E P L S N L
c R T I I T S T E T K P A S Q N P C R T -

12901 GATGCGGATACGCTCACGACGGCCGGAGCCATTGAGTTGCGCAATCACAGCGGTCAAG 12960
-----+-----+-----+-----+-----+-----+-----+
CTACGCGCTATGCGAGTGCTGCCGGCCTCGGTAACCTCAACGCGTTAGTGTCCGCAGTTCC

a D A R Y A H D G R S H - V A Q S Q A S R
b M R D T L T A G A I E L R N H R R Q G
c C A I R S R R P E P L S C A I T G V K A

Figure 11BT

Cont. with 1000000
RMS 10 1000000

13141 TGGTATACTTCTGCACGTATTCACCTTTTATTTTGTGTTATATGAAGACTAAAAGCC 13200
-----+-----+-----+-----+-----+-----+-----+
ACCATATGAAGACGTGCATAAGTGGAAAAATAAAACAATATACCTTCTGATTTTTCGG
a W Y T S A R I H L L F C C Y M K D - K A
b G I L L H V F T F Y F V V I - K T K K P
c V Y F C T Y S P F I L L L Y E R L K S R

13201 GCCGAAGTGGCAGCCAAAAGAAATAGCAGGGGAAATTTCACTCTATTGTAGCGGGGTATT 13260
-----+-----+-----+-----+-----+-----+-----+
CGGCTTCACCGTCGGTTTCTTTATCGTCCCTTTAAAGTCAGATAACATCGCCCCATAA
a A E V A A K R N S R G N F S L L - R G I
b P K W Q P K E I A G E I S V Y C S G V L
c R S G S Q K K - Q G K F Q S I V A G Y Y

13261 ACTATTTCTCAGTGAAAAACAGTTGTTAACGGCGCATTTGCTGGCAAGCTGTTTTCCTCA 13320
-----+-----+-----+-----+-----+-----+-----+
TGATAAGAGAGTCACCTTTTGTCAACAATGCGCGTAACGACCGTTCGACAAAAAGGT
a T I S P V K K Q L L T A H C W Q A V F P
b L F L Q - K N S C - R R I A G K L F F H
c Y F S S E K T V V N G A L L A S C F S T

Figure 11BV

Continued on p. 192
 (P. 192, 193)

Figure 12A
 DNA Sequence of VGC II cluster C

Tn insertion P9B4
 ↓
 1 GGATCCCTTTTCTTAAATGCTGCTAACGTTTCTTGCAAAATGCGTTGATGAGATTCATCC 60
 - - - - - + - - - - - + - - - - - + - - - - - + - - - - - +
 CCTAGGAAAAGAAATTACGACGATTGCAAAAGAACGTTTACGCAACTACTCTAAGTAGG
 61 AGTACACCACCTGATAACAAAGAGCGNCGCATTTGGCNWAMMWTKRNNMRNNSCNNNACTA 120
 - - - - - + - - - - - + - - - - - + - - - - - + - - - - - +
 TCATGTGGTGACTATTGTTTCTCGCNGCGTAACCGNWTKKWAMYNNKYNNSGNNNTGAT
 Tn insertion P7A3
 ↓
 121 AACCGTTCCTATTATCGCAGAAATAATATCATCCCCCTGAGACTGATGAGAGTGACTAA 180
 - - - - - + - - - - - + - - - - - + - - - - - + - - - - - +
 TTGGCAAGAGATAATAGCGTCCTTATTATAGTAGGGGACTCTGACTACTCTCACTGATT
 181 TCTGCCAGTGCAATAACCCGGGAATATCTGCAAGTAATGTTGAACCTTGCGCCATTGCT 240
 - - - - - + - - - - - + - - - - - + - - - - - + - - - - - +
 AGACGGTCACGTTATTGGGCCCTTATAGACGTTTATTACCAACTTGGAAACGCGGTAAACGA
 Tn insertion P964
 ↓
 241 GATCCATTTGTATATCATCATGAATTAACACGCTCCCCGGCCCTTCGCTGGATACTTCAG 300
 - - - - - + - - - - - + - - - - - + - - - - - + - - - - - +
 CTAGGTAAACATATAGTAGTACTTAATTGTGCGAGGGCCCGGGAAGCGACCTATGAAGTC

Figure 12B

301 CATNSSGGTAACCAATTTTATCAAAAACATCCTGCACCTTCTCGTACCAATAAGTCATCAC 360
 -----+-----+-----+-----+-----+-----+-----+
 GTANSSCCATTGGGTAAATAAGTTTGTAGGACGTGAAGAGCATGGTTATTTCAGTAGTG
 361 AGATTACACCATCCCGATACATGACCCCCCATGATTCGAGAGTCGCTCTCACCTTTTGCA 420
 -----+-----+-----+-----+-----+-----+-----+
 TCTAATGTGGTAGGGCTATGTACTGGGGGTACTAAGCTCTCAGCGAGAGTGGAAAAACGT
 421 TCTGTTTCGCTTGACGAGCAATAACCGACAACCTGCAGGCTGCCATCTTCTTCCATTGCG 480
 -----+-----+-----+-----+-----+-----+-----+
 AGACAAGCGAACTGCTCGTTATTGGCCCTGTTGACGTCCGACGGTAGAAGAAAGGTAACGC
 481 CCCGCACATAATGAATAATTGCTTTTGTCTAATAAAAACTTAACCCGCAAAAGGTAAGTCAT 540
 -----+-----+-----+-----+-----+-----+-----+
 GGGCGTGATTACTTATAACGAAAAACAGATTATTTTGAATTGGGCGTTTCCATTTCAGTA
 541 TTACCGTTTCAGGCTGACCACCTAATACTTAACAGGACACCCATTCCACCGATGAAAAATCA 600
 -----+-----+-----+-----+-----+-----+-----+
 AATGGCAAAGTCCGACTGGTGATTATGAATTGTCCCTGTGGGTAAGGTGGCTACTTTTAGT
 601 AGAATACGCCAGCCAACCAACAGTACCCTGATCTGGAACGGGTATTTGATAATCAGCAA 660
 -----+-----+-----+-----+-----+-----+-----+
 TCTTATGCGGTCGGTTGGTGTGTCATGGGACTAGACCTTTGCCCATAAACTATTAGTCGTT

Figure 12C

| | | |
|-----|---|------|
| 661 | GTTCAAAATCCTGTTTACCAAACGCGATASSCACTCCCGCAACCTGCAAAACCCCACTGG
-----+-----+-----+-----+-----+-----+-----+
CAAGTGTAGGACAAATGGTTTGCCTATSSGTGAGGCGCTTGACGCTTTTGGGTGACC | 720 |
| 721 | ATGGTAGCGGCTTATTGGATTAAATCTGCGGCCATTAACTCTAACTCTGGCTTTCCCGG
-----+-----+-----+-----+-----+-----+-----+
TACCATCGCCGAATAAACCTAATTAGACGCCGGTAATTGAGATTGAGACCGAAAGGGCC | 780 |
| 781 | CATCAACAAATAAATACTCTGCTTCTCTCAGAAATAATTTTTCATTTATAGCCAGCG
-----+-----+-----+-----+-----+-----+-----+
GTAGTTGTTTATTGATAGACGGACAAGAGAGTCTTATTAAAAAGTAAATATCGGTCCG | 840 |
| 841 | AATACAAATATCGCATCCCTTCTCCCCCAGTGACAGGTTACCTTCATTCAGCCATACTTC
-----+-----+-----+-----+-----+-----+-----+
TTATGTTTATAGCGTAGGGAAGAGGGGTCACTGTCCAATGGAAGTAAGTCGGTATGAAG | 900 |
| 901 | CCGGCCTTGTAACCGTGACCTAAACGTAATTTTCCAGGAACCTCTTGGATTAAACCAT
-----+-----+-----+-----+-----+-----+-----+
GGCCGGAACATTTTGCACTGGATTTTTCATATAAAGGTCTCTGAGAAACCTAATTGGTA | 960 |
| 961 | GAGATATGCCATTATTACTAGGCTTTAATCAAAAAAGCCCTGATTACACTATGTA
-----+-----+-----+-----+-----+-----+-----+
CTCTATACGGTAATAAATGATGACTCCGAAATTAGTTTTTTCGGACTAATGTGATACAT | 1020 |

Continued on next page

Figure 12D

| | | |
|------|--|------|
| 1021 | CTTGAGTCGTATCATTCGGAACAAATGACCTACACAGGAATATCGCCCAATAAAGGGA
-----+-----+-----+-----+-----+-----+-----+
GAACTCAGCATAGTAAACGCTTTGTTACTGGATGTTGTCTTATAGCGGTTATTTCCCT | 1080 |
| 1081 | TTTTGTTTTGCGAGTGGATTTGTTTACCTTGTTTAAACCCCTCCAGCAATNAGACTTTGC
-----+-----+-----+-----+-----+-----+-----+
AAACAAACGCTCACCTAAACAAATGGAACAAATTTGGAGGGTCTTANTCTGAAACG | 1140 |
| 1141 | CCGGCCAAATAATGTGGCTTGCGAANCRAATTTACAGAAATTTGCACCTCGGGCAGCGGTCT
-----+-----+-----+-----+-----+-----+-----+
GGCCGGTTATTACACCGAACGCTTNGYTAAAGTCTTAAACGTGAAGCCCGTCGCCCCAGA | 1200 |
| 1201 | GTNTYGCYTTKGNSTATCACCTTTGTTGTCCATCCTGAANTATTAAGATTAAGCATTATTT
-----+-----+-----+-----+-----+-----+-----+
CANARCGRAAMCNSATAGTGAAACAAACAGGTAGGACTTNATAATTCTAATTCGTAATAAA | 1260 |
| 1261 | TTTGCGTGCCATTGTCAATTTAACAAGCGAGGTGTAAACGCGWNAACAAAGAACCCGTAGTG
-----+-----+-----+-----+-----+-----+-----+
AAACGCACGGTAACAGTAAATTTGTTGCTCCACATTGCGCWNNTTGTCTTGGGCATCAC | 1320 |
| 1321 | ATGGATTCAAAGTTTAGCCACTTTTCTCCCTGCAGTTTGGTATAGAAAGTAATTTTITA
-----+-----+-----+-----+-----+-----+-----+
TACCTAAGTTCAAATCGGTGAAAAAGAGGGACGTCAAACCATATCTTTCATTATAAAAT | 1380 |

Continued on page 50

Figure 12E

| | | |
|------|--|------|
| 1381 | TCCAGCACAGCCTGGATATTATTTAAAGTCACACAGATGGCTGGAAAGTACATAAGCC | 1440 |
| | AGGTCGTGCGGACCTATAATAAATTTCAGTGGTGCTACCGACCCCTTTCATGTATTCCG | |
| 1441 | TGAGAGCTTTTTCAGGGCAATTCAGACGCACCATAAAGTTTGAGGTATCGCTGATTACC | 1500 |
| | ACTCTCGAAAAGGTCCCGTAAGTCTGCGTGGTATTTCAAACTCCATAGCGACTAATGG | |
| 1501 | GTTGANNAAACCACCTAGCACCAACCGTCATTCAAACCTGTATTGAACGCAATTTCTTGCCA | 1560 |
| | CAACTNNTTGGTGATCGTGGTGGCAGTAAGTTTGACATACCTTGCGTTAAAGAACGGT | |
| 1561 | CCCAGCGACACTGCCGTTCCCAGTCGATGCCCTAACTGGTTAATAATCTCCAGCATTAACA | 1620 |
| | GGGTCGCTGTGACGGCAAGGGGTCAGCTACGGATTGACCAATTATAGAGGTCGTAATTGT | |
| 1621 | TCGATAAATTTTCACCGAAATCTCTATCATCTGCTGGCGTTGATCTAATTCCTGTGATGAGT | 1680 |
| | AGCTATTAAAGTGGCTTTAGAGATAGTAGACGACCGCAACTAGATTAGACACTACTCA | |
| 1681 | TTCCGATACNNNGCCATATTGGNNNNCATAATCACGAACGATCACTGCATTCCTGGCGTNGG | 1740 |
| | AAGGCTATGNNNCGGTATAACCNNGTATTAGTGCTTGCTAGTGACGTAAGACCGCANCC | |

Continuing sequence

Cont. cont. 209447.60
R. 209447.60

Figure 12F

| | | | |
|------|--|------|------|
| 1741 | GTCGGCAGCAACATNGGCAATGCCCTGTGTAGCGGGTGAACCAATTGTTTCNTCGATGACGT
-----+-----+-----+-----+-----+-----+-----+-----+
CAGCCGTCGTTTGTANCCGTTACGGACACATCGCCCACTTGGTAACAAGNAGCTACTGCA | 1800 | |
| 1801 | CGGGACGCTGGTTTACTCATCTCAGCAATAACACTAACGACCCCTGGNNAACACGACG
-----+-----+-----+-----+-----+-----+-----+-----+
GCCCTGCGACCAAAATGAGTAGAGTGCGTTATGTGATTGCTGGGACCNNTTGGTGCTGC | 1860 | |
| 1861 | GACTGATCGCGATATTGGTACTGGGTATCCATCGCAGTGGCATACTTAAGCGTGTATATA
-----+-----+-----+-----+-----+-----+-----+-----+
CTGACTAGCGCTATAACCATGACCCATAGGTAGCGTCACCGTATGAATTGCGACATATAT | 1920 | |
| 1921 | CTTACACTCACCGCACTGTCCTTTCGTTTGATTAAACGCATTATCCAGCACTGAAGCTAAT
-----+-----+-----+-----+-----+-----+-----+-----+
GAATGTGAGTGGCGTGACAGAAAGCAAACTAATTGCCGTAATAGGTCGTGACTTCGATTA | 1980 | |
| 1981 | TGACTAATACGAGTCAGGCAGCTGGGAACACCGCTCACCTCCACAGCTTTGGTACCGGTA
-----+-----+-----+-----+-----+-----+-----+-----+
ACTGATTATGCTCAGTCCGTCGACCCCTTGTGGCGAGTGGAGGTGTCGAAACCATGGCCAT | 2040 | |
| 2041 | <p style="text-align: center;">Tn insertion P7G2</p> <p style="text-align: center;">↓</p> <p>ATTTCCTTAACCTCGCATCCCGGTGATGAAAGGATATTCTGGCTGCGTAAGTAATGAATG
-----+-----+-----+-----+-----+-----+-----+-----+
TAAAGAAATTGGAGCGTAGGGCCACTACTTTCCTATAAGACCGACGCAATTCATTACTTAC</p> | | 2100 |

Figure 12G

| | | |
|------|--|------|
| 2101 | AACCGTCCAGTAGATAAAATATTGAAAGTGATAACCTGATGTTTAAATAACGATGCAGGA
-----+-----+-----+-----+-----+-----+-----+
TTGGCAGGTCATCTATTTTATAAAGTTTCACTATTGGACTACAAAATTATTGCTACGTCCT | 2160 |
| 2161 | TATACATATAACATGCTGCCATCAAAACGAGTAAGCAAATCATATTTGTGCTGCCAGGTTA
-----+-----+-----+-----+-----+-----+-----+
ATATGTATATTGTACGACGGTAGTTTGGTCCATTTCGTTTAGTATAACACGACGGTCCAAT | 2220 |
| 2221 | TTCAAAATATCGACCGGTGTCAGCGGAATTTTCCACTAAATGTAGCTGTATCAAT
-----+-----+-----+-----+-----+-----+-----+
AAGTTTATAGCTGGCCACCAGGTCCGCCCTTAAAAAGGTGATTACATCGACAAATAGTTA | 2280 |
| 2281 | GGGCTAATAGTAATAGCCGTATCATAGTTCTCTGAGAGCAGATGTNAAAACCTCTGCTAA
-----+-----+-----+-----+-----+-----+-----+
CCCGATTATCATTCGGCATAGTATCAAGAGACTCTCGTCTACANTTTTGGAGACGATT | 2340 |
| 2341 | TGGCATTTGTCTGGCATAAAGGGTGAAGTCATTACCTTTCATGATAACTCATCCTCTT
-----+-----+-----+-----+-----+-----+-----+
ACCGTAAACAGACCGGTATTTCCCACTTCAGTAAATGGAAGGTACTATTGAGTAGTGAGAA | 2400 |
| 2401 | TGCTGTATTGAGTATAAATAGTAAAATTAAGATTAAACGTTTATTACTACCATTTTATA
-----+-----+-----+-----+-----+-----+-----+
ACGACATAACTCATATTATCATTTTAAATTCCTAATTTGCAAAATAAATGATGGTAAAATAT | 2460 |

Continued on p. 12H
20941260

Figure 12I

2821 WTTTAA TGGAATGCC TTTTAA AACTGCC CAGCATGA ATCCCTC CTGACATAA ATGGGAG
 -----+-----+-----+-----+-----+-----+-----+
 WWAATTACCTTACGGAAAATTTTGACGGTCGTA CTTAGGAGGAGTCTGTATTTACCCCTC
 2881 TTTCTATCAAAATTCGCTCACAACCA CATCCGTA AAAAGCCTGATT CACATTTATTTTCGAC
 -----+-----+-----+-----+-----+-----+-----+
 AAAGATAGTTTAAGCGAGTGTGGTG TAGGCATTTTTCGGACTAAGTGTAATAAAGCTG
 2941 TATACTCTTCTTGTA CAATATCAGGATGCTGTACATATACCTTGT CACAGCGATTCT
 -----+-----+-----+-----+-----+-----+-----+
 ATATGAGAAGAACATGTTATAGTCCCTACGACAGATGTATATGGAACAGTGTCCGCTAAGA
 3001 ATCATTCGGATTTTCCGATAAAATTNMMCAATTACATTTTCAGCATTTGACATATAAAACTTA
 -----+-----+-----+-----+-----+-----+-----+
 TAGTAAGCCTAAAAGGCTATTTAANKGTTAATGTAAAAGTCGTA ACTGTATTTTGTGAAT
 3061 CAATTTGNAAAATTA TTTAATAAATAA AC GTTACGATGTTT TTTACATCGCCATCTTATT
 -----+-----+-----+-----+-----+-----+-----+
 GTTAAACNTTTTTAATAAATAATTTATTTGACAAATGCTACAAA AATGTAGCGGTAGAAATAA
 3121 AAAAAGTAATTGTAGTCATCGACTNGGTTATATATGAAGAAATTTATCTTCCCTAATGATA
 -----+-----+-----+-----+-----+-----+-----+
 TTTTTCATTAACATCAGTAGCTGANC CAATATATATACTTCTTTAAATAGAAGGATTACTAT

Cont. Page 12
R. 11/11/11

Figure 12J

| | | |
|------|---|------|
| 3181 | ACACATCGATTAAATCWCTGATGAAACTATATGTACTGCCGATAGTGATCAAGTGCCAAA
-----+-----+-----+-----+-----+-----+-----+
TGTGGTAGCTAATTAGWNGACTACTTTGATATACATGACGCTATCAGTACTAGTTCACGGTTT | 3240 |
| 3241 | GATTTTGCAACAGGCAACTGGAGGAGCAATTATGAATTTSSSTCAATCTCAAGAAATACSS
-----+-----+-----+-----+-----+-----+-----+
CTAAAACGTTGTCCGTTGACCTCCCTTCGTAATACTTAAASSAGTTAGAGTTCCTTATGSS | 3300 |
| 3301 | YSYRNNNNNTCTTTAGTAAATCAGGCTAACTTTTATTTTATTTAACAACAATAATTWT
-----+-----+-----+-----+-----+-----+-----+
RSRYNNNNNAGAAAATCATTAGTCCGATTGAAAAAATAAATAAATGTTGTTATTAAWA | 3360 |
| 3361 | TTGGCTGCTATCTGTGCTTACCGCAGCTTATATATCAATGGTTCRGAACACGGCAGCATAT
-----+-----+-----+-----+-----+-----+-----+
AACCGACGATAGACACGAATGGCGTCGAATATATAGTTACCAAGYCTTTGCCGTCGTATA | 3420 |
| 3421 | AATAGAGGATTTATCCGTTCTATCCGAGATGAATATTGTACTAAGCAATCAACGGTTTGA
-----+-----+-----+-----+-----+-----+-----+
TTATCTCCCTAAATAGGCAAGATAGGCTCTACTTATAACATGATTCGTTAGTTGCCAAACT | 3480 |
| 3481 | AGAAAGCTGAACGTGACGCTAAAAATTTAATGTATCAATGCTCATTAGCGACTGAGATTCA
-----+-----+-----+-----+-----+-----+-----+
TCCTTCGACTTGCACTGCGATTTTAAATTACATAGTTACGAGTAATCGCTGACTCTAAGT | 3540 |

Figure 12K

3541 TCATAACGATATTTCCCTGAGGTGAGCCGGCATCTATCTGTCCGTCCTTCAAATTCAC 3600
 -----+-----+-----+-----+-----+-----+-----+
 AGTATTGCTATAAAGGACTCCACTCGGCCGTAGATAGACAGCCAGGAAGTTTAAACGTG
 3601 MGCCGACGCTNAACGGAGAGAAAGCACCGTCTCTTTCTGCAGTCCCTCTGATATCGATGAAA 3660
 -----+-----+-----+-----+-----+-----+-----+
 KCGGCTGCGANTTGCCTCTCTTCGTGGCAGAGAAAGACGTCAGGAGACTATAGCTACTTT
 Tn insertion P3P4
 3661 ATAGCTTTCGTCCGATAGTTTATTCTTAATCATAAAATGAGATTCGTTATTATCTA 3720
 -----+-----+-----+-----+-----+-----+-----+
 TATCGAAAGCAGCGCTATCAAAATAAGAAATTAGTATTTTACTCTAAAGCAATAATAGAT
 3721 CTGATAACCCCTTCAGATTATCAACTCTACAGCCTTTAAACGCGAAAAGCTTTCCTTTAT 3780
 -----+-----+-----+-----+-----+-----+-----+
 GACTATTGGGAAGTCTAATAAGTTGAGATGTCGGAATTCGCTTTTTCGAAAAGGAAATA
 3781 ACCCAACCCATGCCGGTTTACTGGAGTGAAACAGAAATACATAAACGGCAAAGGATGGC 3840
 -----+-----+-----+-----+-----+-----+-----+
 TGGGTTGGGTACGGCCCAAATGACCTCAGTGTCTTATGTATTTGCCGTTTCCCTACCG
 3841 AACGCTTCCGTTGCCGTTGCCGATCAGGCAAGCGTATTTTGTAGGTGACGGTTAAACT 3900
 -----+-----+-----+-----+-----+-----+-----+
 TTGCGAAGGCAACGCCAAGGCTAGTCCGTTCCGCATAAAAAAACTCCACTGCCAATTGA

Figure 12L

| | | |
|------|---|------|
| 3901 | TCCCGATCTCATTACTAAGAGCCACCTGCCATTAGATAGATAGTATTCGAGTATGGCTGGA
-----+-----+-----+-----+-----+-----+-----+
AGGCTAGAGTAATGATTCTCGGTGACGGTAATCTACTATCATAAGCTCATAACCGACCT | 3960 |
| 3961 | TCAAAACAACCACTTATTGCCGTTTTCATACATCCCGGCAAAAAATACGTACACAGTTAG
-----+-----+-----+-----+-----+-----+-----+
AGTTTGTGTGTAATAACGGCAAAAGTATGTAGGCCGTTTTTTATGCATGTGTCAATC | 4020 |
| 4021 | AAAATGTAAACGCTGCATGATGGATGGCAGCAAAATTCCCGGATTTCTGATATTACGCACAA
-----+-----+-----+-----+-----+-----+-----+
TTTACATTGCGACGTACTACCTACCGTCGTTTAAGGGCCTAAGACTATAATGCGTGTT | 4080 |
| 4081 | CCTTGCAATGGCCCCGGATGGAGTCTGGTTACGCTGTACCCATACGGTAATCTACATAATC
-----+-----+-----+-----+-----+-----+-----+
GGAACGTACCGGGCCCTACCTCAGACCAATGCGACATGGGTATGCCATTAGATGTATTA | 4140 |
| 4141 | GCATCTTAAAAATTATCCTTCAACAAATCCCCCTTTACATTAAACAGCATTTGGTGTGATGA
-----+-----+-----+-----+-----+-----+-----+
CGTAGAATTTTAAATAGGAAGTTGTTTAGGGGAAATGTAATTGTCGTAACCCACAACACTACT | 4200 |
| 4201 | CGTCGGCTTTTGTCTGGTTACTACATCGCTCAGTGGCCAAACCGTTATGGCGTTTGTGTCG
-----+-----+-----+-----+-----+-----+-----+
GCAGCCGAAAAACGACCAATGATGTAGCGAGTGACCGGTTTGGCAATACCGCAAAACAGC | 4260 |

Continued on page 2

Figure 12M

| | | |
|------|---|------|
| 4261 | ATGTCATTAAATAAACCGCAACTGCACCGCTGAGCACACACGTTTACCAGCACACGACTGG
-----+-----+-----+-----+-----+-----+-----+
TACAGTAATTATTTGGCGTTGACGTGGCGACTCGTGTGCAAAATGTCGTGTTGCTGACC | 4320 |
| 4321 | ATGAATTAGATAGTATTGCCGGTGCTTTTAACCAACTGCTTGATACTCTACAAGTCCAAT
-----+-----+-----+-----+-----+-----+-----+
TACTTAATCTATCATAACGGCCACGAAATTTGGTTGACGAACTATGAGATGTTCAAGTTA | 4380 |
| 4381 | ACGACAATCTGGAAAACAAGTCGCAGACGCCACCGCGCTAAATGAAGCAAAAACG
-----+-----+-----+-----+-----+-----+-----+
TGCTGTTAGACCTTTTGTTCAGCGTCTGCGTGGTCCGCGATTACTTCGTTTTTTTGC | 4440 |
| 4441 | CGCTGAGCNAGCTAACAAACGTAAAGCATTCATCTTACGGTAATAAGTCATGAGTTACG
-----+-----+-----+-----+-----+-----+-----+
GCGACTCGNTCGATTGTTTGCAATTTTCGTAAGTAGAATGCCATTATTCACTCAATGC | 4500 |
| 4501 | TACTCCGATGAATGGCGTACTCGGTGCAATTGAATTATTACAAACCCCTTTAAACAT
-----+-----+-----+-----+-----+-----+-----+
ATGAGGCTACTTACCGCATGAGCCACGTTAACTTAATAATGTTGGTGGGAAATTTGTA | 4560 |
| 4561 | AGAGCAACAAGGATTAGCTGATACCGCCAGAAATTGTACACTGTCCTTTGTTAGCTATTAT
-----+-----+-----+-----+-----+-----+-----+
TCTCGTTGTTCCCTAATCGACTATGGCGGTCCTTAAACATGTGACAGAAACAATCGATAATA | 4620 |

Figure 120

4981 AGCAGACAAATTTCGCAAGGTACAGGAATTGGACTGACTATTGCGTCAAGCCTGGCTAA 5040
 -----+-----+-----+-----+-----+-----+-----+
 TCGTCTGTGTTTAAAGCGTTCCATGTCTTAACCTGACTGATAACGCAGTTTCGGACCGATT
 5041 AATGATGGGCGGTAATCTGACACTAAAGTGTCCCCGGGTTGGAACCTGTGTCTCGCT 5100
 -----+-----+-----+-----+-----+-----+-----+
 TTACTACCGCCATTAGACTGTGATTTTTCACAGGGGCCCAACCTTGGACACAGAGCGA
 Tn insertion
 5101 AGTATTACCTTACAAGAATACCAGCCGCTCAACCAATTAAAGGACGCTGTCAGNNNC 5160
 -----+-----+-----+-----+-----+-----+-----+
 TCATAATGGGAATGTTCTTATGTGTCGGCGGAGTTGTTAAATTTCCTGCGACAGTCNNNG
 5161 CGTTCCTGCATCGGCAACTGGCTTGCTGGGGAATACGCGGTGAACCCACCACCGAGC 5220
 -----+-----+-----+-----+-----+-----+-----+
 GCAAGACGGACGTAGCCGTTGACCCGAACGACCCCTTATGCGCCACTTGGTGGGTGGTCCG
 5221 AAAATGCGCTTCTCAANNCNAGAGCTTTTGTAATTTCTCCGGAATACTTACGACCTGGCG 5280
 -----+-----+-----+-----+-----+-----+-----+
 TTTTACGCGAAGAGTTNNGNTCTCGAAAACATAAAGAGGCCCTTTTGAGATGCTGGACCGC
 5281 CAACAGTTAATAATTGTGTACACCAATAATGCCAGTAATAATAATTGTTACCACCTGG 5340
 -----+-----+-----+-----+-----+-----+-----+
 GTTGTCAATTATAACACATGTGGTTTATACGGTCATTAATTATTAACAATGGTGGGACC

Figure 12P

5341 CAGTTGCAGATTCTTTTGGTTGATGATGCCGATATTAATCGGGATATCATCGGCAAAATG 5400
 -----+-----+-----+-----+-----+-----+-----+
 5401 GTCACGTCCTAAGAAAACCACTACTACGGCTATAAATTAGCCCTATAGTCCGTTTAC
 -----+-----+-----+-----+-----+-----+-----+
 CTTGTCAGCCTGGCCCAACACGTCACCTATTGCCGCCAGTAGTAACGAGGCTCTGACTTTA 5460
 -----+-----+-----+-----+-----+-----+-----+
 5461 GAACAGTCGGACCCGGTTGTGCAGTGATAACGGCGTCAATCATTTGCTCCGAGACTGAAAT
 -----+-----+-----+-----+-----+-----+-----+
 TCACAAACAGCAGCATTTCGATTTAGTACTGATTGACATTAGAAATGCCAGAAATAGATGGT 5520
 -----+-----+-----+-----+-----+-----+-----+
 5521 AGTGTGTCGTCGCTAAGCTAAATCATGACTAAGTAAATCTTACGGTCTTTATCTACCA
 -----+-----+-----+-----+-----+-----+-----+
 ATTGAATGTGTACGATTATGGCATGATGAGCCGAATAATTAGATCCTGACTGCATGTTT 5580
 -----+-----+-----+-----+-----+-----+-----+
 TAACTTACACATGCTAATACCGTACTACTCGGCTTATTAAATCTAGGACTGACGTACAAA
 -----+-----+-----+-----+-----+-----+-----+
 5640 GTGGCACTATCCGCTAGCGTASCNVNMAWAWRWTMWTCTRTYGTDDAAAARWDRKDHWT
 -----+-----+-----+-----+-----+-----+-----+
 5581 CACCGTGATAGGCGATCGCATSGBNKCTTWYWAKWAGYARCAHHTTTTTTWYHCYMHDDWA
 -----+-----+-----+-----+-----+-----+-----+
 5641 CATHAYANNNTTACAAACCAGTGACATTGGCTACCTTAGCTCGCTACATCAGTATTGCCG
 -----+-----+-----+-----+-----+-----+-----+
 GTADTRTNNAATGTTTTTGGTCACCTGTAAACCGATGGAATCGAGCGATGTAGTCATAACGGC 5700
 -----+-----+-----+-----+-----+-----+-----+
 CAGAAATACCAACTTTTACGAAATATAGAGCTACAGGAGCAGGATCC 5746
 -----+-----+-----+-----+-----+-----+-----+
 5701 GTCTTATGGTTGAAAAATGCTTTTATATCTCGATGTCTCCTCGTCCCTAGG

Continuation of 07246
 17246.1(1)

COMBINED DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY

(Includes Reference to PCT International Application)

ATTORNEY'S DOCKET NUMBER

RPMS101

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

Identification of Genes

the specification of which (check only one item below):

☐ is attached hereto.

☒ was filed as United States application

Serial No. 08/637,759

on _____,

and was amended

on _____ (if applicable).

☒ was filed as PCT international application

Number PCT/GB95/02875

on 11 December 1995

and was amended under PCT Article 19

on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed:

PRIOR FOREIGN/PCT APPLICATION(S) AND ANY PRIORITY CLAIMS UNDER 35 U.S.C. 119:

| COUNTRY
(if PCT, indicate PCT) | APPLICATION NUMBER | DATE OF FILING
(day, month, year) | PRIORITY CLAIMED
UNDER 35 USC 119 |
|------------------------------------|--------------------|--------------------------------------|---|
| PCT | PCT/US95/02875 | 11 December 1995 | <input checked="" type="checkbox"/> YES <input type="checkbox"/> NO |
| United Kingdom | 9424921.6 | 09 December 1994 | <input checked="" type="checkbox"/> YES <input type="checkbox"/> NO |
| United Kingdom | 9501881.8 | 31 January 1995 | <input checked="" type="checkbox"/> YES <input type="checkbox"/> NO |
| United Kingdom | 9509239.1 | 05 May 1995 | <input checked="" type="checkbox"/> YES <input type="checkbox"/> NO |
| | | | <input type="checkbox"/> YES <input type="checkbox"/> NO |

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) or PCT international application(s) designating the United States of America that is/are listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in that/those prior application(s) in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application(s) and the national or PCT international filing date of this application:

PRIOR U.S. APPLICATIONS OR PCT INTERNATIONAL APPLICATIONS DESIGNATING THE U.S. FOR BENEFIT UNDER 35 U.S.C. 120:

| U.S. APPLICATIONS | | STATUS (Check one) | | |
|---------------------------------------|------------------|---------------------------------------|---------|-----------|
| U.S. APPLICATION NUMBER | U.S. FILING DATE | PATENTED | PENDING | ABANDONED |
| | | | | |
| | | | | |
| | | | | |
| PCT APPLICATIONS DESIGNATING THE U.S. | | | | |
| PCT APPLICATION NO. | PCT FILING DATE | U.S. SERIAL NUMBERS ASSIGNED (if any) | | |
| | | | | |
| | | | | |
| | | | | |

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. (List name and registration number)

Patrea L. Pabst Reg. No. 31,284
 Madeline I. Johnston Reg. No. 36,174
 Dolly A. Vance Reg. No. 39,054

and Correspondence to:

Patrea L. Pabst
 Arnall Golden & Gregory
 2800 One Atlantic Center
 1201 West Peachtree Street
 Atlanta, Georgia 30309-3450

Direct Telephone Calls to:
 (name and telephone number)

Patrea L. Pabst
 (404) 873-8794

| | | | |
|-------------------------|---------------------|--------------------------|--------------------------|
| FULL NAME OF INVENTOR | FAMILY NAME | FIRST GIVEN NAME | SECOND GIVEN NAME |
| | Holden | David | William |
| RESIDENCE & CITIZENSHIP | CITY | STATE OR FOREIGN COUNTRY | COUNTRY OF CITIZENSHIP |
| | London | United Kingdom | United Kingdom |
| POST OFFICE ADDRESS | POST OFFICE ADDRESS | CITY | STATE & ZIP CODE/COUNTRY |
| | 6 Princess Road | London | United Kingdom NW1 8JJ |
| FULL NAME OF INVENTOR | FAMILY NAME | FIRST GIVEN NAME | SECOND GIVEN NAME |
| | | | |
| RESIDENCE & CITIZENSHIP | CITY | STATE OR FOREIGN COUNTRY | COUNTRY OF CITIZENSHIP |
| | | | |
| POST OFFICE ADDRESS | POST OFFICE ADDRESS | CITY | STATE & ZIP CODE/COUNTRY |
| | | | |
| FULL NAME OF INVENTOR | FAMILY NAME | FIRST GIVEN NAME | SECOND GIVEN NAME |
| | | | |
| RESIDENCE & CITIZENSHIP | CITY | STATE OR FOREIGN COUNTRY | COUNTRY OF CITIZENSHIP |
| | | | |
| POST OFFICE ADDRESS | POST OFFICE ADDRESS | CITY | STATE & ZIP CODE/COUNTRY |
| | | | |

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

| | | |
|-----------------------------|---------------------------|---------------------------|
| SIGNATURE OF INVENTOR 201 | SIGNATURE OF INVENTOR 202 | SIGNATURE OF INVENTOR 203 |
| <i>David Holden</i> | | |
| " 5 th June 1996 | DATE | DATE |

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: David William Holden

Serial No.: Continuation of 09/201,945

Group Art Unit: Not Yet Assigned

Filed:

Examiner: Not Yet Assigned

For: IDENTIFICATION OF GENES

Assistant Commissioner for Patents
Washington, D.C. 20231

ASSOCIATE POWER OF ATTORNEY UNDER 37 C.F.R. § 1.34

Sir:


Please recognize as Associate Patent Attorneys and Patent Agent in this case:

| | | |
|------------------|----------|--------|
| Robert A. Hodges | Reg. No. | 41,074 |
| Kevin W. King | Reg. No. | 42,737 |

Please continue to direct all communication to Patrea L. Pabst at the following address:

Patrea L. Pabst
ARNALL GOLDEN & GREGORY, LLP
2800 One Atlantic Center
1201 West Peachtree Street
Atlanta, Georgia 30309-3450
(404) 873-8794; 873-8795 (fax)

Date: November 16, 2000



Patrea L. Pabst
Reg. No. 31,284

ARNALL GOLDEN & GREGORY, LLP
2800 One Atlantic Center
1201 West Peachtree Street
Atlanta, Georgia 30309-3450
(404) 873-8794
(404) 873-8595 (fax)

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT: David William Holden
- (ii) TITLE OF INVENTION: Identification of Genes
- (iii) NUMBER OF SEQUENCES: 501
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: Patrea L. Pabst
 - (B) STREET: 2800 One Atlantic Center
1201 West Peachtree Street
 - (C) CITY: Atlanta
 - (D) STATE: Georgia
 - (E) COUNTRY: USA
 - (F) ZIP: 30309-3450
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Floppy disk
 - (B) COMPUTER: IBM PC compatible
 - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 - (D) SOFTWARE: PatentIn Release #1.0, Version #1.30
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER:
 - (B) FILING DATE: 01-DEC-1998
 - (C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: 08/637,759
 - (B) FILING DATE: 03-MAY-1996
 - (C) CLASSIFICATION:
- (viii) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: PCT/GB95/02875
 - (B) FILING DATE: 11-DEC-1995
 - (C) CLASSIFICATION:
- (ix) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: Pabst, Patrea L.
 - (B) REGISTRATION NUMBER: 31,284
 - (C) REFERENCE/DOCKET NUMBER: RPMS 101 CON 2
- (x) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: (404) 873-8794
 - (B) TELEFAX: (404) 873-8795

(2) INFORMATION FOR SEQ ID NO: 1:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 89 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: cDNA
- (iii) HYPOTHETICAL: NO
- (iii) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Synthetic oligonucleotide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

CTAGGTACCT ACAACCTCAA GCTTNKNKNK NKNKNKNKNK NKNKNKNKNK NKNKNKNKNK 60

NKNKAAGCTT GGTTAGAATG GGTACCATG 89

- (2) INFORMATION FOR SEQ ID NO: 2:
- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 18 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: cDNA
 - (iii) HYPOTHETICAL: NO
 - (iii) ANTI-SENSE: NO
 - (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Synthetic oligonucleotide
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

TACCTACAAC CTCAAGCT

18

- (2) INFORMATION FOR SEQ ID NO: 3:
- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 18 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: cDNA
 - (iii) HYPOTHETICAL: NO
 - (iii) ANTI-SENSE: NO
 - (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Synthetic oligonucleotide
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

CATGGTACCC ATTCTAAC

18

- (2) INFORMATION FOR SEQ ID NO: 4:
- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 18 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: cDNA
 - (iii) HYPOTHETICAL: NO
 - (iii) ANTI-SENSE: NO
 - (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Synthetic oligonucleotide
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

TACCCATTCT AACCAAGC

18

- (2) INFORMATION FOR SEQ ID NO: 5:
- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 18 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: cDNA
 - (iii) HYPOTHETICAL: NO
 - (iii) ANTI-SENSE: NO

- (vi) ORIGINAL SOURCE:
 (A) ORGANISM: Synthetic oligonucleotide

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

CTAGGTACCT ACAACCTC

18

- (2) INFORMATION FOR SEQ ID NO: 6:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 20 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(iii) HYPOTHETICAL: NO
(iii) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
 (A) ORGANISM: Synthetic oligonucleotide

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

CCTAGGCGGC CAGATCTGAT

20

- (2) INFORMATION FOR SEQ ID NO: 7:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 21 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(iii) HYPOTHETICAL: NO
(iii) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
 (A) ORGANISM: Synthetic oligonucleotide

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

GCACTTGTGT ATAAGAGTCA G

21

- (2) INFORMATION FOR SEQ ID NO: 8:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 300 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(iii) HYPOTHETICAL: NO
(iii) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
 (A) ORGANISM: Partial sequence of Salmonella typhimurium
 virulence gene

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

GGTCTTAATG TACGGGCATG GTCTGCATCG ATAACTCCGG CACGCAAATC GCCATCGATA

60

CTCATTTGTT TGGCTGGCAT CCCATCAAGC GAGAAACGTG CGCTAACTTC CGCCACCCTC

120

TCGATACCTT TTGTAATGAC AATAAATTGC ACGATAGTAA TGATGGTAAA TACGACCAAC 180
 CCAACGGTGA GATTTCCTCC TACGACAAAC TTACCGAAAG CATCCACAAA TATTACCGGC 240
 ATTATGTTGT AACAGTACCC AGCCGTGATG TGCTGATTGG GGAGTTAACA ACCGATTTAT 300

(2) INFORMATION FOR SEQ ID NO: 9:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 300 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (iii) HYPOTHETICAL: NO
- (iii) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Partial sequence of *Salmonella typhimurium* virulence gene

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:

GCGCGGACGC TAGTGTGGTG GGTGACAGCC AGACGTTACC GAACGGGATG GGGCAGATCT 60
 GTTGGCTTAC AAAAGACATG GCCCATAAGG CGCAAGGTTT TGGGACTGGA CGTTTTTCGCG 120
 GGCAGACAAC GTATCTCTGT CTTATTAAAA TGTGTCCTGC TTCGGCATAT GTATCGAACC 180
 CTCGGAGCAA AGTCGTTTGG GCGCAGAATT AGTACGTTTG GGTCGGTTGC TGTTATTCCT 240
 TGGGCTCGGA AAAAGAGTGC CAGCGTGAAG GAGTGGGATT TGGCAGACTG GCCGCCTAAT 300

(2) INFORMATION FOR SEQ ID NO: 10:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 300 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (iii) HYPOTHETICAL: NO
- (iii) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Partial sequence of *Salmonella typhimurium* virulence gene

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:

CACTATAGGG AAAGCTTGCA TGCCTGCAGG TCGACTCTAG AGGATCTACT AGTCATATGG 60
 ATTGCACTTG TGTATAAGAG TCAGGATTAG AGGACATGCG CCGGGAACCA TACTATCTTT 120
 TTCCGGTGCT TCGACGCCAT TTGCGGAAAC CACAGACTTT TTGCGGCGAA TGAGGATAAT 180
 TGGCAATGCT AACAACGCTG AAAAGAAAGC GAGAGTGATA AAAGGAAAGC CAGGAATTAA 240
 AGCGAGGAGC ATTAAACCA CAGCGGCTAA TATGAGCGAC TGAGGTTGTC TGGCAATTG 300

(2) INFORMATION FOR SEQ ID NO: 11:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 300 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (iii) HYPOTHETICAL: NO
- (iii) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Partial sequence of Salmonella typhimurium virulence gene

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:

TGCAGGCCGA CTCTAGAGGA TCCCCGGGTA CCGGTAATTT CTTTAACCTC GCATCCCGGT 60
GGATGAAAGG ATATTCTGGC TGCCTAAGTA ATGAATGAAC CGCCCAGTAG ATAAAATATT 120
GAAAGTGATA ACCTGATGTT TTAATAACGA TGCAGGATAT ACATATAACA TGCTGGCATC 180
AAACCAGGTA AGCAAATCAT ATTGTGCTGC CAGGTTATTC AAACATATCGA CCGGTGGTCC 240
AGGCGGGAAT TTTTCCACTA AATGTAGGTG GGATCAATGG GCTAATTGGT ATAGGCGGAT 300

(2) INFORMATION FOR SEQ ID NO: 12:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 324 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (iii) HYPOTHETICAL: NO
- (iii) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Partial sequence of Salmonella typhimurium virulence gene

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:

CCTGTGATTC CGGATGAAAT AGCTTTTACG AAAGCTGTCA GACNTGCTGA AGAATACGCT 60
GCAAATGGTA AGCTTGTAAC TTTTGGGTAT TGTTCACACG CATGCTGAAA CGGGTTATGG 120
ATATATTCGT CGCGGTGAGT TGATAGGAAA TGACGCTTAT GCAGTGGCTG AATTGTGGA 180
GAAACCGGAT ATCGATACCG CCCGTGACTA TTTCAAATCA GGGGAAATAT TACTGGCCTA 240
GCGGCGATGT TTTTATTTTCG CGCAAAGCCC TTATTTAAAC GAATTAAACG TATCTATCAC 300
CCCCAAATTC ATACAGCTTG TGAA 324

(2) INFORMATION FOR SEQ ID NO: 13:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 292 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double

- (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (iii) HYPOTHETICAL: NO
- (iii) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Partial sequence of Salmonella typhimurium virulence gene

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13:

```

T T A C T A A A C A   G G G C C C C G G A   C C A T G T A A A C   A C C A C G C T T G   C C A A C A C T A A   A A A A C G A T G C   60
T T G C C G T A A A   A A A A T T G A A C   G T T A T T T A C T   T A A T A C G C C T   A T T T T A T T T A   C A T T A T G C A C   120
G G A C A G A G G G   T G A G G A T T A A   A T G G A T A A T A   T T G A T A A T A A   G T A T A C T C C A   C A G C T A T G T A   180
A A A T T T T G G G   G G C T A T A T C G   G A T T T G G T T G   T T T T A A T T T   A G C C T T A T G G   C T T T C A C T A G   240
G A T G T G T C T A   T T T T T T T T G T   G G T C A A G C A C   A G A G A T T T A T   T C C C C A A C C A   C C   292

```

(2) INFORMATION FOR SEQ ID NO: 14:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 300 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (iii) HYPOTHETICAL: NO
- (iii) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Partial sequence of Salmonella typhimurium virulence gene

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14:

```

T T T C C T T G C C   G T G A C A G T C C   G G G A T G C G A G   G T T A A C G A A A   T T A C C G G C A C   C A A G C T G T G   60
G A G G T G A G C G   G T G T C C C C A G   C T G C C T G A C T   C G T A T T A G T C   A A T T A G C T T C   A G T G C T G G A T   120
A A T G C G T T A A   T C A A A C G A A A   A G A C A G T G C G   G T G A G T G T A A   G T A T A T A C A C   G C T T A A G T A T   180
G C C A C T G C G A   T G G A T A C C C A   G T A C C A T T A T   C G C G A T C A G T   C C G T C G T G G T   T C C A G G G G T C   240
G C C T A G T G T A   T T G C G T G A G A   T G A G T A A C A C   C A G C G T C C C G   A C G T C A T C G A   C G A A C A A T G G   300

```

(2) INFORMATION FOR SEQ ID NO: 15:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 297 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (iii) HYPOTHETICAL: NO
- (iii) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Partial sequence of Salmonella typhimurium virulence gene

AAGCACGCCA CAGGCTACAC CACAGCCCGG AGGGGGCCGG AAAGTGCTGG GATCTTGATT 240
 AATGAAAAAG GCAAAGGGAA GAGATAGGAT GATGCATGCT GGTGGAGGC AGATTATTCA 300
 TCTTCG 306

(2) INFORMATION FOR SEQ ID NO: 18:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 297 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iii) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Partial sequence of *Salmonella typhimurium* virulence gene

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18:

AGTTGCCGTA TTTATTAAAT ATTCACCTCA GGTCAATATG GAGGTCTTCC CGGCTAAAAA 60
 TCATTGCTTT ACTAGAGATA TCACTCCCTG GGTGCAATA CAGTACGATT AGTTATCTTG 120
 ATGCAGCCTG CTGATTTCAG AATGGCAGCT GACGTACCCG CGAGACAAAC ATTCTGGATT 180
 ATGGACGTTA TCAACGCCAA TATAGGGAAG GTGGTGAAGT GGTGATGAA ATACCCCTAT 240
 CCCTTG CATG TTATCGCTGA CAGGACTGTT ATCAGGAGCG GGCATCCTCG ATCGGCT 297

(2) INFORMATION FOR SEQ ID NO: 19:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 297 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iii) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Partial sequence of *Salmonella typhimurium* virulence gene

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19:

CAAGAGACAG ATCCAAC TCG GGCCGATCGC CATAACGCCA GCAGTTTGAA AGATGAAAGC 60
 CCAGCTTATC CAGCCATTCC GGTACAGCGT AACGAGCAGG TTGCCAGAAA TAACGATAAA 120
 GTTGCAACAC CTCGGGATCA GGTGGCTCA AAAACGGGGT CTCAGGCAAA AATAGCCGAT 180
 CAGGATGCCC ACTCCTAATA ACAGTCCTGT CAACGATAAC ATCAACGGAT AAGGGTATTT 240
 CATCAACCAC TTCACCACCT TCCCTTTATT GGCCTTGGAT AACGTCCATA ATCCAGA 297

(2) INFORMATION FOR SEQ ID NO: 20:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 298 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (iii) HYPOTHETICAL: NO
- (iii) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Partial sequence of Salmonella typhimurium virulence gene

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20:

| | |
|---|-----|
| AGGGCTTTAT TGATTCCATT TTTACACTGA TGAATGTTCC GTTGCCTGC CCGGATTACA | 60 |
| GCCGGATCCT CTAGAGTCGA CCTGCAGAAC CGAGCCAGGA GCAAATTAAT TTTTTTGGGC | 120 |
| AATTGCTGAA AGATGAAGCA TCCACCAGTA ACGCCAGTGC TTTATTACCG CAGGTTATGT | 180 |
| TGACCAGACA AATAGATTAT ATGCAGTTAA CGGTAGGCGT CGATTATCTT GTCAGAATAT | 240 |
| CAGGCGCAGC ATCGCAAGCG CTTAATAAGC TGGGTAACAT GGCATGAAGG GGCAACCC | 298 |

(2) INFORMATION FOR SEQ ID NO: 21:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 298 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (iii) HYPOTHETICAL: NO
- (iii) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Partial sequence of Salmonella typhimurium virulence gene

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21:

| | |
|---|-----|
| CACTATAGGG AAAGCTTGCA TGCCTGCAGG TCGACTCTAG AGGATCTACT AGTCATATGG | 60 |
| ATTCCTAGGC GGCCAGATCT GATCAAGAGA CAGATCCAAC TCGGGCCGAT CGCCATAACG | 120 |
| CCAGCAGTTT GAAAGATGAA AGCCAGCTT ATCCAGCCAT TCCGGTACAG CGTAACGAGC | 180 |
| AGGTTGCCAG AAATAACGAT AAAGTTGCAA CACCTCGGGA TCAGGTCGGC TCAAAAACGG | 240 |
| GGTCTCAGGC AAAAATAGCC GATCAGGATG CCCACTCCTA ATAACAGTCC TGTCAACG | 298 |

(2) INFORMATION FOR SEQ ID NO: 22:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 301 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (iii) HYPOTHETICAL: NO

- (iii) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Partial sequence of Salmonella typhimurium virulence gene

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 22:

```

CCCCCCCCCT TCTCCTGGCT TACACAGCCC CAGACCGGCG CTGGAAGAGG CCATTCCCGC      60
CATAAGGAG GCCAGCAACA TATTTTCACG CGCCGCCAGA TCGTGGCCGT AACCCACGGC      120
TTTCGGCAGC GATTTGCCAA TCATCGCTAT CGCGCCAATC GCCAGGCTGT CGGTAAACGG      180
CGTGGCGTTG AGCGCGCTGT AGGCCTCAAT CGCATGCGTC AACGCATCGA TACCGGTCAT      240
CGCCGTCACG TTTGGCGGAA CGCCTTCGGT CACGGAAGCA TCAAGAATCG CCACGTCCGG      300
C                                                                    301

```

(2) INFORMATION FOR SEQ ID NO: 23:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 289 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (iii) HYPOTHETICAL: NO
- (iii) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Partial sequence of Salmonella typhimurium virulence gene

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 23:

```

CGCGAACGTG CGCCGCAACT GCTTGTGGAC GGTGAATTGC AGTTTGACGC CGCTTTCGTG      60
CCGGAGGTG CCGCGCAAAA AGCGCCTGAC AGCCCGCTGC AAGGCCGCGC CAACGTGATG      120
ATTTTCCCGT CGCTGGAGGC GGGCAATATT GGCTACAAAA TCACTCAGCG TCTGGGAGGC      180
TATCGCGCTG TTGGGCCGCT AATTCAGGGG CTTGGCGCGC CGCTTCACGA CCTCTCCCGA      240
GGCTGTAGCG TGCAGGAAAT TATCGAACTG CGGTTGGTGA GAAAACCAA                  289

```

(2) INFORMATION FOR SEQ ID NO: 24:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 303 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (iii) HYPOTHETICAL: NO
- (iii) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Partial sequence of Salmonella typhimurium virulence gene

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 24:

| | |
|---|-----|
| CGCCCTAGCA TGCCTGGCGT TGTCCGGTTA TTGCTCGTCA AGCGAACAGA TGCAAAAGGT | 60 |
| GAGAGCGACT CTCGAATCAT GGGGGGTCAT GTATCGGGAT GGTGTAATCT GTGATGACTT | 120 |
| ATTGGTACGA GAAGTGCAGG ATGTTTTGGA TAAAAATGGG TTACCCGCAT GCTGAAGTAT | 180 |
| CCAGCGAAGG GCCGGGGAGC GTGTTAATTC ATGATGATAT ACAAATGGAT CAGCAATGGC | 240 |
| GCAAGGTTCA ACCATTACTT GCAGATATTC CCGGGTTATT GCACTGGCAG ATTAGTCACT | 300 |
| CTC | 303 |

(2) INFORMATION FOR SEQ ID NO: 25:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 300 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (iii) HYPOTHETICAL: NO
- (iii) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Partial sequence of Salmonella typhimurium virulence gene

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 25:

| | |
|---|-----|
| CCCTTCCCAG GCTCGACAGG TACACAGCCA GCCACTGGTG CAGGCAGTTA CTGCTTTTCA | 60 |
| TCATGGGAAG GAGCAATATC CTGATATATT AAAGAAAGAG CGGGATCCCC TTTCTTTACT | 120 |
| GCTGCTAACG TTTCTTGCAA AATGCGTTGA TGAGATTCAT CCAGCACACC ACTGATAACA | 180 |
| AAAGAGCGCC GCATTGGCGT AACATTGACA AGCCCCACTA AACCGCTCTC TATTATCGCA | 240 |
| GAAATAATAT CATCCCCCTG AGACTGATGA GAGTGACTAT TCTGCCAGCG CAAATAACCC | 300 |

(2) INFORMATION FOR SEQ ID NO: 26:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 303 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (iii) HYPOTHETICAL: NO
- (iii) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Partial sequence of Salmonella typhimurium virulence gene

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 26:

| | |
|--|-----|
| ATACCGAGTA TTAAGCGGCT GTGTAAATC GTCATCCAAC AACATACGCA GCGAGCCGCC | 60 |
| ACGCCGAAA AACCGCATCG TGTCATGTGC CTGTTGTAGG GTCGGGTCTT TTTTCATGAG | 120 |

TACGTTTTCT GCGCTATCAT ACTGGAAATT TCCCCCACT TACTGATAAG CCCTGTCAGT 180
 TGGGTAAGGA CAGAGTTAAG CTCCTGAGAC ATTTTTTGA ATGGTTATCT TTCCCCGACT 240
 CATAAAATCG GTATTCCCGC TGGGGGCAAT ATCCAAAGAC GCTTTGGTCG CCCGTAGGGC 300
 ACC 303

(2) INFORMATION FOR SEQ ID NO: 27:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 300 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (iii) HYPOTHETICAL: NO
- (iii) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Partial sequence of Salmonella typhimurium virulence gene

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 27:

GCCGTATGCC TGCAGTTGCC CGGTTATTGC TCGTCAAGCG AACCGATGCC AAAGGTGAGA 60
 GCGACTCTCG AATCATGGGG GGTCACTAT CGGGATGGTG TAATCTGTGA TGA CT TATTG 120
 GTACGAGAAG TGCAGGATGT TTTGGTAAAA ATGGGTTACC CCCATGCTGA AGTATCCAGC 180
 GAAGGGGCGG GGAGCGTGTT AATTCACGAT GATATTCAAA TGGGTCAGCA ATGGGGCAAG 240
 GTTCAACCCC CACTTGCAGA TAT TCCCCC CCTATTGGAC TGGCAGATTA G TCACTCTCA 300

(2) INFORMATION FOR SEQ ID NO: 28:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 300 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (iii) HYPOTHETICAL: NO
- (iii) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Partial sequence of Salmonella typhimurium virulence gene

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 28:

GGGCGACCTG CCCGCGGCGC AACTTTCCCC GAAGCGTTTT CCATTTCTTT GTTCTTAAAT 60
 GACCTGGAAA GCTTACCTAA GCCTTGCTTT GCCTATGTGA CAATACTGCT TGGAGAACAC 120
 CCGGACGTCC ATGATTATGC TATACAGATC ACAGCGGATG GGGGATGGTG AATCGGTTAT 180
 TATACCACAA GTCGCAGCTC TGAGCTTATT GCTATTGAGA TAGAAAAACA CCCCCTTCA 240

ACTTGGATTT TGAATAATGT AATACGCAAT CACCATACAC TATATTCGGG TGGCGTATAA 300

(2) INFORMATION FOR SEQ ID NO: 29:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 266 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iii) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Partial sequence of *Salmonella typhimurium* virulence gene

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 29:

| | |
|--|-----|
| TTTCGAGCTGG GGCACCGCTA ATATCTTTAA CCTCGCATCC CGGTGATGAA AGGATATTCT | 60 |
| GGCTGCGTAA GTAATGAATG AACCGCCCAG CAGATAAAAT ATTGACAGTG ATAACCCGAT | 120 |
| GTTTTTTTAA CGATGCAGGC TATACATATA ACATAGCTGG CCACCAACAC AGCTGAAGTA | 180 |
| AATCATATTG TTGCTGCCAG GCTACTTCAC ACTATTGTCC GGCGGGCCAG CGGGGATTTT | 240 |
| CCCCCTAAAT CTCGCTGGTT CTCAAA | 266 |

(2) INFORMATION FOR SEQ ID NO: 30:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 300 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iii) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Partial sequence of *Salmonella typhimurium* virulence gene

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 30:

| | |
|---|-----|
| AGTCTACGAT TTCGCTATAT CTTCTCTTAA TCATGGCCGC CATTTGTGGA TGCGATTTTA | 60 |
| AAATATCCGG GCGATCTTTC ATTAATAAAT AAAGATTTCC CATGACTTCA CAGATAAAGG | 120 |
| TATCGGTATT TTGAGTGATA CGTAACAATT CGTTCTCTTC GTGTGGGTCC ATGATGCGAA | 180 |
| GAATAATGGT GGCATCATTT TCATGAGGAT TATGAACCCG AAATCTTTCT CTTTGCGATG | 240 |
| CGCAGGCTAA CTCTTTCAAC TCAAAAAAAA TCTCTGTAAG CCGCTCTCGT GTGGGGGCGC | 300 |

(2) INFORMATION FOR SEQ ID NO: 31:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 299 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 33:

| | |
|---|-----|
| TTCCATATTG CTCGTCCGGG GAGCGTGTTA ATTCTTGATG ATATACCAAT GGATCTGCAA | 60 |
| TGGCGCAAGG TTCAACCATT ACTTGGAGAT ATTCCCGGGT TATTGTACTG GGAGATTAGT | 120 |
| CACTCTCATC AGTCTCAGGG GGGTGATGTT ATTTCTGGGA TAATAGAGCA ACGGCGTTAG | 180 |
| CAGGGGTCGG TCAGTAGTCA CGGCCAACTT CGGTGCACTT TTGCGTATCA CTGGGGTATC | 240 |
| ATAACTGAAT CTCATCCCCC CCACTTTGGT AATCACAC | 278 |

(2) INFORMATION FOR SEQ ID NO: 34:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 301 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (iii) HYPOTHETICAL: NO
- (iii) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Partial sequence of Salmonella typhimurium virulence gene

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 34:

| | |
|---|-----|
| AATTCTTTTA CCTCCATAAG CTGCGTGGCA TAGCGATACA GAGTATTAAG CGGGTGTGTT | 60 |
| ACATCGTCAT CCAACAACAT ACGCAGCGAG CCGCCACGCC GGAAAAACCG CATCGTGTCA | 120 |
| TGTGCCTGTT GTAGGGTCGG GTCTTTTTTTT CATGAGTACG TGTCTGCGC TATCATACTG | 180 |
| GAAATTTCCC CCCACTTACT GATAAGCCCT GTCAGTTGGG TAAGGACAGC GTTAAGCTCC | 240 |
| TGAGACATTT TTTGAGTTGT TATCTGCCCC CCGACTCATA AGATCGGGTA TTCCGCGGTG | 300 |
| G | 301 |

(2) INFORMATION FOR SEQ ID NO: 35:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 297 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (iii) HYPOTHETICAL: NO
- (iii) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Partial sequence of Salmonella typhimurium virulence gene

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 35:

| | |
|---|----|
| ATATCCCTAA TGCTTTTCCT TAAAATAAAT ACCACGGAAG GATACTGGCC ACCTAGCCAA | 60 |
|---|----|

ATTTAGAAAG CAATGAACAT CCGGTTTATT CCTGAAAACG ATTACTCCGG CGCACGTTGT 120
TCTGGCGTTA CCTGAGCCAG CAAACGATAT AATGGGGTGG TGACCCGCAT ACCGGTCATT 180
GGCATCCCAT CCACACCGGA GGGAGTAAAA CTCATTAGGC CATAGGTAAT ATCATTAAAGA 240
CGCTCTAATA AATGAGGGTG GGGGGCCCAA ACTACCACTC CAGTATGTAT TGAGTCA 297

(2) INFORMATION FOR SEQ ID NO: 36:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 291 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (iii) HYPOTHETICAL: NO
- (iii) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Partial sequence of Salmonella typhimurium virulence gene

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 36:

CCCATGGGCG CAATTTGTTG CGCAGCGTTT ACCCGACCAT CGCGTTTATG AGCTGTAATT 60
CATGGGGGGT AAAAACGGGC GTGACGACCC CAACGGAAGA TAAGGCCGGG CTTAAACAGG 120
AGATTATTGC TAATGCGCAG CGCAAAGTGT TGCTGGCGGA CAGCAGTAAG TATGGCGCGC 180
ATTCGCTCTT TAATGTGGTG CCGCTTGAGC GCTTTAATGA CGTGATTACC GACGTCAATC 240
TGCCGCCGTC AGCGCAGGTT GAACTGAAAG GGCGCGCTTT TTGCGCTAAC G 291

(2) INFORMATION FOR SEQ ID NO: 37:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 13417 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (iii) HYPOTHETICAL: NO
- (iii) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: DNA sequence of VGC II from centre to left hand end

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 37:

CTGCAGAACC GAGCCAGGAG CAAATTAATT TTTTGAACA ATTGCTGAAA GATGAAGCAT 60
CCACCAGTAA CGCCAGTGCT TTATTACCGC AGGTTATGTT GACCAGACAA ATGGATTATA 120
TGCAGTTAAC GGTAGGCGTC GATTATCTTG CCAGAATATC ACGGCGCAGC ATGCCAAGCG 180
CTTAATAAGC TGGATAACAT GGCATGAAGG TTCATCGTAT AGTATTTCTT ACTGTCCTTA 240
CGTTCTTTCT TACGGCATGT GATGTGGATC TTTATCGCTC ATTGCCAGAA GATGAAGCGA 300

ATCAAATGCT GGCATTACTT ATGCAGCATC ATATTGATGC GAAAAAAAC AGGAAGAGGA 360
TGGTGTAACC TTACGTGTCG AGCAGTCGGC AGTTTATTAA TGCGGTTGAG GCTACTTAGA 420
CTTAACGGTT ATCCGCATAG GGCAGTTTAC AACGGCGGAT AAGATGTTTC CGGCTAATCA 480
GTTAGTGGA TCACCCAGG AAGAACAGGC AGAAGATTAA TTTTAA GAAACAAAGAA 540
TTGAAGGAAT GCTGAGTCAG ATGGAGGGGC GTGATTAATG GCAAAAGTGA CCATTGCGCT 600
ACCGACTTAT GATGAGGGAA GTAACGCTTC TCCGAGCTCA GTTGCCGTAT TTATAAAATA 660
TTCACCTCAG GTCAATATGG AGGCCTTTCG GGTAAAAAT AAAGATTTAA TAGAGATGTC 720
AATCCCTGGG TTGCAATACA GTAAGATTAG TATCTTGATG CAGCCTGCTG AATTCAGAAT 780
GGTAGCTGAC GTACCCGCGA GACAAACATT CTGGATTATG GACGTTATCA ACGCCAATAA 840
AGGGAAGGTG GTGAAGTGGT TGATGAAATA CCCTTATCCG TTGATGTTAT CGTTGACAGG 900
ACTGTTATTA GGAGTGGGCA TCCTGATCGG CTATTTTTCG CTGAGACGCC GTTTTGTGAGC 960
CGACCTGATC CCGAGGTGTT GCAACTTTAT CGTTATTTCT GGCAACCTGC TCGTTACGCT 1020
GTACCGGAAT GGCTGGATAA GCTGGGCTTT CATCTTCAA CTGCTGGCGT TATGGCGATC 1080
GGCCCGAGTT GGATCGTCTT CTTGACAGAG CGTTAAATAG ACTAAGAGGA AGCTCTGTTA 1140
TTCCAGCCTG TTAAATGAC AGGCAAAAC GGCAGGTTTC TCTTGCGCCG CGTATATCGG 1200
CATTTGCCTT TGGGCTGGGA TTATTCAAAC TCAGGTGTAG TGACTATTTT ATGCTACCAG 1260
AGTATCGGCA ATTGCTTCTA CAGTGGTTTA GCGAGGATGA GATCTGGCAG CTATATGGTT 1320
GGTTGGGGCA AAGAGATGGC AAATTACTTC CTCCGCAAGT GATGCAACAA ACTGCATTGC 1380
AGATCGGTAC CGCCATTCTT AATCGGGAAG CGCATGACGA TGCGGGTTTT ACATGCGCTA 1440
TTAGTATTAT TACCCCTCC GCAGCGTATA CTTTGGCCGA AGACTTCTCT TACCGAGATT 1500
ATCTTCATGG AGCATTTGCT ATGAGTTTAA CTTCACTTCC TCTGACGGAA ATTAACCATA 1560
AGCTACCCGC TCGAAATATT ATTGAGTCAC AGTGGATAAC ATTACAATTA ACTTTATTTG 1620
CGCAAGAGCA ACAAGCTAAG AGAGTTTCAC ATGCTATTGT GAGCTCCGCT TACCGTAAGG 1680
CTGAAAAAAT CATCCGAGAC GCCTATCGTT ATCAGCGTGA ACAGAAAGTT GAGCAGCAAC 1740
AAGAACTAGC GTGCTTGCGT AAAAATACGC TGGAAAAAAT GGAAGTGGAA TGGCTGGAAC 1800
AGCATGTAAA ACATTTACAA GACGATGAAA ATCAATTTTCG TTCATTGGTC GATCACGCAG 1860
CGCATCATAT TAAAAATAGT ATAGAACAGG TTCTGTTGGC CTGGTTTCGAC CAACAGTCGG 1920
TAGACAGTGT TATGTGCCAT CGTCTGGCAC GCCAGGCCAC GGCTATGGCG GAAGAGGGAG 1980

CGCTTTATTT GCGTATTCAT CCTGAAAAAG AGGCATTGAT GCGAGAAACT TTTGGCAAGC 2040
GGTTTACGTT GATTATCGAG CCTGGTTTCT CTCCCATCA GGCTGAACTT TCCTCAACAC 2100
GATATGCCGT TGAATTTTCA CTTTCTCGTC ATTTCAACGC GTTACTGAAA TGGTTACGTA 2160
ATGGTGAAGA TAAAAGAGGT AGCGATGAAT ATTAAATTA ATGAGATAAA AATGACGCCC 2220
CCTACAGCAT TTACCCCTGG CCAGGTTATA GAGGAACAAG AGGTTATTTT GCCTTCAATG 2280
TTAGCTCTCC AGGAGTTACA GGAAACGACG GGGGCAGCGC TCTATGAGAC GATGGAAGAA 2340
ATAGGAATGG CGCTGAGTGG TAAACTGCGC GAAAATTATA AATTCAGTGA TGCTGAGAAA 2400
CTGGAGCGCA GACAGCAGGC TTTGCTGCGT TTGATAAAAC AAATACAGGA GGATAATGGG 2460
GCAACGTTGC GTCCGCTTAC CGAAGAGAAT AGTGATCCTG ATTTACAGAA TGCCTATCAA 2520
ATTATCGCTC TTGCAATGGC GCTTACTGCC GGCGGGTTGT CAAAAAGAA AAAACGCGAT 2580
TTGCAATCGC AACTGGATAC GTTACAGCGG AGGAGGGATG GGAAGTTGCC GTTTTTAGTT 2640
TACTGGAAGT TGGCGAAGTG GATACCGTAC GCTGTCTCTT CTGAAGCGTT TTATGCAACA 2700
GGCGATAGAC AACGATGAAA TGCCCTTATC GCAGTGGTTC AGACGCGTGG CAGACTGGCC 2760
GGATCGCTGT GAACGGGTCC GTATTTTGCT AAGAGCAGTA GCCTTTGAAC TTAGCATATG 2820
CATCGAACCC TCGGAGCAA GTCGTTTGGC CGCAGCATTG GTACGTTTGC GTCGTTTGTCT 2880
GTTATTCCTT GGCCTTGAAA AAGAGTGCCA GCGTGAGGAG TGGATTGACC AGTTGCCGCC 2940
TAATACATTA CTGCCGCTAC TACTCGATAT TATTTGTGAG CGCTGGCTTT TCAGTGATTG 3000
GTTGCTTGAT AGACTTACCG CTATAGTTTC TTCATCGAAG ATGTTCAATC GGTTACTCCA 3060
ACAAGTTGAT GCGCAGTTTA TGCTGATACC CGATAACTGT TTTAACGACG AAGATCAACG 3120
TGAACAAATT CTCGAAACGC TTCGTGAAGT AAAGATAAAT CAGGTTTTAT TCTGATACCT 3180
GGCTTTCAAT ATTTAGGTAA ATTGGCTTTC TGGCTCATCA TGAGGCGTCA GGATGGATTG 3240
GGATCTCATT ACTGAACGTA ATATTCAGCT TTTTATTCAA TTAGCAGGAT TAGCTGAACG 3300
GCCTTTAGCA ACCAATATGT TCTGGCGGCA AGGACAATAT GAAACTATCA TAACGGTCGT 3360
ATTCTCTTAT GTCAGATACT CAAGCAAACC TTCTTAGACG AAGAACTGCT TTTTAAAGCG 3420
TTGGCTAACT GGAAACCCGC AGCGTTCCAG GGTATTCCTC AACGATTATT TTTGTTGCGC 3480
GATGGGCTTG CAATGAGTTG TTCTCCACCT CTTTCCAGCT CCGCCGAGCT CTGGTTACGA 3540
TTACATCATC GACAAATAAA ATTTGNTGGA GTCGCAATGC GTTCATGGTT AGGTGAGGGA 3600
GTCAGGGCGC AACAGTGGCT CAGTGTATGC GCGGGTCGGC AGGATATGGT TCTGGCGACG 3660
GTGTTATTAA TCGCTATTGT GATGATGCTG TTACCCTTGC CGACCTGGAT GGTGATATC 3720

| | |
|--|------|
| CTGATTACTA TCAACCTTAT GTTTTTCAGTG ATCCTGCTCT TAATTGCTAT TTATCTTAGT | 3780 |
| GACCTCTCG ATTTATCGGT ATTTCCGTCT TTATTACTTA TTACTACATT ATATCGTTTG | 3840 |
| TCACTCACAA TCAGCACATC ACGGCTGGTA CTGTTACAAC ATAATGCCGG TAATATTGTG | 3900 |
| GATGCTTTCG GTAAGTTTGT CGTAGGAGGA AATCTCACCG TTGGGTGGT CGTATTTACC | 3960 |
| ATCATTACTA TCGTGCAATT TATTGTCAAT AAAAAAGGTA TCGAGAGGGT GGCGGAAGTT | 4020 |
| AGCGCACGTT TCTCGCTTGA TGGGATGCCA GGCAAACAAA TGAGTATCGA TGGCGATTGT | 4080 |
| CGTGCCGGAG TTATCGATGC AGACCATGCC CGTACATTAA GACAGCATGT CCAGCAGGAA | 4140 |
| AGCCGCTTTC TCGGTGCGAT GGACGGTGCG ATGAAATTTG TTAAAGGCGA TACGATTGCC | 4200 |
| GGTATTATTG TTGTTCTGGT GAACATTATC GGCGGTATCA TTATCGCTAT CGTACAATAT | 4260 |
| GATATGTCGA TGAGTGAGGC TGTTCACTAT TATAGCGTAC TGTCAATCGG AGATGGTTTA | 4320 |
| TGTGGGCAAA TTCCATCGCT GCTGATTTCC CTTAGCGCGG GAATTATTGT CACCCGTGTC | 4380 |
| CCGGGTGAGA AACGCCAGAA CCTGGCGACA GAGTTGAGTT CTCAAATTGC CAGACAACCT | 4440 |
| CAGTCGCTCA TATTAACCGC TGTGGTTTTA ATGCTCCTCG CTTTAATTCC TGGCTTTCTT | 4500 |
| TTTATCACTC TCGCTTTCTT TTCAGCGTTG TTAGCATTGC CAATTATCCT CATTCGCCGC | 4560 |
| AAAAAGTCTG TGGTTTCCGC AAATGGCGTC GAAGCACCGG AAAAAGATAG TATGGTTCCC | 4620 |
| GGCGCATGTC CTCTAATCTT ACGTCTTAGC CCGACGTTAC ATTCTGCCGA CCTGATTCGT | 4680 |
| GATATTGACG CCATGAGATG GTTTTTATTT GAGGATACCG GCGTCCCTCT CCCTGAGGTG | 4740 |
| AATATTGAGG TTTTGCTGA ACCCACCAGAA AAATTGACGG TACTGCTATA TCAGGAACCC | 4800 |
| GTATTTAGTT TATCTATTCC CGCTCAGGCG GATTATTTAT TGATAGGCGC GGACGCTAGT | 4860 |
| GTGGTGGGTG ACAGCCAGAC GTTACCGAAC GGGATGGGGC AGATCTGTTG GCTTACAAAA | 4920 |
| GACATGGCCC ATAAGGCGCA AGGTTTTGGA CTGGACGTTT TCGCGGGCAG CCAACGTATC | 4980 |
| TCTGCCTTAT TAAAATGTGT CCTGCTTCGG CATATGGGAG AGTTTATTGG TGTTACAGAA | 5040 |
| ACGCGTTATC TAATGAATGC GATGGAAAAA AACTACTCTG AGCTGGTGAA AGAGCTTCAG | 5100 |
| CGCCAGTTAC CCATTAATAA AATCGCTGAA ACTTTGCAAC GGCTTGATATC AGAGCGGGTT | 5160 |
| TCTATTAGAG ATTTACGTCT TATTTTCGGC ACCTTAATTG ACTGGGCGCC ACGTGAAAAA | 5220 |
| GATGTCTGA TGTGACAGA ATATGTCCGT ATCGCGCTTC GTCGTCATAT TCTGCGTCGT | 5280 |
| CTTAATCCGG AAGGAAAACC GCTGCCGATT TTGCGGATCG GCGAAGGTAT TGAAAACCTC | 5340 |
| GTGCGTGAAT CCATTCGCCA GACGGCAATG GGGACCTATA CTGCGCTGTC GTCTCGTCAT | 5400 |

AAGACGCAGA TCCTGCAACT TATCGAGCAG GCGCTGAAGC AGTCAGCCAA ATTATTCATT 5460
 GTCACCTTCTG TCGACACCCG ACGTTTCTTG CGAAAAATTA CAGAAGCCAC CTTGTTTCGAC 5520
 GTACCGATTT TGTCATGGCA GGAATTAGGA GAGGAGAGCC TTATACAAGT GGTAGAAAAGT 5580
 ATTGACCTTA GCGAAGAGGA GTTGGCGGAC AATGAAGAAT GAATTGATGC AACGTCTGAG 5640
 GCTGAAATAT CCGCCCCCG ATGGTTATTG TCGATGGGGC CGAATTCAGG ATGTCAGCGC 5700
 AACGTTGTTA AATGCGTGGT TGCCTGGGGT ATTTATGGGC GAGTTGTGCT GTATAAAGCC 5760
 TGGAGAAGAA CTTGCTGAAG TCGTGGGGAT TAATGGCAGC AAAGCTTTGC TATCTCCTTT 5820
 TACGAGTACA ATCGGGCTTC ACTGCGGGCA GCAAGTGATG GCCTTAAGCG ACGCCATCAG 5880
 GTTCCCGTGG GCGAAGCGTT ATTAGGGCGA GTTATTGATG GCTTTGGTTCG TCCCCTTGAT 5940
 GGCCGCGAAC TGCCCGACGT CTGCTGGAAA GACTATGATG CAATGCCTCC TCCCGCAATG 6000
 GTTCGACAGC CTATCACTCA ACCATTAATG ACGGGGATTC GCGCTATTGA TAGCGTTGCG 6060
 ACCTGTGGCG AAGGGCAACG AGTGGGTATT TTTTCTGCTC CTGGCGTGGG GAAAAGCACG 6120
 CTTCTGGCGA TGCTGTGTAA TGCGCCAGAC GCAGACAGCA ATGTTCTGGT GTTAATTGGT 6180
 GAACGTGGAC GAGAAGTCCG CGAATTCATC GATTTTACAC TGTCTGAAGA GACCCGAAAA 6240
 CGTTGTGTCA TTGTTGTGCG AACCTCTGAC AGACCCGCCT TAGAGCGCGT GAGGGCGCTG 6300
 TTTGTGGCCA CCACGATAGC AGAATTTTTT CGCGATAATG GAAAGCGAGT CGTCTTGCTT 6360
 GCCGACTCAC TGACGCGTTA TGCCAGGGCC GCACGGAAAT CGCTCTGGCG CCGGAGAGAC 6420
 CGCGGTTTCT GGAGAATATC GCCAGGCGTA TTTAGTGCAT TGCCACGACT TTTAGAACGT 6480
 ACGGGAATGG GAGAAAAAGG CAGTATTACC GCATTTTATA CGGTACTGGT GGAAGGCGAT 6540
 GATATGAATG AAGCCGTTGG CGGATGAAGT CCGTTCCTG CTTGATGGAC ATATTGTACT 6600
 ATCCCGACGG CTTGCAGAGA GGGGGCATT TCTGCCATT GACGTGTTGG CAACGCTCAG 6660
 CCGCGTTTTT CCAGTCGTTA CCAGCCATGA GCATCGTCAA CTGGCGGCGA TATTGCGACG 6720
 GTGCCTGGCG CTTTACCAGG AGGTTGAACT GTTAATACGC ATTGGGGAAT ACCAGCGAGG 6780
 AGTTGATACA GATACTGACA AAGCCATTGA TACCTATCCG GATATTTGCA CATTTTTGCG 6840
 ACAAAGTAAG GATGAAGTAT GCGGACCCGA GCTACTTATA GAAAAATTAC ACCAAATACT 6900
 CACCGAGTGA TCATGGAAAC TTTGCTGGAG ATAATCGCGC GGCTGAAAAG CAATTACGCG 6960
 GCAAGCTTAC CGTACTTGAT CAGCAGCAAC AGGCGATTAT TACGGAACAG CAGATTTGCC 7020
 AGACGCGCGC TTTAGCAGTG TCTACCAGAC TGAAAGAATT AATGGGCTGG CAAGGTACGT 7080
 TATCTTGTC TTTATTGTTG GATAAGAAAC AACAAATGGC CGGGTTATTC ACTCAGGCGC 7140

| | |
|---|------|
| AGAGCTTTTT GACGCAACGG CAAGCAGTTA GAGAATCAGT ATCAGCAGCT TGTCTCCCGG | 7200 |
| CGAAGCGAAT TACAGAAGAA TTTTAATGCG CTTATGAAAA AGAAAGAAAA AATTACTATG | 7260 |
| GTATTAAGCG ATGCGTATTA CCAAAGTTGA GGGAAGTCTT GGGTTGCCAT GCCAGTCTTA | 7320 |
| TCAGGATGAT AACGAGGCGG AGGCGGAACG TATGGACTTT GAACAACTCA TGCACCAGGC | 7380 |
| ATTACCCATT GGTGAGAATA ATCCTCCTGC AGCATTGAAT AAGAACGTGG TTTTCACGCA | 7440 |
| ACGTTATCGT GTTAGTGGCG GTTATCTTGA CGGTGTAGAG TGTGAAGTAT GTGAATCAGG | 7500 |
| GGGGCTAATC CAGTTAAGAA TCAATGTCCC TCATCATGAA ATTTACCGTT CGATGAAAGC | 7560 |
| GCTAAAGCAG TGGCTGGAGT CTCAGTTGCT GCATATGGGG TATATAATTT CCCTGGAGAT | 7620 |
| ATTCTATGTT AAGAATAGCG AATGAAGAGC GTCCGTGGGT GGAGATACTT CCAACGCAAG | 7680 |
| GCGCTACCAT TGGTGAGCTG ACATTGAGTA TGCAACAATA TCCAGTACAG CAAGGGACAT | 7740 |
| TATTTACCAT AAATTATCAT AATGAGCTGG GTAGGGTGTG GATTGCAGAA CAATGCTGGC | 7800 |
| AGCGCTGGTG TGAAGGGCTA ATTGGCACCG CTAATCGATC GGCTATCGAT CCTGAATTGC | 7860 |
| TATATGGAAT AGCTGAATGG GGGCTGGCGC CGTTATTGCA AGCCAGTGAT GCAACCTCT | 7920 |
| GTCAGAACGA GCCGCCAACA TCCTGCAGTA ATCTACCACA TCAGCTAGCG TTGCATATTA | 7980 |
| AATGGACAGT TGAAGAGCAT GAGTTCATA GCATTATTTT TACATGGCCA ACGGGTTTTT | 8040 |
| TGCGCAATAT AGTCGGAGAG CTTTCTGCTG AGCGACAACA GATTTATCCT GCCCTCCTG | 8100 |
| TGGTAGTCCC TGTATATTCA GGCTGGTGCC AGCTTACATT AATCGAACTT GAGTCTATCG | 8160 |
| AAATCGGCAT GGGCGTTCGG ATTCATTGCT TCGGCGACAT CAGACTCGGT TTTTTTGCTA | 8220 |
| TTCAACTACC TGGGGGAATC TACGCAAGGG TGTTGCTGAC AGAGGATAAC ACGATGAAAT | 8280 |
| TTGACGAATT AGTCCAGGAT ATCGAAACGC TACTTGCGTC AGGGAGCCCA ATGTCAAAGA | 8340 |
| GTGACGGAAC GTCTTCAGTC GAACTTGAGC AGATACCACA ACAGGTGCTC TTTGAGGTCG | 8400 |
| GACGTGCGAG TCTGGAAATT GGACAATTAC GACAACTTAA AACGGGGGAC GTTTTGCCTG | 8460 |
| TAGGTGGATG TTTTGCGCCA GAGGTGACGA TAAGAGTAAA TGACCGTATT ATTGGGCAAG | 8520 |
| GTGAGTTGAT TGCCTGTGGC AATGAATTTA TGGTGCGTAT TACACGTTGG TATCTTTGCA | 8580 |
| AAAATACAGC GTAAACCTGA TAAGAAAAAT AATATGCGAA CAATATAATA GCGTTCCAGG | 8640 |
| TCGTGTCATG AGAGATACAG TATGTCTTTA CCCGATTTCG CTTTGCAACT GATTGGTATA | 8700 |
| TTGTTTCTGC TTTCAATACT GCCTCTCATT ATCGTCATGG GAACTTCTTT CCTTAAACTG | 8760 |
| GCGGTGGTAT TTTCGATTTT ACGAAATGCT CTGGGTATTC AACAAGTCCC CCCAAATATC | 8820 |

| | |
|--|-------|
| GCACTGTATG GCCTTGCGCT TGTACTTTCC TTATTCATTA TGGGGCCGAC GCTATTAGCT | 8880 |
| GTAAAAGAGC GCTGGCATCC GGTTCAGGTC GCTGGCGCTC CTTTCTGGAC GTCTGAGTGG | 8940 |
| GACAGTAAAG CATTAGCGCC TTATCGACAG TTTTTCGAAA AAAACTCTGA AGAGAAGGAA | 9000 |
| GCCAATTATT TTCGGAATTT GATAAACGA ACCTGGCCTG AAGACATAAA AAGAAAGATA | 9060 |
| AAACCTGATT CTTTGCTCAT ATTAATTCCG GCATTTACGG TGAGTCAGTT AACGCAGGCA | 9120 |
| TTTCGGATTG GATTACTTAT TTATCTTCCC TTTCTGGCTA TTGACCTGCT TATTTCAAAT | 9180 |
| ATACTGCTGG CTATGGGGAT GATGATGGTG TCGCCGATGA CCATTTCAAT ACCGTTTAAAG | 9240 |
| CTGCTAATAT TTTTACTGGC AGGCGGTTGG GATCTGACAC TGGCGCAATT GGTACAGAGC | 9300 |
| TTTTCATGAA TGATTCTGAA TTGACGCAAT TTGTAACGCA ACTTTTATGG ATCGTCCTTT | 9360 |
| TTACGTCTAT GCCGGTAGTG TTGGTGGCAT CGGTAGTTGG TGTCATCGTA AGCCTTGTTT | 9420 |
| AGGCCTTGAC TCAAATACAG GACCAAACGC TACAGTTCAT GATTAAATTA TTGGCAATTG | 9480 |
| CAATAACCTT AATGGTCAGC TACCCATGGC TTAGCGGTAT CCTGTTGAAT TATACCCGGC | 9540 |
| AGATAATGTT ACGAATTGGA GAGCATGGTT GAATGGCACA ACAGGTAAAT GAGTGGCTTA | 9600 |
| TTGCATTGGC TGTGGCTTTT ATTCGACCAT TGAGCCTTTC TTTATTACTT CCCTTATTAA | 9660 |
| AAAGTGGCAG TTTAGGGGCC GCACTTTTAC GTAATGGCGT GCTTATGTCA CTTACCTTTC | 9720 |
| CGATATTACC AATCATTTAC CAGCAGAAGA TTATGATGCA TATTGGTAAA GATTACAGTT | 9780 |
| GGTTAGGGTT AGTCACTGGA GAGGTGATTA TTGGTTTTTC AATTGGGTTT TGTGCGGCGG | 9840 |
| TTCCCTTTTG GGCCGTTGAT ATGGCGGGGT TTCTGCTTGA TACTTTACGT GGCGCGACAA | 9900 |
| TGGGTACGAT ATTCAATTCT ACAATAGAAG CTGAAACCTC ACTTTTTGGC TTGCTTTTCA | 9960 |
| GCCAGTTCTT GTGTGTTATT TTCTTTATAA GCGCGGCAT GGAGTTTATA TTAAACATTC | 10020 |
| TGTATGAGTC ATATCAATAT TTACCACCAG GCGTACTTT ATTATTTGAC CAGCAATTTT | 10080 |
| TAAAATATAT CCAGGCAGAG TGGAGAACGC TTTATCAATT ATGTATCAGC TTCTCTCTTC | 10140 |
| CTGCCATAAT ATGTATGGTA TTAGCCGATC TGGCTTTAGG TCTTTTAAAT CGGTCGGCAC | 10200 |
| AACAATTGAA TGTGTTTTTC TTCTCAATGC CGCTCAAAAAG TATATTGGTT CTACTGACGY | 10260 |
| CCTGATCTCA TTCCCTTATG CTCTTCATCA CTATTTGGTT GAAAGCGATA AATTTTATAT | 10320 |
| TTATCTAAAA GACTGGTTTC CATCTGTATG AGCGAGAAAA CAGAACAGCC TACAGAAAAAG | 10380 |
| AAATTACGTG ATGGCCGTAA GGAAGGGCAG GTTGTCAAAA GTATTGAAAT AACATCATTA | 10440 |
| TTTCAGCTGA TTGCGCTTTA TTTGTATTTT CATTTCTTTA CTGAAAAGAT GATTTTGATA | 10500 |
| CTGATTGAGT CAATAACTTT CACATTACAA TTAGTAAATA AACCATTTTC TTATGCATTA | 10560 |

| | | | | | | |
|-------------|------------|------------|------------|------------|-------------|-------|
| ACGCAATTGA | GTCATGCTTT | AATAGAGTCA | CTGACTTCTG | CACTGCTGTT | TCTGGGCGCT | 10620 |
| GGGGTAATAG | TTGCTACTGT | GGGTAGCGTG | TTTCTTCAGG | TGGGGGTGGT | TATTGCCAGC | 10680 |
| AAGGCCATTG | GTTTTAAAAG | CGAGCATATA | AATCCGGTAA | GTAATTTTAA | GCAGATATTC | 10740 |
| TCTTTACATA | GCGTAGTAGA | ATTATGTAAA | TCCAGCCTAA | AAGTTATCAT | GCTATCTCTT | 10800 |
| ATCTTTGCCT | TTTTCTTTTA | TTATTATGCC | AGTACTTTTC | GGGCGCTACC | GTACTGTGGG | 10860 |
| TTAGCCTGTG | GCGTGCTTGT | GGTTTCTTCT | TTAATAAAAT | GGTTATGGGT | AGGGGTGATG | 10920 |
| GTTTTTTTATA | TCGTCGTTGG | CATACTGGAC | TATTCTTTTC | AATATTATAA | GATTAGAAAA | 10980 |
| GCTATCTAAA | AATGAGTAAA | GATGACGTAA | AACAGGAGCA | TAAAGATCTG | GAGGGCGACC | 11040 |
| CTCAAATGAA | GACGCGGCGT | CGGAAATGCA | GAGTGAAATA | CAAAGTGGGA | GTTTAGCTCA | 11100 |
| ATCTGTTAAA | CAATCTGTTG | CGGTAGTGCG | TAATCCAACG | CATATTGCGG | TTTGTCTTGG | 11160 |
| CTATCATCCC | ACCGATATGC | CAATACCACG | CGTCCTGGAA | AAAGGCAGTG | ATGCTCAAGC | 11220 |
| TAACTATATT | GTTAACATCG | CTGAACGCAA | CTGCATCCCC | GTTGTTGAAA | ATGTTGAGCT | 11280 |
| GGCCCGCTCA | TTATTTTTTG | AAGTGGAACG | CGGAGATAAA | ATTCCTGAAA | CGTTATTTGA | 11340 |
| ACCCGTTGCA | GCCTTGTTAC | GATGGTGAT | GAAGATAGAT | TATGCGCATT | CTACCGAAAC | 11400 |
| ACCATAAATG | CTTTTGGTAT | GCTTCTTCAG | GCCACTGCGA | AGGTTAAGAG | GGTAATAGCG | 11460 |
| TATAGAGCAG | TGCTTGACGA | TAAAGGTGAG | AGACTGAAAA | TAATCGCTTT | TAGCCTGGCA | 11520 |
| CAAGCACCAG | ATAGCGTATT | ATAAAATTAA | ACAAGATAAT | GGATTGGTGC | GTCTGAATGG | 11580 |
| ACTCGAACCA | CTCGACCCCC | ACCATGTCAA | GGTGGTGCTC | TAACCAACTG | AGCTATGAAC | 11640 |
| GGCAACGTTG | TAGGTGACAA | CGGGGACGAA | TATTAGCGTC | ACAACCGCAA | TGAGGCAAGA | 11700 |
| GGGAAATCGC | AATTTTCTTC | CTGAAATCAC | CTGATTGCGG | TGGAAATATG | CAACATGTCTG | 11760 |
| AGAAAATAGC | CGCCATGCGA | CGGCTATCGT | CGTATTATCG | GAGCGCGCTG | CAAAATGATG | 11820 |
| GCGGACGGCT | GACGTTGTAG | ATAGCGCATC | CGTAGCATCA | TTAACACCGC | CGCCGAGGTC | 11880 |
| AGGCCGATGA | TGAACCCCAT | CCAGAAGCCT | GCCGGTCCCA | TACGATCCAC | CACCAAATCC | 11940 |
| GTTAACGCCA | GGATATAACC | GCTGGGTAAA | CCTAACACCC | AGTAGGCGGT | AAAGGTGATA | 12000 |
| AAAAAGATGG | AACGCGTATC | TTTATAACCG | CGCAGAATAC | CGCTGCCGAT | AACCTGTATA | 12060 |
| GAGTCGGAAG | TCTGGTAAAC | CGCAGCGAGC | AGCATTAATT | GCGGCAAGCG | CCACGACCTC | 12120 |
| AGGGTTGTCA | TTGTAGAGCA | AAGCAATATG | CTTACGCAGA | GTAACGGTAA | AAATAGCGGT | 12180 |
| AACCACAGCC | ATACAAATGC | CGACGCCTAA | ACCGGTACGC | GCTGCGTTTG | CGCATCCAGC | 12240 |

| | | | | | | |
|------------|------------|------------|------------|-------------|------------|-------|
| GTGAGCCCT | GGCCCAGACC | GATAACCCAC | TCGAATCGTT | ACCGCCGACG | CCAGCGACAT | 12300 |
| CGGCAGTACG | AACATCAGCG | AGCTAAAGTT | AAGCGCAATC | TGATGACCGG | CGACATCCAC | 12360 |
| AATACCTAAT | GGCGAAACCA | GCAGCGCAAC | GACCGCAAAT | AACGTCACCT | CAAAGAACAG | 12420 |
| CCAGCGCAAT | CGGCAACCCC | AGTTGAATCA | GGCGCTTCAT | GACGACGCTA | TCGGGTTTGC | 12480 |
| CAAAGCCTTT | TTCATTACGA | ATATCACGCA | TTGAACGCGC | GTGTTTAAATG | TAAGAAAGCA | 12540 |
| TGGCGATAAA | CATCACCCAA | TAGACCGCCG | CAGTCGCAAC | GCCGCAGCCG | ATACCGCCGA | 12600 |
| GTTCCGGCAT | ACCAAAATGG | CCATAGATAA | AAATATAGTT | CACCGGAATA | TTCACCAGCA | 12660 |
| GGCCCAAAA | TCCCATCACC | ATACCCGGTT | TGGTTTTGGC | CAGACCTTCG | CACTGGTTTC | 12720 |
| GCGCTACCTG | AAAGAAAAGG | TATCCTGCGC | CCCACAGCAG | CGCGCGAAGA | TAACCCACGG | 12780 |
| CTTTATCGGC | CAGCGCCGGA | TCAATATTAT | GCATAGAGCG | GATAATGTAT | CCGGCATTCC | 12840 |
| ACAGGACGAT | CATCACCAGC | ACGGAGACAA | AGCCCGCCAG | CCAGAACCCT | TGTCGAACCT | 12900 |
| GATGCGCGAT | ACGCTCACGA | CGGCCGGAGC | CATTGAGTTG | CGCAATCACA | GGCGTCAAGG | 12960 |
| CCAGCAGTAA | GCCGTGACCA | AACAAAATGG | CGGGAAGCAG | ATAGAGGTGC | CGATAGCGAC | 13020 |
| GGCAGCCATG | TCCGTAGCGC | TATAGCCTCC | CGCCATGACG | GTATCGACGA | ATCCATTGCG | 13080 |
| GTCTATACCA | CTTGCGCAAG | GATCACCGGT | ATCTGAACGC | TAATAACTGA | CGCGCTTCAC | 13140 |
| TGGTATACTT | CTGCACGTAT | TCACCTTTTA | TTTTGTTGTT | ATATGAAAAG | CTAAAAAGCC | 13200 |
| GCCGAAGTGG | CAGCCAAAAG | AAATAGCAGG | GGAAATTTCA | GTCTATTGTA | GCGGGGTATT | 13260 |
| ACTATTTCTC | CAGTGAAAAA | ACAGTTGTTA | ACGGCGCATT | GCTGGCAAGC | TGTTTTTCCA | 13320 |
| CCTGCTATTG | TGCTGAACAG | TTCTGCTTTT | ATTTATTTCA | GGAGTTGAAG | ATATGTTTAC | 13380 |
| GGGGATCGTA | CAGGGTACCG | CGAACTGGT | ATCGATA | | | 13417 |

(2) INFORMATION FOR SEQ ID NO: 38:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 5746 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: DNA sequence of VGC II cluster C

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 38:

GGATCCTTTT TCTTTAATGC TGCTAACGTT TCTTGCAAAA TGC GTTGATG AGATTCATCC 60

AGTACACCAC TGATAACAAA AGAGCGNCGC ATTGGCNWAM MWTKRNNMRN NSCNNNACTA 120

| | |
|--|------|
| AACCGTTCTC TATTATCGCA GAAATAATAT CATCCCCCTG AGACTGATGA GAGTGAATAA | 180 |
| TCTGCCAGTG CAATAACCCG GGAATATCTG CAAGTAATGG TTGAACCTTG CGCCATTGCT | 240 |
| GATCCATTTG TATATCATCA TGAATTAACA CGCTCCCCGG CCCTTCGCTG GATACTTCAG | 300 |
| CATNSSGGTA ACCCATTTTT ATCAAAACAT CCTGCACTTC TCGTACCAAT AAGTCATCAC | 360 |
| AGATTACACC ATCCCGATAC ATGACCCCCC ATGATTGAG AGTCGCTCTC ACCTTTTGCA | 420 |
| TCTGTTGCTG TGACGAGCAA TAACCGGACA ACTGCAGGCT GCCATCTTCT TTCCATTGCG | 480 |
| CCCGCACATA ATGAATATTG CTTTTGTCTA ATAAAACTT AACCCGAAA GGTAAGTCAT | 540 |
| TTACCGTTTC AGGCTGACCA CTAATACTTA ACAGGACACC CATTCCACCG ATGAAAATCA | 600 |
| AGAATACGCC AGCCAACCAC CAGTACCCTG ATCTGGAAAC GGGTATTGA TAATCAGCAA | 660 |
| GTTTACAATC CTGTTTACCA AACGCGATAS SCACTCCCGC AACCTGAAA ACCCCACTGG | 720 |
| ATGGTAGCGG CTTATTTGGA TTAAATCTGC GGCCATTAACTCTG GCTTTCCCGG | 780 |
| CATCAACAAA TAACTATCT GCCTGTTCTC TCAGAATAAT TTTTTCATTT ATAGCCAGCG | 840 |
| AATACAAATA TCGCATCCCT TCTCCCCCAG TGACAGGTTA CCTTCATTCA GCCATACTTC | 900 |
| CCGGCCTTGT AAAACGTGAC CTAAAAACG TATTTTCCAG GAACTCTTTG GATTAACCAT | 960 |
| GAGATATGCC ATTATTTACT ACTGAGGCTT TAATCAAAAA AAGCCTGATT AACTATGTA | 1020 |
| CTTGAGTCGT ATCATTGCGA AACAAATGAC CTACAACAGG AATATCGCCC AATAAAGGGA | 1080 |
| TTTTGTTTTG CGAGTGGATT TGTTTACCTT GTTTAAACCC TCCCAGCAAT NAGACTTTGC | 1140 |
| CCGGCCAATA ATGTGGCTTG CGAANCRATT TCAGAATTTT GCACTTCGGG CAGCGGGTCT | 1200 |
| GTNTYGCYTT KGNSTATCAC TTTGTTGTCC ATCCTGAANT ATTAAAGATTA AGCATTATTT | 1260 |
| TTTGCGTGCC ATTGTCATTT AACAAGCGAG GTGTAACGCG WNAACAAAGA ACCCGTAGTG | 1320 |
| ATGGATTCAA GTTTAGCCAC TTTTCTCCC TGCACTTTGG TATAGAAAGT AATATTTTTA | 1380 |
| TCCAGCACAG CCTGGATATT ATTTAAAGTC ACCACAGATG GCTGGGAAAG TACATAAGCC | 1440 |
| TGAGAGCTTT TTTCCAGGGC ATTCAGACGC ACCATAAAGT TTGAGGTATC GCTGATTACC | 1500 |
| GTTGANNAAC CACTAGCACC ACCGTCATTC AAACCTGTAT TGAACGCAAT TTTCTTGCCA | 1560 |
| CCCAGCGACA CTGCCGTTCC CCAGTCGATG CCTAACTGGT TAATATCTCC AGCATTAACA | 1620 |
| TCGATAATTT TCACCGAAAT CTCTATCATC TGCTGGCGTT GATCTAATTC TGTGATGAGT | 1680 |
| TTCCGATACN NNGCCATATT GGNNNCATAA TCACGAACGA TCACTGCATT CTGGCGTNGG | 1740 |
| GTCGGCAGCA AACATNGGCA ATGCCTGTGT AGCGGGTGAA CCATTGTTCTN TCGATGACGT | 1800 |

| | |
|---|------|
| CGGGACGCTG GTTTTACTCA TCTCACGCAA TACACTAACG ACCCCTGGNN AACCACGACG | 1860 |
| GACTGATCGC GATATTGGTA CTGGGTATCC ATCGCAGTGG CATACTTAAG CGTGTATATA | 1920 |
| CTTACACTCA CCGCACTGTC TTTTCGTTTG ATTAACGCAT TATCCAGCAC TGAAGCTAAT | 1980 |
| TGACTAATAC GAGTCAGGCA GCTGGGAACA CCGCTCACCT CCACAGCTTT GGTACCGGTA | 2040 |
| ATTTCTTTAA CCTCGCATCC CGGTGATGAA AGGATATTCT GGCTGCGTAA GTAATGAATG | 2100 |
| AACCGTCCAG TAGATAAAAT ATTGAAAGTG ATAACCTGAT GTTTTAATAA CGATGCAGGA | 2160 |
| TATACATATA ACATGCTGCC ATCAAACCAG GTAAGCAAAT CATATTGTGC TGCCAGGTTA | 2220 |
| TTCAAAATAT CGACCGGTGG TCCAGGCGGA ATTTTCCAC TAAATGTAGC TGTTATCAAT | 2280 |
| GGGCTAATAG TAATAGCCGT ATCATAGTTC TCTGAGAGCA GATGTNAAAA CCTCTGCTAA | 2340 |
| TGGCATTGT CTGGCATAAA GGGTGAAGTC ATTACCTTTC CATGATAACT CATCACTCTT | 2400 |
| TGCTGTATTG AGTATAAATA GTAAAATTAA GATTAAACGT TTATTTACTA CCATTTTATA | 2460 |
| CCCCACCCGA ATAAAGTTTA TGGTGATTGC GTATTACATT TTTNAAAAAT GCAAGTTAAA | 2520 |
| GCCAGGTGTT TTTCTATCTC AATAGCAATA AGCTCAGAGC TACTACTTGT GGTATAATAA | 2580 |
| CCGTTTAACC ATCCCCCATC CGCTGTGAGC TGTATAGCAT AATCATGGAC GTCCGGGTGT | 2640 |
| GCGCAARCRG TAGTGTCCAM TAGGCAAGAC AAGGCTTAGG TAAGCTTTCC AGGTCATTTA | 2700 |
| AGAACAAAGA AATAGAAAAT GCTTCTGAGA AAATTTCTYC YBHNNNNNNN NNNNNNNNN | 2760 |
| NNNNNNMNCA TCAATAGTCA TTATCCAGGA TSSKMTWWYM NYYKSSSCYS WKATMYYSWR | 2820 |
| WWTAAATGGA ATGCCTTTTA AACTGCCAG CATGAATCCC TCCTCAGACA TAAATGGGAG | 2880 |
| TTTCTATCAA ATTCGCTCAC AACCACATCC GTAAAAAGCC TGATTACAT TTATTTGAC | 2940 |
| TATACTCTTC TTGTACAATA TCAGGATGCT GTCTACATAT ACCTTGTCAC AGGCGATTCT | 3000 |
| ATCATTCGGA TTTTCCGATA AATTNMCAA TTACATTTTC AGCATTGACA TAAAACTTA | 3060 |
| CAATTTGNAA AATTATTTAT TAAATAAACT GTTACGATGT TTTTACATCG CCATCTTATT | 3120 |
| AAAAAGTAAT TGTAGTCATC GACTNGGTTA TATATGAAGA AATTTATCTT CCTAATGATA | 3180 |
| ACACCATCGA TTAATCWCT GATGAAACTA TATGTACTGC GATAGTGATC AAGTGCCAAA | 3240 |
| GATTTTGCAA CAGGCAACTG GAGGGAAGCA TTATGAATTT SSTCAATCTC AAGAATACSS | 3300 |
| YSYRNNNNNN TCTTTAGTAA TCAGGCTAAC TTTTTTATTT TTATTAACAA CAATAATTWT | 3360 |
| TTGGCTGCTA TCTGTGCTTA CCGCAGCTTA TATATCAATG GTTCRGAAAC GGCAGCATAT | 3420 |
| AATAGAGGAT TTATCCGTTC TATCCGAGAT GAATATTGTA CTAAGCAATC AACGGTTTGA | 3480 |
| AGAAGCTGAA CGTGACGCTA AAAATTTAAT GTATCAATGC TCATTAGCGA CTGAGATTCA | 3540 |

| | |
|---|------|
| TCATAACGAT ATTTTCCCTG AGGTGAGCCG GCATCTATCT GTCGGTCCTT CAAATGAC | 3600 |
| MGCCGACGCT NAACGGAGAG AAGCACCGTC TCTTTCTGCA GTCCTCTGAT ATCGATGAAA | 3660 |
| ATAGCTTTTCG TCGCGATAGT TTTATTCTTA ATCATAAAAA TGAGATTTTCG TTATTATCTA | 3720 |
| CTGATAACCC TTCAGATTAT TCAACTCTAC AGCCTTTAAC GCGAAAAAGC TTTCCTTTAT | 3780 |
| ACCCAACCCA TGCCGGGTTT TACTGGAGTG AACCAGAATA CATAAACGGC AAAGGATGGC | 3840 |
| AACGCTTCCG TTGCGGTTGC CGATCAGGCA AGGCGTATTT TTTGAGGTGA CGGTAAACT | 3900 |
| TCCCAGTCTC ATTACTAAGA GCCACCTGCC ATTAGATGAT AGTATTCGAG TATGGCTGGA | 3960 |
| TCAAAACAAC CACTTATTGC CGTTTTCATA CATCCCGGCA AAAAATACGT ACACAGTTAG | 4020 |
| AAAATGTAAC GCTGCATGAT GGATGGCAGC AAATTCCCGG ATTTCTGATA TTACGCACAA | 4080 |
| CCTTGCAATG CCCCAGGATG AGTCTGGTTA CGCTGTACCC ATACGGTAAT CTACATAATC | 4140 |
| GCATCTTAAA AATTATCCTT CAACAAATCC CCTTTACATT AACAGCATTG GTGTTGATGA | 4200 |
| CGTCGGCTTT TTGCTGGTTA CTACATCGCT CACTGGCCAA ACCGTTATGG CGTTTGTGTCG | 4260 |
| ATGTCATTAA TAAAACCGCA ACTGCACCGC TGAGCACACG TTTACCAGCA CAACGACTGG | 4320 |
| ATGAATTAGA TAGTATTGCC GGTGCTTTTA ACCAACTGCT TGATACTCTA CAAGTCCAAT | 4380 |
| ACGACAATCT GGAAAACAAA GTCGCAGACG CACCCAGGCG CTAAATGAAG CAAAAAACG | 4440 |
| CGCTGAGCNA GCTAACAAAC GTAAAAGCAT TCATCTTACG GTAATAAGTC ATGAGTTACG | 4500 |
| TACTCCGATG AATGGCGTAC TCGGTGCAAT TGAATTATTA CAAACCACCC CTTTAAACAT | 4560 |
| AGAGCAACAA GGATTAGCTG ATACCGCCAG AAATTGTACA CTGTCTTTGT TAGCTATTAT | 4620 |
| TAATAATCTG CTGGATTTTT CACGCATCGA GTCTGGTCAT TTCACATTAC ATATGGAAGA | 4680 |
| AACAGCGTTA CTGCCGTTAC TGGACCAGGC AATGCAAACC ATCCAGGGGC CAGCGCNAAA | 4740 |
| GCAAAAAACT GTCATTACGT ACTTTTGTGCG GTCAACATGT CCCTCTCTAT TTTCATACCG | 4800 |
| ACAGTATCCG TTTACNNCAA ATTTTGGTTA ATTTACTCGG GAACGCGGTA AAATTTACCG | 4860 |
| AAACCGGAGG ATACGTCTGA CGGTCAAGCG TCATGAGGAA CAATTAATAT TTCTGCTTAG | 4920 |
| CGATAGCGGT AAAGGGATTG AAATACAGCA GCAGTCTCAA ATCTTTACTG CTTTTATCA | 4980 |
| AGCAGACACA AATTCGCAAG GTACAGGAAT TGGACTGACT ATTGCGTCAA GCCTGGCTAA | 5040 |
| AATGATGGGC GGTAATCTGA CACTAAAAAG TGTCCCCGGG GTTGGAACCT GTGTCTCGCT | 5100 |
| AGTATTACCC TTACAAGAAT ACCAGCCGCC TCAACCAATT AAAGGGACGC TGTCAGNNNC | 5160 |
| CGTTCTGCCT GCATCGGCAA CTGGCTTGCT GGGGAATACG CGGTGAACCA CCCCACCAGC | 5220 |

| | | | | | | |
|-------------|-------------|------------|-------------|------------|------------|------|
| AAAAATGCGCT | TCTCAANN CN | AGAGCTTTTG | TATTTCTCCG | GAAAACTCTA | CGACCTGGCG | 5280 |
| CAACAGTTAA | TATTGTGTAC | ACCAAATATG | CCAGTAATAA | ATAATTTGTT | ACCACCCTGG | 5340 |
| CAGTTGCAGA | TTCTTTTGGT | TGATGATGCC | GATATTAATC | GGGATATCAT | CGGCAAAATG | 5400 |
| CTTGTCAGCC | TGGGCCAACA | CGTCACTATT | GCCGCCAGTA | GTAACGAGGC | TCTGACTTTA | 5460 |
| TCACAACAGC | AGCGATT CGA | TTTAGTACTG | ATTGACATTA | GAATGCCAGA | AATAGATGGT | 5520 |
| ATTGAATGTG | TACGATTATG | GCATGATGAG | CCGAATAAIT | TAGATCCTGA | CTGCATGTTT | 5580 |
| GTGGCACTAT | CCGCTAGCGT | ASCVNMAGAW | RWTMWT CRTY | GTDDAAAAAA | WRDGRKDHWT | 5640 |
| CATHAYANNT | TACAAAACCA | GTGACATTGG | CTACCTTAGC | TCGCTACATC | AGTATTGCCG | 5700 |
| CAGAATACCA | ACTTTTACGA | AATATAGAGC | TACAGGAGCA | GGATCC | | 5746 |

(2) INFORMATION FOR SEQ ID NO: 39:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 141 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (iii) HYPOTHETICAL: NO
- (iii) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 39:

| | | | | | | |
|------------|------------|------------|------------|------------|------------|-----|
| CCACCAGCCG | CTGGGGTACC | AGGGCCAGGC | GACGGATATT | GAAATTCACG | CCCGCGAAAT | 60 |
| TTTGAAAGTA | AAAGGGCGCA | TGAATGAACT | TATGRMKYKM | MATACGGGTC | ANTCTCTTGA | 120 |
| GCAGATTGAA | SGTGATACTG | A | | | | 141 |

(2) INFORMATION FOR SEQ ID NO: 40:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 66 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (iii) HYPOTHETICAL: NO
- (iii) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 40:

TGAAGCGGTA GAGTACGGTT TGGTTGACTC AATTTTGACC CATCGTAATT GATGCCCTGG 60
ACGCAA 66

(2) INFORMATION FOR SEQ ID NO: 41:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 141 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double

- (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (iii) HYPOTHETICAL: NO
- (iii) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 41:

| | |
|---|-----|
| CCAACCGTTG GCGGGCTACC AGGGCCAGGC GACCGATATC GAAATTCATG CCCGTGAAAT | 60 |
| TCTGAAAGTT AAAGGGCGCA TGAATGAACT TATGGCGCTT CATACGGGTC AATCATTAGA | 120 |
| ACAGATTGAA CGTGATACCG A | 141 |

(2) INFORMATION FOR SEQ ID NO: 42:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 66 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (iii) HYPOTHETICAL: NO
- (iii) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 42:

| | |
|---|----|
| TGAAGCGGTG GAATACGGTC TGGTCGATTC GATTCTGACC CATCGTAATT GATGCCAGAG | 60 |
| GCGCAA | 66 |

(2) INFORMATION FOR SEQ ID NO: 43:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 107 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (iii) HYPOTHETICAL: NO
- (iii) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 43:

| | |
|---|-----|
| GATATCGAAA TTCATGCCCC TGAAATTCTG AAAGTTAAAG GGCGCATGAA TGAACCTATG | 60 |
| GCGCTTCATA CGGGTCAATC ATTAGAACAG ATTGAACGTG ATACCGA | 107 |

(2) INFORMATION FOR SEQ ID NO: 44:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 66 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (iii) HYPOTHETICAL: NO
- (iii) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 44:

| | |
|---|----|
| TGAAGCGGTG GAATACGGTC TGGTCGATTC GATTCTGACC CATCGTAATT GATGCCAGAG | 60 |
|---|----|

(2) INFORMATION FOR SEQ ID NO:45:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 15 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:45:

Leu Gln Asn Arg Ala Arg Ser Lys Leu Ile Phe Leu Asn Asn Cys
 1 5 10 15

(2) INFORMATION FOR SEQ ID NO:46:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 17 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:46:

Lys Met Lys His Pro Pro Val Thr Pro Val Leu Tyr Tyr Arg Arg Leu
 1 5 10 15

Cys

(2) INFORMATION FOR SEQ ID NO:47:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 8 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:47:

Pro Asp Lys Trp Ile Ile Cys Ser
 1 5

(2) INFORMATION FOR SEQ ID NO:48:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 23 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:48:

Ala Ser Ile Ile Leu Pro Glu Tyr His Gly Ala Ala Cys Gln Ala Leu
1 5 10 15

Asn Lys Leu Asp Asn Met Ala
20

(2) INFORMATION FOR SEQ ID NO:49:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 4 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:49:

Arg Phe Ile Val
1

(2) INFORMATION FOR SEQ ID NO:50:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 79 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:50:

Tyr Phe Leu Leu Ser Leu Arg Ser Phe Leu Arg His Val Met Trp Ile
1 5 10 15

Phe Ile Ala His Cys Gln Lys Met Lys Arg Ile Lys Cys Trp His Tyr
20 25 30

Leu Cys Ser Ile Ile Leu Met Arg Lys Lys Thr Gly Arg Gly Trp Cys
35 40 45

Asn Leu Thr Cys Arg Ala Val Gly Ser Leu Leu Met Arg Leu Arg Leu
50 55 60

Leu Arg Leu Asn Gly Tyr Pro His Arg Ala Val Tyr Asn Gly Gly
65 70 75

(2) INFORMATION FOR SEQ ID NO:51:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 4 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:51:

Asp Val Ser Gly

1

(2) INFORMATION FOR SEQ ID NO:52:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 16 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:52:

Ser Val Ser Gly Ile Thr Pro Gly Arg Thr Gly Arg Arg Leu Ile Phe

1

5

10

15

(2) INFORMATION FOR SEQ ID NO:53:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 8 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:53:

Lys Asn Lys Glu Leu Lys Glu Cys

1

5

(2) INFORMATION FOR SEQ ID NO:54:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 18 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:54:

Val Arg Trp Arg Gly Val Ile Asn Gly Lys Ser Asp His Cys Ala Thr

1

5

10

15

Asp Leu

(2) INFORMATION FOR SEQ ID NO:55:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 25 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:55:

Arg Phe Ser Glu Leu Ser Cys Arg Ile Tyr Lys Ile Phe Thr Ser Gly
1 5 10 15

Gln Tyr Gly Gly Leu Ser Gly Lys Asn
20 25

(2) INFORMATION FOR SEQ ID NO:56:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 13 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:56:

Arg Phe Asn Arg Asp Val Asn Pro Trp Val Ala Ile Gln
1 5 10

(2) INFORMATION FOR SEQ ID NO:57:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:57:

Tyr Leu Asp Ala Ala Cys
1 5

(2) INFORMATION FOR SEQ ID NO:58:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 5 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:58:

Ile Gln Asn Gly Ser
1 5

(2) INFORMATION FOR SEQ ID NO:59:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 16 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein
(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:59:

Arg Thr Arg Glu Thr Asn Ile Leu Asp Tyr Gly Arg Tyr Gln Arg Gln
1 5 10 15

(2) INFORMATION FOR SEQ ID NO:60:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 91 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein
(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:60:

Arg Glu Gly Gly Glu Val Val Asp Glu Ile Pro Leu Ser Val Asp Val
1 5 10 15

Ile Val Asp Arg Thr Val Ile Arg Ser Gly His Pro Asp Arg Leu Phe
20 25 30

Leu Pro Glu Thr Pro Phe Leu Ser Arg Pro Asp Pro Glu Val Leu Gln
35 40 45

Leu Tyr Arg Tyr Phe Trp Gln Pro Ala Arg Tyr Ala Val Pro Glu Trp
50 55 60

Leu Asp Lys Leu Gly Phe His Leu Gln Thr Ala Gly Val Met Ala Ile
65 70 75 80

Gly Pro Ser Trp Ile Val Phe Leu Thr Glu Arg
85 90

(2) INFORMATION FOR SEQ ID NO:61:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 9 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein
(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:61:

Glu Glu Ala Leu Leu Phe Gln Pro Val
1 5

(2) INFORMATION FOR SEQ ID NO:62:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 68 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein
(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:62:

Met Thr Gly Lys Asn Gly Arg Phe Val Leu Arg Arg Val Tyr Arg His
1 5 10 15
Leu Pro Leu Gly Trp Asp Tyr Ser Asn Ser Gly Val Val Thr Ile Leu
20 25 30
Cys Tyr Gln Ser Ile Gly Asn Cys Phe Tyr Ser Gly Leu Ala Arg Met
35 40 45
Arg Ser Gly Ser Tyr Met Val Gly Trp Gly Lys Glu Met Ala Asn Tyr
50 55 60
Phe Leu Arg Lys
65

(2) INFORMATION FOR SEQ ID NO:63:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 53 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:63:

Cys Asn Lys Leu His Cys Arg Ser Val Pro Pro Phe Leu Ile Gly Lys
1 5 10 15
Arg Met Thr Met Arg Val Leu His Ala Leu Leu Val Leu Leu Pro Pro
20 25 30
Pro Gln Arg Ile Leu Trp Pro Lys Thr Ser Leu Thr Glu Ile Ile Phe
35 40 45
Met Glu His Leu Leu
50

(2) INFORMATION FOR SEQ ID NO:64:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:64:

Val Leu Leu His Phe Leu
1 5

(2) INFORMATION FOR SEQ ID NO:65:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 17 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:65:

Arg Lys Leu Thr Ile Ser Tyr Pro Leu Glu Ile Leu Leu Ser His Ser
1 5 10 15

Gly

(2) INFORMATION FOR SEQ ID NO:66:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 16 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:66:

Leu Tyr Leu Arg Lys Ser Asn Lys Leu Arg Glu Phe His Met Leu Leu
1 5 10 15

(2) INFORMATION FOR SEQ ID NO:67:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 28 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:67:

Ala Pro Leu Thr Val Arg Leu Lys Lys Ser Ser Glu Thr Pro Ile Val
1 5 10 15

Ile Ser Val Asn Arg Lys Leu Ser Ser Asn Lys Asn
20 25

(2) INFORMATION FOR SEQ ID NO:68:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 19 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:68:

Arg Ala Cys Val Lys Ile Arg Trp Lys Lys Trp Lys Trp Asn Gly Trp
 1 5 10 15

Asn Ser Met

(2) INFORMATION FOR SEQ ID NO:69:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 24 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:69:

Asn Ile Tyr Lys Thr Met Lys Ile Asn Phe Val His Trp Ser Ile Thr
 1 5 10 15

Gln Arg Ile Ile Leu Lys Ile Val
 20

(2) INFORMATION FOR SEQ ID NO:70:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 12 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:70:

Asn Arg Phe Cys Trp Pro Gly Ser Thr Asn Ser Arg
 1 5 10

(2) INFORMATION FOR SEQ ID NO:71:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 31 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:71:

Thr Val Leu Cys Ala Ile Val Trp His Ala Arg Pro Arg Leu Trp Arg
 1 5 10 15

Lys Arg Glu Arg Phe Ile Cys Val Phe Ile Leu Lys Lys Arg His
 20 25 30

(2) INFORMATION FOR SEQ ID NO:72:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 amino acids

- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:72:

Cys Glu Lys Leu Leu Ala Ser Gly Leu Arg
 1 5 10

(2) INFORMATION FOR SEQ ID NO:73:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 31 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:73:

Leu Ser Ser Leu Val Ser Leu Pro Ile Arg Leu Asn Phe Pro Gln His
 1 5 10 15
 Asp Met Pro Leu Asn Phe His Phe Leu Val Ile Ser Thr Arg Tyr
 20 25 30

(2) INFORMATION FOR SEQ ID NO:74:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 189 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:74:

Asn Gly Tyr Val Met Val Lys Ile Lys Glu Val Ala Met Asn Ile Lys
 1 5 10 15
 Ile Asn Glu Ile Lys Met Thr Pro Pro Thr Ala Phe Thr Pro Gly Gln
 20 25 30
 Val Ile Glu Glu Gln Glu Val Ile Ser Pro Ser Met Leu Ala Leu Gln
 35 40 45
 Glu Leu Gln Glu Thr Thr Gly Ala Ala Leu Tyr Glu Thr Met Glu Glu
 50 55 60
 Ile Gly Met Ala Leu Ser Gly Lys Leu Arg Glu Asn Tyr Lys Phe Thr
 65 70 75 80
 Asp Ala Glu Lys Leu Glu Arg Arg Gln Gln Ala Leu Leu Arg Leu Ile
 85 90 95

Lys Gln Ile Gln Glu Asp Asn Gly Ala Thr Leu Arg Pro Leu Thr Glu
 100 105 110
 Glu Asn Ser Asp Pro Asp Leu Gln Asn Ala Tyr Gln Ile Ile Ala Leu
 115 120 125
 Ala Met Ala Leu Thr Ala Gly Gly Leu Ser Lys Lys Lys Lys Arg Asp
 130 135 140
 Leu Gln Ser Gln Leu Asp Thr Leu Gln Arg Arg Arg Asp Gly Asn Leu
 145 150 155 160
 Pro Phe Leu Val Tyr Trp Asn Leu Ala Lys Trp Ile Pro Tyr Ala Val
 165 170 175
 Leu Ser Glu Ala Phe Tyr Ala Thr Gly Asp Arg Gln Arg
 180 185

(2) INFORMATION FOR SEQ ID NO:75:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 17 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:75:

Asn Ala Leu Ile Ala Val Val Gln Thr Arg Gly Arg Leu Ala Gly Ser
 1 5 10 15
 Leu

(2) INFORMATION FOR SEQ ID NO:76:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 11 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:76:

Thr Gly Pro Tyr Phe Ala Lys Ser Ser Ser Leu
 1 5 10

(2) INFORMATION FOR SEQ ID NO:77:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 27 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:81:

Ala Leu Ala Phe Gln
1 5

(2) INFORMATION FOR SEQ ID NO:82:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 18 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:82:

Thr Tyr Arg Tyr Ser Phe Phe Ile Glu Asp Val Gln Ser Val Thr Pro
1 5 10 15

Thr Thr

(2) INFORMATION FOR SEQ ID NO:83:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 8 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:83:

Cys Ala Val Tyr Ala Asp Thr Arg
1 5

(2) INFORMATION FOR SEQ ID NO:84:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 5 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:84:

Arg Arg Arg Ser Thr
1 5

(2) INFORMATION FOR SEQ ID NO:85:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 7 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 759 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:89:

```

Asn Tyr His Asn Gly Arg Ile Leu Leu Cys Gln Ile Leu Lys Gln Thr
 1             5             10             15

Phe Leu Asp Glu Glu Leu Leu Phe Lys Ala Leu Ala Asn Trp Lys Pro
      20             25             30

Ala Ala Phe Gln Gly Ile Pro Gln Arg Leu Phe Leu Leu Arg Asp Gly
      35             40             45

Leu Ala Met Ser Cys Ser Pro Pro Leu Ser Ser Ser Ala Glu Leu Trp
      50             55             60

Leu Arg Leu His His Arg Gln Ile Lys Phe Xaa Gly Val Ala Met Arg
      65             70             75             80

Ser Trp Leu Gly Glu Gly Val Arg Ala Gln Gln Trp Leu Ser Val Cys
      85             90             95

Ala Gly Arg Gln Asp Met Val Leu Ala Thr Val Leu Leu Ile Ala Ile
      100            105            110

Val Met Met Leu Leu Pro Leu Pro Thr Trp Met Val Asp Ile Leu Ile
      115            120            125

Thr Ile Asn Leu Met Phe Ser Val Ile Leu Leu Leu Ile Ala Ile Tyr
      130            135            140

Leu Ser Asp Pro Leu Asp Leu Ser Val Phe Pro Ser Leu Leu Leu Ile
      145            150            155            160

Thr Thr Leu Tyr Arg Leu Ser Leu Thr Ile Ser Thr Ser Arg Leu Val
      165            170            175

Leu Leu Gln His Asn Ala Gly Asn Ile Val Asp Ala Phe Gly Lys Phe
      180            185            190

Val Val Gly Gly Asn Leu Thr Val Gly Leu Val Val Phe Thr Ile Ile
      195            200            205

Thr Ile Val Gln Phe Ile Val Ile Thr Lys Gly Ile Glu Arg Val Ala
      210            215            220

Glu Val Ser Ala Arg Phe Ser Leu Asp Gly Met Pro Gly Lys Gln Met
      225            230            235            240

Ser Ile Asp Gly Asp Leu Arg Ala Gly Val Ile Asp Ala Asp His Ala
      245            250            255

```

Arg Thr Leu Arg Gln His Val Gln Gln Glu Ser Arg Phe Leu Gly Ala
260 265 270

Met Asp Gly Ala Met Lys Phe Val Lys Gly Asp Thr Ile Ala Gly Ile
275 280 285

Ile Val Val Leu Val Asn Ile Ile Gly Gly Ile Ile Ile Ala Ile Val
290 295 300

Gln Tyr Asp Met Ser Met Ser Glu Ala Val His Thr Tyr Ser Val Leu
305 310 315 320

Ser Ile Gly Asp Gly Leu Cys Gly Gln Ile Pro Ser Leu Leu Ile Ser
325 330 335

Leu Ser Ala Gly Ile Ile Val Thr Arg Val Pro Gly Glu Lys Arg Gln
340 345 350

Asn Leu Ala Thr Glu Leu Ser Ser Gln Ile Ala Arg Gln Pro Gln Ser
355 360 365

Leu Ile Leu Thr Ala Val Val Leu Met Leu Leu Ala Leu Ile Pro Gly
370 375 380

Phe Pro Phe Ile Thr Leu Ala Phe Phe Ser Ala Leu Leu Ala Leu Pro
385 390 395 400

Ile Ile Leu Ile Arg Arg Lys Lys Ser Val Val Ser Ala Asn Gly Val
405 410 415

Glu Ala Pro Glu Lys Asp Ser Met Val Pro Gly Ala Cys Pro Leu Ile
420 425 430

Leu Arg Leu Ser Pro Thr Leu His Ser Ala Asp Leu Ile Arg Asp Ile
435 440 445

Asp Ala Met Arg Trp Phe Leu Phe Glu Asp Thr Gly Val Pro Leu Pro
450 455 460

Glu Val Asn Ile Glu Val Leu Pro Glu Pro Thr Glu Lys Leu Thr Val
465 470 475 480

Leu Leu Tyr Gln Glu Pro Val Phe Ser Leu Ser Ile Pro Ala Gln Ala
485 490 495

Asp Tyr Leu Leu Ile Gly Ala Asp Ala Ser Val Val Gly Asp Ser Gln
500 505 510

Thr Leu Pro Asn Gly Met Gly Gln Ile Cys Trp Leu Thr Lys Asp Met
515 520 525

Ala His Lys Ala Gln Gly Phe Gly Leu Asp Val Phe Ala Gly Ser Gln
530 535 540

Arg Ile Ser Ala Leu Leu Lys Cys Val Leu Leu Arg His Met Gly Glu
545 550 555 560

Phe Ile Gly Val Gln Glu Thr Arg Tyr Leu Met Asn Ala Met Glu Lys
565 570 575

Asn Tyr Ser Glu Leu Val Lys Glu Leu Gln Arg Gln Leu Pro Ile Asn
580 585 590

Lys Ile Ala Glu Thr Leu Gln Arg Leu Val Ser Glu Arg Val Ser Ile
595 600 605

Arg Asp Leu Arg Leu Ile Phe Gly Thr Leu Ile Asp Trp Ala Pro Arg
610 615 620

Glu Lys Asp Val Leu Met Leu Thr Glu Tyr Val Arg Ile Ala Leu Arg
625 630 635 640

Arg His Ile Leu Arg Arg Leu Asn Pro Glu Gly Lys Pro Leu Pro Ile
645 650 655

Leu Arg Ile Gly Glu Gly Ile Glu Asn Leu Val Arg Glu Ser Ile Arg
660 665 670

Gln Thr Ala Met Gly Thr Tyr Thr Ala Leu Ser Ser Arg His Lys Thr
675 680 685

Gln Ile Leu Gln Leu Ile Glu Gln Ala Leu Lys Gln Ser Ala Lys Leu
690 695 700

Phe Ile Val Thr Ser Val Asp Thr Arg Arg Phe Leu Arg Lys Ile Thr
705 710 715 720

Glu Ala Thr Leu Phe Asp Val Pro Ile Leu Ser Trp Gln Glu Leu Gly
725 730 735

Glu Glu Ser Leu Ile Gln Val Val Glu Ser Ile Asp Leu Ser Glu Glu
740 745 750

Glu Leu Ala Asp Asn Glu Glu
755

(2) INFORMATION FOR SEQ ID NO:90:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 51 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:90:

Ile Asp Ala Thr Ser Glu Ala Glu Ile Ser Ala Pro Arg Trp Leu Leu
1 5 10 15

Ser Met Gly Pro Asn Ser Gly Cys Gln Arg Asn Val Val Lys Cys Val
20 25 30

Glu Glu Thr Arg Lys Arg Cys Val Ile Val Val Ala Thr Ser Asp Arg
 145 150 155 160
 Pro Ala Leu Glu Arg Val Arg Ala Leu Phe Val Ala Thr Thr Ile Ala
 165 170 175
 Glu Phe Phe Arg Asp Asn Gly Lys Arg Val Val Leu Leu Ala Asp Ser
 180 185 190
 Leu Thr Arg Tyr Ala Arg Ala Ala Arg Lys Ser Leu Trp Arg Arg Arg
 195 200 205
 Asp Arg Gly Phe Trp Arg Ile Ser Pro Gly Val Phe Ser Ala Leu Pro
 210 215 220
 Arg Leu Leu Glu Arg Thr Gly Met Gly Glu Lys Gly Ser Ile Thr Ala
 225 230 235 240
 Phe Tyr Thr Val Leu Val Glu Gly Asp Asp Met Asn Glu Ala Val Gly
 245 250 255

Gly

- (2) INFORMATION FOR SEQ ID NO:93:
- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 5 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: protein
 - (iii) HYPOTHETICAL: NO
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:93:

Ser Pro Phe Thr Ala
 1 5

- (2) INFORMATION FOR SEQ ID NO:94:
- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 18 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: protein
 - (iii) HYPOTHETICAL: NO
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:94:

Trp Thr Tyr Cys Thr Ile Pro Thr Ala Cys Arg Glu Gly Ala Leu Ser
 1 5 10 15

Cys His

- (2) INFORMATION FOR SEQ ID NO:95:
- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 15 amino acids

- (A) LENGTH: 59 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:99:

Ser Met Arg Thr Arg Ala Thr Tyr Arg Lys Ile Thr Pro Asn Thr His
 1 5 10 15

Arg Val Ile Met Glu Thr Leu Leu Glu Ile Ile Ala Arg Leu Lys Ser
 20 25 30

Asn Tyr Ala Ala Ser Leu Pro Tyr Leu Ile Ser Ser Asn Arg Arg Leu
 35 40 45

Leu Arg Asn Ser Arg Phe Ala Arg Arg Ala Leu
 50 55

- (2) INFORMATION FOR SEQ ID NO:100:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 5 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: protein
 - (iii) HYPOTHETICAL: NO
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:100:

Gln Cys Leu Pro Asp
 1 5

- (2) INFORMATION FOR SEQ ID NO:101:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 29 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: protein
 - (iii) HYPOTHETICAL: NO
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:101:

Trp Ala Gly Lys Val Arg Tyr Leu Val Ile Tyr Cys Trp Ile Arg Asn
 1 5 10 15

Asn Lys Trp Pro Gly Tyr Ser Leu Arg Arg Arg Ala Phe
 20 25

- (2) INFORMATION FOR SEQ ID NO:102:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 45 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single

(2) INFORMATION FOR SEQ ID NO:106:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:106:

Ser Ser Cys Ser Ile Glu
1 5

(2) INFORMATION FOR SEQ ID NO:107:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:107:

Glu Arg Gly Phe His Ala Thr Leu Ser Cys
1 5 10

(2) INFORMATION FOR SEQ ID NO:108:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 4 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:108:

Trp Arg Leu Ser
1

(2) INFORMATION FOR SEQ ID NO:109:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 4 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:109:

Arg Cys Arg Val
1

(2) INFORMATION FOR SEQ ID NO:110:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 14 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:110:

Ile Arg Gly Ala Asn Pro Val Lys Asn Gln Cys Pro Ser Ser
 1 5 10

(2) INFORMATION FOR SEQ ID NO:111:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 30 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:111:

Asn Leu Pro Phe Asp Glu Ser Ala Lys Ala Val Ala Gly Val Ser Val
 1 5 10 15

Ala Ala Tyr Gly Val Tyr Asn Phe Pro Gly Asp Ile Leu Cys
 20 25 30

(2) INFORMATION FOR SEQ ID NO:112:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 20 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:112:

Arg Met Lys Ser Val Arg Gly Trp Arg Tyr Phe Gln Arg Lys Ala Leu
 1 5 10 15

Pro Leu Val Ser
 20

(2) INFORMATION FOR SEQ ID NO:113:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 14 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:113:

Val Cys Asn Asn Ile Gln Tyr Ser Lys Gly His Tyr Leu Pro
 1 5 10

(2) INFORMATION FOR SEQ ID NO:114:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 22 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:114:

Ile Ile Ile Met Ser Trp Val Gly Cys Gly Leu Gln Asn Asn Ala Gly
 1 5 10 15

Ser Ala Gly Val Lys Gly
 20

(2) INFORMATION FOR SEQ ID NO:115:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 16 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:115:

Leu Ala Pro Leu Ile Asp Arg Leu Ser Ile Leu Asn Cys Tyr Met Glu
 1 5 10 15

(2) INFORMATION FOR SEQ ID NO:116:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 31 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:116:

Leu Asn Gly Gly Trp Arg Arg Tyr Cys Lys Pro Val Met Gln Pro Ser
 1 5 10 15

Val Arg Thr Ser Arg Gln His Pro Ala Val Ile Tyr His Ile Ser
 20 25 30

(2) INFORMATION FOR SEQ ID NO:117:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 27 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 7 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:124:

Val Asp Val Leu Arg Gln Arg
 1 5

- (2) INFORMATION FOR SEQ ID NO:125:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 9 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: protein
 - (iii) HYPOTHETICAL: NO
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:125:

Met Thr Val Leu Leu Gly Lys Val Ser
 1 5

- (2) INFORMATION FOR SEQ ID NO:126:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 32 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: protein
 - (iii) HYPOTHETICAL: NO
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:126:

Leu Pro Val Ala Met Asn Leu Trp Cys Val Leu His Val Gly Ile Phe
 1 5 10 15

Ala Lys Ile Gln Arg Lys Pro Asp Lys Lys Asn Asn Met Arg Thr Ile
 20 25 30

- (2) INFORMATION FOR SEQ ID NO:127:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 225 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: protein
 - (iii) HYPOTHETICAL: NO
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:127:

Arg Ser Arg Ser Cys His Glu Arg Tyr Ser Met Ser Leu Pro Asp Ser
 1 5 10 15
 56

Pro Leu Gln Leu Ile Gly Ile Leu Phe Leu Leu Ser Ile Leu Pro Leu
20 25 30

Ile Ile Val Met Gly Thr Ser Phe Leu Lys Leu Ala Val Val Phe Ser
35 40 45

Ile Leu Arg Asn Ala Leu Gly Ile Gln Gln Val Pro Pro Asn Ile Ala
50 55 60

Leu Tyr Gly Leu Ala Leu Val Leu Ser Leu Phe Ile Met Gly Pro Thr
65 70 75 80

Leu Leu Ala Val Lys Glu Arg Trp His Pro Val Gln Val Ala Gly Ala
85 90 95

Pro Phe Trp Thr Ser Glu Trp Asp Ser Lys Ala Leu Ala Pro Tyr Arg
100 105 110

Gln Phe Leu Gln Lys Asn Ser Glu Glu Lys Glu Ala Asn Tyr Phe Arg
115 120 125

Asn Leu Ile Lys Arg Thr Trp Pro Glu Asp Ile Lys Arg Lys Ile Lys
130 135 140

Pro Asp Ser Leu Leu Ile Leu Ile Pro Ala Phe Thr Val Ser Gln Leu
145 150 155 160

Thr Gln Ala Phe Arg Ile Gly Leu Leu Ile Tyr Leu Pro Phe Leu Ala
165 170 175

Ile Asp Leu Leu Ile Ser Asn Ile Leu Leu Ala Met Gly Met Met Met
180 185 190

Val Ser Pro Met Thr Ile Ser Leu Pro Phe Lys Leu Leu Ile Phe Leu
195 200 205

Leu Ala Gly Gly Trp Asp Leu Thr Leu Ala Gln Leu Val Gln Ser Phe
210 215 220

Ser
225

(2) INFORMATION FOR SEQ ID NO:128:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 4 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:128:

Met Ile Leu Asn
1

(2) INFORMATION FOR SEQ ID NO:129:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 13 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:129:

Arg Asn Phe Tyr Gly Ser Ser Phe Leu Arg Leu Cys Arg
1 5 10

(2) INFORMATION FOR SEQ ID NO:130:

```

(i) SEQUENCE CHARACTERISTICS:
    (A) LENGTH: 5 amino acids
    (B) TYPE: amino acid
    (C) STRANDEDNESS: single
    (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(iii) HYPOTHETICAL: NO

```

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:130:

Cys Trp Trp His Arg
1 5

(2) INFORMATION FOR SEQ ID NO:131:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 4 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:131:

Leu Val Ser Ser
1

(2) INFORMATION FOR SEQ ID NO:132:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 5 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:132:

Ala Leu Phe Arg Pro
1 5

(2) INFORMATION FOR SEQ ID NO:133:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:133:

Leu Lys Tyr Arg Thr Lys Arg Tyr Ser Ser
 1 5 10

- (2) INFORMATION FOR SEQ ID NO:134:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 7 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: protein
 - (iii) HYPOTHETICAL: NO
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:134:

Leu Asn Tyr Trp Gln Leu Gln
 1 5

- (2) INFORMATION FOR SEQ ID NO:135:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 11 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: protein
 - (iii) HYPOTHETICAL: NO
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:135:

Trp Ser Ala Thr His Gly Leu Ala Val Ser Cys
 1 5 10

- (2) INFORMATION FOR SEQ ID NO:136:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 5 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: protein
 - (iii) HYPOTHETICAL: NO
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:136:

Ile Ile Pro Gly Arg
 1 5

- (2) INFORMATION FOR SEQ ID NO:137:
 - (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 13 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:137:

Cys Tyr Glu Leu Glu Ser Met Val Glu Trp His Asn Arg
 1 5 10

- (2) INFORMATION FOR SEQ ID NO:138:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 14 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: protein
 - (iii) HYPOTHETICAL: NO
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:138:

Met Ser Gly Leu Leu His Trp Leu Trp Leu Leu Phe Asp His
 1 5 10

- (2) INFORMATION FOR SEQ ID NO:139:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 8 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: protein
 - (iii) HYPOTHETICAL: NO
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:139:

Ala Phe Leu Tyr Tyr Phe Pro Tyr
 1 5

- (2) INFORMATION FOR SEQ ID NO:140:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 4 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: protein
 - (iii) HYPOTHETICAL: NO
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:140:

Lys Val Ala Val
 1

- (2) INFORMATION FOR SEQ ID NO:141:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 26 amino acids

- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:141:

Gly Pro His Phe Tyr Val Met Ala Cys Leu Cys His Leu Pro Phe Arg
 1 5 10 15
 Tyr Tyr Gln Ser Phe Thr Ser Arg Arg Leu
 20 25

- (2) INFORMATION FOR SEQ ID NO:142:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 9 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: protein
 - (iii) HYPOTHETICAL: NO
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:142:

Cys Ile Leu Val Lys Ile Thr Val Gly
 1 5

- (2) INFORMATION FOR SEQ ID NO:143:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 4 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: protein
 - (iii) HYPOTHETICAL: NO
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:143:

Ser Leu Glu Arg
 1

- (2) INFORMATION FOR SEQ ID NO:144:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 39 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: protein
 - (iii) HYPOTHETICAL: NO
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:144:

Leu Leu Val Phe Gln Leu Gly Phe Val Arg Arg Phe Pro Phe Gly Pro
 1 5 10 15
 Leu Ile Trp Arg Gly Phe Cys Leu Ile Leu Tyr Val Ala Arg Gln Trp
 61

00977" 2094760

Val Arg Tyr Ser Ile Leu Gln
35

(2) INFORMATION FOR SEQ ID NO:145:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 20 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:145:

Lys Leu Lys Pro His Phe Leu Ala Cys Phe Ser Ala Ser Ser Cys Val
1 5 10 15

Leu Phe Ser Leu
20

(2) INFORMATION FOR SEQ ID NO:146:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 7 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:146:

Ala Ala Ala Trp Ser Leu Tyr
1 5

(2) INFORMATION FOR SEQ ID NO:147:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 22 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:147:

Thr Phe Cys Met Ser His Ile Asn Ile Tyr His Gln Gly Val Leu Tyr
1 5 10 15

Tyr Leu Thr Ser Asn Phe
20

(2) INFORMATION FOR SEQ ID NO:148:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 21 amino acids
 - (B) TYPE: amino acid

- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:148:

Asn Ile Ser Arg Gln Ser Gly Glu Arg Phe Ile Asn Tyr Val Ser Ala
 1 5 10 15
 Ser Leu Phe Leu Pro
 20

- (2) INFORMATION FOR SEQ ID NO:149:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 4 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: protein
 - (iii) HYPOTHETICAL: NO
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:149:

Tyr Val Trp Tyr
 1

- (2) INFORMATION FOR SEQ ID NO:150:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 4 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: protein
 - (iii) HYPOTHETICAL: NO
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:150:

Pro Ile Trp Leu
 1

- (2) INFORMATION FOR SEQ ID NO:151:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: protein
 - (iii) HYPOTHETICAL: NO
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:151:

Ile Gly Arg His Asn Asn
 1 5

- (2) INFORMATION FOR SEQ ID NO:152:
 - (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 15 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:152:

Met Cys Phe Ser Ser Gln Cys Arg Ser Lys Val Tyr Trp Phe Tyr
 1 5 10 15

- (2) INFORMATION FOR SEQ ID NO:153:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 14 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: protein
 - (iii) HYPOTHETICAL: NO
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:153:

Xaa Pro Asp Leu Ile Pro Leu Cys Ser Ser Ser Leu Phe Gly
 1 5 10

- (2) INFORMATION FOR SEQ ID NO:154:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 225 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: protein
 - (iii) HYPOTHETICAL: NO
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:154:

Ile Leu Tyr Leu Ser Lys Arg Leu Val Ser Ile Cys Met Ser Glu Lys
 1 5 10 15

Thr Glu Gln Pro Thr Glu Lys Lys Leu Arg Asp Gly Arg Lys Glu Gly
 20 25 30

Gln Val Val Lys Ser Ile Glu Ile Thr Ser Leu Phe Gln Leu Ile Ala
 35 40 45

Leu Tyr Leu Tyr Phe His Phe Phe Thr Glu Lys Met Ile Leu Ile Leu
 50 55 60

Ile Glu Ser Ile Thr Phe Thr Leu Gln Leu Val Asn Lys Pro Phe Ser
 65 70 75 80

Tyr Ala Leu Thr Gln Leu Ser His Ala Leu Ile Glu Ser Leu Thr Ser
 85 90 95

Ala Leu Leu Phe Leu Gly Ala Gly Val Ile Val Ala Thr Val Gly Ser
 100 105 110

Figure 1 displays the effect of the 1997 Asian financial crisis on the growth rate of the real GDP per capita in 1998 for 10 Asian countries. The figure consists of 10 subplots, one for each country: China, Hong Kong, Korea, Japan, Singapore, Taiwan, Thailand, Malaysia, Indonesia, and the Philippines. Each subplot shows the growth rate of real GDP per capita on the y-axis (ranging from -10 to 10) against the year on the x-axis (1996, 1997, 1998). A horizontal line at 0 represents zero growth. Data points are shown for 1996 and 1997, with a vertical line indicating the 1998 projection. The 1998 projection is shown as a shaded area representing a confidence interval. The legend indicates that the shaded area represents the 95% confidence interval for the 1998 projection. The 1998 projection is generally lower than the 1997 growth rate, indicating a negative impact of the crisis on growth in 1998.

66

(A) LENGTH: 7 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 (ii) MOLECULE TYPE: protein
 (iii) HYPOTHETICAL: NO
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:161:

Thr Gln Leu His Pro Arg Cys
 1 5

(2) INFORMATION FOR SEQ ID NO:162:
 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 7 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 (ii) MOLECULE TYPE: protein
 (iii) HYPOTHETICAL: NO
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:162:

Ala Gly Pro Leu Ile Ile Phe
 1 5

(2) INFORMATION FOR SEQ ID NO:163:
 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 5 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 (ii) MOLECULE TYPE: protein
 (iii) HYPOTHETICAL: NO
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:163:

Ser Gly Thr Arg Arg
 1 5

(2) INFORMATION FOR SEQ ID NO:164:
 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 67 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 (ii) MOLECULE TYPE: protein
 (iii) HYPOTHETICAL: NO
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:164:

Thr Arg Cys Ser Leu Val Thr Tyr Gly Asp Glu Asp Arg Leu Cys Ala
 1 5 10 15

Phe Tyr Arg Asn Thr Ile Asn Ala Phe Gly Met Leu Leu Gln Ala Thr
 20 25 30

Ala Lys Val Lys Arg Val Ile Ala Tyr Arg Ala Val Leu Asp Asp Lys
 35 40 45

Gly Glu Arg Leu Lys Ile Ile Ala Phe Ser Leu Ala Gln Ala Pro Asp
 50 55 60

Ser Val Leu
 65

(2) INFORMATION FOR SEQ ID NO:165:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 23 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:165:

Trp Ile Gly Ala Ser Glu Trp Thr Arg Thr Thr Arg Pro Pro Pro Cys
 1 5 10 15

Gln Gly Gly Ala Leu Thr Asn
 20

(2) INFORMATION FOR SEQ ID NO:166:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 14 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:166:

Ala Met Asn Gly Asn Val Val Gly Asp Asn Gly Asp Glu Tyr
 1 5 10

(2) INFORMATION FOR SEQ ID NO:167:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 15 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:167:

Arg His Asn Arg Asn Glu Ala Arg Gly Lys Ser Gln Phe Ser Ser
 1 5 10 15

(2) INFORMATION FOR SEQ ID NO:168:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 14 amino acids

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:169:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:170:

69

(C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 (ii) MOLECULE TYPE: protein
 (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:175:

Thr Gly Thr Arg Cys Val Cys Ala Ser Ser Val Glu Pro Trp Pro Arg
 1 5 10 15
 Pro Ile Thr His Ser Asn Arg Tyr Arg Arg Ser Gln Arg His Arg Gln
 20 25 30
 Tyr Glu His Gln Arg Ala Lys Val Lys Arg Asn Leu Met Thr Gly Asp
 35 40 45
 Ile His Asn Thr
 50

(2) INFORMATION FOR SEQ ID NO:176:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 (ii) MOLECULE TYPE: protein
 (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:176:

Trp Arg Asn Gln Gln Arg Asn Asp Arg Lys
 1 5 10

(2) INFORMATION FOR SEQ ID NO:177:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 19 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 (ii) MOLECULE TYPE: protein
 (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:177:

Arg His Phe Lys Glu Gln Pro Ala Gln Ser Ala Thr Pro Val Glu Ser
 1 5 10 15
 Gly Ala Ser

(2) INFORMATION FOR SEQ ID NO:178:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 21 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 (ii) MOLECULE TYPE: protein
 (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:178:

Arg Arg Tyr Arg Val Cys Gln Ser Leu Phe His Tyr Glu Tyr His Ala
1 5 10 15
Leu Asn Ala Arg Val
20

(2) INFORMATION FOR SEQ ID NO:179:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:179:

Cys Lys Lys Ala Trp Arg
1 5

(2) INFORMATION FOR SEQ ID NO:180:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 26 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:180:

Thr Ser Pro Asn Arg Pro Pro Gln Ser Gln Arg Arg Ser Arg Tyr Arg
1 5 10 15

Arg Val Pro Ala Tyr Gln Asn Gly His Arg
20 25

(2) INFORMATION FOR SEQ ID NO:181:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 61 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:181:

Lys Tyr Ser Ser Pro Glu Tyr Ser Pro Ala Gly Pro Lys Ile Pro Ser
1 5 10 15

Pro Tyr Pro Val Trp Phe Trp Pro Asp Leu Arg Thr Gly Phe Ala Leu
20 25 30

Pro Glu Arg Lys Gly Ile Leu Arg Pro Thr Ala Ala Arg Glu Asp Asn
 35 40 45

Pro Arg Leu Tyr Arg Pro Ala Pro Asp Gln Tyr Tyr Ala
 50 55 60

(2) INFORMATION FOR SEQ ID NO:182:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 36 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:182:

Cys Ile Arg His Ser Thr Gly Arg Ser Ser Pro Ala Arg Arg Gln Ser
 1 5 10 15

Pro Pro Ala Arg Thr Leu Val Glu Pro Asp Ala Arg Tyr Ala His Asp
 20 25 30

Gly Arg Ser His
 35

(2) INFORMATION FOR SEQ ID NO:183:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 59 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:183:

Val Ala Gln Ser Gln Ala Ser Arg Pro Ala Val Ser Arg Asp Gln Thr
 1 5 10 15

Lys Trp Arg Glu Ala Asp Arg Gly Ala Asp Ser Asp Gly Ser His Val
 20 25 30

Arg Ser Ala Ile Ala Ser Arg His Asp Gly Ile Asp Glu Ser Ile Ala
 35 40 45

Val Tyr Thr Thr Cys Ala Arg Ile Thr Gly Ile
 50 55

(2) INFORMATION FOR SEQ ID NO:184:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 25 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

Figure 1 consists of seven bar charts, labeled (a) through (g), arranged vertically. Each chart plots the concentration of *E. coli* O157:H7 in log₁₀ CFU/g against time in hours (0 to 24).
 (a) Control: The concentration increases from 10¹ log₁₀ CFU/g at 0h to 10⁸ log₁₀ CFU/g at 24h.
 (b) 10% NaCl: The concentration decreases from 10¹ log₁₀ CFU/g at 0h to 10⁰ log₁₀ CFU/g at 24h.
 (c) 10% NaCl + 10% NaOH: The concentration decreases from 10¹ log₁₀ CFU/g at 0h to 10⁰ log₁₀ CFU/g at 24h.
 (d) 10% NaCl + 10% NaOH + 10% Na₂S₂O₅: The concentration decreases from 10¹ log₁₀ CFU/g at 0h to 10⁰ log₁₀ CFU/g at 24h.
 (e) 10% NaCl + 10% NaOH + 10% Na₂S₂O₅ + 10% Na₂S₂O₃: The concentration decreases from 10¹ log₁₀ CFU/g at 0h to 10⁰ log₁₀ CFU/g at 24h.
 (f) 10% NaCl + 10% NaOH + 10% Na₂S₂O₅ + 10% Na₂S₂O₃ + 10% Na₂S₂O₈: The concentration decreases from 10¹ log₁₀ CFU/g at 0h to 10⁰ log₁₀ CFU/g at 24h.
 (g) 10% NaCl + 10% NaOH + 10% Na₂S₂O₅ + 10% Na₂S₂O₃ + 10% Na₂S₂O₈ + 10% Na₂S₂O₄: The concentration decreases from 10¹ log₁₀ CFU/g at 0h to 10⁰ log₁₀ CFU/g at 24h.

74

(2) INFORMATION FOR SEQ ID NO:188:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 8 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:188:

Cys Arg Thr Glu Pro Gly Ala Asn

1

5

(2) INFORMATION FOR SEQ ID NO:189:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 5 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:189:

Thr Ile Ala Glu Arg

1

5

(2) INFORMATION FOR SEQ ID NO:190:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 4 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:190:

Ser Ile His Gln

1

(2) INFORMATION FOR SEQ ID NO:191:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 63 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:191:

Arg Gln Cys Phe Ile Thr Ala Gly Tyr Val Asp Gln Thr Asn Gly Leu

1 5 10 15

Tyr Ala Val Asn Gly Arg Arg Arg Leu Ser Cys Gln Asn Ile Thr Ala
 20 25 30

Gln His Ala Lys Arg Leu Ile Ser Trp Ile Thr Trp His Glu Gly Ser
 35 40 45

Ser Tyr Ser Ile Ser Tyr Cys Pro Tyr Val Leu Ser Tyr Gly Met
 50 55 60

- (2) INFORMATION FOR SEQ ID NO:192:
- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: protein
 - (iii) HYPOTHETICAL: NO
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:192:

Cys Gly Ser Leu Ser Leu Ile Ala Arg Arg
 1 5 10

- (2) INFORMATION FOR SEQ ID NO:193:
- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 13 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: protein
 - (iii) HYPOTHETICAL: NO
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:193:

Ser Glu Ser Asn Ala Gly Ile Thr Tyr Ala Ala Ser Tyr
 1 5 10

- (2) INFORMATION FOR SEQ ID NO:194:
- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 20 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: protein
 - (iii) HYPOTHETICAL: NO
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:194:

Cys Glu Lys Lys Gln Glu Glu Asp Gly Val Thr Leu Arg Val Glu Gln
 1 5 10 15

Ser Ala Val Tyr
 20

- (2) INFORMATION FOR SEQ ID NO:195:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 36 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:195:

Gly Tyr Leu Asp Leu Thr Val Ile Arg Ile Gly Gln Phe Thr Thr Ala
 1 5 10 15
 Asp Lys Met Phe Pro Ala Asn Gln Leu Val Val Ser Pro Gln Glu Glu
 20 25 30
 Gln Ala Glu Asp
 35

- (2) INFORMATION FOR SEQ ID NO:196:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 7 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: protein
 - (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:196:

Phe Phe Lys Arg Thr Lys Asn
 1 5

- (2) INFORMATION FOR SEQ ID NO:197:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 9 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: protein
 - (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:197:

Arg Asn Ala Glu Ser Asp Gly Gly Ala
 1 5

- (2) INFORMATION FOR SEQ ID NO:198:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 127 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: protein
 - (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:198:

Leu Met Ala Lys Val Thr Ile Ala Leu Pro Thr Tyr Asp Glu Gly Ser
 1 5 10 15
 Asn Ala Ser Pro Ser Ser Val Ala Val Phe Ile Lys Tyr Ser Pro Gln
 20 25 30
 Val Asn Met Glu Ala Phe Arg Val Lys Ile Lys Asp Leu Ile Glu Met
 35 40 45
 Ser Ile Pro Gly Leu Gln Tyr Ser Lys Ile Ser Ile Leu Met Gln Pro
 50 55 60
 Ala Glu Phe Arg Met Val Ala Asp Val Pro Ala Arg Gln Thr Phe Trp
 65 70 75 80
 Ile Met Asp Val Ile Asn Ala Asn Lys Gly Lys Val Val Lys Trp Leu
 85 90 95
 Met Lys Tyr Pro Tyr Pro Leu Met Leu Ser Leu Thr Gly Leu Leu Leu
 100 105 110
 Gly Val Gly Ile Leu Ile Gly Tyr Phe Cys Leu Arg Arg Arg Phe
 115 120 125

(2) INFORMATION FOR SEQ ID NO:199:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 48 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:199:

Ala Asp Leu Ile Pro Arg Cys Cys Asn Phe Ile Val Ile Ser Gly Asn
 1 5 10 15
 Leu Leu Val Thr Leu Tyr Arg Asn Gly Trp Ile Ser Trp Ala Phe Ile
 20 25 30
 Phe Lys Leu Leu Ala Leu Trp Arg Ser Ala Arg Val Gly Ser Ser Ser
 35 40 45

(2) INFORMATION FOR SEQ ID NO:200:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 4 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:200:

Gln Ser Val Lys

1

(2) INFORMATION FOR SEQ ID NO:201:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 12 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:201:

Thr Lys Arg Lys Leu Cys Tyr Ser Ser Leu Phe Lys
1 5 10

(2) INFORMATION FOR SEQ ID NO:202:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 26 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:202:

Gln Ala Lys Thr Ala Gly Ser Ser Cys Ala Ala Tyr Ile Gly Ile Cys
1 5 10 15

Leu Trp Ala Gly Ile Ile Gln Thr Gln Val
20 25

(2) INFORMATION FOR SEQ ID NO:203:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 15 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:203:

Leu Phe Tyr Ala Thr Arg Val Ser Ala Ile Ala Ser Thr Val Val
1 5 10 15

(2) INFORMATION FOR SEQ ID NO:204:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 33 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:204:

Asp Leu Ala Ala Ile Trp Leu Val Gly Ala Lys Arg Trp Gln Ile Thr
 1 5 10 15

Ser Ser Ala Ser Asp Ala Thr Asn Cys Ile Ala Asp Arg Tyr Arg His
 20 25 30

Ser

(2) INFORMATION FOR SEQ ID NO:205:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 4 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:205:

Ser Gly Ser Ala
 1

(2) INFORMATION FOR SEQ ID NO:206:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 8 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:206:

Arg Cys Gly Phe Tyr Met Arg Tyr
 1 5

(2) INFORMATION FOR SEQ ID NO:207:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 36 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:207:

Tyr Tyr Tyr Pro Leu Arg Ser Val Tyr Phe Gly Arg Arg Leu Leu Leu
 1 5 10 15

Pro Arg Leu Ser Ser Trp Ser Ile Cys Tyr Glu Phe Tyr Phe Thr Ser
 20 25 30

Ser Asp Gly Asn
 35

(2) INFORMATION FOR SEQ ID NO:208:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 7 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:208:

Ala Thr Arg Ser Lys Tyr Tyr
1 5

(2) INFORMATION FOR SEQ ID NO:209:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 17 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:209:

Val Thr Val Asp Asn Ile Thr Ile Asn Phe Ile Cys Ala Arg Ala Thr
1 5 10 15

Ser

(2) INFORMATION FOR SEQ ID NO:210:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 12 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:210:

Glu Ser Phe Thr Cys Tyr Cys Glu Leu Arg Leu Pro
1 5 10

(2) INFORMATION FOR SEQ ID NO:211:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 11 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:211:

Lys Asn His Pro Arg Arg Leu Ser Leu Ser Ala
1 5 10

(2) INFORMATION FOR SEQ ID NO:212:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 9 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:212:

Ala Ala Thr Arg Thr Ser Val Leu Ala

1 5

(2) INFORMATION FOR SEQ ID NO:213:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 21 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:213:

Lys Tyr Ala Gly Lys Asn Gly Ser Gly Met Ala Gly Thr Ala Cys Lys

1 5 10 15

Thr Phe Thr Arg Arg

20

(2) INFORMATION FOR SEQ ID NO:214:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 14 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:214:

Lys Ser Ile Ser Phe Ile Gly Arg Ser Arg Ser Ala Ser Tyr

1 5 10

(2) INFORMATION FOR SEQ ID NO:215:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 41 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:215:

Tyr Arg Thr Gly Ser Val Gly Leu Val Arg Pro Thr Val Gly Arg Gln
1 5 10 15

Cys Tyr Val Pro Ser Ser Gly Thr Pro Gly His Gly Tyr Gly Gly Arg
20 25 30

Gly Ser Ala Leu Phe Ala Tyr Ser Ser
35 40

(2) INFORMATION FOR SEQ ID NO:216:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 26 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:216:

Lys Arg Gly Ile Asp Ala Arg Asn Phe Trp Gln Ala Val Tyr Val Asp
1 5 10 15

Tyr Arg Ala Trp Phe Leu Ser Arg Ser Gly
20 25

(2) INFORMATION FOR SEQ ID NO:217:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 8 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:217:

Thr Phe Leu Asn Thr Ile Cys Arg
1 5

(2) INFORMATION FOR SEQ ID NO:218:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 15 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:218:

Ile Phe Thr Phe Ser Ser Phe Gln Arg Val Thr Glu Met Val Thr
1 5 10 15

(2) INFORMATION FOR SEQ ID NO:219:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids

(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:219:

Ile Leu Lys Leu Met Arg
1 5

(2) INFORMATION FOR SEQ ID NO:220:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 11 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:220:

Arg Pro Leu Gln His Leu Pro Leu Ala Arg Leu
1 5 10

(2) INFORMATION FOR SEQ ID NO:221:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:221:

Arg Asn Lys Arg Leu Phe Arg Leu Gln Cys
1 5 10

(2) INFORMATION FOR SEQ ID NO:222:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:222:

Leu Ser Arg Ser Tyr Arg Lys Arg Arg Gly Gln Arg Ser Met Arg Arg
1 5 10 15

Trp Lys Lys

(2) INFORMATION FOR SEQ ID NO:223:

(i) SEQUENCE CHARACTERISTICS:

Figure 1 consists of 12 subplots, labeled (a) through (l), each showing the rate of polymerization (R_p) in mol/L·h on the y-axis against a different parameter on the x-axis. The parameters are: (a) [MMA], (b) [BPO], (c) [C₆H₆], (d) [C₆H₅COOH], (e) [C₆H₅COONa], (f) [C₆H₅COOCH₃], (g) [C₆H₅COOC₂H₅], (h) [C₆H₅COOC₃H₇], (i) [C₆H₅COOC₄H₉], (j) [C₆H₅COOC₆H₁₃], (k) [C₆H₅COOC₈H₁₇], and (l) [C₆H₅COOC₁₂H₂₅]. The y-axis for all plots ranges from 0 to 0.002 mol/L·h. The x-axis scales vary: (a) [MMA] from 0 to 1.0 M; (b) [BPO] from 0 to 0.002 M; (c) [C₆H₆] from 0 to 1.0 M; (d) [C₆H₅COOH] from 0 to 0.002 M; (e) [C₆H₅COONa] from 0 to 0.002 M; (f) [C₆H₅COOCH₃] from 0 to 0.002 M; (g) [C₆H₅COOC₂H₅] from 0 to 0.002 M; (h) [C₆H₅COOC₃H₇] from 0 to 0.002 M; (i) [C₆H₅COOC₄H₉] from 0 to 0.002 M; (j) [C₆H₅COOC₆H₁₃] from 0 to 0.002 M; (k) [C₆H₅COOC₈H₁₇] from 0 to 0.002 M; and (l) [C₆H₅COOC₁₂H₂₅] from 0 to 0.002 M. The plots show that R_p increases with increasing [MMA] and [BPO], and decreases with increasing [C₆H₆]. The effect of the various esters is also shown, with R_p generally decreasing as the ester concentration increases.

Ser Ala Asp Ser Arg Leu Cys Cys Val
20 25

(iii) HYPOTHETICAL: NO

Arg Phe
65

(iii) HYPOTHETICAL: NO

Arg Phe Met Gln Gln Ala Ile Asp Asn Asp Glu Met Pro Leu Ser Gln
20 25 30

Trp Phe Arg Arg Val Ala Asp Trp Pro Asp Arg Cys Glu Arg Val Arg
35 40 45

Ile Leu Leu Arg Ala Val Ala Phe Glu Leu Ser Ile Cys Ile Glu Pro
50 55 60

Ser Glu Gln Ser Arg Leu Ala Ala Ala Leu Val Arg Leu Arg Arg Leu
65 70 75 80

Leu Leu Phe Leu Gly Leu Glu Lys Glu Cys Gln Arg Glu Glu Trp Ile
85 90 95

Cys Gln Leu Pro Pro Asn Thr Leu Leu Pro Leu Leu Leu Asp Ile Ile
100 105 110

Cys Glu Arg Trp Leu Phe Ser Asp Trp Leu Leu Asp Arg Leu Thr Ala
115 120 125

Ile Val Ser Ser Ser Lys Met Phe Asn Arg Leu Leu Gln Gln Leu Asp
130 135 140

Ala Gln Phe Met Leu Ile Pro Asp Asn Cys Phe Asn Asp Glu Asp Gln
145 150 155 160

Arg Glu Gln Ile Leu Glu Thr Leu Arg Glu Val Lys Ile Asn Gln Val
165 170 175

Leu Phe

(2) INFORMATION FOR SEQ ID NO:226:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:226:

Tyr Leu Ala Phe Asn Ile
1 5

(2) INFORMATION FOR SEQ ID NO:227:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 8 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:227:

Val Asn Trp Leu Ser Gly Ser Ser
1 5

(2) INFORMATION FOR SEQ ID NO:228:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 57 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:228:

Gly Val Arg Met Asp Trp Asp Leu Ile Thr Glu Arg Asn Ile Gln Leu
1 5 10 15
Phe Ile Gln Leu Ala Gly Leu Ala Glu Arg Pro Leu Ala Thr Asn Met
20 25 30
Phe Trp Arg Gln Gly Gln Tyr Glu Thr Ile Ile Thr Val Val Phe Ser
35 40 45
Tyr Val Arg Tyr Ser Ser Lys Pro Ser
50 55

(2) INFORMATION FOR SEQ ID NO:229:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 32 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:229:

Thr Lys Asn Cys Phe Leu Lys Arg Trp Leu Thr Gly Asn Pro Gln Arg
1 5 10 15
Ser Arg Val Phe Leu Asn Asp Tyr Phe Cys Cys Ala Met Gly Leu Gln
20 25 30

(2) INFORMATION FOR SEQ ID NO:230:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:230:

Val Val Leu His Leu Phe Pro Ala Pro Pro Ser Ser Gly Tyr Asp Tyr
1 5 10 15
Ile Ile Asp Lys
20

Leu Leu Ser Thr Leu Cys Phe Gln
1 5

(2) INFORMATION FOR SEQ ID NO:235:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 53 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:235:

Leu Leu Phe Ile Leu Val Thr Leu Ser Ile Tyr Arg Tyr Phe Arg Leu
1 5 10 15

Tyr Tyr Leu Leu Leu His Tyr Ile Val Cys His Ser Gln Ser Ala His
20 25 30

His Gly Trp Tyr Cys Tyr Asn Ile Met Pro Val Ile Leu Trp Met Leu
35 40 45

Ser Val Ser Leu Ser
50

(2) INFORMATION FOR SEQ ID NO:236:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 45 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:236:

Glu Glu Ile Ser Pro Leu Gly Trp Ser Tyr Leu Pro Ser Leu Leu Ser
1 5 10 15

Cys Asn Leu Leu Ser Leu Gln Lys Val Ser Arg Gly Trp Arg Lys Leu
20 25 30

Ala His Val Ser Arg Leu Met Gly Cys Gln Ala Asn Lys
35 40 45

(2) INFORMATION FOR SEQ ID NO:237:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 18 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:237:

Val Ser Met Ala Ile Cys Val Pro Glu Leu Ser Met Gln Thr Met Pro
 1 5 10 15

Val His

(2) INFORMATION FOR SEQ ID NO:238:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 17 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:238:

Asp Ser Met Ser Ser Arg Lys Ala Ala Phe Ser Val Arg Trp Thr Val
 1 5 10 15

Arg

(2) INFORMATION FOR SEQ ID NO:239:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 15 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:239:

Asn Leu Leu Lys Ala Ile Arg Leu Pro Val Leu Leu Leu Phe Trp
 1 5 10 15

(2) INFORMATION FOR SEQ ID NO:240:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 16 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:240:

Thr Leu Ser Ala Val Ser Leu Ser Leu Ser Tyr Asn Met Ile Cys Arg
 1 5 10 15

(2) INFORMATION FOR SEQ ID NO:241:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 23 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:241:

Val Arg Leu Phe Thr Leu Ile Ala Tyr Cys Gln Ser Glu Met Val Tyr
1 5 10 15

Val Gly Lys Phe His Arg Cys
20

(2) INFORMATION FOR SEQ ID NO:242:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 23 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:242:

Phe Pro Leu Ala Arg Glu Leu Leu Ser Pro Val Ser Arg Val Arg Asn
1 5 10 15

Ala Arg Thr Trp Arg Gln Ser
20

(2) INFORMATION FOR SEQ ID NO:243:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 12 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:243:

Val Leu Lys Leu Pro Asp Asn Leu Ser Arg Ser Tyr
1 5 10

(2) INFORMATION FOR SEQ ID NO:244:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 4 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:244:

Pro Leu Trp Phe
1

(2) INFORMATION FOR SEQ ID NO:245:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 4 amino acids

(B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 (ii) MOLECULE TYPE: protein
 (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:245:

Cys Ser Ser Leu
 1

(2) INFORMATION FOR SEQ ID NO:246:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 15 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 (ii) MOLECULE TYPE: protein
 (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:246:

Phe Leu Ala Phe Leu Leu Ser Leu Ser Leu Ser Phe Gln Arg Cys
 1 5 10 15

(2) INFORMATION FOR SEQ ID NO:247:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 33 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 (ii) MOLECULE TYPE: protein
 (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:247:

His Cys Gln Leu Ser Ser Phe Ala Ala Lys Ser Leu Trp Phe Pro Gln
 1 5 10 15

Met Ala Ser Lys His Arg Lys Lys Ile Val Trp Phe Pro Ala His Val
 20 25 30

Leu

(2) INFORMATION FOR SEQ ID NO:248:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 12 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 (ii) MOLECULE TYPE: protein
 (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:248:

Ser Tyr Val Leu Ala Arg Arg Tyr Ile Leu Pro Thr
 1 5 10

(2) INFORMATION FOR SEQ ID NO:249:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:249:

Phe Val Ile Leu Thr Pro

1 5

(2) INFORMATION FOR SEQ ID NO:250:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 14 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:250:

Asp Gly Phe Tyr Leu Arg Ile Pro Ala Ser Leu Ser Leu Arg

1 5 10

(2) INFORMATION FOR SEQ ID NO:251:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 11 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:251:

Ile Leu Arg Phe Cys Leu Asn Pro Pro Lys Asn

1 5 10

(2) INFORMATION FOR SEQ ID NO:252:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 21 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:252:

Arg Tyr Cys Tyr Ile Arg Asn Pro Tyr Leu Val Tyr Leu Phe Pro Leu

1 5 10 15

Arg Arg Ile Ile Tyr
20

(2) INFORMATION FOR SEQ ID NO:253:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 48 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:253:

Ala Arg Thr Leu Val Trp Trp Val Thr Ala Arg Arg Tyr Arg Thr Gly
1 5 10 15

Trp Gly Arg Ser Val Gly Leu Gln Lys Thr Trp Pro Ile Arg Arg Lys
20 25 30

Val Leu Asp Trp Thr Phe Ser Arg Ala Ala Asn Val Ser Leu Pro Tyr
35 40 45

(2) INFORMATION FOR SEQ ID NO:254:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 19 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:254:

Asn Val Ser Cys Phe Gly Ile Trp Glu Ser Leu Leu Val Phe Arg Lys
1 5 10 15

Arg Val Ile

(2) INFORMATION FOR SEQ ID NO:255:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:255:

Met Arg Trp Lys Lys Thr Thr Leu Ser Trp
1 5 10

(2) INFORMATION FOR SEQ ID NO:256:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 35 amino acids
 - (B) TYPE: amino acid

(C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 (ii) MOLECULE TYPE: protein
 (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:256:

Lys Ser Phe Ser Ala Ser Tyr Pro Leu Ile Lys Ser Leu Lys Leu Cys
 1 5 10 15
 Asn Gly Leu Tyr Gln Ser Gly Phe Leu Leu Glu Ile Tyr Val Leu Phe
 20 25 30
 Ser Ala Pro
 35

(2) INFORMATION FOR SEQ ID NO:257:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 (ii) MOLECULE TYPE: protein
 (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:257:

Leu Thr Gly Arg His Val Lys Lys Met Ser
 1 5 10

(2) INFORMATION FOR SEQ ID NO:258:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 66 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 (ii) MOLECULE TYPE: protein
 (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:258:

Gln Asn Met Ser Val Ser Arg Phe Val Val Ile Phe Cys Val Val Leu
 1 5 10 15
 Ile Arg Lys Glu Asn Arg Cys Arg Phe Cys Gly Ser Ala Lys Val Leu
 20 25 30
 Lys Thr Ser Cys Val Asn Pro Phe Ala Arg Arg Gln Trp Gly Pro Ile
 35 40 45
 Leu Arg Cys Arg Leu Val Ile Arg Arg Arg Ser Cys Asn Leu Ser Ser
 50 55 60
 Arg Arg
 65

(2) INFORMATION FOR SEQ ID NO:259:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 36 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:259:

Ser Ser Gln Pro Asn Tyr Ser Leu Ser Leu Leu Ser Thr Pro Asp Val
 1 5 10 15
 Ser Cys Glu Lys Leu Gln Lys Pro Pro Cys Ser Thr Tyr Arg Phe Cys
 20 25 30
 His Gly Arg Asn
 35

(2) INFORMATION FOR SEQ ID NO:260:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 8 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:260:

Glu Arg Arg Ala Leu Tyr Lys Trp
 1 5

(2) INFORMATION FOR SEQ ID NO:261:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 109 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:261:

Lys Val Leu Thr Leu Ala Lys Arg Ser Trp Arg Thr Met Lys Asn Glu
 1 5 10 15
 Leu Met Gln Arg Leu Arg Leu Lys Tyr Pro Pro Pro Asp Gly Tyr Cys
 20 25 30
 Arg Trp Gly Arg Ile Gln Asp Val Ser Ala Thr Leu Leu Asn Ala Trp
 35 40 45
 Leu Pro Gly Val Phe Met Gly Glu Leu Cys Cys Ile Lys Pro Gly Glu
 50 55 60
 Glu Leu Ala Glu Val Val Gly Ile Asn Gly Ser Lys Ala Leu Leu Ser

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:264:

Leu Val Asn Val Asp Glu Lys Ser Ala Asn Ser Ser Ile Leu His Cys
1 5 10 15

Leu Lys Arg Pro Glu Asn Val Val Ser Leu Leu Ser Gln Pro Leu Thr
20 25 30

Asp Pro Pro
35

(2) INFORMATION FOR SEQ ID NO:265:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 8 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:265:

Gly Arg Cys Leu Trp Pro Pro Arg
1 5

(2) INFORMATION FOR SEQ ID NO:266:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 17 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:266:

Gln Asn Phe Phe Ala Ile Met Glu Ser Glu Ser Ser Cys Leu Pro Thr
1 5 10 15

His

(2) INFORMATION FOR SEQ ID NO:267:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 33 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:267:

Arg Val Met Pro Gly Pro His Gly Asn Arg Ser Gly Ala Gly Glu Thr
1 5 10 15

Ala Val Ser Gly Glu Tyr Arg Gln Ala Tyr Leu Val His Cys His Asp
20 25 30

Phe

(2) INFORMATION FOR SEQ ID NO:268:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 23 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:268:

Asn Val Arg Glu Trp Glu Lys Lys Ala Val Leu Pro His Phe Ile Arg
1 5 10 15

Tyr Trp Trp Lys Ala Met Ile
20

(2) INFORMATION FOR SEQ ID NO:269:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 120 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:269:

Met Lys Pro Leu Ala Asp Glu Val Arg Ser Leu Leu Asp Gly His Ile
1 5 10 15

Val Leu Ser Arg Arg Leu Ala Glu Arg Gly His Tyr Pro Ala Ile Asp
20 25 30

Val Leu Ala Thr Leu Ser Arg Val Phe Pro Val Val Thr Ser His Glu
35 40 45

His Arg Gln Leu Ala Ala Ile Leu Arg Arg Cys Leu Ala Leu Tyr Gln
50 55 60

Glu Val Glu Leu Leu Ile Arg Ile Gly Glu Tyr Gln Arg Gly Val Asp
65 70 75 80

Thr Asp Thr Asp Lys Ala Ile Asp Thr Tyr Pro Asp Ile Cys Thr Phe
85 90 95

Leu Arg Gln Ser Lys Asp Glu Val Cys Gly Pro Glu Leu Leu Ile Glu
100 105 110

Lys Leu His Gln Ile Leu Thr Glu
115 120

(2) INFORMATION FOR SEQ ID NO:270:

- (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 7 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:270:

Ser Trp Lys Leu Cys Trp Arg
1 5

(2) INFORMATION FOR SEQ ID NO:271:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:271:

Lys Ala Ile Thr Arg Gln Ala Tyr Arg Thr
1 5 10

(2) INFORMATION FOR SEQ ID NO:272:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 41 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:272:

Ser Ala Ala Thr Gly Asp Tyr Tyr Gly Thr Ala Asp Leu Pro Asp Ala
1 5 10 15

Arg Phe Ser Ser Val Tyr Gln Thr Glu Arg Ile Asn Gly Leu Ala Arg
20 25 30

Tyr Val Ile Leu Ser Phe Ile Val Gly
35 40

(2) INFORMATION FOR SEQ ID NO:273:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 21 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:273:

Ala Leu Asn Lys Asn Val Val Phe Thr Gln Arg Tyr Arg Val Ser Gly
50 55 60

Gly Tyr Leu Asp Gly Val Glu Cys Glu Val Cys Glu Ser Gly Gly Leu
65 70 75 80

Ile Gln Leu Arg Ile Asn Val Pro His His Glu Ile Tyr Arg Ser Met
85 90 95

Lys Ala Leu Lys Gln Trp Leu Glu Ser Gln Leu Leu His Met Gly Tyr
100 105 110

Ile Ile Ser Leu Glu Ile Phe Tyr Val Lys Asn Ser Glu
115 120 125

(2) INFORMATION FOR SEQ ID NO:277:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 16 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:277:

Arg Ala Ser Val Gly Gly Asp Thr Ser Asn Ala Arg Arg Tyr His Trp
1 5 10 15

(2) INFORMATION FOR SEQ ID NO:278:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:278:

Ala Asp Ile Glu Tyr Ala Thr Ile Ser Ser Thr Ala Arg Asp Ile Ile
1 5 10 15

Tyr His Lys Leu Ser
20

(2) INFORMATION FOR SEQ ID NO:279:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 12 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:279:

Gly Val Asp Cys Arg Thr Met Leu Ala Ala Leu Val
1 5 10

(2) INFORMATION FOR SEQ ID NO:280:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:280:

Arg Ala Asn Trp His Arg
1 5

(2) INFORMATION FOR SEQ ID NO:281:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:281:

Ser Ile Gly Tyr Arg Ser
1 5

(2) INFORMATION FOR SEQ ID NO:282:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:282:

Ile Ala Ile Trp Asn Ser
1 5

(2) INFORMATION FOR SEQ ID NO:283:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:283:

Met Gly Ala Gly Ala Val Ile Ala Ser Gln
103

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 7 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:291:

Arg Asn Val Phe Ser Arg Thr
1 5

- (2) INFORMATION FOR SEQ ID NO:292:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 8 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: protein
 - (iii) HYPOTHETICAL: NO
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:292:

Ala Asp Thr Thr Thr Gly Ala Leu
1 5

- (2) INFORMATION FOR SEQ ID NO:293:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 14 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: protein
 - (iii) HYPOTHETICAL: NO
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:293:

Gly Arg Thr Cys Glu Ser Gly Asn Trp Thr Ile Thr Thr Thr
1 5 10

- (2) INFORMATION FOR SEQ ID NO:294:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 20 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: protein
 - (iii) HYPOTHETICAL: NO
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:294:

Asn Gly Gly Arg Phe Ala Cys Arg Trp Met Phe Cys Ala Arg Gly Asp
1 5 10 15

Asp Lys Ser Lys
20

(2) INFORMATION FOR SEQ ID NO:295:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 6 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:295:

Pro Tyr Tyr Trp Ala Arg

1 5

(2) INFORMATION FOR SEQ ID NO:296:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 6 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:296:

Val Asp Cys Leu Trp Gln

1 5

(2) INFORMATION FOR SEQ ID NO:297:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 48 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:297:

Ile Tyr Gly Ala Tyr Tyr Thr Leu Val Ser Leu Gln Lys Tyr Ser Val
1 5 10 15

Asn Leu Ile Arg Lys Ile Ile Cys Glu Gln Tyr Asn Ser Val Pro Gly
20 25 30

Arg Val Met Arg Asp Thr Val Cys Leu Tyr Pro Ile Arg Leu Cys Asn
35 40 45

(2) INFORMATION FOR SEQ ID NO:298:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 61 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:298:

Leu Val Tyr Cys Phe Cys Phe Gln Tyr Cys Leu Ser Leu Ser Ser Trp
1 5 10 15
Glu Leu Leu Ser Leu Asn Trp Arg Trp Tyr Phe Arg Phe Tyr Glu Met
20 25 30
Leu Trp Val Phe Asn Lys Ser Pro Gln Ile Ser His Cys Met Ala Leu
35 40 45
Arg Leu Tyr Phe Pro Tyr Ser Leu Trp Gly Arg Arg Tyr
50 55 60

(2) INFORMATION FOR SEQ ID NO:299:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 23 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:299:

Lys Ser Ala Gly Ile Arg Phe Arg Ser Leu Ala Leu Leu Ser Gly Arg
1 5 10 15
Leu Ser Gly Thr Val Lys His
20

(2) INFORMATION FOR SEQ ID NO:300:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 21 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:300:

Arg Leu Ile Asp Ser Phe Cys Lys Lys Thr Leu Lys Arg Arg Lys Pro
1 5 10 15
Ile Ile Phe Gly Ile
20

(2) INFORMATION FOR SEQ ID NO:301:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 7 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:301:

Asn Glu Pro Gly Leu Lys Thr
1 5

(2) INFORMATION FOR SEQ ID NO:302:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 7 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:302:

Asn Leu Ile Leu Cys Ser Tyr
1 5

(2) INFORMATION FOR SEQ ID NO:303:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 5 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:303:

Phe Arg His Leu Arg
1 5

(2) INFORMATION FOR SEQ ID NO:304:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 29 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:304:

Arg Arg His Phe Gly Leu Asp Tyr Leu Phe Ile Phe Pro Phe Trp Leu
1 5 10 15

Leu Thr Cys Leu Phe Gln Ile Tyr Cys Trp Leu Trp Gly
20 25

(2) INFORMATION FOR SEQ ID NO:305:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 4 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein
(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:305:

Trp Cys Arg Arg
1

(2) INFORMATION FOR SEQ ID NO:306:
(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 8 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:306:

Pro Phe His Tyr Arg Leu Ser Cys
1 5

(2) INFORMATION FOR SEQ ID NO:307:
(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 9 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:307:

Tyr Phe Tyr Trp Gln Ala Val Gly Ile
1 5

(2) INFORMATION FOR SEQ ID NO:308:
(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 11 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:308:

His Trp Arg Asn Trp Tyr Arg Ala Phe His Glu
1 5 10

(2) INFORMATION FOR SEQ ID NO:309:
(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 48 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:309:

Ile Asp Ala Ile Cys Asn Ala Thr Phe Met Asp Arg Pro Phe Tyr Val
1 5 10 15
Tyr Ala Gly Ser Val Gly Gly Ile Gly Ser Trp Cys His Arg Lys Pro
20 25 30
Cys Ser Gly Leu Asp Ser Asn Thr Gly Pro Asn Ala Thr Val His Asp
35 40 45

(2) INFORMATION FOR SEQ ID NO:310:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 15 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:310:

Ile Ile Gly Asn Cys Asn Asn Leu Asn Gly Gln Leu Pro Met Ala
1 5 10 15

(2) INFORMATION FOR SEQ ID NO:311:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 25 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:311:

Arg Tyr Pro Val Glu Leu Tyr Pro Ala Asp Asn Val Thr Asn Trp Arg
1 5 10 15

Ala Trp Leu Asn Gly Thr Thr Gly Lys
20 25

(2) INFORMATION FOR SEQ ID NO:312:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 33 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:312:

Val Ala Tyr Cys Ile Gly Cys Gly Phe Tyr Ser Thr Ile Glu Pro Phe
1 5 10 15

Phe Ile Thr Ser Leu Ile Lys Lys Trp Gln Phe Arg Gly Arg Thr Phe
 20 25 30

Thr

(2) INFORMATION FOR SEQ ID NO:313:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 24 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:313:

Trp Arg Ala Tyr Val Thr Tyr Leu Ser Asp Ile Thr Asn His Leu Pro
 1 5 10 15

Ala Glu Asp Tyr Asp Ala Tyr Trp
 20

(2) INFORMATION FOR SEQ ID NO:314:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 29 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:314:

Arg Leu Gln Leu Val Arg Val Ser His Trp Arg Gly Asp Tyr Trp Phe
 1 5 10 15

Phe Asn Trp Val Leu Cys Gly Gly Ser Leu Leu Gly Arg
 20 25

(2) INFORMATION FOR SEQ ID NO:315:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:315:

Tyr Gly Gly Val Ser Ala
 1 5

(2) INFORMATION FOR SEQ ID NO:316:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 17 amino acids

- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:316:

Tyr Phe Thr Trp Arg Asp Asn Gly Tyr Asp Ile Gln Phe Tyr Asn Arg
 1 5 10 15

Ser

- (2) INFORMATION FOR SEQ ID NO:317:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 30 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: protein
 - (iii) HYPOTHETICAL: NO
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:317:

Asn Leu Thr Phe Trp Leu Ala Phe Gln Pro Val Leu Val Cys Tyr Phe
 1 5 10 15

Leu Tyr Lys Arg Arg His Gly Val Tyr Ile Lys His Ser Val
 20 25 30

- (2) INFORMATION FOR SEQ ID NO:318:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 13 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: protein
 - (iii) HYPOTHETICAL: NO
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:318:

Val Ile Ser Ile Phe Thr Thr Arg Ala Tyr Phe Ile Ile
 1 5 10

- (2) INFORMATION FOR SEQ ID NO:319:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 93 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: protein
 - (iii) HYPOTHETICAL: NO
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:319:

Pro Ala Ile Phe Lys Ile Tyr Pro Gly Arg Val Glu Asn Ala Leu Ser
 1 5 10 15
 113

Ile Met Tyr Gln Leu Leu Ser Ser Cys His Asn Met Tyr Gly Ile Ser
20 25 30

Arg Ser Gly Phe Arg Ser Phe Lys Ser Val Gly Thr Thr Ile Glu Cys
35 40 45

Val Phe Leu Leu Asn Ala Ala Gln Lys Tyr Ile Gly Ser Thr Asp Xaa
50 55 60

Leu Ile Ser Phe Pro Tyr Ala Leu His His Tyr Leu Val Glu Ser Asp
65 70 75 80

Lys Phe Tyr Ile Tyr Leu Lys Asp Trp Phe Pro Ser Val
85 90

(2) INFORMATION FOR SEQ ID NO:320:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 26 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:320:

Ala Arg Lys Gln Asn Ser Leu Gln Lys Arg Asn Tyr Val Met Ala Val
1 5 10 15

Arg Lys Gly Arg Leu Ser Lys Val Leu Lys
20 25

(2) INFORMATION FOR SEQ ID NO:321:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 5 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:321:

His His Tyr Phe Ser
1 5

(2) INFORMATION FOR SEQ ID NO:322:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 13 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:322:

Leu Arg Phe Ile Cys Ile Phe Ile Ser Leu Leu Lys Arg
 1 5 10

- (2) INFORMATION FOR SEQ ID NO:323:
- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 5 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: protein
 - (iii) HYPOTHETICAL: NO
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:323:

Leu Ser His Tyr Asn
 1 5

- (2) INFORMATION FOR SEQ ID NO:324:
- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 7 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: protein
 - (iii) HYPOTHETICAL: NO
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:324:

Ile Asn His Phe Leu Met His
 1 5

- (2) INFORMATION FOR SEQ ID NO:325:
- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: protein
 - (iii) HYPOTHETICAL: NO
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:325:

Leu Leu His Cys Cys Phe Trp Ala Leu Gly
 1 5 10

- (2) INFORMATION FOR SEQ ID NO:326:
- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 26 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: protein
 - (iii) HYPOTHETICAL: NO
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:326:

Leu Leu Leu Trp Val Ala Cys Phe Phe Arg Trp Gly Trp Leu Leu Pro
 1 5 10 15

Ala Arg Pro Leu Val Leu Lys Ala Ser Ile
 20 25

(2) INFORMATION FOR SEQ ID NO:327:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 11 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:327:

Val Ile Leu Ser Arg Tyr Ser Leu Tyr Ile Ala
 1 5 10

(2) INFORMATION FOR SEQ ID NO:328:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:328:

Asn Tyr Val Asn Pro Ala
 1 5

(2) INFORMATION FOR SEQ ID NO:329:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 27 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:329:

Lys Leu Ser Cys Tyr Leu Leu Ser Leu Pro Phe Ser Phe Ile Ile Met
 1 5 10 15

Pro Val Leu Phe Gly Arg Tyr Arg Thr Val Gly
 20 25

(2) INFORMATION FOR SEQ ID NO:330:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 9 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein
(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:330:

Pro Val Ala Cys Leu Trp Phe Leu Leu
1 5

(2) INFORMATION FOR SEQ ID NO:331:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 4 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:331:

Asn Gly Tyr Gly
1

(2) INFORMATION FOR SEQ ID NO:332:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:332:

Trp Phe Phe Ile Ser Ser Leu Ala Tyr Trp Thr Ile Leu Phe Asn Ile
1 5 10 15

Ile Arg Leu Glu Lys Leu Ser Lys Asn Glu
20 25

(2) INFORMATION FOR SEQ ID NO:333:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 5 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:333:

Arg Lys Thr Gly Ala
1 5

(2) INFORMATION FOR SEQ ID NO:334:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 127 amino acids
(B) TYPE: amino acid

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Arg | Ser | Gly | Gly | Arg | Pro | Ser | Asn | Glu | Asp | Ala | Ala | Ser | Glu | Met | Gln |
| 1 | | | | 5 | | | | | 10 | | | | | 15 | |
| Ser | Glu | Ile | Gln | Ser | Gly | Ser | Leu | Ala | Gln | Ser | Val | Lys | Gln | Ser | Val |
| | | | 20 | | | | | 25 | | | | | 30 | | |
| Ala | Val | Val | Arg | Asn | Pro | Thr | His | Ile | Ala | Val | Cys | Leu | Gly | Tyr | His |
| | | 35 | | | | | 40 | | | | | 45 | | | |
| Pro | Thr | Asp | Met | Pro | Ile | Pro | Arg | Val | Leu | Glu | Lys | Gly | Ser | Asp | Ala |
| | 50 | | | | | 55 | | | | | 60 | | | | |
| Gln | Ala | Asn | Tyr | Ile | Val | Asn | Ile | Ala | Glu | Arg | Asn | Cys | Ile | Pro | Val |
| 65 | | | | | 70 | | | | | 75 | | | | | 80 |
| Val | Glu | Asn | Val | Glu | Leu | Ala | Arg | Ser | Leu | Phe | Phe | Glu | Val | Glu | Arg |
| | | | | 85 | | | | | 90 | | | | | 95 | |
| Gly | Asp | Lys | Ile | Pro | Glu | Thr | Leu | Phe | Glu | Pro | Val | Ala | Ala | Leu | Leu |
| | | | 100 | | | | | 105 | | | | | 110 | | |
| Arg | Met | Val | Met | Lys | Ile | Asp | Tyr | Ala | His | Ser | Thr | Glu | Thr | Pro | |
| | | 115 | | | | 120 | | | | | | 125 | | | |

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 15 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

Met Leu Leu Val Cys Phe Phe Arg Pro Leu Arg Arg Leu Arg Gly
1 5 10 15

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 12 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

Arg Ile Glu Gln Cys Leu Thr Ile Lys Val Arg Asp
118

1 5 10

(2) INFORMATION FOR SEQ ID NO:337:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 39 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:337:

Ser Leu Leu Ala Trp His Lys His Gln Ile Ala Tyr Tyr Lys Ile Lys
1 5 10 15

Gln Asp Asn Gly Leu Val Arg Leu Asn Gly Leu Glu Pro Leu Asp Pro
20 25 30

His His Val Lys Val Val Leu
35

(2) INFORMATION FOR SEQ ID NO:338:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 4 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:338:

Pro Thr Glu Leu
1

(2) INFORMATION FOR SEQ ID NO:339:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 4 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:339:

Thr Ala Thr Leu
1

(2) INFORMATION FOR SEQ ID NO:340:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 26 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:340:

Val Thr Thr Gly Thr Asn Ile Ser Val Thr Thr Ala Met Arg Gln Glu
1 5 10 15
Gly Asn Arg Asn Phe Leu Pro Glu Ile Thr
20 25

(2) INFORMATION FOR SEQ ID NO:341:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 27 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:341:

Leu Arg Trp Lys Tyr Ala Thr Cys Arg Glu Asn Ser Arg His Ala Thr
1 5 10 15
Ala Ile Val Val Leu Ser Glu Arg Ala Ala Lys
20 25

(2) INFORMATION FOR SEQ ID NO:342:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 23 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:342:

Trp Arg Thr Ala Asp Val Val Asp Ser Ala Ser Val Ala Ser Leu Thr
1 5 10 15
Pro Pro Pro Arg Ser Gly Arg
20

(2) INFORMATION FOR SEQ ID NO:343:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 32 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:343:

Thr Pro Ser Arg Ser Leu Pro Val Pro Tyr Asp Pro Pro Pro Asn Pro
1 5 10 15
120

Leu Thr Pro Gly Tyr Asn Arg Trp Val Asn Leu Thr Pro Ser Arg Arg
 20 25 30

(2) INFORMATION FOR SEQ ID NO:344:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 16 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:344:

Lys Arg Trp Asn Ala Tyr Leu Tyr Asn Arg Ala Glu Tyr Arg Cys Arg
 1 5 10 15

(2) INFORMATION FOR SEQ ID NO:345:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 24 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:345:

Ser Arg Lys Ser Gly Lys Pro Gln Arg Ala Ala Leu Ile Ala Ala Ser
 1 5 10 15

Ala Thr Thr Ser Gly Leu Ser Leu
 20

(2) INFORMATION FOR SEQ ID NO:346:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 42 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:346:

Ser Lys Ala Ile Cys Leu Arg Arg Val Thr Val Lys Ile Ala Val Thr
 1 5 10 15

Thr Ala Ile Gln Met Pro Thr Pro Lys Pro Val Arg Ala Ala Phe Ala
 20 25 30

His Pro Ala Leu Ser Pro Gly Pro Asp Arg
 35 40

(2) INFORMATION FOR SEQ ID NO:347:

- (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 25 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 (ii) MOLECULE TYPE: protein
 (iii) HYPOTHETICAL: NO
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:347:

Pro Thr Arg Ile Val Thr Ala Ala Ala Ser Asp Ile Gly Ser Thr Asn
 1 5 10 15

Ile Ser Glu Leu Lys Leu Ser Ala Ile
 20 25

(2) INFORMATION FOR SEQ ID NO:348:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 55 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 (ii) MOLECULE TYPE: protein
 (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:348:

Pro Ala Thr Ser Thr Ile Pro Asn Gly Glu Thr Ser Ser Ala Thr Thr
 1 5 10 15

Ala Asn Asn Val Thr Ser Lys Asn Ser Gln Arg Asn Arg Gln Pro Gln
 20 25 30

Leu Asn Gln Ala Leu His Asp Asp Ala Ile Gly Phe Ala Lys Ala Phe
 35 40 45

Phe Ile Thr Asn Ile Thr His
 50 55

(2) INFORMATION FOR SEQ ID NO:349:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 151 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 (ii) MOLECULE TYPE: protein
 (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:349:

Thr Arg Val Phe Asn Val Arg Lys His Gly Asp Lys His His Pro Ile
 1 5 10 15

Asp Arg Arg Ser Arg Asn Ala Ala Ala Asp Thr Ala Glu Phe Arg His
 20 25 30

Thr Lys Met Ala Ile Asp Lys Asn Ile Val His Arg Asn Ile His Gln
 35 40 45

0091T"2004T250

Gln Ala Gln Lys Ser His His His Thr Arg Phe Gly Phe Gly Gln Thr
50 55 60

Phe Ala Leu Val Ser Arg Tyr Leu Lys Glu Lys Val Ser Cys Ala Pro
65 70 75 80

Gln Gln Arg Ala Lys Ile Thr His Gly Phe Ile Gly Gln Arg Arg Ile
85 90 95

Asn Ile Met His Arg Ala Asp Asn Val Ser Gly Ile Pro Gln Asp Asp
100 105 110

His His Gln His Gly Asp Lys Ala Arg Gln Pro Glu Pro Leu Ser Asn
115 120 125

Leu Met Arg Asp Thr Leu Thr Thr Ala Gly Ala Ile Glu Leu Arg Asn
130 135 140

His Arg Arg Gln Gly Gln Gln
145 150

(2) INFORMATION FOR SEQ ID NO:350:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 24 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:350:

Ala Val Thr Lys Gln Asn Gly Gly Lys Gln Ile Glu Val Pro Ile Ala
1 5 10 15

Thr Ala Ala Met Ser Val Ala Leu
20

(2) INFORMATION FOR SEQ ID NO:351:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 25 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:351:

Pro Pro Ala Met Thr Val Ser Thr Asn Pro Leu Arg Ser Ile Pro Leu
1 5 10 15

Ala Gln Gly Ser Pro Val Ser Glu Arg
20 25

(2) INFORMATION FOR SEQ ID NO:352:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 19 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 (ii) MOLECULE TYPE: protein
 (iii) HYPOTHETICAL: NO
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:352:

Leu Thr Arg Phe Thr Gly Ile Leu Leu His Val Phe Thr Phe Tyr Phe
1 5 10 15

Val Val Ile

(2) INFORMATION FOR SEQ ID NO:353:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 29 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:353:

Lys Thr Lys Lys Pro Pro Lys Trp Gln Pro Lys Glu Ile Ala Gly Glu
1 5 10 15

Ile Ser Val Tyr Cys Ser Gly Val Leu Leu Phe Leu Gln
20 25

(2) INFORMATION FOR SEO ID NO:354:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 4 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 (ii) MOLECULE TYPE: protein
 (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:354:

Lys Asn Ser Cys
1

(2) INFORMATION FOR SEQ ID NO:355:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 14 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:355:

Arg Arg Ile Ala Gly Lys Leu Phe Phe His Leu Leu Leu Cys
 1 5 10

(2) INFORMATION FOR SEQ ID NO:356:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 27 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:356:

Thr Val Leu Leu Leu Phe Ile Ser Gly Val Glu Asp Met Phe Thr Gly
 1 5 10 15

Ile Val Gln Gly Thr Ala Lys Leu Val Ser Ile
 20 25

(2) INFORMATION FOR SEQ ID NO:357:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 60 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:357:

Ala Glu Pro Ser Gln Glu Gln Ile Asn Phe Phe Glu Gln Leu Leu Lys
 1 5 10 15

Asp Glu Ala Ser Thr Ser Asn Ala Ser Ala Leu Leu Pro Gln Val Met
 20 25 30

Leu Thr Arg Gln Met Asp Tyr Met Gln Leu Thr Val Gly Val Asp Tyr
 35 40 45

Leu Ala Arg Ile Ser Arg Arg Ser Met Pro Ser Ala
 50 55 60

(2) INFORMATION FOR SEQ ID NO:358:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 56 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:358:

His Gly Met Lys Val His Arg Ile Val Phe Leu Thr Val Leu Thr Phe
 1 5 10 15
 125

CCSF1"20041150

(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:362:

Trp Tyr His Pro Arg Lys Asn Arg Gln Lys Ile Asn Phe Leu Lys Glu
1 5 10 15
Gln Arg Ile Glu Gly Met Leu Ser Gln Met Glu Gly Arg Asp
20 25 30

(2) INFORMATION FOR SEQ ID NO:363:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:363:

Pro Leu Arg Tyr Arg Leu Met Met Arg Glu Val Thr Leu Leu Arg Ala
1 5 10 15
Gln Leu Pro Tyr Leu
20

(2) INFORMATION FOR SEQ ID NO:364:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 12 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:364:

Asn Ile His Leu Arg Ser Ile Trp Arg Pro Phe Gly
1 5 10

(2) INFORMATION FOR SEQ ID NO:365:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 4 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:365:

Lys Leu Lys Ile
1

(2) INFORMATION FOR SEQ ID NO:366:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 14 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:366:

Arg Cys Gln Ser Leu Gly Cys Asn Thr Val Arg Leu Val Ser
1 5 10

(2) INFORMATION FOR SEQ ID NO:367:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 8 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:367:

Cys Ser Leu Leu Asn Ser Glu Trp
1 5

(2) INFORMATION FOR SEQ ID NO:368:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 22 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:368:

Leu Thr Tyr Pro Arg Asp Lys His Ser Gly Leu Trp Thr Leu Ser Thr
1 5 10 15

Pro Ile Lys Gly Arg Trp
20

(2) INFORMATION FOR SEQ ID NO:369:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 5 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:369:

Asn Thr Leu Ile Arg

1

5

(2) INFORMATION FOR SEQ ID NO:370:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 4 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:370:

Gln Asp Cys Tyr

1

(2) INFORMATION FOR SEQ ID NO:371:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 4 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:371:

Glu Trp Ala Ser

1

(2) INFORMATION FOR SEQ ID NO:372:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 5 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:372:

Ser Ala Ile Phe Ala

1

5

(2) INFORMATION FOR SEQ ID NO:373:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 7 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:373:

Asp Ala Val Phe Glu Pro Thr

1

5

(2) INFORMATION FOR SEQ ID NO:374:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 23 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:374:

Ser Arg Gly Val Ala Thr Leu Ser Leu Phe Leu Ala Thr Cys Ser Leu
1 5 10 15

Arg Cys Thr Gly Met Ala Gly
20

(2) INFORMATION FOR SEQ ID NO:375:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 384 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:375:

Ala Gly Leu Ser Ser Ser Asn Cys Trp Arg Tyr Gly Asp Arg Pro Glu
1 5 10 15

Leu Asp Arg Leu Leu Asp Arg Ala Leu Asn Arg Leu Arg Gly Ser Ser
20 25 30

Val Ile Pro Ala Cys Leu Asn Asp Arg Gln Lys Arg Gln Val Arg Leu
35 40 45

Ala Pro Arg Ile Ser Ala Phe Ala Phe Gly Leu Gly Leu Phe Lys Leu
50 55 60

Arg Cys Ser Asp Tyr Phe Met Leu Pro Glu Tyr Arg Gln Leu Leu Leu
65 70 75 80

Gln Trp Phe Ser Glu Asp Glu Ile Trp Gln Leu Tyr Gly Trp Leu Gly
85 90 95

Gln Arg Asp Gly Lys Leu Leu Pro Pro Gln Val Met Gln Gln Thr Ala
100 105 110

Leu Gln Ile Gly Thr Ala Ile Leu Asn Arg Glu Ala His Asp Asp Ala
115 120 125

Gly Phe Thr Cys Ala Ile Ser Ile Ile Thr Pro Ser Ala Ala Tyr Thr
130 135 140

Leu Ala Glu Asp Phe Ser Tyr Arg Asp Tyr Leu His Gly Ala Phe Ala
130

| | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|--|
| 145 | | | | | 150 | | | | | 155 | | | | | 160 | |
| Met | Ser | Phe | Thr | Ser | Leu | Pro | Leu | Thr | Glu | Ile | Asn | His | Lys | Leu | Pro | |
| | | | | 165 | | | | | 170 | | | | | 175 | | |
| Ala | Arg | Asn | Ile | Ile | Glu | Ser | Gln | Trp | Ile | Thr | Leu | Gln | Leu | Thr | Leu | |
| | | | | 180 | | | | | 185 | | | | | 190 | | |
| Phe | Ala | Gln | Glu | Gln | Gln | Ala | Lys | Arg | Val | Ser | His | Ala | Ile | Val | Ser | |
| | | | | 195 | | | | | 200 | | | | | 205 | | |
| Ser | Ala | Tyr | Arg | Lys | Ala | Glu | Lys | Ile | Ile | Arg | Asp | Ala | Tyr | Arg | Tyr | |
| | | | | 210 | | | | | 215 | | | | | 220 | | |
| Gln | Arg | Glu | Gln | Lys | Val | Glu | Gln | Gln | Gln | Glu | Leu | Ala | Cys | Leu | Arg | |
| 225 | | | | | 230 | | | | | 235 | | | | | 240 | |
| Lys | Asn | Thr | Leu | Glu | Lys | Met | Glu | Val | Glu | Trp | Leu | Glu | Gln | His | Val | |
| | | | | 245 | | | | | 250 | | | | | 255 | | |
| Lys | His | Leu | Gln | Asp | Asp | Glu | Asn | Gln | Phe | Arg | Ser | Leu | Val | Asp | His | |
| | | | | 260 | | | | | 265 | | | | | 270 | | |
| Ala | Ala | His | His | Ile | Lys | Asn | Ser | Ile | Glu | Gln | Val | Leu | Leu | Ala | Trp | |
| | | | | 275 | | | | | 280 | | | | | 285 | | |
| Phe | Asp | Gln | Gln | Ser | Val | Asp | Ser | Val | Met | Cys | His | Arg | Leu | Ala | Arg | |
| | | | | 290 | | | | | 295 | | | | | 300 | | |
| Gln | Ala | Thr | Ala | Met | Ala | Glu | Glu | Gly | Ala | Leu | Tyr | Leu | Arg | Ile | His | |
| 305 | | | | | 310 | | | | | 315 | | | | | 320 | |
| Pro | Glu | Lys | Glu | Ala | Leu | Met | Arg | Glu | Thr | Phe | Gly | Lys | Arg | Phe | Thr | |
| | | | | 325 | | | | | 330 | | | | | 335 | | |
| Leu | Ile | Ile | Glu | Pro | Gly | Phe | Ser | Pro | Asp | Gln | Ala | Glu | Leu | Ser | Ser | |
| | | | | 340 | | | | | 345 | | | | | 350 | | |
| Thr | Arg | Tyr | Ala | Val | Glu | Phe | Ser | Leu | Ser | Arg | His | Phe | Asn | Ala | Leu | |
| | | | | 355 | | | | | 360 | | | | | 365 | | |
| Leu | Lys | Trp | Leu | Arg | Asn | Gly | Glu | Asp | Lys | Arg | Gly | Ser | Asp | Glu | Tyr | |
| | | | | 370 | | | | | 375 | | | | | 380 | | |

(2) INFORMATION FOR SEQ ID NO:376:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:376:

Gly Thr Arg Gly Tyr Phe Ala Phe Asn Val Ser Ser Pro Gly Val Thr
 20 25 30

Gly Asn Asp Gly Gly Ser Ala Leu
 35 40

(2) INFORMATION FOR SEQ ID NO:377:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 11 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:377:

Asp Asp Gly Arg Asn Arg Asn Gly Ala Glu Trp
 1 5 10

(2) INFORMATION FOR SEQ ID NO:378:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 5 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:378:

Thr Ala Arg Lys Leu
 1 5

(2) INFORMATION FOR SEQ ID NO:379:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 19 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:379:

Glu Thr Gly Ala Gln Thr Ala Gly Phe Ala Ala Phe Asp Lys Thr Asn
 1 5 10 15

Thr Gly Gly

(2) INFORMATION FOR SEQ ID NO:380:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 11 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein
(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:380:

Trp Gly Asn Val Ala Ser Ala Tyr Arg Arg Glu
1 5 10

(2) INFORMATION FOR SEQ ID NO:381:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 60 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:381:

Phe Thr Glu Cys Val Ser Asn Tyr Arg Ser Cys Asn Gly Ala Tyr Cys
1 5 10 15

Arg Arg Val Val Lys Lys Glu Lys Thr Arg Phe Ala Ile Ala Thr Gly
20 25 30

Tyr Val Thr Ala Glu Glu Gly Trp Glu Leu Ala Val Phe Ser Leu Leu
35 40 45

Glu Leu Gly Glu Val Asp Thr Val Arg Cys Pro Leu
50 55 60

(2) INFORMATION FOR SEQ ID NO:382:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 7 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:382:

Ser Val Leu Cys Asn Arg Arg
1 5

(2) INFORMATION FOR SEQ ID NO:383:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:383:

Thr Thr Met Lys Cys Pro Tyr Arg Ser Gly Ser Asp Ala Trp Gln Thr
133

Ser Leu Cys

(2) INFORMATION FOR SEQ ID NO:387:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 21 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:387:

Tyr Pro Ile Thr Val Leu Thr Thr Lys Ile Asn Val Asn Lys Phe Ser
1 5 10 15
Lys Arg Phe Val Lys
20

(2) INFORMATION FOR SEQ ID NO:388:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 13 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:388:

Ile Arg Phe Tyr Ser Asp Thr Trp Leu Ser Ile Phe Arg
1 5 10

(2) INFORMATION FOR SEQ ID NO:389:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 27 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:389:

Ile Gly Phe Leu Ala His His Glu Ala Ser Gly Trp Ile Gly Ile Ser
1 5 10 15

Leu Leu Asn Val Ile Phe Ser Phe Leu Phe Asn
20 25

(2) INFORMATION FOR SEQ ID NO:390:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 4 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein
(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:390:

Leu Asn Gly Leu

1

(2) INFORMATION FOR SEQ ID NO:391:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 14 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:391:

Gln Pro Ile Cys Ser Gly Gly Lys Asp Asn Met Lys Leu Ser

1

5

10

(2) INFORMATION FOR SEQ ID NO:392:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 20 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:392:

Arg Ser Tyr Ser Leu Met Ser Asp Thr Gln Ala Asn Leu Leu Arg Arg

1

5

10

15

Arg Thr Ala Phe

20

(2) INFORMATION FOR SEQ ID NO:393:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 55 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:393:

Leu Glu Thr Arg Ser Val Pro Gly Tyr Ser Ser Thr Ile Ile Phe Val

1

5

10

15

Ala Arg Trp Ala Cys Asn Glu Leu Phe Ser Thr Ser Phe Gln Leu Arg

20

25

30

Arg Ala Leu Val Thr Ile Thr Ser Ser Thr Asn Lys Ile Xaa Trp Ser

136

0974504.1 "2024/07/26"

45

(2) INFORMATION FOR SEO ID NO:394:

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:394:

Thr Leu Ala Asp Leu Asp Gly
35

(2) INFORMATION FOR SEQ ID NO:395:

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:395:

Cys Tyr Leu Ser
20

(2) INFORMATION FOR SEQ ID NO:396:

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:396:

Ile Ser Phe Val Thr His Asn Gln His Ile Thr Ala Gly Thr Val Thr
137

Thr

(2) INFORMATION FOR SEQ ID NO:397:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:397:

Tyr Cys Gly Cys Phe Arg
1 5

(2) INFORMATION FOR SEQ ID NO:398:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 35 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:398:

Val Cys Arg Arg Arg Lys Ser His Arg Trp Val Gly Arg Ile Tyr His
1 5 10 15

His Tyr Tyr Arg Ala Ile Tyr Cys His Tyr Lys Arg Tyr Arg Glu Gly
20 25 30

Gly Gly Ser
35

(2) INFORMATION FOR SEQ ID NO:399:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 5 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:399:

Arg Thr Phe Leu Ala
1 5

(2) INFORMATION FOR SEQ ID NO:400:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 47 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single

(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:400:

Trp Asp Ala Arg Gln Thr Asn Glu Tyr Arg Trp Arg Phe Ala Cys Arg
1 5 10 15
Ser Tyr Arg Cys Arg Pro Cys Pro Tyr Ile Lys Thr Ala Cys Pro Ala
20 25 30
Gly Lys Pro Leu Ser Arg Cys Asp Gly Arg Cys Asp Glu Ile Cys
35 40 45

(2) INFORMATION FOR SEQ ID NO:401:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:401:

Arg Arg Tyr Asp Cys Arg Tyr Tyr Cys Cys Ser Gly Glu His Tyr Arg
1 5 10 15
Arg Tyr His Tyr Arg Tyr Arg Thr Ile
20 25

(2) INFORMATION FOR SEQ ID NO:402:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 4 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:402:

Tyr Val Asp Glu
1

(2) INFORMATION FOR SEQ ID NO:403:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 5 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:403:

Gly Cys Ser His Leu
1 5

(2) INFORMATION FOR SEQ ID NO:404:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:404:

Arg Thr Val Asn Arg Arg Trp Phe Met Trp Ala Asn Ser Ile Ala Ala
1 5 10 15

Asp Phe Pro

(2) INFORMATION FOR SEQ ID NO:405:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:405:

Arg Gly Asn Tyr Cys His Pro Cys Pro Gly
1 5 10

(2) INFORMATION FOR SEQ ID NO:406:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 73 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:406:

Glu Thr Pro Glu Pro Gly Asp Arg Val Glu Phe Ser Asn Cys Gln Thr
1 5 10 15

Thr Ser Val Ala His Ile Asn Arg Cys Gly Phe Asn Ala Pro Arg Phe
20 25 30

Asn Ser Trp Leu Ser Phe Tyr His Ser Arg Phe Leu Phe Ser Val Val
35 40 45

Ser Ile Ala Asn Tyr Pro His Ser Pro Gln Lys Val Cys Gly Phe Arg
50 55 60

Lys Trp Arg Arg Ser Thr Gly Lys Arg

65

70

(2) INFORMATION FOR SEQ ID NO:407:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 12 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:407:

Tyr Gly Ser Arg Arg Met Ser Ser Asn Leu Thr Ser
 1 5 10

(2) INFORMATION FOR SEQ ID NO:408:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:408:

Pro Asp Val Thr Phe Cys Arg Pro Asp Ser
 1 5 10

(2) INFORMATION FOR SEQ ID NO:409:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 7 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:409:

Arg His Glu Met Val Phe Ile
 1 5

(2) INFORMATION FOR SEQ ID NO:410:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 7 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:410:

Gly Tyr Arg Arg Pro Ser Pro
 1 5

(2) INFORMATION FOR SEQ ID NO:411:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 15 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:411:

Thr His Arg Lys Ile Asp Gly Thr Ala Ile Ser Gly Thr Arg Ile
1 5 10 15

(2) INFORMATION FOR SEQ ID NO:412:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 16 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:412:

Phe Ile Tyr Ser Arg Ser Gly Gly Leu Phe Ile Asp Arg Arg Gly Arg
1 5 10 15

(2) INFORMATION FOR SEQ ID NO:413:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:413:

Gln Pro Asp Val Thr Glu Arg Asp Gly Ala Asp Leu Leu Ala Tyr Lys
1 5 10 15

Arg His Gly Pro
20

(2) INFORMATION FOR SEQ ID NO:414:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 48 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:414:

Gly Ala Arg Phe Trp Thr Gly Arg Phe Arg Gly Gln Pro Thr Tyr Leu
 1 5 10 15
 Cys Leu Ile Lys Met Cys Pro Ala Ser Ala Tyr Gly Arg Val Tyr Trp
 20 25 30
 Cys Ser Gly Asn Ala Leu Ser Asn Glu Cys Asp Gly Lys Lys Leu Leu
 35 40 45

(2) INFORMATION FOR SEQ ID NO:415:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 11 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:415:

Ala Gly Glu Arg Ala Ser Ala Pro Val Thr His
 1 5 10

(2) INFORMATION FOR SEQ ID NO:416:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 12 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:416:

Asn Phe Ala Thr Ala Cys Ile Arg Ala Gly Phe Tyr
 1 5 10

(2) INFORMATION FOR SEQ ID NO:417:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:417:

Arg Phe Thr Ser Tyr Phe Arg His Leu Asn
 1 5 10

(2) INFORMATION FOR SEQ ID NO:418:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 4 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein
(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:418:

Leu Gly Ala Thr

1

(2) INFORMATION FOR SEQ ID NO:419:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 22 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:419:

Lys Arg Cys Pro Asp Val Asp Arg Ile Cys Pro Tyr Arg Ala Ser Ser

1

5

10

15

Ser Tyr Ser Ala Ser Ser

20

(2) INFORMATION FOR SEQ ID NO:420:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 15 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:420:

Ser Gly Arg Lys Thr Ala Ala Asp Phe Ala Asp Arg Arg Arg Tyr

1

5

10

15

(2) INFORMATION FOR SEQ ID NO:421:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 4 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:421:

Lys Pro Arg Ala

1

(2) INFORMATION FOR SEQ ID NO:422:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 17 amino acids
 (B) TYPE: amino acid

Ile His Ser Pro Asp Gly Asn Gly Asp Leu Tyr Cys Ala Val Val Ser
1 5 10 15

(2) INFORMATION FOR SEQ ID NO:423:

(A) LENGTH: 60 amino acids

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:423:

Asp Ala Asp Pro Ala Thr Tyr Arg Ala Gly Ala Glu Ala Val Ser Gln
1 5 10 15

Ile Ile His Cys His Phe Cys Arg His Pro Thr Phe Leu Ala Lys Asn
20 25 30

Tyr Arg Ser His Leu Val Arg Arg Thr Asp Phe Val Met Ala Gly Ile
35 40 45

Arg Arg Gly Glu Pro Tyr Thr Ser Gly Arg Lys Tyr
50 55 60

(2) INFORMATION FOR SEQ ID NO:424:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 7 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:424:

Arg Arg Gly Val Gly Gly Gln
1 5

(2) INFORMATION FOR SEQ ID NO:425:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:425:

Asn Ile Arg Pro Pro Met Val Ile Val Asp Gly Ala Glu Phe Arg Met
1 5 10 15

Ser Ala Gln Arg Cys
20

(2) INFORMATION FOR SEQ ID NO:426:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 14 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:426:

Met Arg Gly Cys Leu Gly Tyr Leu Trp Ala Ser Cys Ala Val
1 5 10

(2) INFORMATION FOR SEQ ID NO:427:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 33 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:427:

Ser Leu Glu Lys Asn Leu Leu Lys Ser Trp Gly Leu Met Ala Ala Lys
1 5 10 15

Leu Cys Tyr Leu Leu Leu Arg Val Gln Ser Gly Phe Thr Ala Gly Ser
20 25 30

Lys

(2) INFORMATION FOR SEQ ID NO:428:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 16 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:428:

Ala Thr Pro Ser Gly Ser Arg Gly Arg Ser Val Ile Arg Ala Ser Tyr
1 5 10 15

(2) INFORMATION FOR SEQ ID NO:429:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:429:

Trp Leu Trp Ser Ser Pro
 1 5

- (2) INFORMATION FOR SEQ ID NO:430:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 12 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: protein
 - (iii) HYPOTHETICAL: NO
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:430:

Trp Pro Arg Thr Ala Arg Arg Leu Leu Glu Arg Leu
 1 5 10

- (2) INFORMATION FOR SEQ ID NO:431:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 23 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: protein
 - (iii) HYPOTHETICAL: NO
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:431:

Cys Asn Ala Ser Ser Arg Asn Gly Ser Thr Ala Tyr His Ser Thr Ile
 1 5 10 15

Asn Asp Gly Asp Ser Arg Tyr
 20

- (2) INFORMATION FOR SEQ ID NO:432:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 28 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: protein
 - (iii) HYPOTHETICAL: NO
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:432:

Arg Cys Asp Leu Trp Arg Arg Ala Thr Ser Gly Tyr Phe Phe Cys Ser
 1 5 10 15

Trp Arg Gly Glu Lys His Ala Ser Gly Asp Ala Val
 20 25

(2) INFORMATION FOR SEQ ID NO:433:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 13 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:433:

Cys Ala Arg Arg Arg Gln Gln Cys Ser Gly Val Asn Trp
 1 5 10

(2) INFORMATION FOR SEQ ID NO:434:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 14 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:434:

Thr Trp Thr Arg Ser Pro Arg Ile His Arg Phe Tyr Thr Val
 1 5 10

(2) INFORMATION FOR SEQ ID NO:435:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 13 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:435:

Arg Asp Pro Lys Thr Leu Cys His Cys Cys Arg Asn Leu
 1 5 10

(2) INFORMATION FOR SEQ ID NO:436:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 22 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:436:

Gln Thr Arg Leu Arg Ala Arg Glu Gly Ala Val Cys Gly His His Asp
 1 5 10 15

Ser Arg Ile Phe Ser Arg
 20

(2) INFORMATION FOR SEQ ID NO:437:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 38 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:437:

Trp Lys Ala Ser Arg Leu Ala Cys Arg Leu Thr Asp Ala Leu Cys Gln
 1 5 10 15

Gly Arg Thr Glu Ile Ala Leu Ala Pro Glu Arg Pro Arg Phe Leu Glu
 20 25 30

Asn Ile Ala Arg Arg Ile
 35

(2) INFORMATION FOR SEQ ID NO:438:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 28 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:438:

Cys Ile Ala Thr Thr Phe Arg Thr Tyr Gly Asn Gly Arg Lys Arg Gln
 1 5 10 15

Tyr Tyr Arg Ile Leu Tyr Gly Thr Gly Gly Arg Arg
 20 25

(2) INFORMATION FOR SEQ ID NO:439:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 67 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:439:

Ser Arg Trp Arg Met Lys Ser Val His Cys Leu Met Asp Ile Leu Tyr
 1 5 10 15

Tyr Pro Asp Gly Leu Gln Arg Gly Gly Ile Ile Leu Pro Leu Thr Cys
20 25 30

Trp Gln Arg Ser Ala Ala Phe Phe Gln Ser Leu Pro Ala Met Ser Ile
35 40 45

Val Asn Trp Arg Arg Tyr Cys Asp Gly Ala Trp Arg Phe Thr Arg Arg
50 55 60

Leu Asn Cys
65

(2) INFORMATION FOR SEQ ID NO:440:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 41 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:440:

Tyr Ala Leu Gly Asn Thr Ser Glu Glu Leu Ile Gln Ile Leu Thr Lys
1 5 10 15

Pro Leu Ile Pro Ile Arg Ile Phe Ala His Phe Cys Asp Lys Val Arg
20 25 30

Met Lys Tyr Ala Asp Pro Ser Tyr Leu
35 40

(2) INFORMATION FOR SEQ ID NO:441:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 114 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:441:

Lys Asn Tyr Thr Lys Tyr Ser Pro Ser Asp His Gly Asn Phe Ala Gly
1 5 10 15

Asp Asn Arg Ala Ala Glu Lys Gln Leu Arg Gly Lys Leu Thr Val Leu
20 25 30

Asp Gln Gln Gln Gln Ala Ile Ile Thr Glu Gln Gln Ile Cys Gln Thr
35 40 45

Arg Ala Leu Ala Val Ser Thr Arg Leu Lys Glu Leu Met Gly Trp Gln
50 55 60

Gly Thr Leu Ser Cys His Leu Leu Leu Asp Lys Lys Gln Gln Met Ala
65 70 75 80

Gly Leu Phe Thr Gln Ala Gln Ser Phe Leu Thr Gln Arg Gln Ala Val
85 90 95

Arg Glu Ser Val Ser Ala Ala Cys Leu Pro Ala Lys Arg Ile Thr Glu
100 105 110

Glu Phe

(2) INFORMATION FOR SEQ ID NO:442:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 63 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:442:

Cys Ala Tyr Glu Lys Glu Arg Lys Asn Tyr Tyr Gly Ile Lys Arg Cys
1 5 10 15

Val Leu Pro Lys Leu Arg Glu Val Leu Gly Cys His Ala Ser Leu Ile
20 25 30

Arg Met Ile Thr Arg Arg Arg Arg Asn Val Trp Thr Leu Asn Asn Ser
35 40 45

Cys Thr Arg His Tyr Pro Leu Val Arg Ile Ile Leu Leu Gln His
50 55 60

(2) INFORMATION FOR SEQ ID NO:443:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 19 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:443:

Ile Arg Thr Trp Phe Ser Arg Asn Val Ile Val Leu Val Ala Val Ile
1 5 10 15

Leu Thr Val

(2) INFORMATION FOR SEQ ID NO:444:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 9 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:444:

Ser Val Lys Tyr Val Asn Gln Gly Gly
1 5

(2) INFORMATION FOR SEQ ID NO:445:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 12 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:445:

Glu Ser Met Ser Leu Ile Met Lys Phe Thr Val Arg
1 5 10

(2) INFORMATION FOR SEQ ID NO:446:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 13 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:446:

Ser Ser Gly Trp Ser Leu Ser Cys Cys Ile Trp Gly Ile
1 5 10

(2) INFORMATION FOR SEQ ID NO:447:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 328 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:447:

Phe Pro Trp Arg Tyr Ser Met Leu Arg Ile Ala Asn Glu Glu Arg Pro
1 5 10 15

Trp Val Glu Ile Leu Pro Thr Gln Gly Ala Thr Ile Gly Glu Leu Thr
20 25 30

Leu Ser Met Gln Gln Tyr Pro Val Gln Gln Gly Thr Leu Phe Thr Ile
35 40 45

Asn Tyr His Asn Glu Leu Gly Arg Val Trp Ile Ala Glu Gln Cys Trp
50 55 60

Gln Arg Trp Cys Glu Gly Leu Ile Gly Thr Ala Asn Arg Ser Ala Ile
152

| | | | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|--|--|----|
| 65 | | | | | | 70 | | | | | | 75 | | | | | | 80 |
| Asp | Pro | Glu | Leu | Leu | Tyr | Gly | Ile | Ala | Glu | Trp | Gly | Leu | Ala | Pro | Leu | | | |
| | | | | 85 | | | | | 90 | | | | | 95 | | | | |
| Leu | Gln | Ala | Ser | Asp | Ala | Thr | Leu | Cys | Gln | Asn | Glu | Pro | Pro | Thr | Ser | | | |
| | | | 100 | | | | 105 | | | | 110 | | | | | | | |
| Cys | Ser | Asn | Leu | Pro | His | Gln | Leu | Ala | Leu | His | Ile | Lys | Trp | Thr | Val | | | |
| | | | 115 | | | | 120 | | | | 125 | | | | | | | |
| Glu | Glu | His | Glu | Phe | His | Ser | Ile | Ile | Phe | Thr | Trp | Pro | Thr | Gly | Phe | | | |
| | | 130 | | | | 135 | | | | | 140 | | | | | | | |
| Leu | Arg | Asn | Ile | Val | Gly | Glu | Leu | Ser | Ala | Glu | Arg | Gln | Gln | Ile | Tyr | | | |
| 145 | | | | | 150 | | | | | 155 | | | | | 160 | | | |
| Pro | Ala | Pro | Pro | Val | Val | Val | Pro | Val | Tyr | Ser | Gly | Trp | Cys | Gln | Leu | | | |
| | | | | 165 | | | | | 170 | | | | | 175 | | | | |
| Thr | Leu | Ile | Glu | Leu | Glu | Ser | Ile | Glu | Ile | Gly | Met | Gly | Val | Arg | Ile | | | |
| | | | 180 | | | | 185 | | | | 190 | | | | | | | |
| His | Cys | Phe | Gly | Asp | Ile | Arg | Leu | Gly | Phe | Phe | Ala | Ile | Gln | Leu | Pro | | | |
| | | 195 | | | | 200 | | | | | 205 | | | | | | | |
| Gly | Gly | Ile | Tyr | Ala | Arg | Val | Leu | Leu | Thr | Glu | Asp | Asn | Thr | Met | Lys | | | |
| | | 210 | | | | 215 | | | | | 220 | | | | | | | |
| Phe | Asp | Glu | Leu | Val | Gln | Asp | Ile | Glu | Thr | Leu | Leu | Ala | Ser | Gly | Ser | | | |
| 225 | | | | | 230 | | | | | 235 | | | | | 240 | | | |
| Pro | Met | Ser | Lys | Ser | Asp | Gly | Thr | Ser | Ser | Val | Glu | Leu | Glu | Gln | Ile | | | |
| | | | 245 | | | | 250 | | | | 255 | | | | | | | |
| Pro | Gln | Gln | Val | Leu | Phe | Glu | Val | Gly | Arg | Ala | Ser | Leu | Glu | Ile | Gly | | | |
| | | | 260 | | | | 265 | | | | 270 | | | | | | | |
| Gln | Leu | Arg | Gln | Leu | Lys | Thr | Gly | Asp | Val | Leu | Pro | Val | Gly | Gly | Cys | | | |
| | | 275 | | | | 280 | | | | | 285 | | | | | | | |
| Phe | Ala | Pro | Glu | Val | Thr | Ile | Arg | Val | Asn | Asp | Arg | Ile | Ile | Gly | Gln | | | |
| | | 290 | | | | 295 | | | | | 300 | | | | | | | |
| Gly | Glu | Leu | Ile | Ala | Cys | Gly | Asn | Glu | Phe | Met | Val | Arg | Ile | Thr | Arg | | | |
| 305 | | | | | 310 | | | | | 315 | | | | | 320 | | | |
| Trp | Tyr | Leu | Cys | Lys | Asn | Thr | Ala | | | | | | | | | | | |
| | | | | 325 | | | | | | | | | | | | | | |

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:448:

Tyr Ala Asn Asn Ile Ile Ala Phe Gln Val Val Ser
1 5 10

(2) INFORMATION FOR SEQ ID NO:449:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 34 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:449:

Glu Ile Gln Tyr Val Phe Thr Arg Phe Ala Phe Ala Thr Asp Trp Tyr
1 5 10 15

Ile Val Ser Ala Phe Asn Thr Ala Ser His Tyr Arg His Gly Asn Phe
20 25 30

Phe Pro

(2) INFORMATION FOR SEQ ID NO:450:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 59 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:450:

Thr Gly Gly Gly Ile Phe Asp Phe Thr Lys Cys Ser Gly Tyr Ser Thr
1 5 10 15

Ser Pro Pro Lys Tyr Arg Thr Val Trp Pro Cys Ala Cys Thr Phe Leu
20 25 30

Ile His Tyr Gly Ala Asp Ala Ile Ser Cys Lys Arg Ala Leu Ala Ser
35 40 45

Gly Ser Gly Arg Trp Arg Ser Phe Leu Asp Val
50 55

(2) INFORMATION FOR SEQ ID NO:451:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 13 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(ii) MOLECULE TYPE: protein
 (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:455:

Pro Ala Tyr Phe Lys Tyr Thr Ala Gly Tyr Gly Asp Asp Asp Gly Val
 1 5 10 15
 Ala Asp Asp His Phe Ile Thr Val
 20

(2) INFORMATION FOR SEQ ID NO:456:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 110 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 (ii) MOLECULE TYPE: protein
 (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:456:

Ala Ala Asn Ile Phe Thr Gly Arg Arg Leu Gly Ser Asp Thr Gly Ala
 1 5 10 15
 Ile Gly Thr Glu Leu Phe Met Asn Asp Ser Glu Leu Thr Gln Phe Val
 20 25 30
 Thr Gln Leu Leu Trp Ile Val Leu Phe Thr Ser Met Pro Val Val Leu
 35 40 45
 Val Ala Ser Val Val Gly Val Ile Val Ser Leu Val Gln Ala Leu Thr
 50 55 60
 Gln Ile Gln Asp Gln Thr Leu Gln Phe Met Ile Lys Leu Leu Ala Ile
 65 70 75 80
 Ala Ile Thr Leu Met Val Ser Tyr Pro Trp Leu Ser Gly Ile Leu Leu
 85 90 95
 Asn Tyr Thr Arg Gln Ile Met Leu Arg Ile Gly Glu His Gly
 100 105 110

(2) INFORMATION FOR SEQ ID NO:457:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 230 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 (ii) MOLECULE TYPE: protein
 (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:457:

Met Ala Gln Gln Val Asn Glu Trp Leu Ile Ala Leu Ala Val Ala Phe
 1 5 10 15

Ile Arg Pro Leu Ser Leu Ser Leu Leu Leu Pro Leu Leu Lys Ser Gly
20 25 30

Ser Leu Gly Ala Ala Leu Leu Arg Asn Gly Val Leu Met Ser Leu Thr
35 40 45

Phe Pro Ile Leu Pro Ile Ile Tyr Gln Gln Lys Ile Met Met His Ile
50 55 60

Gly Lys Asp Tyr Ser Trp Leu Gly Leu Val Thr Gly Glu Val Ile Ile
65 70 75 80

Gly Phe Ser Ile Gly Phe Cys Ala Ala Val Pro Phe Trp Ala Val Asp
85 90 95

Met Ala Gly Phe Leu Leu Asp Thr Leu Arg Gly Ala Thr Met Gly Thr
100 105 110

Ile Phe Asn Ser Thr Ile Glu Ala Glu Thr Ser Leu Phe Gly Leu Leu
115 120 125

Phe Ser Gln Phe Leu Cys Val Ile Phe Phe Ile Ser Gly Gly Met Glu
130 135 140

Phe Ile Leu Asn Ile Leu Tyr Glu Ser Tyr Gln Tyr Leu Pro Pro Gly
145 150 155 160

Arg Thr Leu Leu Phe Asp Gln Gln Phe Leu Lys Tyr Ile Gln Ala Glu
165 170 175

Trp Arg Thr Leu Tyr Gln Leu Cys Ile Ser Phe Ser Leu Pro Ala Ile
180 185 190

Ile Cys Met Val Leu Ala Asp Leu Ala Leu Gly Leu Leu Asn Arg Ser
195 200 205

Ala Gln Gln Leu Asn Val Phe Phe Phe Ser Met Pro Leu Lys Ser Ile
210 215 220

Leu Val Leu Leu Thr Xaa
225 230

(2) INFORMATION FOR SEQ ID NO:458:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:458:

Ser His Ser Leu Met Leu Phe Ile Thr Ile Trp Leu Lys Ala Ile Asn
1 5 10 15

Phe Ile Phe Ile

(2) INFORMATION FOR SEQ ID NO:459:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 20 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:459:

Lys Thr Gly Phe His Leu Tyr Glu Arg Glu Asn Arg Thr Ala Tyr Arg
 1 5 10 15

Lys Glu Ile Thr
 20

(2) INFORMATION FOR SEQ ID NO:460:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 8 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:460:

Gly Arg Ala Gly Cys Gln Lys Tyr
 1 5

(2) INFORMATION FOR SEQ ID NO:461:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 18 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:461:

Asn Asn Ile Ile Ile Ser Ala Asp Cys Ala Leu Phe Val Phe Ser Phe
 1 5 10 15

Leu Tyr

(2) INFORMATION FOR SEQ ID NO:462:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 7 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

Figure 1 consists of seven vertically stacked plots showing the time evolution of various quantities for a 1D Ising chain. The top plot shows the magnetization $M(t)$ starting at 1.0 and decaying towards 0. The second plot shows the energy density $e(t)$ starting at 0.5 and decaying towards 0. The third plot shows the entanglement entropy $S(t)$ starting at 0 and increasing linearly. The fourth plot shows the central charge $c(t)$ starting at 0 and increasing linearly. The fifth plot shows the central charge $c(t)$ starting at 0 and increasing linearly. The sixth plot shows the central charge $c(t)$ starting at 0 and increasing linearly. The bottom plot shows the central charge $c(t)$ starting at 0 and increasing linearly.

Lys Asp Asp Phe Asp Thr Asp
1 5

(2) INFORMATION FOR SEQ ID NO:463:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:463:

Val Asn Asn Phe His Ile Thr Ile Ser Lys
1 5 10

(2) INFORMATION FOR SEQ ID NO:464:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 34 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:464:

Thr Ile Phe Leu Cys Ile Asn Ala Ile Glu Ser Cys Phe Asn Arg Val
1 5 10 15

Thr Asp Phe Cys Thr Ala Val Ser Gly Arg Trp Gly Asn Ser Cys Tyr
20 25 30

Cys Gly

(2) INFORMATION FOR SEQ ID NO:465:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 16 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:465:

Arg Val Ser Ser Gly Gly Gly Gly Tyr Cys Gln Gln Gly His Trp Phe
1 5 10 15

(2) INFORMATION FOR SEQ ID NO:466:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 8 amino acids
(B) TYPE: amino acid

Gly Asp Gly Phe Leu Tyr Arg Arg Trp His Thr Gly Leu Phe Phe Ser
 50 55 60

Ile Leu
 65

(2) INFORMATION FOR SEQ ID NO:470:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 39 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:470:

Lys Ser Tyr Leu Lys Met Ser Lys Asp Asp Val Lys Gln Glu His Lys
 1 5 10 15

Asp Leu Glu Gly Asp Pro Gln Met Lys Thr Arg Arg Arg Lys Cys Arg
 20 25 30

Val Lys Tyr Lys Val Gly Val
 35

(2) INFORMATION FOR SEQ ID NO:471:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 9 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:471:

Leu Asn Leu Leu Asn Asn Leu Leu Arg
 1 5

(2) INFORMATION FOR SEQ ID NO:472:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 80 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:472:

Cys Val Ile Gln Arg Ile Leu Arg Phe Val Leu Ala Ile Ile Pro Pro
 1 5 10 15

Ile Cys Gln Tyr His Ala Ser Trp Lys Lys Ala Val Met Leu Lys Leu
 20 25 30

Thr Ile Leu Leu Thr Ser Leu Asn Ala Thr Ala Ser Pro Leu Leu Lys
 35 40 45

Met Leu Ser Trp Pro Ala His Tyr Phe Leu Lys Trp Asn Ala Glu Ile
 50 55 60

Lys Phe Leu Lys Arg Tyr Leu Asn Pro Leu Gln Pro Cys Tyr Val Trp
 65 70 75 80

(2) INFORMATION FOR SEQ ID NO:473:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 22 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:473:

Ile Met Arg Ile Leu Pro Lys His His Lys Cys Phe Trp Tyr Ala Ser
 1 5 10 15

Ser Gly His Cys Glu Gly
 20

(2) INFORMATION FOR SEQ ID NO:474:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 5 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:474:

Glu Gly Asn Ser Val
 1 5

(2) INFORMATION FOR SEQ ID NO:475:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 7 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:475:

Glu Thr Glu Asn Asn Arg Phe
 1 5

(2) INFORMATION FOR SEQ ID NO:476:

- (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 6 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 (ii) MOLECULE TYPE: protein
 (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:476:

Pro Gly Thr Ser Thr Arg
 1 5

(2) INFORMATION FOR SEQ ID NO:477:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 13 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 (ii) MOLECULE TYPE: protein
 (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:477:

Arg Ile Ile Lys Leu Asn Lys Ile Met Asp Trp Cys Val
 1 5 10

(2) INFORMATION FOR SEQ ID NO:478:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 26 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 (ii) MOLECULE TYPE: protein
 (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:478:

Met Asp Ser Asn His Ser Thr Pro Thr Met Ser Arg Trp Cys Ser Asn
 1 5 10 15

Gln Leu Ser Tyr Glu Arg Gln Arg Cys Arg
 20 25

(2) INFORMATION FOR SEQ ID NO:479:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 11 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 (ii) MOLECULE TYPE: protein
 (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:479:

Gln Arg Gly Arg Ile Leu Ala Ser Gln Pro Gln
 1 5 10

(2) INFORMATION FOR SEQ ID NO:480:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 48 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:480:

Gly Lys Arg Glu Ile Ala Ile Phe Phe Leu Lys Ser Pro Asp Cys Gly
1 5 10 15
Gly Asn Met Gln His Val Glu Lys Ile Ala Ala Met Arg Arg Leu Ser
20 25 30
Ser Tyr Tyr Arg Ser Ala Leu Gln Asn Asp Gly Gly Arg Leu Thr Leu
35 40 45

(2) INFORMATION FOR SEQ ID NO:481:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 4 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:481:

Ile Ala His Pro
1

(2) INFORMATION FOR SEQ ID NO:482:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 26 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:482:

His Arg Arg Arg Gly Gln Ala Asp Asp Glu Pro His Pro Glu Ala Cys
1 5 10 15
Arg Ser His Thr Ile His His Gln Ile Arg
20 25

(2) INFORMATION FOR SEQ ID NO:483:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 7 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:483:

Arg Gln Asp Ile Thr Ala Gly
1 5

- (2) INFORMATION FOR SEQ ID NO:484:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 40 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: protein
 - (iii) HYPOTHETICAL: NO

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:484:

His Pro Val Gly Gly Lys Gly Asp Lys Lys Asp Gly Thr Arg Ile Phe
1 5 10 15

Ile Thr Ala Gln Asn Thr Ala Ala Asp Asn Leu Tyr Arg Val Gly Asn
20 25 30

Leu Val Asn Arg Ser Glu Gln His
35 40

- (2) INFORMATION FOR SEQ ID NO:485:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 21 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: protein
 - (iii) HYPOTHETICAL: NO

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:485:

Leu Arg Gln Ala Pro Arg Pro Gln Gly Cys His Cys Arg Ala Lys Gln
1 5 10 15

Tyr Ala Tyr Ala Glu
20

- (2) INFORMATION FOR SEQ ID NO:486:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 20 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: protein
 - (iii) HYPOTHETICAL: NO

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:486:

Pro Gln Pro Tyr Lys Cys Arg Arg Leu Asn Arg Tyr Ala Leu Arg Leu
165

CCSF" 20947ED

20

25

(2) INFORMATION FOR SEQ ID NO:490:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 9 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:490:

Glu Ser Met Ala Ile Asn Ile Thr Gln
 1 5

(2) INFORMATION FOR SEQ ID NO:491:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 20 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:491:

Thr Ala Ala Val Ala Thr Pro Gln Pro Ile Pro Pro Ser Ser Gly Ile
 1 5 10 15

Pro Lys Trp Pro
 20

(2) INFORMATION FOR SEQ ID NO:492:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 30 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:492:

Phe Thr Gly Ile Phe Thr Ser Arg Pro Lys Asn Pro Ile Thr Ile Pro
 1 5 10 15

Gly Leu Val Leu Ala Arg Pro Ser His Trp Phe Arg Ala Thr
 20 25 30

(2) INFORMATION FOR SEQ ID NO:493:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 13 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:493:

Lys Lys Arg Tyr Pro Ala Pro His Ser Ser Ala Arg Arg
1 5 10

(2) INFORMATION FOR SEQ ID NO:494:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 42 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:494:

Pro Thr Ala Leu Ser Ala Ser Ala Gly Ser Ile Leu Cys Ile Glu Arg
1 5 10 15

Ile Met Tyr Pro Ala Phe His Arg Thr Ile Ile Thr Ser Thr Glu Thr
20 25 30

Lys Pro Ala Ser Gln Asn Pro Cys Arg Thr
35 40

(2) INFORMATION FOR SEQ ID NO:495:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 24 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:495:

Cys Ala Ile Arg Ser Arg Arg Pro Glu Pro Leu Ser Cys Ala Ile Thr
1 5 10 15

Gly Val Lys Ala Ser Ser Lys Pro
20

(2) INFORMATION FOR SEQ ID NO:496:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 8 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:496:

Pro Asn Lys Met Ala Gly Ser Arg
1 5

(2) INFORMATION FOR SEQ ID NO:497:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:497:

Arg Arg Gln Pro Cys Pro
1 5

(2) INFORMATION FOR SEQ ID NO:498:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:498:

Arg Tyr Ser Leu Pro Pro
1 5

(2) INFORMATION FOR SEQ ID NO:499:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 23 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:499:

Arg Tyr Arg Arg Ile His Cys Gly Leu Tyr His Leu Arg Lys Asp His
1 5 10 15

Arg Tyr Leu Asn Ala Asn Asn
20

(2) INFORMATION FOR SEQ ID NO:500:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 31 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:500:

Arg Ala Ser Leu Val Tyr Phe Cys Thr Tyr Ser Pro Phe Ile Leu Leu
 1 5 10 15

Leu Tyr Glu Arg Leu Lys Ser Arg Arg Ser Gly Ser Gln Lys Lys
 20 25 30

(2) INFORMATION FOR SEQ ID NO:501:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 63 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:501:

Gln Gly Lys Phe Gln Ser Ile Val Ala Gly Tyr Tyr Tyr Phe Ser Ser
 1 5 10 15

Glu Lys Thr Val Val Asn Gly Ala Leu Leu Ala Ser Cys Phe Ser Thr
 20 25 30

Cys Tyr Cys Ala Glu Gln Phe Cys Phe Tyr Leu Phe Gln Glu Leu Lys
 35 40 45

Ile Cys Leu Arg Gly Ser Tyr Arg Val Pro Arg Asn Trp Tyr Arg
 50 55 60

CCATF"2094T/60